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ABSTRACT 
 
The p38 mitogen activated protein kinase (MAPK) pathway enhances the expression of pro-
inflammatory response genes, including cyclooxgenase (COX)-2 and interleukin (IL)-6 in 
response to stimuli including IL-1. Heat shock protein 27 (HSP27) is a major protein 
phosphorylated by MAPK activated protein kinase 2 (MK2), a downstream kinase of p38 
MAPK. However, the role of HSP27 in inflammation is unclear. Previous work has shown the 
requirement of HSP27 for stabilisation of COX-2 and IL-6 mRNAs following IL-1 treatment of 
HeLa cells. To examine the role of HSP27 in IL-1 signalling I depleted the protein from HeLa 
cells, human alveolar epithelial (A549) cells and human dermal fibroblasts (HDFs) by RNA 
interference (RNAi) using multiple short interfering RNAs (siRNAs). 
 
HSP27 suppression in HeLa cells inhibited IL-1 induced activation of MK2, p38 MAPK and c-
Jun N-terminal kinase (JNK), but not extracellular signal-regulated kinase (ERK). Upstream 
MAPK kinase (MKK) 3, 4, 6 and 7 and TGF-beta-activated kinase 1 (TAK1) were also 
inhibited. HSP27 depletion did not disrupt the constitutive interaction found between TAK1 and 
its binding protein TAB1. HSP27 appeared to impinge on signalling at a point lying between 
cell surface receptors and TAK1 or at TAK1 itself as activation of JNK and p38 MAPK by 
tumour necrosis factor (TNF) was inhibited by HSP27 knockdown.  
 
A transfection procedure was developed for transfection of siRNA into HDF cells. In HDFs and 
A549 cell types HSP27 was required for COX-2 protein expression and the full activation of 
p38 MAPK. However, while TAK1 was shown to be responsible for sustained activation of p38 
MAPK, TAK1 activity was not affected by HSP27 depletion in HDFs. MKK3 (rather than 
MKK6) appeared to be the major HDF activator of p38 MAPK in response to IL-1. My results 
demonstrate that HSP27 has a novel role in augmenting IL-1 signalling in epithelial cell lines 
and fibroblasts.   
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The aim of this project was to investigate the role of heat shock protein (HSP) 27 in 
inflammation, notably interleukin (IL)-1 signalling. This followed on from previous work in our 
laboratory that had shown a role for HSP27 in IL-1-induced expression and post-transcriptional 
regulation of the inflammatory mediators; cyclooxygenase (COX)-2 and IL-6 (Alford, 2006; 
Alford et al., 2007). This introduction focuses on the innate immune system, inflammation, IL-1 
signalling and the reported functions of HSP27 to provide a background for the experiments in 
this thesis. 
 
PART 1:  Immunity and inflammation 
 
1.1 Innate immunity 
 
Innate immunity is the first line of defence of the human body against the invasion of 
pathogens. Innate immunity is an immediate response and does not produce a long-lasting 
defence. If the innate immune system proves unsuccessful then the adaptive immune system is 
activated. However, the activation of the adaptive immune response takes several days during 
which time the innate immune response is required to keep infection under control (Janeway Jr., 
2001). Neutrophils and macrophages are the main cells involved in the innate immune response. 
These cells are activated by pattern recognition receptors (PRRs) on the cell surface that 
recognise pathogen associated molecular patterns (PAMPs) on the invading microorganism. 
Neutrophils and macrophages can then ingest the pathogen by phagocytosis and break it down. 
Macrophages can then secrete cytokines and other mediators to induce inflammation.   
 
1.2 Inflammation 
 
Inflammation is the response of tissues to injury, infection or autoimmune diseases. It is a 
defence mechanism against microorganisms and initiates the repair process.  Inflammation is an 
effector mechanism of both innate and adaptive immunity, it has rapid onset and is generally of 
short duration. There are five signs of inflammation; redness, swelling, heat, pain and loss of 
function. Inflammation is triggered by many events, for example the inflammatory cytokines 
IL-1 and tumour necrosis factor (TNF), complement activation, antigen-antibody interactions 
and signalling through PRRs (Janeway Jr., 2001). One example of PRRs is the toll-like 
receptors (TLR), for example TLR4, which binds to lipopolysaccharide (LPS). The binding of 
PAMPs, IL-1 and TNF to their receptors activates a common set of intracellular signalling 
pathways resulting in the production of many cytokines and chemokines, enzymes and adhesion 
molecules. Chemokines act as chemoattractants to phagocytic cells, such as monocytes and 
neutrophils. Inflammation causes vasodilation which is partly due to production of 
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prostaglandins by COX-2, an induced enzyme. The increase in the expression of adhesion 
molecules on the surface of the vascular endothelial cells of the capillaries causes leucocytes to 
adhere and their migration then follows chemotactic gradients to the site of injury or infection.   
 
Under normal circumstances inflammation resolves once the cause has been removed. This 
requires the synthesis of glucocorticoids, anti-inflammatory cytokines such as IL-10 and other 
factors. If this process is not able to occur then chronic inflammation may ensue and can lead to 
serious tissue damage, destructive inflammation and loss of function. Persistent inflammation 
can be caused by certain microorganisms that are effective at evading the immune response. 
Chronic inflammation may also occur in certain autoimmune diseases such as rheumatoid 
arthritis (RA) and Crohn’s disease. Acute inflammatory reactions are often characterised by the 
presence of polymorphonuclear leucocytes whereas chronic inflammatory diseases are 
characterised by mononuclear cellular infiltrate (Kunkel et al., 1994).  
 
The thorough understanding of the regulation of signalling pathways such as IL-1 should lead to 
the better understanding of current anti-inflammatory drug mechanisms (for example 
glucocorticoids) and help identify new drug targets.  This is important both for the minimisation 
of episodes of chronic and destructive inflammation and to increase the number of treatment 
options for patients, with the consequent hope that less patient inflammation is refractory to 
treatment options. Heat shock proteins have been reported to both dampen and exacerbate the 
immune response and it is possible that heat shock proteins could fine-tune the immune 
response and have potential as drug targets. In this project I will investigate the importance of a 
specific heat shock protein, HSP27, in IL-1 signalling.  
  
1.3 Cytokines and pro-inflammatory mediators 
 
Cytokines are a large group of small peptides, proteins and glycoproteins (>25 kDa) that have 
potent biological effects. Cytokines are released principally from macrophages and T helper 
cells in response to an activating stimulus and mediate their actions through binding to cell 
surface receptors. Most cytokines are secreted but some may be expressed on the cell surface or 
held in reservoirs in the extracellular matrix.   
 
1.3.1 Interleukin-1 
 
IL-1 is a pro-inflammatory cytokine that has two forms: IL-1α and IL-1β. Both forms of IL-1 
are expressed as propeptides by a variety of cells in response to different stimuli. The 
propeptides are approximately 31 kDa. IL-1 was identified originally as the fever inducing 
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endogenous pyrogen (Auron et al., 1984). The two forms of IL-1 signal through the same 
receptor (Kilian et al., 1986) and therefore have similar biological actions. There are three IL-1 
receptors which can either be expressed as cell-surface or soluble receptors: the type I IL-1 
receptor (IL-1RI), type II IL-1 receptor (IL-1RII) and IL-1 receptor accessory protein (IL-
1RAcP) (Braddock and Quinn, 2004; Janssens and Beyaert, 2003). IL-1RI and IL-1RAcP bind 
to IL-1 and instigate the downstream signalling. The signalling pathways activated through 
these receptors will be discussed later. IL-1RII acts as a decoy receptor, which competes with 
IL-1RI for IL-1 and thus acts as a buffer for excess IL-1 (Neumann et al., 2000). Soluble IL-
1RAcP has been shown to act as an endogenous inhibitor of IL-1 (Smeets et al., 2003). The IL-
1R antagonist (IL-1Ra), shares only about 30 % sequence identity to IL-1α and IL-1β 
(Eisenberg et al., 1991), however it has the same β-barrel tertiary structure (Vigers et al., 1994).  
IL-1Ra can bind to the IL-1RI with extremely high affinity (Dripps et al., 1991). The structure 
of IL-1RI bound to IL-1Ra revealed that the C-terminal domain is rotated by 170º compared to 
the IL-1RI in complex with IL-1β (Vigers et al., 2000) and this complex cannot bind to the IL-
1RAcP. Thus IL-1Ra acts as a competitive inhibitor (Arend et al., 1998).  
 
IL-1 expression is induced by a wide variety of stimuli for example LPS (Burchett et al., 1988), 
phorbol 12-myristate 13-acetate (PMA) (Fenton et al., 1988), UV light (Kupper et al., 1987), 
TNF and IL-1 itself (Dinarello et al., 1987; Warner et al., 1987a; Warner et al., 1987b). Some 
stimuli require synergy to induce IL-1 expression for example IL-3 requires co-stimulation with 
LPS (Frendl et al., 1990). 
 
IL-1α is thought to be principally involved in autocrine signalling (Dinarello, 1998). It is active 
in both the precursor and processed mature forms. Once expressed it is mostly retained in the 
cell and only appears in the circulation in severe disease states. Pro-IL-1α may be released from 
a dying cell that is undergoing apoptosis or necrosis and subsequently cleaved to the mature 
form by circulating proteases. Alternatively, IL-1α may be cleaved by the calcium activated 
cysteine protease, calpain (Kobayashi et al., 1990), associated with the cell membrane. In 
contrast, the IL-1β propeptide has very little activity and needs to be cleaved into its mature 
form to exert its potent effects. Pro-IL-1β is cleaved by the IL-1β converting enzyme (ICE or 
caspase-1), a part of the inflammasome (Cerretti et al., 1992; Martinon et al., 2002; Thornberry 
et al., 1992). A group of proteins termed COPs (caspase recruitment domain-only proteins) can 
interact with pro-caspase-1 and prevent its activation and therefore the unnecessary activation of 
IL-1β (Druilhe et al., 2001; Lamkanfi et al., 2004). Characterisation of IL-1β-null mice revealed 
that  IL-1β does not have a role in the healthy individual, however it acts as a pyrogen and an 
acute phase response mediator in a subset of inflammatory disease models, for example when 
challenged with turpentine (Zheng et al., 1995). 
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IL-1 has a similar wide range of actions to the cytokine TNF, often associated with 
inflammation, infection and autoimmune disorders (Dinarello, 1986). IL-1 has a role in many 
chronic, often systemic, inflammatory and auto-immune diseases such as RA, osteoarthritis 
(OA), Crohn’s disease (Braddock and Quinn, 2004), familial Mediterranean fever (Dinarello, 
2005) and some diseases of the central nervous system such as multiple sclerosis (Simi et al., 
2007). IL-1 has therefore been an attractive drug target for disease treatment (Braddock and 
Quinn, 2004). The most important drug to date is the soluble IL-1Ra, Kineret ® (Anakinra), 
which has been approved for use to treat RA.    
 
1.3.2 Interleukin-6 
 
IL-6 is a pleiotropic cytokine that has multifunctional roles in inflammation, the immune 
response, hematopoiesis, the endocrine system and the nervous system (Hirano, 1998). IL-6 
requires the IL-6 receptor (IL-6R) and the signal transducer gp130 (Taga et al., 1989). IL-6-/- 
mice exhibit severely compromised inflammatory acute phase response after tissue damage or 
infection (Kopf et al., 1994). IL-6-/- mice develop normally, however they fail to overcome 
infection with either Vaccinia virus, Listeria monocytogenes or vesicular stomatitis virus.  
 
1.3.3 Interleukin-8 
 
IL-8 (CXCL1) was a founding member of the chemokine superfamily. Inside the cell it is 
generated as a precursor and secreted after the cleavage of the signal peptide. It is released by 
phagocytes and a variety of other cell types in response to inflammatory stimuli such as IL-1 
(Kunkel et al., 1994). Once released, IL-8 acts as a potent chemoattractant for neutrophils. IL-8 
causes neutrophils to undergo calcium translocation, shape change, chemotaxis, actin 
polymerisation, exocytosis of storage proteins and may trigger the respiratory burst (Hoch et al., 
1996). IL-8 causes neutrophils to shed L-selectin and up-regulate the adhesion-promoting 
receptor CD11b/CD18 (CR3). 
 
1.3.4 Tumour necrosis factor  
 
The pleiotropic cytokine TNF is a member of a large family of proteins (Pasparakis et al., 
1996). TNF has a central role in immune and inflammatory processes including the induction of 
local inflammatory response to contain infections. However, TNF can also lead to systemic 
effects such as the acute-phase response, fever and septic shock (Dinarello, 1987). TNF has 
been implicated in many autoimmune diseases, for example overexpression of TNF has been 
reported in RA (Brennan et al., 1990) and Crohn’s disease (Papadakis and Targan, 2000). In 
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contrast underexpression of TNF has been reported in type I diabetes (Christen et al., 2001) and 
systemic lupus erythematosis (Kontoyiannis and Kollias, 2000). A murine model with TNF 
overexpression was generated by the deletion of its adenylate/uridylate-rich element in its 3′ 
untranslated region. These mice exhibit inflammatory arthritis and a Crohn’s-like inflammatory 
bowel disease as a result of increased TNF mRNA stability and TNF production (Kontoyiannis 
et al., 1999). The importance of TNF in autoimmune diseases has led to the development of 
anti-TNF as a therapeutic for RA and Crohn’s disease, for example the chimeric human-mouse 
anti-TNF monoclonal antibody cA2 (infliximab or Remicade). Anti-TNF therapies are delivered 
by subcutaneous injection and are expensive.  
 
1.3.5 Cyclooxygenase-2 
 
There are two isoforms of cyclooxygenase (COX), COX-1 and COX-2. These enzymes catalyse 
the first committed step in the conversion of arachidonic acid to prostaglandin (PG) H2 
(Langenbach et al., 1999). PGH2 can then be metabolised further into the biologically active 
prostaglandins, PGE2, PGI2 (prostacyclin), PGF2α, PGD2 and thromboxane A2. COX-1 is 
constitutively expressed in cells of most tissues and is considered to be the “housekeeping” 
isoform. In contrast COX-2 is not normally expressed in most tissues but is induced by 
mitogens, cytokines and certain other inflammatory agents.  
 
The main biological functions of COX-1 are thought to include platelet aggregation, renal water 
balance and gastric cytoprotection. The functions of COX-2 are thought to include platelet 
disaggregation, inflammation, vasodilation and bone resorption (Morita, 2002). It is thus 
thought that COX-2 is responsible for the upregulation of prostaglandins in response to 
inflammatory stimuli (Smith et al., 2000). Non-steroidal anti-inflammatory drugs (NSAIDs) 
pharmacologically target the COX isoforms and are a common therapeutic for chronic 
inflammatory disorders. NSAIDs can cause gastrointestinal side effects as a result of the 
inhibition of COX-1. COX-2 inhibitors have an increased risk of thrombosis and cardiovascular 
complications (Mitchell and Warner, 2006). 
 
PART 2 Inflammatory cell signalling 
 
1.4 The Interleukin receptor/ Toll-like receptor superfamily 
 
Toll-like receptors (TLRs) are pattern recognition receptors expressed on many cells. The first 
mammalian TLR to be identified was TLR4, cloned on the basis of its homology to Drosophila 
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protein Toll (Medzhitov et al., 1997). Other laboratories identified TLR4 as a result of trying to 
identify the single gene product that caused insensitivity to LPS (Poltorak et al., 1998). Since 
then ten other TLR homologues have been identified in mammals (Arancibia et al., 2007). TLRs 
are highly conserved transmembrane proteins that possess a Toll / IL-1R (TIR) domain and an 
extracellular domain with leucine-rich repeats (LRRs). The LRRs vary between each TLR and 
are responsible for the recognition of the TLR ligands. Examples of ligands include 
lipopolysaccharide (LPS) from Gram-negative bacteria (TLR4), lipoteichoic acid (TLR2), 
flagellin (TLR5) and single-stranded RNA (TLR7 and 8). Conditioned medium from RA 
cultures has been found to contain a potential TLR ligand (Sacre et al., 2007). Recently TLR8 
has been reported to be an important contributor to TNF production in RA (Sacre et al., 2008).  
It is thought that the inhibition of TLR8 would not interfere with signalling triggered by other 
TLRs or inhibit cytokine expression by other mechanisms.  Therefore it has been postulated that 
TLR8 would be a good new drug target in RA, with less side effects than anti-TNF therapy 
(Sacre et al., 2008). The IL-1R is also a homologue of the TLRs and contains the TIR domain. 
 
1.5 IL-1R and TLR signalling 
 
Cell signalling is triggered when a ligand binds a receptor for example IL-1 to the IL-1R. The 
IL-1 receptor can bind to IL-1α, IL-1β and IL-1Ra. The conservation of the cytoplasmic TIR 
domain in the IL-1R and TLRs ensure that many of the downstream signalling components of 
these receptors are shared. This thesis focuses on the signalling downstream of the IL-1R and 
therefore this is described here. However, there are 33 well-characterised members of the 
interleukin family, related to IL-1 (Arend et al., 2008), IL-34 (Lin et al., 2008) and IL-35 
(Collison and Vignali, 2008) have also been very recently discovered. The interleukin family 
members stimulate related signal transduction pathways, therefore it is likely that work to 
discover the importance of HSP27 in IL-1 signalling will have relevance for the regulation of 
signal transduction pathways downstream of the receptors of other interleukin family members 
and the toll-like receptor family.  
 
IL-1RAcP is required for downstream signalling (Greenfeder et al., 1995). Upon IL-1 binding, 
IL-1R and IL-1RAcP form a complex which recruits myeloid differentiation primary response 
gene 88 (MyD88) (Fig. 1) and a second accessory protein Toll-interacting protein (Tollip) 
(Burns et al., 2000). MyD88 contains a TIR domain and a death domain. The death domain on 
MyD88 interacts with the death domain on the Ser / Thr kinases termed IL-1 receptor associated 
kinases (IRAK) 1 and IRAK4. IRAK4 is the protein kinase responsible for the phosphorylation 
of IRAK1 (Lye et al., 2004). The kinase activity of IRAK1 is not required for signalling (Vig et 
al., 1999). Phosphorylated IRAK1 is released from the receptor complex (Fig. 1). 
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Phosphorylated IRAK1 then recruits and binds to TNF receptor associated factor (TRAF) 6, 
which forms homooligomers (Cao et al., 1996).  
 
TRAF proteins are E3 ubiquitin ligases through their N-terminal RING domain. TRAF6 
oligomerisation is thought to activate its ligase activity (Chen, 2005). The RING domain 
contains zinc fingers (Aravind et al., 2003; Rothe et al., 1994). TRAF6, with the aid of the E2 
heterodimeric ubiquitin conjugating enzyme (Ubc13) / ubiquitin-conjugating enzyme variant 
human 1A (Uev1A) complex, catalyzes the formation of lysine 63 (Lys63)-linked polyubiquitin 
chains on TRAF6 (Fig. 1). Lys63 polyubiquitin chains form very different configurations 
compared to the Lys48 polyubiquitin chains that target proteins for proteasomal degradation 
(Varadan et al., 2004). The Lys63 polyubiquitin chain is thought to act as a scaffold to recruit 
downstream signalling proteins, including the MAPK kinase kinase (MKKK), TAK1. The 
MKKKs and downstream kinase cascade will be discussed in more detail later. 
 
Recently IRAK1 and IRAK4 have been reported to phosphorylate Pellino isoforms. This 
activates the E3 ubiquitin-ligase activity of Pellino and together with Ubc13-Uev1A Pellino can 
catalyse the formation of Lys63-linked polyubiquitin chains on IRAK1 (Ordureau et al., 2008). 
This polyubiquitination of IRAK1 has been proposed to act as a scaffold for the recruitment of 
the IκB kinase (IKK) complex through IKKγ (Windheim et al., 2008). As IRAK1 and TRAF6 
interact this brings TAK1 and the IKK complex into close proximity, facilitating the 
phosphorylation and activation of the IKK complex by TAK1.  
 
1.6 TNF-induced cell signalling  
 
TNF can bind to two receptors termed TNF receptor (TNFR)-1 (p55) and -2 (p75) (Idriss and 
Naismith, 2000). TNFR-1 is the receptor which is most important in signalling to nuclear factor-
kappaB (NF-κB) and in the production of IL-6 (Yamada et al., 1998). TNFR-1 exists as a 
monomer in the cell membrane. It is activated by forming a trimer on binding TNF, which is a 
trimer (Fig. 1.1). This leads to the recruitment of the TNFR associated death domain protein 
(TRADD), which, as its name suggests, contains a death domain. Signalling through the TNF 
receptor can transduce apoptotic, inflammatory and survival signals (Sheikh and Huang, 2003). 
The apoptotic and inflammatory pathways diverge at the next proteins recruited to the receptor 
complex. The binding of Fas-associated death domain protein (FADD) to TRADD through their 
death domains leads to apoptotic signalling through caspase 8. The recruitment of the 
intracellular adaptor proteins TRAF2 and TRAF5 to the receptor complex mediates the 
inflammatory response and provides survival signals (Chung et al., 2002) (Fig. 1). Receptor 
interacting protein (Rip)1 is also recruited to TRADD (Hsu et al., 1996) and is ubiquitinated by 
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Figure 1.1: IL-1 and TNF signalling pathways. IL-1 and TNF signalling occurs through 
different plasma membrane receptors. However, the signalling pathways converge at the level of 
the MKKKs, most notably TAK1. 
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TRAF2 (Lee et al., 2004). TAB2 can bind to the Lys63-linked polyubiquitin chains on Rip1 
(Kanayama et al., 2004), leading to the activation of TAK1. 
 
1.7 MKKKs 
 
MKKKs are serine/ threonine protein kinases that phosphorylate and activate the downstream 
MAPK kinases (MKKs). A large variety of candidate MKKKs have been identified and there is 
some controversy over which MKKKs are important in pro-inflammatory signalling. 
 
1.7.1 TAK1 
 
TAK1 is the most widely cited MKKK in the literature for activation of the MAPK cascades in 
response to pro-inflammatory stimuli. TAK1 was identified as important in the TGF-β signal 
transduction pathway (Yamaguchi et al., 1995). TAK1 (Map3K7 gene) knockout mice are early 
embryonic lethal and therefore TAK1-/- mouse embryonic fibroblasts (MEFs) were generated 
(Shim et al., 2005). Experiments using TAK1-/- MEFs have shown that TAK1 is essential for 
JNK and NF-κB signalling in response to TNFα and IL-1β (Shim et al., 2005). Overexpression 
of TAK1 with TAK1 binding protein (TAB)1 in HeLa cells activated NF-κB, JNK and p38 
MAPK pathways and led to the expression of IL-8 from a reporter construct (Holtmann et al., 
2001). TAK1 phosphorylates MKK3, MKK4 and MKK6 (Moriguchi et al., 1996a; Shirakabe et 
al., 1997). TAK1 can also activate MKK7 (Hammaker et al., 2007; Zhou et al., 1999).   
 
TAK1 forms a constitutive complex with TAB1 and binds to TAB2 / TAB3 in response to cell 
stimulation. TAB1 is a pseudophosphatase (Conner et al., 2006), which is critical for the 
activation of TAK1 because TAK1 could not be activated in TAB1-/- MEFs in response to IL-1 
or TNF (Mendoza et al., 2008). Ectopically expressed TAK1, co-expressed with TAB1 becomes 
autophosphorylated (Kishimoto et al., 2000). IL-1 induces the translocation of TAB2 from the 
membrane to the cytosol where it binds to TAK1 and TRAF6 (Takaesu et al., 2000; Takaesu et 
al., 2001). A functional interaction between TAK1 and TAB2/3 is required for TAK1-dependent 
signalling (Besse et al., 2007; Wang et al., 2001). It is thought that the FP motif in the CUE 
domain of TAB2/3 allows the proteins to bind to polyubiquitinated TRAF6 (Kishida et al., 
2005). The polyubiquitinated TRAF6 is able to act as a scaffold to which multiple TAK1 
complexes can bind through TAB2/3 (Kanayama et al., 2004). TAB2 and TAB3 are thought to 
be partially redundant. The proximity of the multiple TAK1 complexes is thought to allow 
TAK1 subunits to cross-phosphorylate residues including Thr187 (Singhirunnusorn et al., 2005) 
in the activation loop, leading to the activation of TAK1 and downstream signalling. 
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Overexpressed TAK1 has been shown to be polyubiquitinated and TAB1 monoubiquitinated in 
response to IL-1, however the functions of these ubiquitinations are unknown (Thiefes et al., 
2006).  
 
Surprisingly, TAK1-/-, TAB1-/- and TAB2-/- mice have very different phenotypes. TAK1-/- 
embryos have neural fold dysmorphogenesis and begin to die around E10. TAB1-/- embryos 
have cardiovascular and lung dysmorphogenesis and are embryonic lethal at late stages of 
gestation (Komatsu et al., 2002). TAB2-/- mice had embryonic lethality about E12.5 due to liver 
degeneration and apoptosis (Sanjo et al., 2003). Although work in TAK1-/- MEFs suggested an 
important role for TAK1 in JNK and NF-κB signalling there have been several reports that this 
is not the case for TAB1-/- (Mendoza et al., 2008; Shim et al., 2005) or TAB2-/- mice (Sanjo et 
al., 2003; Shim et al., 2005). It may be that TAB2 and its homologue TAB3 are redundant. 
However, the role of TAB1 in inflammatory signalling is still controversial because the original 
paper using TAB1-/- MEFs found that TAB1 was essential for TAK1 phosphorylation of MKK6 
and important for TGF-β signalling (Komatsu et al., 2002). 
 
TAB1 has also been reported to cause p38 MAPK activation independently of TAK1 and 
MKK3 (Ge et al., 2002). This is through the autophosphorylation of p38 MAPK. The splice 
variant TAB1beta is only able to interact with p38 MAPK alpha but not TAK1 (Ge et al., 2003). 
The importance of this mechanism of p38 MAPK activation is unclear. 
 
Another protein has recently been identified as a possible TAB, type 2A phosphatase-interacting 
protein, TIP (TAB4) (Prickett et al., 2008). TAB4 was found to co-precipitate with TAK1 and 
stimulate TAK1 phosphorylation in the linker region, above the levels induced by TAB1. TAB4 
was shown to have an FP sequence motif like TAB2 / TAB3 that can bind to polyubiquitin 
chains. 
 
1.7.2 Other MKKKs 
 
It is possible that different MKKKs could contribute to the downstream activation of the three 
MAPK cascades and NF-κB to different extents dependent upon which cell type or stimuli is 
used. Other MKKKs that could be involved include mitogens ERK kinase kinase (MEKK)1-4, 
apoptosis signal-regulating kinase 1(ASK1), p21-activated protein kinase (PAK)1/2, mixed 
lineage kinases (MLKs), NF-κB-inducing kinase (NIK) and tumour progression locus 2 (TPL-2 
/ COT).  
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The MEKK family consists of four kinases with conserved catalytic domains and variable N-
terminal regions; MEKK1-4 (Hagemann and Blank, 2001). MEKK1 is usually considered the 
MKKK primarily responsible for the activation of ERK. However, in embryonic stem cells 
MEKK1 has been reported to be responsible for IL-1- and TNF-induced JNK activation (Xia et 
al., 2000) in cells expressing a MEKK1-β-galactosidase fusion protein with the entirety of the 
kinase domain missing. There could however, be the potential that the rest of the MEKK1 
protein was sufficient to interfere with the function of a potential other MKKKs. MEKK1 can 
bind to MKK4. MEKK1 is thought to link to signalling through TRAF6 through the 
evolutionarily conserved signalling intermediate in Toll pathways (ECSIT) (Kopp et al., 1999). 
Interaction of ECSIT with TRAF6 and MEKK1 leads to the cleavage of MEKK1 and the 
release of active MEKK1, which can then lead to the downstream activation of activator protein 
1 (AP-1) and NF-κB (Kopp et al., 1999). Cheng et al., suggest that MEKK2 is responsible for 
the phosphorylation and activation of JNK through MKK7 (Cheng et al., 2000). This was 
examined by co-transfecting the kinases into COS-1 cells. MEKK3 has been reported to have a 
critical role in TNF signalling to NF-κB (Yang et al., 2001). MEKK3 (Map3K3 gene) knockout 
mice are embryonic lethal at E10.5 - 11.0 with disrupted blood vessel development and defects 
of the structural integrity of the yolk sac (Yang et al., 2000). Yang et al., conclude that MEKK3 
must be intrinsically important in endothelial cells because there is a defect in embryonic not 
maternal blood vessel development in the placentas of the MEKK3-/- embryos. An interaction 
was found between TAK1 and MEKK3 by tandem affinity purification (Di et al., 2008). The 
MEKK3-TAK1 complex consists of non-phosphorylated forms of the two proteins. TAK1 
binding to MEKK3 interfered with the phosphorylation of MEKK3. In the presence of TAB1, 
TAK1 was able to autophosphorylate and this reversed the inhibitory effects upon MEKK3 
phosphorylation in human 293 cells and TAK1-/- MEFs (Di et al., 2008). In contrast to MEKK1, 
2 and 3, MEKK4 has been shown to activate only the JNK pathway (Gerwins et al., 1997).  
 
ASK1 has been implicated in TNF activation of JNK (Nishitoh et al., 1998). Overexpression of 
TRAF2, 5 or 6 was found to activate HA-tagged ASK1. A truncated derivative of TRAF2 
shown to inhibit TNF-induced JNK activation also inhibits ASK1 activation in 293 cells. ASK1 
was found to bind to TAK1 and interfere with the TRAF6-TAK1 interaction, hence inhibiting 
IL-1-, TRAF6- or TAK1-induced NF-κB activity but not NIK-induced activity (Mochida et al., 
2000).  
 
PAK1 / PAK2 are MKKKs that can phosphorylate and activate MKK3 / MKK6 and hence p38 
MAPK in response to stimuli going through small GTPases of the Rho family such as Rac and 
CDC42. RNA interference (RNAi) to deplete cells of PAK1 / PAK2 has been found to block the 
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activation of p38α MAPK and HeLa cell migration in response to stromal cell derived factor 1 
(CXCL12) (Rousseau et al., 2006). They found that p38α MAPK activation mediated cell 
migration in response to the chemo-attractants; platelet-derived growth factor (PDGF-BB), 
hepatocyte growth factor (HGF), CXCL12 and complement factor 5a (C5a). Depletion of 
HSP27 by RNAi blocked C5a induced cell migration and thus they infer that the p38 MAPK 
mediated cell migration was mediated by HSP27. CXCL12- and C5a-induced cell migration is 
critical for many processes including inflammation. 
 
A further family of MKKKs that have been implicated in the activation of MAPKs is the MLKs. 
There are currently seven known mammalian members of this family, of which probably MLK3 
is the most characterised. All of the MLKs have been shown to activate JNK (Gallo and 
Johnson, 2002). The importance of the various MLKs for the activation of JNK and the other 
MAPK cascades in response to different stimuli and cell types has not been fully elucidated. 
However, MLK3 has been shown to activate NF-κB in response to T-cell co-stimulation but not 
TNF or IL-1 (Hehner et al., 2000). There are no reports of MLKs as key components in IL-1 
signalling. 
 
Cells that express a kinase deficient mutant of NIK have been reported to fail to activate NF-
κB-mediated transcription in response to IL-1, TNF, TRADD, Rip or MORT1/FADD (Malinin 
et al., 1997). It has been proposed that the activation of NF-κB by IL-1 stimulation may be 
partially dependent upon hydrogen peroxide-induced activation of NIK leading to the 
phosphorylation and activation of IκB kinase (IKK)α (Li and Engelhardt, 2006). However, NIK 
is thought to only activate NF-κB through the IKK complex and not lead to the activation of the 
MAPK, JNK (Song et al., 1997).  
 
TPL-2 / Cot-/- MEFs exhibit defective ERK, JNK and NF-κB signalling in response to 
stimulation with TNF (Das et al., 2005). However, TPL2-/- MEFs only show defects in ERK 
activation in response to IL-1, indicating that it is not important in the activation of other 
MAPKs or NF-κB in response to IL-1 stimulation (Das et al., 2005).  
 
1.8 MKKs 
 
MKKs are phosphorylated and activated by the MKKKs mentioned above. MKKs are dual-
specificity protein kinases, which can phosphorylate MAPKs at their Thr-Xxx-Tyr motif in the 
activation loop. MAPK ERK kinase (MEK)1 / 2 has been shown to activate ERK 1 / 2, MEK5 
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to activate ERK5, MKK4 / MKK7 to activate JNK1 / JNK2 and MKK3 / MKK6 to activate p38 
MAPK  (Chang and Karin, 2001). 
 
1.8.1 MKK3 and MKK6 
 
Two MKKs are believed to be the direct activators of the p38 MAPK isoforms; MKK3 and 
MKK6. However, although these kinases have been known for some time it is still controversial 
which MKK or both is principally responsible for this activity in vivo. It may be that this 
depends upon the cell type and stimuli used. MKK3 has been reported to selectively activate 
p38α MAPK and p38γ MAPK, whereas MKK6 is a common activator of p38α, p38β2 and p38γ 
MAPK isoforms in COS-7 cells (Enslen et al., 1998). In response to osmotic shock MKK6 has 
been reported to be the most important activator of p38 MAPK (Moriguchi et al., 1996b). 
MKK4 has also been demonstrated to possess the ability to phosphorylate p38 MAPK in vitro 
(Derijard et al., 1995), however it is widely thought to be more important as an activator of JNK 
(Brancho et al., 2003). 
 
MKK3-/- and MKK6-/- mice are viable and exhibit no obvious morphological defects (Tanaka et 
al., 2002; Wysk et al., 1999). However, MKK3-/- MKK6-/- compound knockout mice die during 
mid-gestation at embryonic day 11.0-11.5 (Brancho et al., 2003). These mice have delayed 
development, severe anoxia and resemble the p38 MAPK-/- mice (Adams et al., 2000). This 
suggests that MKK3 and MKK6 selectively activate p38 MAPK and serve redundant, essential 
roles for survival. p38 MAPK signalling in response to UV radiation, osmotic shock and IL-1 is 
not affected (although osmotic shock caused by sorbitol appeared to increase p38 MAPK 
activity) in the MKK3-/- MEFs. In contrast, TNF-induced activation of p38 MAPK was 
substantially reduced in the MKK3-/- MEFs (Wysk et al., 1999) and completely abolished in 
MKK3-/- MKK6-/- MEFs (Brancho et al., 2003). JNK activation was unaffected in MKK3-/- mice 
compared to wild type mice in response to any of the stimuli. Work in MKK3-/- mice has shown 
that LPS-induced IL-1 and IL-6 production was unaffected however, TNF-induced IL-1 and IL-
6 production was ablated (Inoue et al., 2006). This has lead to the speculation that MKK3 could 
prove to be a more selective drug target than p38 MAPK in disease models such as RA 
(Thalhamer et al., 2008). 
 
1.8.2 MKK4 and MKK7 
 
JNK is phosphorylated and activated synergistically by MKK4 and MKK7. MKK4 
preferentially phosphorylates the Tyr of the Thr-Pro-Tyr motif and MKK7 preferentially 
phosphorylates the Thr (Lawler et al., 1998). MKK7 is more distantly related to the highly 
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homologous MKK4 (48 % sequence identity), MKK3 (39 % sequence identity) and MKK6 (41 
% sequence identity) (Lawler et al., 1997). The gene encoding murine MKK7 has 14 exons and 
six MKK7 isoforms can be produced by alternative splicing (Tournier et al., 1999). MKK4 and 
MKK7 are believed to be distributed in both the cytoplasm and the nucleus and this localisation 
is not altered by stimulation of cells with IL-1α or UV-C radiation (Tournier et al., 1999). 
 
1.9 Mitogen activated protein kinases (MAPKs) 
 
There are three parallel MAPK pathways in the cell (Fig. 1.2), which mediate the changes in 
gene expression in response to extracellular signals. The classical MAPK, ERK, was the first 
MAPK to be discovered and is activated in response to mitogens. p38 MAPK and JNK, known 
as stress-activated protein kinases (SAPKs), are activated in response to pro-inflammatory or 
stress stimuli (Clerk et al., 1998; Johnson and Lapadat, 2002). The three MAPKs are activated 
by dual phosphorylation on Thr and Tyr within the motif Thr-Xaa-Tyr (Derijard et al., 1995). 
For ERK the central amino acid of the motif is glutamate, for p38 MAPK family it is glycine 
and for the JNK family it is proline. 
 
1.9.1 p38 MAPK  
 
The p38 MAPK pathway is important in several cellular processes including cell growth, 
differentiation, apoptosis and immune cell activation. p38 MAPK was discovered by several 
different laboratories independently at a similar time. p38 MAPK was identified as the IL-1-
induced protein kinase responsible for the phosphorylation of p50 upon threonine and some 
serine residues. p50 was found to be MK2. MK2 in turn phosphorylated HSP27 upon serine 
(Freshney et al., 1994). p38 MAPK was also identified as the kinase tyrosine phosphorylated in 
response to LPS stimulation (Han et al., 1994). In another study p38 MAPK was the protein 
responsible for the kinase activity that phosphorylated MK2 in response to sodium arsenite, heat 
shock and osmotic stress (Rouse et al., 1994). p38 MAPK was also identified as a target for a 
class of pyridinyl-imidazole compounds, known as cytokine-suppressive anti-inflammatory 
drugs (CSAIDs). These CSAIDs inhibited the expression of IL-1 and TNF in LPS-stimulated 
monocytes (Lee et al., 1994). 
 
Four isoforms of p38 MAPK have been identified; p38α p38β, p38γ and p38δ, which share 60-
70 % sequence identity. Only p38α MAPK and p38β MAPK are inhibited by the pyridinyl-
imidazole drugs, which bind in the ATP-binding pocket. p38α MAPK is thought to be 
ubiquitously expressed and abundant in placenta, brain (cerebellum) and lymphoid tissues.  
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Figure 1.2: Overview of IL-1 and TNF signalling downstream of the MKKK, TAK1. 
TAK1 can activate three main pathways downstream of IL-1 and TNF; JNK, p38 MAPK and 
NF-κB. This leads to the up-regulation of pro-inflammatory mediators through regulation of 
transcription, mRNA stability and translation.  
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p38β is most abundantly found in brain tissues, p38γ has restricted expression and is found 
principally in skeletal muscle and p38δ MAPK is found in the salivary gland, pituitary gland 
and adrenal gland (Wang et al., 1997). There appears to be some differences in the role, 
importance and substrates of the different p38 MAPK isoforms. Knockout of p38α MAPK is 
embryonic lethal in midgestation due to a placental defect (Adams et al., 2000). Studies in p38α 
MAPK-/- mice highlight the importance of p38α MAPK as a kinase for MK2 and as a key 
mediator of IL-1 signal transduction but not apoptosis (Allen et al., 2000). A conditional 
knockout of p38α MAPK in macrophages found a significant inhibition of LPS-induced TNF, 
IL-12 and IL-18 (Kang et al., 2008). However, surprisingly the p38α MAPK conditional 
knockout macrophages had no effect on the LPS-induced production of IL-6 (Kang et al., 2008), 
previously shown to be dependent on p38 MAPK through inhibitor studies (Chae et al., 2001), 
which may be cell-type specific. The p38β MAPK-/- mice are viable with no apparent health 
problems (Beardmore et al., 2005). The activation of p38 MAPK substrates MK2 and MSK1 
was normal in p38β MAPK-/- mice, as was the serum level of LPS-induced inflammatory 
cytokines (Beardmore et al., 2005). The findings from the knockout mice indicate that p38α 
MAPK, not p38β MAPK is the major isoform in the immune response. 
 
p38 MAPK is activated by a variety of stimuli including pro-inflammatory cytokines such as 
IL-1 and TNF and environmental stresses such as UV light, osmotic stress and heat shock 
(Freshney et al., 1994; Han et al., 1994; Rouse et al., 1994). The activation of p38 MAPK 
depends upon the cell type as well as the stimulus. p38 MAPK is thought to be nuclear. Its 
activators MKK3 and MKK6 are believed to be present in both the cytoplasm and the nucleus. 
p38 MAPK itself does not contain a nuclear localisation sequence or nuclear export sequence. 
MK2 has a nuclear localisation sequence which is required for activation in response to a wide 
range of stimuli. Phosphorylation of MK2 by p38 MAPK unveils a nuclear export signal in its 
C-terminus (Engel et al., 1998) that triggers the export of MK2 in a complex with p38 MAPK 
into the cytoplasm (Ben-Levy et al., 1998). The export of the complex requires p38 MAPK 
phosphorylation but not MK2 activity. These experiments were performed using indirect 
immunofluorescence in 293T cells. The p38 MAPK substrate, MK5 (PRAK), has also been 
shown to act as a chaperone for p38α MAPK into the nucleus (Li et al., 2008; New et al., 2003) 
in the murine embryonic fibroblast cell line, NIH 3T3 cells. TAB1, which can lead to p38 
MAPK autophosphorylation and activation in the absence of TAK1, has also been found to bind 
to p38 MAPK and exclude it from the nucleus (Lu et al., 2006).  
 
p38 MAPKs have a variety of substrates, some of which have been mentioned above. These 
include the kinases, MAPK-activated protein kinase (MK)2 (Stokoe et al., 1992a), MK3 
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(Sithanandam et al., 1996), MK5 (New et al., 1998), MAPK-interacting kinase (MNK)1, MNK2 
(Waskiewicz et al., 1997), mitogen- and stress-activated kinase (MSK)1 and MSK2 (Deak et al., 
1998). A brief summary of these kinases is included in this section and the importance of p38 
MAPK activation in inflammation through the activation of this substrate is discussed later.  
 
The generation of MK2-/- MEFs uncovered a role of MK2 in the stabilisation of p38 MAPK 
through its C-terminus in a manner independent of the activity of MK2 (Kotlyarov et al., 2002). 
MK2 is also the kinase responsible for the phosphorylation of HSP27 and a protein termed 
tristetraprolin (TTP). MK3 has some redundancy with MK2 (McLaughlin et al., 1996). MK2-/- 
mice showed an impaired inflammatory response. MK2-/- mice challenged with Listeria 
monocytogenes exhibited an increase in bacterial load associated with an attenuation in TNF 
production (Lehner et al., 2002). Spleen cells from MK2-/- mice had interferon (IFN)-γ synthesis 
after stimulation with Listeria monocytogenes (Lehner et al., 2002). The half-life of IL-6 is 
reduced more than 10-fold in MK2-deficient macrophages (Neininger et al., 2002). MK3-/- mice 
had no defect in the production of inflammatory cytokines or IL-6 stability (Ronkina et al., 
2007). In wild type cells MK3 was expressed at much lower levels and displayed reduced 
kinase activity compared to MK2 (Ronkina et al., 2007). MK2 / MK3 double knockout mice are 
viable however, they do exhibit a further decrease in TNF production and the expression of p38 
MAPK and TTP compared to the MK2-/-mice. MK5 had previously been identified as a kinase 
that could phosphorylate HSP27 (New et al., 1998), however, this has proven not to be 
reproducible (Shi et al., 2003). The MK5-/- mice were viable, fertile with no abnormalities in 
tissue morphology or behaviour (Shi et al., 2003). Spleen cells from MK5-/- show no defect in 
LPS-induced synthesis of TNF, IL-6 or IFN-γ, in contrast to the MK2-/- mouse cells. This 
indicates that MK2 is the more important kinase for this function. 
 
MNK1 and MNK2 are essential for the phosphorylation of eukaryotic translation initiation 
factor 4E (eIF4E) in embryonic fibroblasts and adult tissues (Ueda et al., 2004). However, the 
role of this phosphorylation is unclear. MNK1-/- and MNK2-/- mice are viable, fertile and show 
no defect in translation (Ueda et al., 2004). The phosphorylation of heterogeneous nuclear 
ribonucleoprotein A1 (hnRNPA1) by MNKs has been proposed to have a role in TNF 
translation (Buxade et al., 2005). 
 
MSK1 and MSK2 have been shown to have important roles in transcription, discussed later. 
Studies in MSK1-/- and MSK2-/- mice show that these kinases are required for the 
phosphorylation of the transcription factors Ca2+/cyclic adenosine monophosphate response 
element binding protein (CREB) and activating transcription factor (ATF)-1 (Wiggin et al., 
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2002) and the phosphorylation of histone H3 and high mobility-group protein HMG-14 
(Soloaga et al., 2003). The CREB phosphorylation was shown to be required for the full 
induction of c-Fos and junB in response to UV-C radiation and anisomycin. MSK1 has also 
been proposed to phosphorylate the p65 subunit of NF-κB at Ser 276, leading to the selective 
activation of NF-κB-dependent gene expression (Vermeulen et al., 2003). 
 
1.9.2 JNK 
 
The JNKs are SAPKs activated in response to pro-inflammatory stimuli such as IL-1, TNF and 
LPS and environmental stresses, for example UV radiation. JNK is expressed from three genes; 
JNK1, JNK2 and JNK3. JNK1 and JNK2 are expressed ubiquitously, however, JNK3 has 
limited tissue expression that is largely confined to brain, testis and heart. Alternative splicing 
of these genes produces 10 or more JNK isoforms (Gupta et al., 1996). JNK1, 2 and 3 are 85 % 
identical within their core catalytic domains (Pearson et al., 2001). The three genes have been 
deleted from mice by homologous recombination and the JNK-deficient mice are viable but 
have defects in apoptosis and immune responses. Less is known about the potential role of JNK 
in inflammation because of the lack of specific inhibitors, in contrast to p38 MAPK. However, 
JNK activates transcription factors that are involved in the inflammatory response, for example 
Elk1 and potential components of AP-1 (c-Jun, JunB, JunD and ATF-2) (Davis, 2000), as 
discussed below.  
 
1.9.3 ERK 
 
Extracellular signal-regulated kinase (ERK) was the first MAPK identified and is known as the 
classical MAPK. There are many isoforms of ERK, however, only ERK1, ERK2 and ERK5 
(big MAPK 1) are conventional MAPK that are activated by MKKs. The most potent stimuli of 
ERK are mitogens and in response to these ERK is activated through the Ras-Raf-MEKK-MEK 
pathway. Originally ERK1 and ERK2 were believed to be most important in cell proliferation, 
however, more recently ERK1 and ERK2 signalling has also been implicated in inflammatory 
and immune responses (Dumitru et al., 2000; Eliopoulos et al., 2002). ERK may be 
phosphorylated and activated by inflammatory stimuli such as IL-1 in many cell types. 
However, the mechanism of IL-1-induced activation of ERK is likely to not involve TAK1 and 
is therefore different to that of p38 MAPK and JNK.  
 
The ERK kinase MEK may be activated by the MKKK, TPL-2 (Beinke et al., 2004). TPL-2 is 
found in a complex with p105, an inhibitor of NF-κB, in resting cells (macrophages) (Beinke et 
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al., 2003; Belich et al., 1999). In this complex TPL-2 is stabilised but prevented from 
phosphorylating and activating MEK. However, upon LPS stimulation p105 is phosphorylated 
at two serine residues, polyubiquitinated and digested by the proteasome (Beinke et al., 2004). 
This also leads to the release of TPL-2, which can then phosphorylate and activate MEK, which 
in turn can phosphorylate and activate ERK (Beinke et al., 2004). LPS-induced TNFα and 
COX-2 production was substantially reduced in TPL-2-deficient macrophages due to a lack of 
ERK1/2 activation (Dumitru et al., 2000; Eliopoulos et al., 2002). In the case of TNF this is due 
to defective transport of TNF mRNA from the nucleus to the cytoplasm (Dumitru et al., 2000). 
In contrast, for COX-2 the inhibition is due to a reduction in CREB phosphorylation (Eliopoulos 
et al., 2002).  
 
ERK1 and ERK2 have been reported to phosphorylate and activate certain substrates shared 
with p38 MAPK including MNK1, MNK2 (Waskiewicz et al., 1997), MSK1 (Deak et al., 1998; 
Eliopoulos et al., 2002), as well as other substrates such as p90 ribosomal S6 kinase isozymes 
(Smith et al., 1999). Therefore ERK1 and ERK2 may have a similar function to p38 MAPK in 
the regulation of the transcription, translation and stability of pro-inflammatory mediators. As 
ERK is less strongly activated by pro-inflammatory cytokines, such as IL-1, than p38 MAPK, it 
is believed not to be as important as p38 MAPK in these systems. ERK has been shown to 
phosphorylate and activate MK2 in vitro (Coxon et al., 2003). However, the action of pyridinyl 
imidazole compounds such as SB203580 at concentrations specific for the inhibition of p38 
MAPKα/β isoforms showed that activation of MK2 is mainly dependent on p38 MAPK (Clifton 
et al., 1996). 
 
ERK5 was initially reported to be the member of the ERK family activated by stress stimuli 
including oxidative stress and hyperosmolarity (Abe et al., 1996). ERK5 can also phosphorylate 
some of the same substrates as ERK1 and ERK2 including Sap1a, c-Myc and ribosomal S6 
kinase (Rsk), although the latter is controversial (Nishimoto and Nishida, 2006). ERK5 can also 
induce intermediate-early genes such as c-Jun and c-Fos as well (Kato et al., 1997). However, 
there has been no documented evidence of a role of ERK5 in IL-1 signalling. 
 
1.10 NF-κB 
 
The NF-κB family of transcription factors are also activated downstream of a wide variety of 
pro-inflammatory stimuli including IL-1 that also activate p38 MAPK and JNK (Fig. 1.2). In 
resting cells NF-κB is held in the cytoplasm by a family of inhibitors of NF-κB termed IκBs, of 
which the most important is IκBα. The activation of NF-κB downstream of IL-1 is through the 
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canonical pathway, which involves an IKK complex consisting of IKKα, IKKβ and IKKγ 
(NEMO) (Li et al., 1999). TAK1 can directly phosphorylate the activation loop serine residues 
on IKKβ and activate the IKK complex (Wang et al., 2001). The canonical pathway involves 
the IKKβ and NEMO-dependent degradation of the IκB proteins. This results in the release and 
translocation to the nucleus of mostly RelA containing-heterodimeric NF-κB (Scheidereit, 
2006).  
 
NF-κB can also be activated via the non-canonical pathway. This pathway has slower kinetics, 
takes place over several hours rather than minutes, usually results in long-lasting NF-κB 
activation and is sensitive to ribosomal inhibition (Scheidereit, 2006). The non-canonical 
pathway is activated by a limited number of stimuli including 12 members of the TRAF-binding 
receptors of the TNF superfamily including CD40 and receptor activator of NF-κB (RANK) 
(Hauer et al., 2005) and LPS (Mordmuller et al., 2003). In the non-canonical pathway NIK 
phosphorylates IKKα (Xiao et al., 2001). Active IKKα phosphorylates p100 and promotes C-
terminal processing to produce p52. The NF-κB dimers generated by this pathway are p52-
containing complexes, usually p52/RelB (Scheidereit, 2006). The inducers of the non-canonical 
pathway also stimulate the canonical pathway and the two pathways are linked because the 
canonical pathway is required to drive the production of p100 and RelB (Scheidereit, 2006).  
 
Part 3: Inflammatory gene regulation by the MAPKs and NF-κB 
 
1.11 Transcriptional regulation 
 
The expression of pro-inflammatory mediators usually involves a burst in transcription in 
response to an inflammatory stimulus. The promoters of the inflammatory genes contain 
indispensable cis-elements for several trans-activating factors. The most common sites are for 
NF-κB, AP-1, CAAT/enhancer-binding proteins (C/EBP) and Ets. 
 
A wide range of pro-inflammatory mediators require NF-κB to bind to sites in their promoters 
for transcription to be initiated, for example TNF and COX-2 (Smith et al., 2000). Transfection 
experiments with reporter plasmids found that mutations in the cis-acting regulatory sequences 
attenuate the transcription of COX-2 after stimulation of cells with TNF (Yamamoto et al., 
1995). NF-κB is important in the transcription of adhesion molecules on leucocytes and 
endothelial cells, which allows the extravasation of leucocytes from the circulation to the site of 
infection (Eck et al., 1993). RelA-deficient mice have a severe defect in the recruitment of 
leucocytes to the site of inflammation (Alcamo et al., 2001). NF-κB is also required for the 
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expression of matrix metalloproteinases (MMPs), which are important mediators of local 
inflammation and leucocytes chemotaxis (Hayden et al., 2006). p38 MAPK and ERK may 
control the transactivation of NF-κB at the transcriptional level (Vanden Berghe et al., 1998).  
 
The AP-1 family of transcription factors consist of homo- and hetero-dimers that may contain c-
Jun, JunD, JunB, ATF-2, c-Fos, Fra-1 and Fra-2. ATF-2 possesses histone acetyltransferase 
activity that is controlled by phosphorylation. Phosphorylation enhanced its histone 
acetyltransferase activity and cyclic AMP response element (CRE)-dependent transcription 
(Kawasaki et al., 2000). Expression of c-Fos and c-Jun may be p38 MAPK-dependent. Fra-1, 
Fra-2 and JunB are ERK-dependent. JNK can phosphorylate ATF-2 and c-Jun and hence 
enhance their trans-activation activity and stability (Han et al., 2001; Kallunki et al., 1994). 
Treatment of cells with the JNK inhibitor SP600125 blocked the induction of c-Jun transcription 
in synoviocytes and completely suppressed AP-1 binding and collagenase mRNA accumulation 
in fibroblast-like synoviocytes (Han et al., 2001). However, subsequent work has found that 
SP600125 is not a specific inhibitor of JNK, which casts the previous results into doubt (Bain et 
al., 2003). The accumulation of collagenase mRNA can lead to joint destruction in RA. It is 
thought that pathways involving the phosphorylation and trans-activation of c-Fos and Fra-1/2 
may involve ERK. p38 MAPK has also been recently reported to cause c-Jun, FosB, c-Fos and 
JunB phosphorylation downstream of protein kinase C in T-lymphocytes (Humar et al., 2007). 
 
C/EBPα-ζ are leucine zipper transcription factors that contribute significantly to the expression 
of acute-phase proteins, chemokines and COX-2 (Kracht and Saklatvala, 2002). The p38 MAPK 
inhibitor, SB203580 inhibits the transactivation of C/EBP (Baldassare et al., 1999). CREB-
homologous protein (CHOP) is a member of the C/EBP family that has been shown to be a 
substrate of p38 MAPK (Wang and Ron, 1996). p38α MAPK conditional knockout 
macrophages also had significantly inhibited C/EBP-β activation (Kang et al., 2008). Ets-
domain transcription factors bind to the Ets DNA-binding domain and comprise a large family 
of proteins. Elk-1 and Ets-1 have been shown to bind and promote transcription of the TNFα 
gene (Tsai et al., 2000). Elk-1 and SAP1 form ternary complexes with serum-response factor 
(Whitmarsh et al., 1995) and bind to the serum-response element (SRE) on c-Fos (Ray et al., 
1989) and JunB (Perez-Albuerne et al., 1993). There is also a serum-response element in the 
promoter of IL-6. ERK, JNK and p38 MAPK have been shown to activate Elk1 whereas ERK 
and p38 MAPK but not JNK activate SAP1 (Whitmarsh et al., 1997).  
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1.12 mRNA stabilisation by p38 MAPK 
 
Many proteins involved in the inflammatory response are encoded by short-lived mRNAs. 
Activation of the p38 MAPK pathway by pro-inflammatory stimuli such as IL-1 or TNFα 
stabilises the short-lived inflammatory mRNAs. Stabilisation of these mRNAs increases their 
abundance and sustains their expression, leading to increased expression of inflammatory 
mediator proteins. SB203580, a specific inhibitor of p38 MAPK, when applied to human 
fibroblasts or umbilical vein endothelial cells inhibited IL-1 induced COX-2 protein and mRNA 
levels (Dean et al., 1999; Ridley et al., 1997). This was later reported to be due to an effect on 
COX-2 mRNA stability, rather than on transcription (Dean et al., 1999; Ridley et al., 1998). In 
human monocytes SB203580 also inhibited LPS-induced COX-2 expression (Dean et al., 1999). 
In this case the inhibition observed was found to be due to reduced COX-2 mRNA stability and 
transcription (Dean et al., 1999). p38 MAPK has been found to increase the stability of a large 
number of inflammatory mRNAs including TNFα (Brook et al., 2000; Rutault et al., 2001; 
Wang et al., 1999), IL-1β and Gro-α (Sirenko et al., 1997) and IL-6 (Miyazawa et al., 1998). 
However, recently the conditional knockout of p38α MAPK found no effect on TNF mRNA 
stability after LPS stimulation (Kang et al., 2008). This is likely to be a result of the requirement 
of p38 MAPK for the induction of the mRNA destabilising protein, tristetraprolin (TTP) 
(Mahtani et al., 2001). MK2 has been shown to be involved in p38 MAPK-mediated mRNA 
stabilisation (Lasa et al., 2000; Winzen et al., 1999). 
 
Many mRNAs encoding proteins involved in the inflammatory response including TNF, IL-1, 
IL-6, IL-8, granulocyte macrophage colony stimulating factor (GM-CSF), c-Fos and COX-2 
contain AU-rich elements (AREs) in their 3´ untranslated regions (UTRs) (Caput et al., 1986). 
The AREs from GM-CSF and c-Fos were inserted into the 3´ UTR of rabbit β-globin gene and 
this led to the otherwise stable β-globin mRNA becoming highly unstable (Kabnick and 
Housman, 1988; Shaw and Kamen, 1986). The p38 MAPK pathway has been shown to stabilise 
mRNAs otherwise labile due to the presence of AREs (Dean et al., 2004; Winzen et al., 1999), 
for example COX-2 (Dean et al., 2003; Lasa et al., 2000). AREs have been shown to target 
mRNAs for rapid deadenylation (Shyu et al., 1991; Wilson and Treisman, 1988; Xu et al., 
1997), however AREs have also been implicated to cause 5´ decapping (Gao et al., 2001) and 
promote 3´ - 5´exonuclease decay (Chen et al., 2001; Mukherjee et al., 2002). p38 MAPK has 
been shown to regulate the deadenylation of reporter mRNAs containing either the TNF or 
COX-2 AREs (Dean et al., 2003).  
 
It is likely that p38 MAPK–dependent mRNA stabilisation involves one or more ARE binding 
proteins (AREBPs). Many potential AREBPs have been identified, including TTP (Carballo et 
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al., 1998; Dean et al., 2004). TTP is the AREBP for which there is the strongest evidence of a 
role in inflammatory regulation of mRNA stability and it has also been linked to the p38 MAPK 
pathway (Fig. 1.2). TTP binds AREs including the ARE of TNF (Carballo et al., 1998). TTP-/- 
mice display an inflammatory phenotype including arthritis because of elevated protein levels of 
TNF. TTP promotes in vitro deadenylation of RNA containing the TNF ARE, but not RNA 
containing a mutated version (Lai et al., 2003). Phosphorylation of TTP by MK2 may prevent 
TTP from targeting the ARE-containing mRNA to the decay machinery through the 
sequestration of TTP by 14-3-3 proteins (Stoecklin et al., 2004). This is supported by work with 
the MK2/TTP double knockout mice and TTP mutants (Hitti et al., 2006).  
 
1.13 Translational regulation 
 
Early work indicated that p38 MAPK had an important role in the translation of inflammatory 
cytokines. The inhibition of p38 MAPK with pyridinyl imidazole compounds caused a 
reduction in TNF and IL-1 protein, with little effect on the mRNA levels (Young et al., 1993). 
TNF mRNA was shown to be associated with single ribosomes rather than polysomes with 
ribosomal density-gradient profiling of cytoplasmic extracts from cells treated with LPS and 
p38 MAPK inhibitor (Prichett et al., 1995). More recent work however, found that when a 
different inhibitor, SB203580, was used p38 MAPK inhibition caused a commensurate decrease 
in TNF protein and mRNA levels in LPS-treated monocytes (Dean et al., 1999). This suggested 
that in human monocytes p38 MAPK mainly regulates TNF mRNA levels. However, there is 
some controversy because there is evidence that murine TNF expressed by macrophages is 
regulated mainly at the level of translation (Kotlyarov et al., 1999). There has also been some 
evidence that ERK and p38 MAPK have a role in the translation of pro-inflammatory mediators, 
such as TNFα, through the activation of Mnk1 (Buxade et al., 2005).  
 
Part 4: Regulation of inflammatory signalling 
 
IL-1 is a potent pro-inflammatory stimulus and as mentioned previously it is important that this 
pathway is tightly regulated to ensure that the response does not lead to chronic inflammatory 
conditions. The regulation of the IL-1 signalling pathway occurs at many levels, to ensure that 
both the initial stimulus and the downstream signalling and gene expression are switched off 
when appropriate. 
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1.14 Deubiquitinating enzymes 
 
Lysine 63-linked polyubiquitination is increasingly recognised as an important mechanism for 
the propagation of the signal from the IL-1, TLRs and TNF receptors. Ubiquitination, like 
phosphorylation is a reversible process and can be removed through the use of deubiquitinating 
enzymes (DUBs). Three DUBs, which have so far been implicated in the regulation of IL-1 and 
TNF signalling include cylindromatosis (CYLD), A20 and Cezanne (Sun, 2008). CYLD has 
been shown to interact with and deubiquitinate Lys63-linked chains on TRAF6 (Kovalenko et 
al., 2003; Yoshida et al., 2005), Rip1 (Wright et al., 2007) and NEMO (Kovalenko et al., 2003). 
A20 has been reported to deubiquitinate TRAF6 (Boone et al., 2004), Rip1 (Wertz et al., 2004) 
and NEMO (Mauro et al., 2006). A20 is unique because it also possesses E3 ubiquitin ligase 
activity and is thought to remove Lys63-linked chains and add Lys48-linked polyubiquitin 
chains to Rip1 at the same time, causing Rip1 to be targeted to the proteasome and degraded 
(Wertz et al., 2004). A20-/- mice have persistent activation of NF-κB by TNF causing 
multiorgan inflammation, cachexia and neonatal lethality (Lee et al., 2000). Cezanne is a 
homologue of A20 and has been reported to deubiquitinate Rip1 leading to the negative 
regulation of the IKK complex (Enesa et al., 2008).  
 
1.15 Phosphatases 
 
A key component of IL-1 signalling is the protein kinase cascades. The signal is propagated 
through the pathway through a series of phosphorylations, which lead to the activation of the 
substrate proteins. If the activation of proteins occurs through phosphorylation it would 
therefore follow that dephosphorylation of the pathways would lead to inactivation. Different 
phosphatases have been implicated in the dephosphorylation of various points in the signalling 
cascade. For example there have been many phosphatases reported to possess TAK1 
dephosphorylation activity. Protein phosphatase (PP) 2A has also been implicated as a negative 
regulator of TAK1, through dephosphorylating TAK1 at the activation site (Thr183) in 
mesanglial cells (Kim et al., 2008). PP6, a type 2A phosphatase, has reported to 
dephosphorylate TAK1 at Thr187 (Kajino et al., 2006). PP2C isoforms have also been 
implicated in TAK1 dephosphorylation (Li et al., 2003).  
 
The importance of phosphorylation at both the tyrosine and threonine residues mean that 
dephosphorylation by tyrosine-specific phosphatases, serine / threonine-specific phosphatases or 
dual-specificity (threonine/tyrosine) protein phosphatases can inactivate the MAPKs (Keyse, 
2000). PP2A has also been demonstrated to interact with and dephosphorylate p38 MAPK (Lee 
et al., 2003; Sundaresan and Farndale, 2002). The dual-specificity phosphatase (MAP kinase 
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phosphatases/ MKP) family are thought to be the primary phosphatases responsible for the 
dephosphorylation of the MAPKs. There are 10 mammalian MKPs, which exhibit different 
substrate specificity, subcellular localisation and regulation. MKP1 is the archetype (Wang and 
Liu, 2007). MKP1 preferentially dephosphorylates p38 MAPK and JNK (Franklin and Kraft, 
1997). 
 
1.16 Protein scaffolds 
 
The regulation of signalling specificity is thought to occur is through the formation of specific 
signalling complexes, with the aid of scaffold proteins. Scaffold proteins can bind to more than 
one component of the pathway simultaneously, bringing the pathway components together. This 
also increases the signalling efficiency and speed in response to a signal. In the upstream 
signalling pathways polyubiquitination of TRAF6 or Rip1 is thought to act as a scaffold on 
which the downstream signalling complexes can form, as discussed above. Other scaffold 
proteins that have been postulated to have important roles in these signalling pathways include 
JNK-interacting protein (JIP)-1. JIP1 sequesters JNK in the cytosol and selectively enhances 
JNK activation mediated by MLK3 (Whitmarsh et al., 1998). JIP-1 forms complexes that 
contain MLK3, MKK7 and JNK. MEK Partner 1 (MP-1) is a scaffold protein that specifically 
binds MEK1 and ERK1. The Elk1 transcription factor was used to activate a reporter to 
measure ERK activation (Schaeffer et al., 1998). MP-1 did not interact with MEK1 previously 
phosphorylated by B-Raf, indicating that this complex, as well as that mediated by JIP-1, is 
dissociated upon phosphorylation and activation of the components. Several scaffold proteins 
have also been proposed for p38 MAPK including Sin1, which has been shown to bind to ATF-
2 and p38 MAPK (Makino et al., 2006) and JIP4 by a mechanism involving MKK3 and MKK6 
(Kelkar et al., 2005).  
 
1.17 Protein stability 
 
Protein turnover is the balance between the synthesis and degradation of a particular protein in 
the cell. Protein turnover is highly variable. Chaperones are often required to ensure that a 
newly synthesised protein is folded correctly. However, some proteins also require the presence 
of a chaperone to stabilise the protein and once removed from the chaperone these proteins are 
often rapidly degraded. Heat shock proteins are a highly conserved family of chaperones. Some 
family members are constitutively expressed in certain cell types but the expression of many is 
upregulated in response to stress, such as heat shock. One family member, HSP90 has been 
shown to act as a chaperone and regulate protein stability for many proteins involved in signal 
transduction cascades.  
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In the IL-1 signalling pathway HSP90 has been shown to be a chaperone for IRAK1, TAK1 and 
has been reported to be part of the IKK complex. The HSP90·Cdc37 chaperone module has 
been shown to be required for the maintenance of IRAK1 (De Nardo et al., 2005) in 
macrophages. Although HSP90 expression increases upon stressful stimulation of the cells 
(LPS) Cdc37 expression does not and this is believed to tip the balance leading to the 
degradation of IRAK1 and subsequent downstream signalling. HSP90 can regulate IL-1β-
induced signalling through the interaction and maintenance of stability of TAK1 in HEK293 
and HeLa cells (Shi et al., 2008) as demonstrated through the use of the HSP90 inhibitor, 
geldanamycin, RNAi and overexpression studies. However, HSP90 is not required for the 
activation of TAK1 and did not alter its activity in response to IL-1 or LPS (Liu et al., 2008). 
TAK1 cannot bind to TAB1 and HSP90 simultaneously and it is believed that when there is a 
pool of free TAB1 this displaces HSP90 and binds to TAK1 (Liu et al., 2008). 
 
Part 5: Heat shock protein 27 (HSP27) 
 
1.18 The small heat shock protein family 
 
There are five families of heat shock proteins; the 110 kDa HSPs, 90 kDa HSPs, 70 kDa HSPs, 
60 kDa HSPs and the small heat shock proteins (sometimes the 40 kDa HSPs are also classed as 
a family). HSP expression is induced by various stresses including heat shock (Landry et al., 
1982; Landry et al., 1989), oxidative (Iwaki et al., 1993) and osmotic stress (Garmyn et al., 
2001). There are ten members of the small heat shock protein (sHSP) family in the human 
genome; HSPB1-10 (Kappe et al., 2003). This is a ubiquitous family of molecular chaperones of 
typical size 16 – 25 kDa. Members of the sHSP family include HSP27 (HSPB1) αA-crystallin 
(HSPB4) and αB-crystallin (HSPB5) (Kappe et al., 2003). These proteins are characterised by a 
conserved C-terminal region, the α-crystallin domain, a variable N-terminal domain and 
occasionally a variable C-terminal tail. Members of the small heat shock family are widely 
spread throughout all kingdoms and their existence has been reported from bacteria to humans. 
The only notable absence of small heat shock protein family members is in some parasites and / 
or pathogens of humans and animals (Narberhaus, 2002). 
 
1.19 HSP25, the murine orthologue of HSP27 
 
The murine orthologue of HSP27, HSP25, is expressed in a wide variety of tissues (Gernold et 
al., 1993; Klemenz et al., 1993). HSP25 is phosphorylated on sites equivalent to the human 
Ser15 and Ser82 (Ser86) (Stokoe et al., 1992b). HSP25 has been analysed in MK2-/- mice 
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(Kotlyarov et al., 1999; Vertii et al., 2006). In these mice there is no detectable phosphorylation 
of HSP25 at Ser86 and no detectable in vitro binding to 14-3-3 protein (Vertii et al., 2006). This 
paper gives evidence that the phosphorylation of HSP25 plays a role in the disaggregation of the 
HSP25 complex. There was no detectable effect of MK2-dependent phosphorylation of HSP25 
on actin reorganisation in MEFs.  
 
1.20 Phosphorylation and oligomerisation states of HSP27 
 
IL-1 and TNF have long been known to cause the phosphorylation of HSP27 (Kaur et al., 1989; 
Saklatvala et al., 1991), although both the function of the protein, and its phosphorylation are 
not well understood. The functions of HSP27 are likely to be influenced by its phosphorylation 
state. Human HSP27 is phosphorylated at three sites with the sequence Arg-Xxx-Xxx-Ser by 
MK2; serine 15 (Ser15), Ser78 and Ser82 (Landry et al., 1992; Stokoe et al., 1992b). MK3 
(McLaughlin et al., 1996), the delta isoform of protein kinase C (PKC) (Maizels et al., 1998) 
and protein kinase D (Doppler et al., 2005) have all been shown to phosphorylate HSP27 on at 
least one of the sites phosphorylated by MK2. cGMP-dependent protein kinase has been shown 
to phosphorylate HSP27 on Thr143. HSP27 phosphorylated on Thr143 has been proposed to 
inhibit platelet aggregation, in contrast to HSP27 phosphorylated by MK2 (Butt et al., 2001). 
 
All the members of the sHSP family form large homo-oligomers (Haslbeck et al., 2005). Non-
phosphorylated HSP27 analysed by size-exclusion liquid chromatography forms oligomers of 
530 kDa, equivalent to 24 subunits (Rogalla et al., 1999). Upon phosphorylation the 24-mer 
dissociates into tetramers (~110 kDa), dimers or monomers (Lelj-Garolla and Mauk, 2005). The 
oligomerisation state of HSP27 has been demonstrated as important in certain actions of HSP27. 
HSP27 can not only form large oligomers with itself but is also capable of the formation of 
large heterooligomers with other members of the sHSP family including αB-crystallin (Fu and 
Liang, 2002) and HSP22 (Benndorf et al., 2001). 
 
The importance of the phosphorylation state of HSP27 upon the oligomerisation and function of 
HSP27 suggests that the regulation of HSP27 through dephosphorylation is also of relevance. 
The only reports on HSP27 dephosphorylation suggest that PP2A is the principle HSP27 
phosphatase (Cairns et al., 1994; Tar et al., 2006). PP1 has been reported to dephosphorylate 
HSP27 in vitro, but only PP2A is required in vivo (Cairns et al., 1994). 
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1.21 Cellular Functions of HSP27 
 
1.21.1 Cytoprotection 
 
HSP27 can protect cells against heat shock (Landry et al., 1989) and apoptotic agents. Many 
mechanisms have been suggested to account for the cytoprotective action of HSP27, however 
there is no clear consensus. For example HSP27 overexpression diminishes the reactive oxygen 
species (ROS) burst induced by TNF and increases the glutathione content of L929 cells and 
this has been suggested as the anti-apoptotic mechanism (Mehlen et al., 1996a). HSP27 also 
protects against Fas / APO-1 mediated apoptosis in L929 cells and against the PKC inhibitor, 
staurosporine (Mehlen et al., 1996b). Phosphorylated HSP27 dimers bind to Daxx, a mediator of 
Fas-induced apoptosis. This prevents Daxx from interacting with ASK1 and Fas and prevents 
Daxx-mediated apoptosis (Charette et al., 2000). HSP27 inhibits F-actin fragmentation caused 
by hydrogen peroxide and menadione (Huot et al., 1996). HSP27 is protective against various 
cytotoxic drugs. For example, in colorectal cancer cells HSP27 protects against apoptosis 
mediated by doxorubicin and cisplatin (Garrido et al., 1997). As well as reducing ROS in cells, 
HSP27 confers resistance to staurosporine, etoposide and Fas by inhibiting cytochrome c release 
from the mitochondria (Paul et al., 2002). The protection against F-actin fragmentation has been 
postulated to be partially responsible for the inhibition of cytochrome c release from the 
mitochondria and to interfere with the Bid intracellular redistribution involved in apoptosis 
(Paul et al., 2002). 
 
1.21.2 Chaperone function of HSP27 
 
HSP27, like most other heat shock proteins, possesses chaperone activity. It is thought that each 
small HSP complex can bind to several non-native polypeptide chains. The interactions between 
the chaperone and unfolded protein are thought to be stable at physiological temperatures. It is 
believed that other chaperones may help facilitate substrate release. HSP oligomers are dynamic 
and the constant recycling of subunits may expose substrate binding sites (Haslbeck et al., 
2005). The chaperone activity of HSP27 is thought to be ATP independent, which is unusual. 
Few substrates for HSP27 chaperone activity have been identified. A Chinese hamster cell line 
overexpressing HSP27 was found to form heat-induced nuclear protein aggregates, however 
these cells exhibited an enhanced rate of recovery from nuclear protein aggregation as thermo-
tolerant cells (Kampinga et al., 1994). At stoichiometric amounts both murine HSP25 and 
human HSP27 interact with and prevent the heat-induced aggregation of two model proteins; 
dimeric citrate synthase from pig heart and α-glucosidase from yeast (Jakob et al., 1993). 
HSP25 and HSP27 also promoted functional re-folding of these proteins after urea denaturation 
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(Jakob et al., 1993). A change in temperature from 10 to 40 ºC augmented the size of HSP27 
homo-oligomers and increased the chaperone activity of HSP27 as shown buy the inhibition of 
ditheothreitol-induced insulin aggregation (Lelj-Garolla and Mauk, 2006). The ability of HSP27 
to act as a chaperone to citrate synthase was decreased upon the phosphorylation of HSP27 and 
reduction in oligomeric size (Rogalla et al., 1999). Therefore the chaperone activity of HSP27 is 
thought to depend on its phosphorylation and oligomeric state.  
 
1.21.3 Cytoskeletal dynamics 
 
HSP27 has also been shown to be involved in migration of endothelial cells (Piotrowicz et al., 
1998), smooth muscle cells (Hedges et al., 1999) and in pinocytosis by fibroblasts (Lavoie et al., 
1993b). KRIBB3 (5-(5-ethyl-2-hydroxy-4-methoxyphenyl)-4-(4-methoxyphenyl) isoxazole) 
(Shin et al., 2005), has been suggested to be a synthetic inhibitor of HSP27. KRIBB3 blocked 
cell migration and invasion in a human breast cancer cell line (MDA-MB-231) due to the 
inhibition of PKC-dependent HSP27 phosphorylation. Cell migration involves microfilament 
reorganisation. HSP27 has been proposed to be an F-actin cap binding protein which can inhibit 
actin polymerisation in vitro (Landry and Huot, 1995; Miron et al., 1991). Phosphorylation of 
HSP27 leads to an increase in the stability of actin microfilaments and a faster recovery of 
disrupted filaments after stress (Guay et al., 1997; Lavoie et al., 1993a). Another influence of 
HSP27 interacting with and affecting cytoskeletal dynamics is wound healing. A study using 
stably transfected fibroblast cell lines which either over- or underexpress HSP27 found a role of 
HSP27 in fibroblast adhesion, elongation and migration in the context of wound healing assays 
(Hirano et al., 2004). 
 
1.22 Other protein-protein interactions of HSP27 
 
A large number of proteins have been identified as potential binding partners for HSP27. In 
some cells, such as HeLa cells, constitutively expressed HSP27 makes up a large proportion of 
total cellular proteins and therefore it is not clear if all the interactions proposed are specific. A 
few examples other examples of HSP27 interacting partners are discussed here.  
 
Immunoprecipitation and glutathione S-transferase (GST) pull-down studies found that Akt 
forms a complex with p38 MAPK, MK2 and HSP27 in neutrophils (Rane et al., 2001). HSP27 
dissociates from the complex upon stimulation with formyl-methionyl-leucyl-phenylalanine. 
Akt was phosphorylated and activated by p38 MAPK-dependent MK2 (Rane et al., 2001).  
Further work went on to show that HSP27 regulates Akt activation and cellular apoptosis 
through mediating the interaction of MK2 with Akt (Wu et al., 2007).   
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A yeast two-hybrid screen from a rat kidney gromuleri identified hic-5, a focal adhesion kinase 
as an interaction partner for HSP27 (Jia et al., 2001). This interaction was found to inhibit the 
protection from heat-induced cell death conferred by the overexpression of HSP27 in 293T 
cells. The same group had shown an interaction with PASS1 in the rat (Liu et al., 2000).  
 
Zoubeidi et al., report that the androgen-bound androgen receptor can lead to the 
phosphorylation of HSP27 (Zoubeidi et al., 2007). Phosphorylated HSP27 can then displace the 
androgen receptor from its complex with HSP90 and chaperone it to the nucleus where it is then 
able to activate transcriptional activity. 
 
1.23 HSP27 in disease 
 
Variations in HSP27 expression levels or mutations in the protein sequence have been 
implicated in a large number of diseases. A list of diseases for which HSP27 has been involved 
is included in Table 1. 
 
1.23.1 Neurodegenerative disorders 
 
HSP27 has been implicated in the pathology of many diseases, directly and indirectly. Recently, 
five mutations in HSP27 have been identified that cause autosomal dominant Charcot-Marie-
Tooth (CMT) disease type 2F and distal hereditary motor neuropathies (dHMN) (Evgrafov et 
al., 2004; Ismailov et al., 2001; Tang et al., 2005). The mutations are 379C→T (R127W), 
404C→T (S135F), 406C→T (R136W), 452C→T (T151I) and 545C→T (P182L). Four of the 
mutations occur in the conserved α-crystallin domain. CMT disease is the most common 
inherited neuromuscular disease, affecting 1 in 2500 people. Co-transfection of neurofilament 
light chain together with a mutant HSP27 altered neurofilament assembly, suggesting that the 
mutations may affect function of the protein. 
 
HSP27 has also been implicated in various protein conformation diseases, characterised by the 
build up of accumulated proteins. As shown on table 1 higher levels of HSP27 have been found 
in Alzheimer’s disease, Alexander disease and Parkinson’s disease patients suffering from 
dementia. HSP27 has been shown to bind preferentially to hyperphosphorylated tau, found in 
the paired helical filaments that are the hallmark of Alzheimer’s disease, and lead to its 
dephosphorylation and degradation. HSP27 has been shown to rescue hyperphosphorylated tau-
mediated cell death (Shimura et al., 2004). HSP27 has also been shown to prevent cellular 
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Disease type Disease Mutation in 
HSP27 
known? 
Expression of 
HSP27 
Reference 
Neuropathies Charcot-Marie Tooth 
Disease type 2; distal 
hereditary motor 
neuropathies 
R127W, 
S135F,  
R136W, 
T151I, P182L 
 (Chung et al., 
2008; 
Evgrafov et 
al., 2004; 
Houlden et 
al., 2008; 
Tang et al., 
2005; Zhai et 
al., 2007) 
Alexander Disease  Increased in 
Alexander 
central nervous 
system tissues 
and present in 
Rosenthal fibres 
(Head et al., 
1993) 
Alzheimer’s disease  Increased 
expression in the 
cortex 
(Renkawek 
et al., 1993) 
Protein 
conformation 
diseases 
(neuropathies) 
Parkinson’s disease 
with dementia 
  (Renkawek 
et al., 1999) 
Cardiovascular 
diseases 
Atherosclerosis  Decreased in the 
plasma 
(Martin-
Ventura et 
al., 2004) 
Breast  Increased (Love and 
King, 1994) 
Gastric  Increased (Chen et al., 
2004a) 
Ovarian  Increased (Langdon et 
al., 1995) 
Cancer 
Prostate  Increased (Cornford et 
al., 2000) 
Ichthyosis bullous ichthyosiform 
erythroderma, annular 
epidermolytic ichthyosi
X-linked recessive 
ichthyosis, congenital 
hemidysplasia with 
ichthyosiform nevus an
limb defects syndrome
 Reduced (Jonak et al., 
2005). 
 
Table 1: HSP27 in diseases: List of diseases where a mutation in HSP27 or a change of 
expression has been reported. 
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polyglutamine toxicity and suppress the increase in reactive oxygen species by huntingtin, the 
protein that aggregates in Huntington’s disease (Wyttenbach et al., 2002). 
 
1.23.2 Cancer 
 
HSP27 has been implicated in the growth and invasiveness of certain cancers, because it is 
cytoprotective against many cell stresses including chemotherapeutic drugs used to treat 
cancers. It can be overexpressed in many cancers, including breast (Love and King, 1994), 
prostate (Cornford et al., 2000), gastric (Chen et al., 2004a) and ovarian (Langdon et al., 1995). 
Cells from a colon adenocarcinoma induced in a BDIX rat highlights a role for HSP27 in 
tumouriginicity in syngeneic animals (Garrido et al., 1998).  
 
Work in MDA-MB-231 breast cancer cells that overexpress HSP27 show that HSP27 up-
regulates MMP-9 expression and activity and down-regulates the Src-tyrosine kinase Yes 
expression. Their results imply that Yes may have a role in regulating MMP-9 expression and in 
vitro invasion. This has been postulated as a way in which HSP27 can influence tumour 
metastasis (Hansen et al., 2001). 
 
Bruey et al., show that large oligomers of HSP27 are the structural requirement for the 
antiapoptotic activity of HSP27. Cell-cell contact induces the formation of large oligomers of 
HSP27 regardless of the phosphorylation state of the serine residues and this increases cell 
tumourigenicity (Bruey et al., 2000).  
 
1.23.3 Atherosclerosis and cardiovascular diseases 
 
HSP27 has been suggested as a biomarker for atherosclerosis (Duran et al., 2006; Martin-
Ventura et al., 2004). HSP27 is decreased in the plasma of atherosclerotic patients relative to 
healthy subjects (Martin-Ventura et al., 2004). This was supported by work suggesting that 
HSP27 phosphorylated at serine residues 78 and 82 was associated with healthy blood vessels 
and lost from vessels of patients with accelerated graft atherosclerosis (a serious long-term 
complication of heart transplantation) (De Souza et al., 2005). The degradation of extracellular 
HSP27 by plasmin in atherosclerotic plaques could reflect a pathological vascular remodelling 
process where the balance between proteases and antiproteases is tipped towards the degradative 
process (Martin-Ventura et al., 2006). This study also suggests that intracellular HSP27 could 
have a protective role in the vascular wall by preventing apoptosis, a determinant of plaque 
instability. In contrast, HSP27 has been associated with dilated cardiomyopathy (Knowlton et 
al., 1998), with expression levels twice that of normal hearts. 
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1.23.4 Other Diseases 
 
HSP27 is expressed mainly in the upper epidermal layers of human skin. Loss of HSP27 in 
these layers is a rare phenomenon, associated with specific genetic defects (Jonak et al., 2005). 
These defects are postulated to be either in suprabasal keratins or in enzymes involved in 
cholesterol biosynthesis. Loss of HSP27 was found to be associated with bullous ichthyosiform 
erythroderma, annular epidermolytic ichthyosis, X-linked recessive ichthyosis and congenital 
hemidysplasia with ichthyosiform nevus and limb defects syndrome (Jonak et al., 2005). 
 
1.24 HSP27 function in inflammation 
 
HSP27 has been shown to be important in a lot of disease states as mentioned above. Many of 
these disease states involve an inflammatory process. MK2, known to phosphorylate HSP27, is 
activated by the p38 MAPK pathway downstream of stress signals including IL-1, TNF and 
LPS (Clifton et al., 1996; Kotlyarov et al., 2002). As the p38 MAPK pathway is involved in the 
inflammatory response HSP27 may have a function in inflammation. Phosphomimetic mutants 
of HSP27, in which the serine phosphorylation sites are mutated to glutamate, caused 
stabilisation of COX-2 ARE reporter mRNA (Lasa et al., 2000). This stabilisation is weak when 
compared with overexpressed MKK6 or MK2 and may indicate that HSP27 can act to fine-tune 
the pathway. However, other members of our laboratory were unable to reproduce these results 
and it was unclear if HSP27 had a role in the stabilisation of COX-2 mRNA. 
 
There have been some suggestions in the literature that HSP27 may be involved in 
inflammation, however it was unclear if HSP27 had a pro- or anti-inflammatory effect. HSP27 
expression has been characterised as up-regulated in certain chronic inflammatory conditions 
such as uveitis in the rabbit (Rocha et al., 1996). In contrast methotrexate, an effective treatment 
for the chronic inflammatory condition, rheumatoid arthritis, was found to increase the 
prostaglandin D2-stimulated HSP27 expression in osteoblasts (Yoshida et al., 2004).  
 
It has been previously reported that HSP27 associates with the IKK complex in response to 
TNFα. Phosphorylation of HSP27 enhanced this association and resulted in a decrease in IKK 
activity (Park et al., 2003). A further study showed by co-immunoprecipitation that HSP27 had 
a role in suppressing NF-κB activation at an IKK-level (Kammanadiminti and Chadee, 2006). 
They found by co-immunoprecipitation that HSP27 interacts with IKK-α and IKK-β. This 
association was found to increase in response to soluble amebic protein-treated conditioned 
epithelial cells. HSP27 has also been proposed to have a protective anti-inflammatory effect in 
angiotensin-II-induced hypertension and inflammation in the aorta (Chen et al., 2004c). HSP27 
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and HSP70 levels are increased in response to angiotensin II, this was elevated still further in 
response to heat shock. HSP27 has also been suggested to suppress heart inflammation (Chen et 
al., 2004b) and may protect against inflammatory injury by the suppression of NF-κB and AP-1 
in vascular smooth muscle cells (Chen and Currie, 2006). Addition of exogenous HSP27 to 
monocytes has been reported to stimulate the production of IL-10 and to a lesser extent TNF 
through p38 MAPK (De et al., 2000) and has therefore been postulated to act as an anti-
inflammatory agent. 
 
HSP27 has also been reported to have a pro-inflammatory role, for example HSP27 
overexpression has been shown to increase NF-κB relocalisation, DNA binding and 
transcriptional activity in response to etoposide, TNFα and IL-1β through enhancing the 
degradation of phosphorylated IκBα by the proteosome (Parcellier et al., 2003). HSP27 was 
found to bind to polyubiquitin chains and the 26S proteosome both in vitro and in vivo 
(Parcellier et al., 2003). Previous work from our laboratory using RNAi to deplete HSP27 from 
cells showed that HSP27 is required for IL-1-induced expression of COX-2 and IL-6 protein 
and mRNA in HeLa cells (Alford, 2006; Alford et al., 2007). Three siRNA oligonucleotides 
targeted against different HSP27 mRNA each suppressed HSP27 expression. All three siRNAs 
inhibited COX-2, IL-6 and IL-8 protein expression. COX-2 and IL-6 reduction in IL-1-induced 
mRNA expression was demonstrated to be due to a decrease in mRNA stability (Alford et al., 
2007). The stability of a wide variety of other mRNAs was unaffected in HSP27 siRNA-
transfected cells, including GADD45, Bcl-x, c-FOS, p53 and Bax (Alford, 2006). The 
involvement of HSP27 in inflammatory mRNA stabilisation suggests that HSP27, together with 
the p38 MAPK pathway may play a role in chronic inflammatory diseases.  
 
PART 6: Project Aims 
 
Despite the identification of HSP27 as a protein that is phosphorylated in response to IL-1 
stimulation in fibroblasts almost twenty years ago (Guesdon and Saklatvala, 1991) and its 
subsequent identification as a component of the p38 MAPK pathway it is still unclear what the 
role of this protein is in inflammation. As mentioned above, work by a previous student in the 
laboratory using RNAi had shown that HSP27 is required for the stabilisation of IL-1-induced 
COX-2 and IL-6 in HeLa cells. The initial aim of this project was to use HSP25-/- mice to 
determine if HSP27/25 has an important role in inflammation in vivo. A second aim of this 
project was to determine if HSP27 regulates IL-1 signalling as well as gene expression in HeLa 
cells using RNAi. If IL-1 signalling were regulated by HSP27 it would be important to 
determine the point in the pathway where the regulation occurs and the mechanism by 
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examining the activity of the pathway components following HSP27 depletion using RNAi. A 
further part of the project was to determine if the regulation of inflammatory gene expression / 
signalling by HSP27 is a general or HeLa cell-specific mechanism.  
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PART 1: MATERIALS 
 
2.1 General reagents 
 
All general reagents were purchased from Sigma-Aldrich (Poole, Dorset, UK) unless otherwise 
stated. [α-32P]-dATP was originally purchased from GE Healthcare (Amersham, UK), but for 
the fibroblast work was from Perkin Elmer (Waltham, Massachusetts, USA). Acrylamide 30 % 
(w/v) / bis-acrylamide 0.8 % was from Severn Biotech Ltd (Kiddeminster, UK). Dithiothreitol 
(DTT) was from Alexis Corporation (San Diego, CA, USA). ‘QIAamp® RNA Blood Minikit’ 
was from Qiagen Ltd. (Crawley, West Sussex, UK). ‘UltraMobius 1000 Plasmid kit’ from 
Novagen (San Diego, CA, USA). Deionised water purified by reverse osmosis was used for all 
general applications. 
 
2.2 Antibodies and antisera 
 
Antigen Polyclonal / 
monoclonal  
Species Dilution  
(WB) 
Supplier Catalogue 
Number 
Phospho-HSP27 
(Ser78) 
monoclonal Mouse 1:2000 Upstate (Lake 
Placid, NY, 
USA) 
05-645 
HSP25 polyclonal rabbit 1:1000 StressGen 
Bioreagents (Ann 
Arbor, USA) 
SPA-801 
HSP25 [p86] 
(MS) 
polyclonal rabbit 1:1000 Biosource 
Invitrogen 
Corporation 
(Carlsbad, CA, 
USA) 
44536G 
COX-2 (human) polyclonal rabbit 1:500 Alexis 
Biochemicals 
(San Diego, CA, 
USA) 
ALX-210-
712 
Phospho-ATF-2 polyclonal rabbit 1:1000 Cell Signaling 
Technology 
(Danvers, MA, 
USA) 
9221 
Phospho-p38 
MAPK (Thr180 
/ Tyr182) 
polyclonal rabbit 1:500 Cell Signaling 
Technology  
9211 
p38α MAPK 
(L53F8) 
monoclonal mouse 1:1000 Cell Signaling 
Technology   
9228 
p38α MAPK  monoclonal rabbit 1:50 Cell Signaling 
Technology   
9218 
Phospho-JNK 
(Thr183 / 
Tyr185) 
polyclonal rabbit 1:1000 Cell Signaling 
Technology 
9251 
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Phospho-p44/42 
(Thr202 / 
Tyr204) 
polyclonal rabbit 1:1000 Cell Signaling 
Technology 
9101 
FLAG (M2) monoclonal mouse 1:2000 Sigma-Aldrich 
(Saint Louis, 
Missouri, USA) 
F3165 
HA (12CA5) monoclonal mouse 1 μg  / ml Roche Applied 
Science 
(Indianapolis, 
USA) 
1583816 
Phospho-MKK3 
/ MKK6 
monoclonal rabbit 1:1000 Cell Signaling 
Technology  
9236 
Anti-MKK6 NT monoclonal rabbit 1:50 (IP) 
1:1000 
(WB) 
Upstate  04-383 
Phospho-TAK1 
(Thr187) 
Affinity 
purified 
rabbit 1:1000 Prof. Hiroaki 
Sakurai 
laboratory 
 
TAK1 (M-579) polyclonal rabbit 1:200 Santa Cruz 
Biotechnology 
(New England 
BioLabs, Hitchin, 
Herts, UK) 
sc-7162 
TAB1 Polyclonal? sheep 1:200 
IP: 1 µg 
Prof. P. Cohen 
laboratory 
 
TAB1 polyclonal rabbit 1:1000 Cell Signaling 
Technology   
3225 
TAB2 (K-20) polyclonal goat 1:200 Santa Cruz 
Biotechnology 
Sc-11851 
TAB3 (T-14) polyclonal goat 1:200 Santa Cruz 
Biotechnology 
Sc-46550 
TRAF6 (H-274) polyclonal rabbit 1:200 Santa-Cruz 
Biotechnology 
Sc-7221 
IRAK1 (H-273) polyclonal rabbit 1:200 Santa Cruz 
Biotechnology 
Sc-7883 
IRAK4 polyclonal rabbit 1:1000 ProSci 
Incorporated 
3125 
MyD88 polyclonal rabbit 1:1000 Abcam Ab2064 
Ubiquitin 
(P4D1) 
monoclonal mouse 1:200 Santa Cruz 
Biotechnology 
Sc-8017 
IκBα (C-15) Polyclonal 
IgG 
rabbit 1:200 Santa Cruz 
Biotechnology 
Sc-203 
α-tubulin 
Clone DM 1A 
monoclonal Mouse 
ascites 
fluid 
1:20 000 Sigma-Aldrich  T 9026 
α-actin 
Clone AC-40 
monoclonal Mouse 
ascites 
fluid 
1:1000 Sigma-Aldrich  A4700 
MK2, long form Immunoaffini
ty purified 
IgG 
rabbit  Upstate 07-241 
MK2, clone 
7H4.2 
monoclonal mouse  Upstate/Millipore 04-539 
Histone H1 (AE- Monoclonal mouse 1:1000 Santa Cruz Sc-8030 
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4) IgG2A Biotechnology 
MKP-1 
(DUSP1) (M-18) 
polyclonal rabbit 1:100 Santa Cruz 
Biotechnology 
Sc-1102 
MKP-1 
(DUSP1) (V-15) 
polyclonal rabbit 1:100 Santa Cruz 
Biotechnology 
Sc-1199 
Alexa Fluor 488 
goat anti-rabbit 
Affinity 
purified 
goat 1:100 Invitrogen A11008 
Alexa Fluor 488 
goat anti-mouse 
Affinity 
purified 
goat 1:100  Invitrogen A11001 
Alexa Fluor 647 
goat anti-mouse 
Affinity 
purified 
goat 1:100 Invitrogen A21235 
HSP27 antiserum rabbit 1:10 000 Prof. Saklatvala 
laboratory 
 
p38 α MAPK 
(SAK7a for 
western blots, 
SAK7b for 
kinase assays) 
antiserum rabbit 1:1000 Prof. Saklatvala 
laboratory 
 
JNK, long JNK2 
(SAK9) 
antiserum rabbit 1:1000 Prof. Saklatvala 
laboratory 
 
ERK (SAK2) antiserum rabbit 1:1000 Prof. Saklatvala 
laboratory 
 
MKK3 (RAW1) antiserum rabbit 1:1000 Prof. Saklatvala 
laboratory 
 
MKK3 / MKK6 
(RAW2) 
antiserum rabbit 1:1000 Prof. Saklatvala 
laboratory 
 
MKK3 / MKK6 
(RAW3) 
antiserum rabbit 1:1000  Prof. Saklatvala 
laboratory 
 
MKK6 (RAW4) antiserum rabbit 1:1000 Prof. Saklatvala 
laboratory 
 
MKK6 (RAW5) antiserum rabbit 1:1000 Prof. Saklatvala 
laboratory 
 
Normal rabbit 
IgG 
IgG rabbit  Santa Cruz 
Biotechnology 
Sc-2027 
Normal Sheep 
IgG 
IgG sheep  Santa Cruz 
Biotechnology 
Sc-2717 
Normal mouse 
IgG 
IgG mouse  Santa Cruz 
Biotechnology 
Sc-2025 
 
Table 2.1: List of antibodies and anti-sera used. 
 
The secondary antibodies used for western blotting were all horse radish peroxidise (HRP)-
conjugated. These were rabbit anti-mouse, swine anti-rabbit, rabbit anti-sheep or rabbit anti-goat 
purchased from Dako (Glostrup, Denmark). The secondary antibodies used for confocal 
microscopy were labelled with the Alexa Fluor dyes from Invitrogen (Paisley, UK). Primary 
antibodies were stored in the presence of 0.02 % sodium azide. Most primary antibodies were 
diluted in phosphate buffered saline (PBS) containing 0.1 % Tween-20 and 5 % Marvel. 
Primary antibodies against phosphorylated proteins were diluted in Tris buffered saline (TBS) 
containing 0.1 % Tween-20 and 5 % bovine serum albumin (BSA).  
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2.3 Protein Inhibitors 
 
Inhibitor Specificity Working 
Concentration 
Source 
Aprotinin Serine protease 3 µg / ml Sigma-Aldrich 
Phenyl methyl 
sulphonyl fluoride 
(PMSF) 
Serine protease 1 mM Sigma-Aldrich 
Pepstatin A Aspartic protease 1 µg / ml Sigma-Aldrich 
E64 Cysteine protease 10 µM Sigma-Aldrich 
Iodoacetamide * Cysteine protease 50 mM Sigma-Aldrich 
N-Ethylmaleimide 
(NEM) * 
Cysteine protease 10 mM Sigma-Aldrich 
Microcystin Protein 
phosphatase 1 
Protein 
phosphatase 2A  
1 µM Alexis 
Corporation 
Sodium fluoride Serine/threonine 
protein 
phosphatases 
2 – 50 mM Sigma-Aldrich 
Sodium 
orthovanadate 
ATPase, alkaline 
phosphatase, 
tyrosine 
phosphatases 
0.1 – 1 mM Sigma-Aldrich 
SB202190 * p38 MAPK 1 µM, 10 µM Calbiochem 
(Novabiochem, 
Beeston, 
Nottingham, UK) 
MG132 * Proteosome  10 µM Sigma-Aldrich 
 
Table 2.2: List of protein inhibitors used. 
* Iodoacetamide and NEM were used in all buffers when ubiquitinated proteins were desired to 
be detected. MG132 was used only to determine that the anti-ubiquitin antibodies were working. 
SB202190 was only used in specific experiments to inhibit p38 MAPK. 
 
2.4 Buffers 
 
2.4.1 General buffers 
 
Phosphate buffered saline (PBS) (made from a 10 x concentrated solution)   
8.9 mM Na2HPO4, 3.6 mM NaH2PO4, 2.7 mM KCl and 120 mM NaCl adjusted to pH 7.0 
           
Tris buffered saline (TBS)             
20 mM Tris-HCl and 137 mM NaCl adjusted to pH 7.6  
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2.4.2 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) buffers 
4 x SDS-PAGE sample buffer              
250 mM Tris, pH 6.8, 35 % glycerol, 8 % SDS and 0.2 mg / ml bromophenol blue 
Prior to use dithiothreitol (DTT) was added to 50 mM. 
 
Running Buffer (National Diagnostics, Atlanta, USA)     
25 mM Tris, 192 mM glycine and 0.1 % (w / v) SDS 
 
Coomassie Blue staining solution     
0.1 % (w / v) Coomassie Brilliant Blue G, 50 % (v / v) methanol and 20 % (v / v) glacial acetic 
acid.  
 
Fixer and Destain                   
50 % (v / v) methanol and 5 % acetic acid. 
 
Bradford Reagent            
0.1 % (w / v) Coomassie Brilliant Blue G, 0.05 % ethanol and 8.5 % (v / v) H3PO4 
 
2.4.3 Western blotting buffers 
 
Whole cell lysis buffer          
50 mM Tris HCl pH 7.5, 250 mM sodium chloride, 3 mM EDTA, 3 mM EGTA, 1 % Triton X-
100 (v / v), 0.5 % IGEPAL CA-350 (v / v), 10% glycerol (v / v), 2 mM DTT, 1 mM sodium 
orthovanadate and 2 mM sodium fluoride with protease and phosphatase inhibitors 
 
Western blot transfer buffer                
25 mM Tris, 192 mM glycine and 20 % (v / v) methanol 
 
2.4.4 Kinase assay buffers 
 
2.4.4.1 MK2, p38 MAPK, JNK, MKK3 and MKK6 kinase assay buffers. 
 
Kinase lysis buffer            
20 mM HEPES pH 7.4, 50 mM β-glycerophosphate, 2 mM EGTA, 1 % Triton X-100 (v / v), 10 
% glycerol (v / v), 10 mM sodium fluoride, 1 mM sodium orthovanadate and 2 mM DTT with 
protease and phosphatase inhibitors. 
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2 x RIPA: 
100 mM Tris/HCl pH 7.4, 300 mM sodium chloride, 20 mM sodium pyrophosphate, 2 mM 
EDTA, 50 mM β-glycerophosphate, 200 µM sodium orthovanadate, 2 % Igepal CA-630 (v / v), 
1 % deoxycholic acid (w / v) and 0.2 % SDS (w / v) 
 
3 x kinase wash buffer: 
60 mM HEPES pH 7.4, 600 mM sodium chloride, 60mM β-glycerophosphate, 30 mM sodium 
fluoride, 300 µM sodium orthovanadate, 1.5 mM EDTA, 1.5 mM EGTA, 30 mM magnesium 
chloride and 0.15 % Brij35 (v / v) 
 
Kinase assay reaction mix (one reaction): 
10 µl 3 x kinase wash buffer, 1 µg substrate (0.5 µg recombinant MK2 for p38 MAPK assay), 
20 µM ATP, 0.4 µl [γ32P]-ATP, 2 μM DTT made up to 30 µl with deionised water.  
 
2.4.4.2 TAK1 kinase assay buffers. 
 
TAK1 lysis buffer:          
50 mM Tris-HCl pH 7.5, 0.1 mM EGTA, 1 mM EDTA, 1 % Triton X-100 (v / v), 1 mM sodium 
orthovanadate, 50 mM sodium fluoride, 5 mM sodium pyrophosphate, 0.27 M sucrose, 2 mM 
DTT with protease and phosphatase inhibitors 
 
Buffer B:           
50 mM Tris HCl pH 7.5, 0.1 mM EGTA, 0.1 mg / ml BSA, 10 mM magnesium chloride, 0.1 
mM sodium orthovanadate, 2 mM DTT and 1 μM microcystin 
 
2.4.5 Lysis buffer for ubiquitination experiments 
 
SDS buffer: 
50 mM Tris HCl pH 7.5, 1 % (w / v) SDS, 50 mM iodoacetamide, 10 mM NEM, protease and 
phosphatase inhibitors 
 
Renaturation buffer: 
50 mM Tris HCl pH 7.5, 150 mM NaCl, 2 % (v / v) Igepal CA-630, 1 mM DTT, 50 mM 
iodoacetamide, 10 mM NEM, with protease and phosphatase inhibitors 
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2.4.6 Cell fractionation buffers 
 
2.4.6.1 Detergent lysis 
 
Cytoplasmic lysis buffer           
10 mM HEPES pH 7.6, 3 mM magnesium chloride, 40 mM potassium chloride, 2 mM DTT, 5 
% glycerol (v / v), 0.5 % IGEPAL CA-350 (v / v), 2 mM sodium fluoride, 1 mM sodium 
orthovanadate and protease and phosphatase inhibitors 
 
Wash buffer             
10 mM HEPES pH 7.6, 1.5 mM magnesium chloride, 10 mM potassium chloride, 1 mM DTT, 2 
mM sodium fluoride, 1 mM sodium orthovanadate and protease and phosphatase inhibitors 
 
Nuclear Extraction buffer           
20 mM HEPES pH 7.6, 0.42 M sodium chloride, 25 % glycerol (v / v), 1.5 mM magnesium 
chloride, 0.2 mM EDTA, 1 mM DTT, 2 mM sodium fluoride, 1 mM sodium orthovanadate and 
protease and phosphatase inhibitors 
 
2.4.6.2 Dounce homogenisation 
 
Cytoplasmic lysis buffer           
10 mM HEPES pH 7.9, 1.5 mM magnesium chloride, 10 mM potassium chloride, 0.5 mM DTT, 
2 mM sodium fluoride, 1 mM sodium orthovanadate and protease and phosphatase inhibitors 
 
2.5 Cell culture reagents 
 
Dulbecco’s modified Eagle’s medium (DMEM) was obtained from PAA (Pasching, Austria). 
Eagle’s Minimum Essential Medium (EMEM) was purchased from BioWhittaker, Cambrex Bio 
Science Walkersville, Inc. (Walkersville, USA). Foetal calf serum (FCS) was purchased from 
Biosera (Ringmer, UK). Opti-MEM I medium was obtained from Gibco (Paisley, UK). 50 ml 
aliquots of FCS were stored at -20ºC until required and used at final concentrations of 5 and 10 
ml in the medium. Media was supplemented with final concentrations of 0.1 U ml-1 penicillin 
and 0.1 mg ml-1 streptomycin (PenStrep) (PAA). EMEM media was also supplemented with 2 
mM glutamine (PAA). Trypsin-EDTA was purchased from PAA.  
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PART 2: Methods 
 
2.6 Cell Culture  
 
All cell culture was performed in a Class II vertical laminar flow cabinet.  
 
2.6.1 HeLa cells 
 
HeLa (human cervical epidermal carcinoma) cells obtained from Yamanouchi Pharmaceutical 
Co, Ltd (Oxford, UK) were cultured in DMEM supplemented with 10 % FCS, PenStrep. 
American Tissue Culture Collection (Tedddington, UK), ATCC, HeLa cells were cultured in 
EMEM supplemented with 2 mM glutamine (PAA), 10% (v / v) FCS and PenStrep. Cells were 
maintained in a humidified environment at 37°C, 5% CO2. Cells were washed with PBS and 
trypsinised with trypsin-EDTA for 5 min at 37 ºC, 5 % CO2. Cells were centrifuged at 400 x g 
for 5 min and resuspended in the appropriate volume of fresh medium. For general maintenance 
the seeding ratios were 1:6 or 1:8 depending on the number of days between splitting. Cells 
were maintained until passage 16. 
 
2.6.2 Human alveolar basal epithelial (A549) cells  
 
A549 cells (cultured respiratory epithelial cells from a human lung tumour) were cultured in 
DMEM containing 10 % (v / v) FCS and PenStrep. Cells were maintained and subcultured 
according to section 2.6.1. Cells were maintained until passage 16.  
 
2.6.3 Human dermal fibroblasts (HDFs) 
 
Normal neonatal human dermal fibroblasts (HDF) cells from Clonetics, Cambrex Bio Science 
Walkersville, Inc. were grown in DMEM containing 10 % (v / v) FCS and PenStrep.  Cells were 
maintained and subcultured according to section 2.6.1. Seeding ratios in the HDFs were 1:3. 
Cells were maintained until passage 12. 
 
2.6.4 Mouse embryonic fibroblasts (MEFs) 
 
Immortalised MK2 - / - mouse embryonic fibroblast (MEF) lines were kindly provided by Alexey 
Kotlyarov (Universität Hamburg, Germany). Four cells lines were gifted; mock virus MEF 
MK2 - / - (mock); virus MEF MK2 - / - PMMP-EGFP (Leec) (empty vector); virus PMMP-EGFP 
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MK2 - / - WT (WT); virus PMMP-EGFP MK2 - / - K76R. Cells were cultured in DMEM 
supplemented with 10 % (v / v) FCS and PenStrep.  
 
2.6.5 Freezing down and thawing cells 
 
Prior to splitting the medium required to freeze down the cells was made and put on ice. For all 
the cell types used, except L929, frozen storage media was DMEM containing 20 % (v / v) FCS 
and 10 % (v / v) DMSO. Cell sheets were washed with pre-warmed PBS and trypsinised. The 
trypsin was inactivated in normal growth medium and spun down at 400 x g for 5 min. Cell 
pellets were resuspended in frozen storage media and pipetted into sterile Cryovials ® (Simport 
plastics, Beloeil, QC, Canada). The cryovials were placed, surrounded by cotton wool in a 
beaker at – 70 °C overnight. This enabled slow freezing of the cells. The next day the cells were 
transferred to the liquid nitrogen store for long term storage.  
 
Cells were removed from the liquid nitrogen store, placed in the 37 °C waterbath for not longer 
than 2 min and transferred into the appropriate size flask containing normal growth medium. 
The next day the medium was replaced. In the case of NHDF cells 1/3 vial from a T175 was 
placed in each flask to ensure the maximum use of cells was gained at a low passage. 
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2.7 RNA interference 
 
2.7.1 siRNA oligonucleotides.  
 
siRNA oligonucleotides targeted against HSP27 (Fig. 2.1) were designed according to the 
guidelines set out by the Tuschl Laboratory (Elbashir et al., 2002) by a former PhD student in 
the laboratory. Early work used protected siRNA obtained from Dharmacon (Lafayette, USA) 
and stored in a lyophilised form at -20 °C. The siRNA was deprotected when required following 
the manufacturer’s instructions. Latterly previously deprotected siRNA was purchased from 
Dharmacon or Eurofin MWG Operon (Ebersberg, Germany) in a lyophilised form, diluted to 
the stock concentration of 10 µM and stored in 50 µl aliquots at -20 °C before use. Aliquots 
were freeze thawed three times. Scramble (Scr) and HSP27 dsRNA oligonucleotides contained 
a 3΄ dTdT overhang and luciferase contained a 3΄ UU overhang. The siRNA sequences were as 
follows: 
           Sense Sequence           
Luciferase       UAAGGCUAUGAAGAGAUACUU           
Scramble 2 (Scr)   CAGUCGCGUUUGCGACUGGdTdT         
HSP27#1         GGAUGGCGUGGUGGAGAUCdTdT        
HSP27#2         CGAGAUCACCAUCCCAGUCdTdT          
HSP27#5         UGCCCAAGCUAGCCACGCAdTdT          
HSP27#7     GCUGCAAAAUCCGAUGAGACdTdT (Rocchi et al., 2006)  
HSP27#8     GAUCACCAUCCCAGUCACCdTdT  (Rocchi et al., 2006) 
HSP27#9     ACGGUCAAGACCAAGGAUGdTdT (Park et al., 2003) 
TAK1#1     UGGCUUAUCUUACACUGGAdTdT      (Singhirunnusorn et al., 2005) 
TAK1#2     GUAGAUCCAUCCAAGACUUdTdT (Blonska et al., 2005) 
 
HSP27#5 and HSP27#7 siRNAs modified with a 2´ O-Me group at position 2 on the antisense 
strand were purchased together with the unmodified sense strand from Eurofin MWG Operon 
(Ebersberg, Germany). The guide and passenger strands were resuspended in the appropriate 
volume of 5 x siMAXTM buffer (30 mM HEPES pH 7.3, 100 mM KCl, 1 mM MgCl2; from 
MWG) to 100 µM and equal volumes (200 µl of each) combined. The mixture was placed at 95 
ºC for 5 min and allowed to cool to room temperature in the heat block. 40 µl 10 M ammonium 
acetate and 1.5 ml ethanol was added to each siRNA mixed and vortexed. The siRNA duplex 
was incubated at -20 ºC for 16 h. The siRNA was centrifuged at 14 000 x g for 30 min, 4 ºC. 
The supernatant was removed and the pellets allowed to air dry. Pellets were resuspended in 
400 µl 1 x siMAXTM buffer and siRNA duplexes were stored as for unmodified siRNAs.   
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gcccagcgcc ccgcactttt ctgagcagac gtccagagca gagtcagcca gcatgaccga 
gcgccgcgtc cccttctcgc tcctgcgggg ccccagctgg gaccccttcc gcgactggta 
cccgcatagc cgcctcttcg accaggcctt cgggctgccc cggctgccgg aggagtggtc 
gcagtggtta ggcggcagca gctggccagg ctacgtgcgc cccctgcccc ccgccgccat 
cgagagcccc gcagtggccg cgcccgccta cagccgcgcg ctcagccggc aactcagcag 
cggggtctcg gagatccggc acactgcgga ccgctggcgc gtgtccctgg atgtcaacca 
cttcgccccg gacgagctga cggtcaagac caaggatggc gtggtggaga tcaccggcaa 
gcacgaggag cggcaggacg agcatggcta catctcccgg tgcttcacgc ggaaatacac 
gctgcccccc ggtgtggacc ccacccaagt ttcctcctcc ctgtcccctg agggcacact 
gaccgtggag gcccccatgc ccaagctagc cacgcagtcc aacgagatca ccatcccagt 
caccttcgag tcgcgggccc agcttggggg cccagaagct gcaaaatccg atgagactgc 
cgccaagtaa agccttagcc cggatgccca cccctgctgc cgccactggc tgtgcctccc 
ccgccacctg tgtgttcttt tgatacattt atcttctgtt tttctcaaat aaagttcaaa 
gcaaccacc  
 
 
Key: 
hsp27#1  hsp27#2  hsp27#3  hsp27#4 
hsp27#5  hsp27#6  hsp27#7   hsp27#8 
hsp27#9  
 
Figure 2.1: Nucleotide sequence of HSP27 showing the sequences and positions of the 
HSP27 siRNAs. Nucleotide sequence for human HSP27 adapted from X54079. Sequence in 
blue is non-coding, the black sequence is the coding frame, different siRNA oligonucleotides 
are marked in colour and the corresponding siRNA is shown in the key. The aug start site for 
translation and uaa stop codon are underlined.  
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2.7.2 siRNA Transfection 
 
2.7.2.1  HeLa cells and HDFs (later work) 
 
Yamanouchi HeLa cells were seeded at 1 x 105 cells per well in six well plates and cultured for 
24 h in DMEM containing 10 % (v / v) FCS. ATCC HeLa cells were seeded at 5.5 x 104 cells 
per well. For each transfection (1 well in a six well plate) 10 µl of 1 μM siRNA was mixed with 
175 µl Opti-MEM I medium by gentle pipetting. 4 µl of Oligofectamine (Invitrogen, Paisley, 
UK) was mixed with 11 µl Opti-MEM I in a sterile Eppendorf tube. The solutions were 
incubated for 10 min, combined, mixed by gentle pipetting and incubated for 20 min at room 
temperature. During this incubation the medium was removed from the cells and they were 
washed with 2 ml PBS per well. 800 µl Opti-MEM I was added to each well. Following the 20 
min incubation the transfection mixture was mixed gently by pipetting and then 200 µl of lipid / 
siRNA complex was added to each well. The solution in the wells was mixed by gentle 
horizontal back and forth and side-to-side agitation. After 4 h the medium was removed, the 
cells washed in PBS and 1.5 ml Opti-MEM I containing 5 % (v / v) FCS and PenStrep was 
added. The cells were incubated at 37 °C, 5 % CO2 for 72 h before stimulation and lysis. The 
final concentration of siRNA added to the cells was 10 nM. For any dilution of siRNA, 1 x 
siRNA buffer from Dharmacon was used (20 mM potassium chloride, 6 mM HEPES (pH 7.5), 
0.2 mM magnesium chloride). For a less potent siRNA, HSP27#2, in HeLa cells and later work 
in human fibroblasts a second transfection was performed using oligofectamine 24 hours after 
the first. The cells were lysed 48 hours after the second transfection. 
 
2.7.2.2 HDFs (early work) and A549 cells  
 
HDFs were seeded at 6 x 104 cells per well in six well plates and cultured for 24 h in DMEM 
containing 10 % FCS. For each transfection into a well of a six well plate 6 µl of Lipofectamine 
2000 (Invitrogen) was mixed with 244 µl Opti-MEM I. 2.5 µl siRNA (final concentration of 10 
nM) was mixed in a final volume of 250 µl. These solutions were incubated for 5 min at room 
temperature. The solutions were combined and incubated at room temperature for 20 min to 
allow for complex formation. During this incubation the medium was removed and the cells 
were washed in 2 ml Opti-MEM I. 2 ml Opti-MEM I was added to each well. After the 
incubation 500 µl of the lipid / siRNA complex was added to each well. After 4 h incubation at 
37°C, 5 % CO2 the media was removed, the cells washed with 2 ml Opti-MEM I and 2.5 ml 
Opti-MEM I containing 5 % (v / v) FCS and PenStrep was added. A second round of 
transfection was performed 24 h after the initial transfection. In some experiments cells were 
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treated with a final concentration of 20 ng ml-1 IL-1α 48 h following transfection. For some 
signalling experiments the fibroblasts were seeded at 2.95 x 105 cells per 10 cm dish and the 
transfection procedure was scaled up 5.9 times. 
 
2.8 DNA transfection 
  
2.8.1 P1asmids 
 
pCMV FLAG 2 (Sigma-Aldrich), pCMV FLAG HSP27 (Lasa et al., 2000), pCMV FLAG 
HSP27 AAA (Lasa et al., 2000), pCMV FLAG HSP27 EEE (Lasa et al., 2000), pmaxGFP 
(Amaxa biosystems, Cologne, Germany), pSR HA-p38 (Gift from A. Clark) and MKK6E (gift 
from C. Tudor). pCMV FLAG HSP27 constructs containing four mismatches within the 21-
nucleotide target sequence designed to be resistant to HSP27#5 siRNA were provided by JL 
Dean. 
 
2.8.2 Calcium phosphate DNA transfection  
 
1 x 105 HeLa cells were seeded in each well of a six well plate and cultured for 24 h. Calcium 
phosphate transfection of HeLa cells was performed following the manufacturer’s (Sigma-
Aldrich) instructions. Briefly, 2 h before transfection the medium was removed from the cells 
and 2 ml fresh DMEM, 10 % (v / v) FCS, PenStrep was added to the cells. 5 μl DNA (HSP27 
DNA was made up to 5 μl using pCMV FLAG 2 (empty vector) and mixed with 49 μl distilled 
water and 6 μl 2.5 M calcium chloride. 2 x HEPES-buffered saline (60 µl per well transfected) 
was bubbled using an automatic pipette pump. The DNA solution was added dropwise to the 
bubbling HEPES-buffered saline and vortexed for 4 seconds before incubation at room 
temperature for 20 min. The DNA calcium phosphate solution was added to the cells dropwise 
and agitated to mix. After 16 h incubation at 37 °C, 5 % CO2 the medium was removed and 2 
ml fresh DMEM 10 % (v / v) FCS, PenStrep was added. 
 
2.8.3 Lipofection of DNA  
 
Lipofection using SuperFect (Qiagen, Crawley, West Sussex, UK) was performed previously 
(Lasa et al., 2000). Briefly, cells were seeded so that they would be 70 % confluent on the day 
of transfection. The total amount of DNA used per point was made up to 1 µg in 100 μl serum 
free medium. For each well of a six-well plate 5 μl SuperFect reagent was added to the DNA 
solution and gently pipetted up and down several times to mix. The solution is left 10 min for 
the DNA-lipid complexes to form. During this time the cells were washed once with PBS and 
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495 μl DMEM containing 10 % (v / v) FCS and PenStrep is added to each well. After pipetting 
up and down once again the 105 μl SuperFect DNA mixture was added to each well. The wells 
were mixed by moving the plate back and forth, and side to side. The DNA was left on the cells 
at 37 ºC 5 % CO2. After 3 h the medium was removed and DMEM containing 10 % (v / v) FCS 
and PenStrep was added to the cells. Cells were incubated for 24 h prior to lysis. 
 
2.8.4 Co-transfection of siRNA and DNA 
 
2.8.4.1 Co-transfection of siRNA and DNA in HeLa cells 
 
A siRNA transfection was performed, section 2.7.2.1. The Calcium phosphate transfection kit 
was allowed to equilibrate to room temperature. 4 h after the siRNA / lipid complex was added 
to the cells, the media was replaced with 2 ml DMEM 10% FCS, PenStrep. The DNA was 
transfected using calcium phosphate, Section 2.8.2. 48 h after the DNA / calcium phosphate 
precipitate was removed, cells were stimulated with IL-1 and lysed. 
 
2.8.4.2 Co-transfection of human fibroblasts with siRNA and DNA 
 
3 x 106 HDFs were seeded in 10 cm dishes. siRNA and DNA were simultaneously co-
transfected using Lipofectamine 2000 as described above, however a total of 1 µg of plasmid 
DNA was added with the siRNA. 24 h after the co-transfection, a second siRNA transfection 
was performed. 48 h after the second addition of siRNA, the cells were stimulated with IL-1 and 
lysed. 
 
2.9 Sample preparation and western blotting 
 
2.9.1 Cell Lysis 
 
Cells were lysed for western blot analysis using whole cell lysis buffer, unless otherwise stated. 
On the day of lysis the cells were stimulated either with 20 ng ml-1 IL-1α or 20 / 100 ng ml-1 
TNFα (Promega, Southampton, UK). Cells were washed in 1 ml PBS and 100 µl lysis buffer 
was added to each well of a six well plate. The plates were incubated on ice for 10 min. Lysates 
were then scraped using a cell scraper and pipetted into 1.5 ml Eppendorf tubes. Lysates were 
clarified at 16 000 x g for 10 min. Lysates were transferred to fresh Eppendorf tubes and either 
used immediately or fast frozen in liquid nitrogen and stored at -70 ºC. 
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2.9.2 Mouse dissection 
 
C57Bl/6 mice were dissected with the assistance of A. Hazlehurst. The organs were 
homogenised using a Power Gen 125 homogeniser (Fisher Scientific, Loughborough, UK) in 5 
ml whole cell lysis buffer on ice. A Bradford assay (Bradford, 1976) was carried out and 25 µg 
total protein of each tissue was loaded on SDS-PAGE.  
 
2.9.3 Bradford assay 
 
The total protein concentration in cell lysates was measured using a Bradford assay (Bradford, 
1976). 3-5 µl of sample was added to a final volume of 1 ml Bradford reagent, with the same 
amount of lysis buffer as the blank. The absorbance of this solution was measured at 595 nm 
using a spectrophotometer. The protein concentrations were estimated by comparison with a 
standard curve. The standard curve was made by measuring the absorbances of known 
concentrations of bovine serum albumin (BSA). The measurements were often performed in 
duplicate.  
 
2.9.4 SDS-PAGE 
 
SDS-PAGE sample buffer (final dilution 1 x) was added to equal amounts of protein from lysed 
cells. Prior to loading onto the gel the samples were incubated at 95 ºC for 5 min. SigmaMarker 
molecular weight markers were used. Proteins were separated using a discontinuous stacking / 
separating gel electrophoresis system according to the method described by Laemmli (Garfin, 
1990; Laemmli, 1970). The resolving gel comprised 380 mM Tris-HCl pH 8.8, 0.1 % (w / v) 
SDS and 10 or 12 % acrylamide. The stacking gel comprised 125 mM Tris-HCl pH 6.8, 0.1 % 
(w / v) SDS and 5 % acrylamide. Gels were electrophoresed in an electrophoresis apparatus 
(Cambridge Electrophoresis, Cambridge, UK).  
 
2.9.5 Transfer onto polyvinyline difluoride (PVDF) or nitrocellulose membrane. 
 
PVDF membrane (‘Polyscreen® PVDF Transfer Membrane’, PerkinElmer Life Sciences, 
Beaconsfield, UK) was hydrated in methanol for 3-4 min and then rinsed in deionised water 
(dH2O) and transfer buffer. The membrane was laid out onto three sheets of soaked Whatman® 
3MM filter paper. The electrophoresed resolving gel was placed on top of the membrane and a 
further three sheets of filter paper placed above the gel. Air bubbles were carefully removed by 
rolling a 10 ml pipette over the surface. The sandwich was placed between two sponges pre-
soaked in transfer buffer and placed in the transfer tank (BioRad, Hemel Hampstead, UK). The 
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proteins were transferred onto the membrane by electrophoresis for 1 h at 100 V in transfer 
buffer at 4 ºC. Where recommended, proteins were instead transferred onto a nitrocellulose 
membrane, for example when intending to use anti-phospho-HSP27 antibodies. When 
nitrocellulose was used the procedure was the same however, the membrane was hydrated in 
water. The PVDF membranes were stained with Coommassie Brilliant Blue G. PVDF 
membranes were destained using 70 % (v / v) methanol. The position of the markers was 
marked using a ballpoint pen. 
 
2.9.6 Western blotting 
 
All steps were carried out with agitation on a shaking platform. The membrane was blocked in 5 
% (w / v) Marvel (non-fat dried milk powder) in PBS-T / TBS-T for 1 h at room temperature or 
overnight at 4 ºC. This was followed by incubation with the primary antibody at the appropriate 
dilution in 5 % Marvel PBS-T or BSA in TBS-T for 1 h room temperature or overnight at 4 ºC. 
Membranes were washed vigorously in PBS-T / TBS-T three times for 10 min and incubated 
with the appropriate dilution of horse-radish peroxidase conjugated secondary antibody in 5 % 
Marvel PBS-T / TBS-T for 1 h at room temperature. The membrane was washed again three 
times in fresh PBS-T / TBS-T for 10 min. Bound antibody was visualised by enhanced 
chemiluminescence (ECL) (GE Healthcare, Chalfront St. Giles, UK) following the 
manufacturer’s instructions. The antibody used to detect total p38 MAPK in western blots at the 
beginning of this work was the in-house antibody, Sak7b. However, due to the detection of 
multiple non-specific bands it was decided to use an alternative commercial antibody from Cell 
Signaling Technology for the remainder of the work. 
 
2.9.7 Stripping and reprobing western blots 
 
Membranes were rehydrated in methanol and the methanol washed off. The membranes were 
washed vigorously for 15 min with 1 x stripping solution (ReBlot Plus Strong, Chemicon, 
Hampshire, UK). Membranes were washed 3 times for 10 min before re-blocking for 30 min at 
room temperature. Primary antibodies used to detect phosphorylated proteins were used for 
immunodetection first. Membranes were reprobed for HSP27 and the loading control α-tubulin 
later because these proteins are very abundant and the primary antibodies are very sensitive.  
 
2.10 Human IL-6 and IL-8 ELISAs  
 
Concentrations of IL-6 and IL-8 in the culture medium were detected using kits of matched 
antibody pairs (BD Biosciences Pharmingen, Oxford, UK). All steps were carried out with 100 
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µl volumes. ELISAs were performed on a 96-well EIA/ RIA plate (Corning Incorporated, NY, 
USA). IL-6 and IL-8 capture and detecting monoclonal antibodies were from BD Biosciences 
Pharmingen, Oxford, UK). Plates were coated with 1 µg ml-1 capture antibody and left at 4 ºC 
overnight. The capture antibody was removed and the plate washed three times in PBS 
containing 0.1 % Tween 20. The plate was blocked in 2 % BSA in PBS-T for 1 h room 
temperature. The samples were diluted appropriately in Opti-MEM I because this was the 
culture media on the cells. The dilutions used were neat, 1:10, 1:20 and 1:40. Triplicates were 
made for each dilution. A standard curve was made in duplicate for IL-6 / IL-8 protein standard 
(BD Bioscience Pharmingen). Six serial 1:3 dilutions were made from a starting concentration 
of 10 µg ml-1 of the protein standard and a blank was used as a final point on the standard curve. 
The blocking solution was removed and the plate washed three times in PBS-T. The standards 
and samples were added to the plate and left at room temp for 2 h. The standards and samples 
were then removed from the plate and washed 3 times in PBS-T. The biotinylated detecting 
antibody was diluted to 0.5 µg ml-1 in 0.5 % (w / v) BSA in PBS, applied to the plate and 
incubated for 1 h at room temp. The plate was then washed three times in PBS-T. The 
streptavidin-HRP conjugate (R & D Systems, Abingdon, UK) 1: 400 dilution was added to the 
plate and incubated for 1 h at room temperature. The plate was washed three times with PBS-T. 
Equal amounts of 3,3’,5,5’-tetramethylbezidine (TMB) substrate (Kirkegaard and Perry 
Limited, Maryland, USA) were combined with peroxidise substrate solution (KPL, MD, USA). 
100 µl TMB mixture was added into the wells to allow colorimetric detection of the captured 
protein. The reaction was stopped by addition of 1 M sulphuric acid. The absorbance was 
measured at 450 nm on an ELISA Multiskan bichromic plate reader (Thermo Electron 
Corporation, Basingstoke, UK). The data was analysed using Ascent software (Thermo Electron 
Corporation). Statistics were not performed on the results of this study except for standard error 
of the mean because there was either a clear difference (even with error bars) or no clear 
difference (the differences were not greater than the error bars on each variable) between the 
variables in these experiments. Therefore it was thought that statistics would not add to the data. 
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2.11 Kinase assays 
 
Kinase assay Immunoprecipitating antibody / 
antiserum 
Substrate 
MK2 Anti-MK2 Recombinant HSP27 (StressGen, 
#SPP-715) 
p38 MAPK Anti-p38 MAPK  Recombinant MK2, inactive 
(Upstate, #14-349) 
JNK Anti-JNK Recombinant ATF-2 (amino acids 
19-96) (Upstate) 
MKK3 MKK3 antiserum (RAW1) GST-p38 MAPK (Prof. Saklatvala 
laboratory) 
MKK6 Anti-MKK6 GST-p38 MAPK (Prof. Saklatvala 
laboratory) 
TAK1 Anti-TAB1 (Prof. P. Cohen 
laboratory) 
MBP-MKK6 (Prof. P. Cohen 
laboratory) 
Table 2.3: Kinase assay immunoprecipitating antibodies and substrates 
Statistics were not performed on these assays for the same reasons as 2.10. 
2.11.1 MK2, p38 MAPK and JNK kinase assays 
 
Cells were stimulated and lysed as for western blots (section 2.2.4.1) but kinase lysis buffer was 
used. A Bradford assay (section 2.2.4.3) was performed to determine the total protein in the 
lysate. All steps were carried out at 4 ºC to preserve kinase activity. 30 µl of protein G beads 
(Sigma-Aldrich) were added into each Eppendorf and washed with 500 μl kinase lysis buffer. 
The beads were centrifuged at 9 600 x g for 1 min at 4°C. The supernatant was removed. Cell 
lysate equivalent to 100-200 µg total protein made up to 500 μl with kinase lysis buffer was 
added to the beads. 5 µl of the appropriate antiserum or 1 μg of purified anti-MK2 antibody was 
added. The beads were vortexed briefly, tubes placed on a rotating wheel and incubated 
overnight at 4 °C. The samples were centrifuged for 1 min at 10 000 x g, 4 °C and the 
supernatant removed. The beads were washed four times with 1 x RIPA and twice with fresh 1 
x kinase wash buffer containing freshly added DTT (2 mM final concentration). After each 
wash the beads were centrifuged for 1 min at 10 000 x g, 4 °C. 30 µl of the appropriate kinase 
assay reaction mix was added to each sample and incubated with shaking for 30 min at room 
temperature with 1 μg recombinant protein substrate (except for p38 MAPK assay where 0.5 μg 
recombinant MK2 was used) and [γ32P]-ATP. For MK2 kinase assays this incubation was 40 
min. The reaction was stopped by the addition of 10 µl 4 x SDS-PAGE sample buffer and 
mixed by pipetting. The samples were centrifuged at 10 000 x g for 1 min, 4 °C and the 
supernatant loaded onto a 10 % SDS-polyacrylamide gel and electrophoresed. The gel was 
stained with Coomassie Brilliant Blue G, destained with 50 % (v / v) methanol, 5 % (v / v) 
acetic acid overnight and dried on 3MM paper using a gel dryer (BioRad) for 2 h at 80 °C under 
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vacuum. Phosphate incorporation was visualised and quantified by autoradiography using a 
phosphorimager Fuji FLA-2000 (Raytek Scientific Ltd, Sheffield, UK). Table 2.3 shows the 
immunoprecipitating antibodies and substrates for each kinase assay. 
 
2.11.2 MKK3 and MKK6 kinase assays 
 
The kinase assay was performed as in section 2.2.6.1 however, the samples were lysed in whole 
cell lysis buffer and the incubation step with the antibody was for 3 h. 
 
2.11.3 TAK1 kinase assay 
 
This kinase assay is based on the co-immunoprecipitation of TAK1 with its binding protein, 
TAB1. Cells were stimulated with IL-1α for stated times. Cells were washed twice with ice-cold 
PBS and lysed for 10 min in TAK1 lysis buffer. Cell lysates containing 100-300 µg total protein 
were made up to a volume of 300 µl with TAK1 lysis buffer and incubated for 1 h with rotation 
with 1 µg anti-TAB1 antibody per point. 30 µl protein G beads (Sigma Aldrich) were pre-
washed with 500 µl TAK1 lysis buffer and incubated for a further 1 h. Samples were spun down 
at 10 000 x g for 1 min and the supernatant was removed by aspiration. Samples were washed 
three times with 1 ml TAK1 lysis buffer containing 0.5 M sodium chloride, in the absence of 
sucrose (the sucrose caused the beads to become stickier and not wash properly). The beads 
were washed a final time in 1 ml 50 mM Tris HCl pH 7.5. Buffer B was freshly prepared and 50 
µg ml-1 inactive MBP-MKK6, 0.1 mM cold ATP, 0.2 mM [α-32P] ATP was added. The reaction 
was performed in the hot block at 30 ºC for 30 min and stopped by the addition of 15 μl 4 x 
loading buffer. Samples were then incubated for 8 min at 95 ºC, centrifuged at 16 000 x g to 
pellet the beads. Supernatants were analysed by SDS-PAGE on a polyacrylamide gel.  
 
2.12 Ubiquitination assays 
 
This method was adapted from Jaffray et al., (Jaffray and Hay, 2006). Briefly, cells were serum 
starved for 3 h. Where used MG-132 (10 µM final concentration) pre-incubated on the cells for 
1 h prior to IL-1α stimulation. Cells were washed three times with 1 ml ice-cold PBS. Cells 
were scraped in SDS buffer (500 µl per 10 cm dish) and heated at 90 ºC for 10 min. Samples 
were spun through a QiaShredder 250 column (Qiagen) at 16 000 x g for 1 min. Lysates were 
diluted 1 in 10 in renaturation buffer and centrifuged at 900 x g, 4 ºC for 15 min. 60 µl protein 
G beads were washed in 1 ml renaturation buffer. Equal amounts of total protein in cell lysates 
were added to the pre-washed protein G beads and samples were incubated with 1 µg antibody 
overnight for IRAK1 and IKKγ or 2 h for TRAF6 at 4 ºC. The beads were pelleted at 900 x g, 4 
Chapter 2   Materials and Methods 
   
 75
ºC and the supernatant kept for analysis. Beads were washed five times in renaturation buffer, 
with a centrifugation step of 2 min at 10 000 x g between each wash. Each pellet was 
resuspended in 60 µl 2 x sample buffer, boiled for 8 min at 95 ºC and analysed by SDS-PAGE 
and western blotting. Variations on this protocol were tried including addition of sample buffer 
and analysis by SDS-PAGE following the QiaShredder step. 
 
2.13 Cell fractionation experiments 
 
2.13.1 Detergent lysis 
 
Cells were grown until confluent in 10 cm dishes and then stimulated with IL-1α for the times 
indicated. The cell sheet was washed once with 5 ml ice-cold PBS. All subsequent steps were 
performed at 4 ºC. Cells were scraped into 1 ml PBS, and spun down at 400 x g for 5 min. Cell 
pellets were resuspended in 250 μl cytoplasmic lysis buffer and incubated 10 min on ice. 
Samples were centrifuged at 400 x g for 10 min and the supernatant (cytoplasm) removed 
carefully. The pellet was washed twice in 200 μl wash buffer and centrifuged at 400 x g for 5 
min. The nuclei were resuspended in 50 μl nuclear extraction buffer and incubated on ice for 30 
min, vortexing at medium speed for 10-15 sec, every 10 min. The nuclear extract was clarified 
by centrifugation at 16 000 x g for 15 min. The supernatant was carefully removed and the 
pellet discarded. The same proportion of cytoplasmic extract and nuclear extract (cell 
equivalent) was analysed by SDS-PAGE. This enabled direct comparison of the amount of 
protein in the cytoplasmic and nuclear fractions.   
 
2.13.2 Dounce homogenisation 
 
Cells were cultured until confluent in 10 cm dishes. The cells were stimulated with IL-1 and 
washed once with 5 ml ice-cold PBS. All subsequent steps were performed at 4 ºC. Cells were 
scraped into 1 ml PBS, spun down at 400 x g for 5 min and the supernatant discarded. Cells 
were incubated on ice for 10 min with swelling buffer and lysed with 20 strokes of the tight 
fitting of a 1 ml Dounce homogeniser (Wheaton, USA). Samples were transferred into 
Eppendorf tubes on ice. The nuclei were spun down at 1 600 x g, 4 ºC for 10 min. The 
supernatant (cytoplasmic fraction) was transferred into a fresh Eppendorf tube. The residual 
cytoplasmic fraction was removed by pipetting. 200 µl whole cell lysis buffer was used to 
resuspend the nuclear pellet. The nuclei were sonicated for 10 min in a sonicating water bath. 
The nuclear extract was clarified by centrifugation at 16 000 x g for 10 min at 4 ºC.  
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2.13.3 Confocal microscopy 
 
2.13.3.1 Immunofluorescence  
 
200 000 HDFs were seeded into Lab-Tek Chamber Slide System (nunc, Thermo Fisher 
Scientific, Langenselbold, Germany), 2 wells per glass slide. The following day these were 
stimulated with IL-1 and fixed. Alternatively, 30 000 cells were seeded into the slide system and 
an RNAi experiment performed as in section 2.7.2.1. One set of wells were lysed as a control in 
TAK1 / TAB1 lysis buffer as in section 2.11.3. The other set were treated for 
immunolocalisation by confocal microscopy. PBS was used for most antibodies however, for 
anti-phosphorylated p38 MAPK TBS was used. Fresh paraformaldehyde (4 % w / v) was made 
in 100 ml PBS and heated for 15 min at 65 °C. The cells were washed with 1 ml PBS for 5 min 
and fixed in 4 % paraformaldehyde for 10 min, room temperature. The fixer was aspirated off, 
cells washed with 1 ml PBS for 5 min and permeabilised by incubation in 0.1 % Triton X-100 
PBS for 3 min. Samples were blocked in 15 % BSA PBS for 1 h, room temperature. Blocking 
solution was removed. The cells were re-permeabilised in 0.1 % Triton X-100 in PBS for 5 min 
and then incubated in 500 μl primary antibody overnight at 4 °C (1:500 anti-HSP27 together 
with 1:100 mouse monoclonal anti-p38α MAPK in 15 % (w / v) BSA in PBS or 1:100 anti-
phosphorylated p38 MAPK (Thr180 / Tyr182) in 15 % (w / v) BSA TBS. Primary antibody was 
removed and the cells washed twice in 1 ml PBS for 5 min, once in 0.1 % Triton X-100 for 3 
min and twice more in 1 ml PBS for 10 min. The cells were incubated in 1:1000 secondary 
antibody and 1:200 of the nuclear stain, propidium iodide (Invitrogen) for 90 min, room 
temperature, rotating, in the dark. The secondary antibody was removed and the cell sheet 
washed four times in 1 ml PBS for 10 min. 200 μl sterile 50 % (v / v) glycerol PBS was added 
to the cell sheet and the cover glass (VWR International, Lutterworth, Leic, UK) added. The 
outside edges were sealed with nail varnish.     
 
2.13.3.2 Image collection 
 
Optical imaging was performed using a x 60 oil immersion lens on a Perkin Elmer Ultraview 
Spinning Disc confocal microscope (PerkinElmer, Waltham, Massachusetts, USA) with a 
Hamamatsu Orca CCD camera (Hamamatsu Photonics UK Ltd, Welwyn Garden City, UK) 
attached. The same laser setting was used for all slides for each stain. Intensity measurements of 
fluorescence inside the cytoplasm and the nucleus were obtained by defining these areas and 
analysing using the ImageJ software (National Institute of Health, Maryland, USA).  
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2.14 Methylthiazolium (MTT) assay 
 
Cells were treated as usual and on the day of lysis the medium was removed from the wells to 
leave a final volume of 900 µl (per well of a 6 well plate). 100 µl MTT solution was added 
(final concentration of 0.5 mg ml-1). The cells were incubated for 4 h at 37 °C to form crystals. 1 
ml of solution containing 10 % SDS and 10 mM HCl was added to the cells to solubilise the 
crystals and this was incubated at 37 °C overnight. The optical density was determined by 
measuring the absorbance at 570 nm of 100 µl of each sample in triplicate in a 96 well ELISA 
plate using a Multiskan biochromic plate reader (Thermo Electron Corporation). 
 
2.15 Flow cytometry 
 
HeLa cells or HDFs were seeded in 6 well plates and transfected with siRNA. The cells were 
transfected with 50 ng pmaxGFP DNA made up to 1 µg or 5 µg respectively with pCMV FLAG 
DNA (Empty vector) for SuperFect or calcium phosphate transfections. The cells were then 
grown until confluent (96 h after seeding). Cells were washed with PBS and trypsinised for 5 
min at 37 °C using 1 ml trypsin-EDTA per well. The plates were agitated and the trypsinised 
cells diluted in 2 ml PBS. The cells were centrifuged at 500 x g for 5 min, room temperature. 
The supernatant was discarded and the pellet resuspended in 200 µl PBS. The live cell 
population was identified by cell size and granularity. The argon blue laser of the BD LSR flow 
cytometer (BD Bioscience, Oxford, UK), which excites at wavelength 488 nm was used to 
identify the GFP positive cells. The fluorescence emitted by GFP positive cells was detected in 
the green (FITC) channel. 20 000 or 10 000 cells were counted per sample for HeLa and HDFs 
respectively. 
 
2.16 Transformation of competent cells 
 
A waterbath was pre-heated to 42 ºC. 1 µl previously maxi-prepped DNA was added to 25 µl 
competent Top 10 cells on ice and gently tapped. The cells were incubated on ice for 30 min. 
The bacteria were heat shocked at 42 ºC for exactly 45 sec and returned to ice. 400 µl of Luria 
Bertoni (LB) media without antibiotics to each tube and incubate with shaking at 37 ºC for 30 
min to allow the bacteria to recover. 200 µl of a 1:10 dilution was spread onto an LB agar plate 
containing the appropriate antibiotic. 
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2.17 ‘Maxiprep’ of DNA 
 
The ‘Maxiprep’ system allows for large scale preparations of plasmid DNA using the 
‘UltraMobius 1000 Plasmid kit’ from Novagen. Single colonies were picked from an LB-agar 
plate and cultured in 100 ml LB containing the appropriate antibiotic at 37 ºC with agitation, 
overnight. Centrifugation at 5 000 x g for 15 min at 4 ºC was used to pellet the bacteria. The 
medium was removed, the bacteria lysed by alkaline lysis. Neutralisation, anion-exchange 
chromatography with a column supplied with the kit and precipitation with isopropanol was 
carried out exactly according to the manufacturer’s instructions. The DNA pellet was washed 
with 70 % ice-cold ethanol and resuspended in 100 – 500 µl DNase free water, depending upon 
the pellet size. The concentration of the plasmid DNA was determined by measuring the 
absorbance of a dilution at 260 nm (A260). The purity of the DNA was assessed by measuring 
the absorbance at 280 nm (A280) and calculating the ratio A260/A280. 
 
2.18 RNA extraction 
 
RNA was isolated from cells using the RNA Blood Mini kit (Qiagen Ltd.) following the 
manufacturer’s instructions. Briefly, the cells were stimulated for the appropriate time with IL-
1, washed in ice-cold PBS and lysed in RLT lysis buffer. The lysate is homogenised with a 
QIAshredder, solubilised with 70 % ethanol and annealed to a QIAamp spin column. The 
sample was washed and the RNA eluted in RNAse free water. The concentration of RNA was 
determined by measuring the absorbance at 260 nm (A260). 
 
2.19 Real Time Polymerase Chain Reaction (qRT-PCR) 
 
Real time PCR was used to measure the gene expression. The RNA was taken from the RNA 
extraction step and reverse transcription and PCR steps were performed. Following the protocol 
that I used these steps were combined. A Reverse Transcriptase qPCR mastermix No ROX kit 
from Eurogentec (Southampton, UK) was used. RNA samples were diluted 5-fold. The reaction 
mix per sample was 2.45 µl water, 5 µl buffer, 0.05 µl Euroscript reverse transcriptase and 
RNase inhibitor mix, 0.5 µl probe and 2 µl (0.1 µg) RNA. The probes used were DUSP1 
(MKP1) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Applied Biosystems, 
Foster City, CA, USA). The cycle used was 30 min at 48 ºC for the reverse transcription to 
generate cDNA, 10 min at 95 ºC, followed by 45 cycles of 3 sec at 95 ºC and 30 sec at 60 ºC in 
a thermal cycler Rotor-Gene 6000 series machine (Corbett Life Science, Sydney, Australia). 
The data was analysed using ΔΔCt relative quantification on the Rotor-Gene 6000 software 
(Corbett Life Science). 
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3.1 Introduction 
 
p38 MAPK has long been known to play an important role in inflammation, particularly through 
the stabilisation of ARE-containing mRNAs of inflammatory mediators. HSP27 is a substrate of 
MK2, a kinase downstream of p38 MAPK. Therefore, it was thought that HSP27 may play a 
role in mediating regulation by p38 MAPK of mRNAs of the inflammatory response. A 
previous PhD student in the laboratory, Kate Alford, found that depletion of HSP27 inhibited 
the IL-1-induced expression of IL-6 and COX-2 protein and mRNA. A widely used strategy to 
examine the function of a gene / protein in vivo is to generate a ‘knockout’ mouse. A ‘knockout’ 
mouse has a targeted deletion of both copies of the gene of interest. Conditional and constitutive 
HSP25-/- mice were in the process of being generated commercially by GenOway at the 
beginning of my project to allow the investigation of HSP25 function in inflammation in vivo. 
 
3.2 Tissue specific expression of HSP25 
 
To investigate HSP25 function in mice it was first necessary to determine the tissue distribution 
of the small heat shock protein. Tissues from a c57BL/6 mouse were dissected and each tissue 
sample was homogenised in 5 ml whole cell lysis buffer.  Lysates containing 25 μg total protein 
were loaded on a SDS-PAGE gel and analysed by western blot for HSP25. This showed that 
HSP25 was variably expressed in different tissue types. HSP25 was constitutively expressed in 
many organs that contain smooth muscle, for example stomach and colon (Fig. 3.1). High levels 
of HSP25 were found in muscle (Fig. 3.1), which is in agreement with previous reports (Neufer 
and Benjamin, 1996; Pichon et al., 2004).   
 
Unfortunately, the generation of HSP25-/- mice was delayed and therefore a different strategy 
was needed. It was decided to try and elucidate the mechanism whereby HSP25 / 27 amplifies 
inflammatory gene expression. Many techniques exist to study in vitro mechanisms including 
overexpression and loss of function. The strategy chosen was a loss of function approach using 
transient depletion of the protein from the cell by RNA interference (RNAi) with siRNAs. This 
strategy was chosen because it would allow a rapid analysis of the function of HSP25/27 in 
inflammatory gene expression and IL-1 signalling. An analysis of cell types expressing HSP25 / 
27 was performed to determine which cell types would be best suited for this purpose.  
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Figure 3.1: Tissue distribution of HSP25 in C57BL/6 mice.  
A C57BL/6 mouse was dissected and the organs / tissues homogenised in whole cell lysis 
buffer. For each tissue sample 25 μg of total protein was loaded and analysed by SDS-PAGE 
and western blot was performed for HSP25. This western blot is representative of two 
experiments. 
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3.3 The expression of HSP27 in different cell types  
 
The murine cell types examined were mouse embryonic fibroblasts (MEFs), L929 cells (mouse 
areolar fibroblasts), RAW 264.7 (murine macrophage-like) cells and primary bone marrow 
derived macrophages. Of these HSP25 was only detected in MEFs (Fig. 3.2A/B). It has been 
documented in the literature that L929 cells do not express HSP25 however, it is surprising that 
two different fibroblast cell populations differ so greatly in the protein expression levels of 
HSP25. 
 
The human cell types tested for HSP27 included a mixture of cell lines and primary cells. For 
the cell lines 293 (human embryonic kidney epithelial), A549 (human alveolar epithelial), HeLa 
(human cervical epidermal carcinoma) and THP-1 cells (human monocytic leukaemia) were 
examined. Neonatal human dermal fibroblasts (HDFs) were also examined. Primary cells that 
were elutriated from buffy coat blood packs included human monocytes and T cells. The 
extraction of granulocytes from the buffy coat blood packs was unsuccessful due to the age of 
the blood packs and the short lifespan of granulocytes. Instead fresh granulocytes were provided 
by laboratory members. Some monocytes were differentiated into macrophages using either 
macrophage colony-stimulating factor (M-CSF) or granulocyte monocyte colony-stimulating 
factor (GM-CSF). All cell types were lysed in whole cell lysis buffer and equal amounts of total 
protein in the cell lysate were analysed by western blot. This approach was used to eliminate the 
difficulties in the comparison of loading controls, such as tubulin, due to variable expression in 
different cell types.  
 
HSP27 was constitutively expressed in all of the immortalised human cell lines tested; HeLa, 
293, THP-1 and to a lesser extent A549 cells (Fig. 3.2C). HSP27 expression was comparatively 
weak in A549 cells in two experiments, which was unexpected because HSP27 is thought to be 
expressed strongly in A549 cells (Skandrani et al., 2006). These results may suggest that HSP27 
is expressed during the immortalisation of the cells; however HDF cells also expressed a similar 
level of HSP27 protein as HeLa cells (Fig. 3.2C). Endothelial cells and chondrocytes express 
roughly equivalent amounts of HSP27 protein levels as HeLa cells and HDFs (Jonathan Dean, 
unpublished). The expression of HSP27 in all passaged human cell types tested raised a concern 
that HSP27 is induced upon the maintenance and passage of cells in culture. Therefore L. 
Rawlinson tested for HSP27 expression in freshly extracted cartilage tissue. HSP27 expression 
was also found in freshly extracted cartilage tissue indicating that at least for chondrocytes the 
expression of HSP27 is present in this human tissue.  
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HSP27 was not detected in granulocytes or T cells (Fig. 3.2C and D). With overnight exposures 
a faint band could be detected in primary human monocytes. However, there was high 
expression of HSP27 in M-CSF- and, to a greater extent, GM-CSF- differentiated macrophages. 
A titration of recombinant HSP27 protein run in parallel to the samples allowed an 
approximation of the protein expression levels to be determined. In the M-CSF-differentiated 
macrophages HSP27 makes up about 0.015 % of the total cellular protein in comparison to 
0.025 % for GM-CSF differentiated macrophages and 0.125 % in HDF cells. The very high 
expression in HDF was not surprising: HSP27 is an extremely abundant protein and similar 
levels of expression have been reported previously (Sakaguchi et al., 2001). 
 
The difference in expression levels of HSP27 in primary human monocytes and THP-1 cells 
may be because THP-1 cells are a monocytic leukemia cell line and HSP27 is well known to be 
overexpressed in many cancers. The observation that HSP27 is expressed in both M-CSF- and 
GM-CSF-differentiated macrophages but not murine bone marrow-derived macrophages or 
RAW 264.7 cells was a surprise. This may be a species difference. Alternatively, HSP27 
expression could be artificially induced by the process of differentiation using either M-CSF or 
to a greater extent GM-CSF. The lack of constitutive expression in bone marrow-derived 
macrophages or RAW 264.7 cells does not mean that HSP27 is never expressed in these cells. 
There have been reports of induction of HSP25 / 27 in response to stresses such as heat shock 
(Champagne et al., 1999; Landry et al., 1982) and exposure to LPS in intestinal epithelial cells 
(Kojima et al., 2004). 
 
HeLa cells were chosen as the system of choice to study the role of HSP27 in IL-1 signalling. 
The abundance of constitutive HSP27 in HeLa cells and their ease of transfection made the 
HeLa cell the ideal system to probe the function of HSP27 in inflammatory gene expression. 
Early work investigating the effect of HSP27 depletion on IL-6 and COX-2 gene expression in 
the laboratory was also performed in HeLa cells. It would be of great interest to examine HSP27 
function in endothelial cells however, endothelial cells are difficult to transfect and attempts to 
deplete HSP27 from human umbilical vein endothelial cells have failed. The supply of 
endothelial cells was also limited. Human dermal fibroblasts are more difficult to transfect than 
HeLa cells but were identified as a potential primary cell to verify the results in HeLa cells.  
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Figure 3.2: Expression of murine HSP25 or human HSP27 in different cell types. A / B. 
Expression levels of HSP25 in murine cell types. Different cells types were harvested in whole 
cell lysis buffer. 15 μg total protein was separated by SDS-PAGE and western blots were 
performed for HSP25. C / D. Expression levels of HSP27 in human cell types. Different cells 
types were harvested in whole cell lysis buffer. 20 μg total protein was separated by SDS-PAGE 
and western blots were performed for HSP27. A titration of recombinant HSP27 was run in 
parallel to the cell lysates to provide an approximation for the amount of HSP27 in 20 µg total 
cell lysate in each cell type. These blots are representative of at least two independent 
experiments. Primary human monocytes, macrophages, granulocytes and T cells were provided 
by Lynn Williams and Bernard Gregory.  
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3.4 HSP27 depletion inhibits IL-1-induced COX-2 protein expression in two sources of 
HeLa cells 
 
Previous work in our laboratory has shown that depletion of HSP27 by RNAi inhibited the 
induction by IL-1 of COX-2, IL-6 and IL-8 in HeLa cells. These experiments were performed in 
cells obtained as a gift from Yamanouchi Ltd. Given the variability in the properties of HeLa 
cells from different laboratories it was decided to test whether these results could be repeated in 
HeLa cells from the American Tissue Culture Collection (ATCC). Six siRNA oligonucleotides 
that target HSP27 mRNA (HSP27#1-#6) had been used previously in our laboratory. The three 
that had been found to deplete HSP27 protein most strongly (#1, #2, #5) were chosen for this 
analysis to control for off-target transcript silencing. 
 
HeLa cells were transfected with a relatively low dose (10 nM) of HSP27 siRNAs, to minimise 
off-target effects. A non-targeting control siRNA (Scramble) was also used, or the cells were 
left untransfected. 72 h after the addition of the siRNA / lipid complexes cells were stimulated 
with IL-1 (20 ng ml-1) for 4 h and lysed. Western blots were performed on the lysates for COX-
2, HSP27 and α-tubulin (as a loading control). A single siRNA transfection with Oligofectamine 
in ATCC HeLa cells did not inhibit COX-2 protein induction by IL-1 (Fig. 3.3A). The lack of 
inhibition of COX-2 expression in the ATCC HeLa cells may have been a result of only a weak 
depletion of HSP27 in these cells. Other transfection reagents were used to try to improve the 
depletion but to no avail (data not shown); therefore a different strategy was adopted. Cells were 
subjected to two rounds of siRNA transfection using Oligofectamine, 24 h apart. 48 h after the 
second transfection the cells were stimulated with IL-1 for 4 h and lysed. Sequential transfection 
of ATCC HeLa cells with HSP27 siRNA improved the degree of depletion of HSP27 protein 
(Fig. 3.3B) to such an extent that only a residual HSP27 was detected for HSP27#2 and #5 with 
an overnight exposure (data not shown). IL-1-induced COX-2 protein was inhibited by all three 
siRNAs. HSP27#5 inhibited COX-2 protein expression the most strongly (Fig. 3.3B).   
 
These results suggest that strong depletion of HSP27 causes inhibition of IL-1-induced COX-2 
protein expression but a poor knockdown is insufficient. One explanation may be that there is a 
threshold of HSP27 required in the cell for the induction of COX-2 expression by IL-1. 
Alternatively, if few cells were successfully transfected the HSP27 present in the non-
transfected cells could mask any regulation in cells where HSP27 had been depleted. The results 
in this section also indicate that the inhibition of IL-1-induced COX-2 protein is not an artefact 
associated with Yamanouchi HeLa cells or an off-target effect of the siRNA. Cells from 
Yamanouchi were used for the rest of the experiments on HeLa cells because in these cells only 
one siRNA transfection is required to achieve strong depletion of HSP27. 
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Figure 3.3: HSP27 depletion following sequential but not single transfection inhibits IL-1-
induced COX-2 protein expression in American Tissue Culture Collection HeLa cells. 
ATCC HeLa cells were subjected to one round of siRNA transfection (A) with Scramble 
dsRNA or three siRNA oligonucleotides targeting different sequences in HSP27 mRNA; 
HSP27#1, HSP27#2 and HSP27#5. After 72 h cells were stimulated with 20 ng ml-1 IL-1 for 4 
h, harvested and lysed in whole cell lysis buffer. SDS-PAGE and western blotting were 
performed to detect COX-2, HSP27 and the loading control, α-tubulin. A second round of 
transfection 24 h after the first was performed to improve HSP27 depletion (B). These blots are 
representative of four independent experiments. 
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3.5 IL-1-induced phosphorylation of HSP27 
 
The actinomycin D chases that had shown the role of HSP27 in the stabilisation of IL-1-induced 
COX-2 mRNA had been performed at 1.5 hr post-IL-1 stimulation (Alford, 2006). At this time 
after stimulation the activity of a kinase involved in mRNA stabilisation, MK2, is believed to 
have returned to a basal level. However, HSP27 is a major substrate of MK2 and the 
actinomycin D chases suggested that HSP27 may mediate the stabilisation of COX-2 mRNA. It 
was therefore pertinent to determine if HSP27 is still phosphorylated at this relatively late time 
point, 90 min, post-IL-1 stimulation. HSP27 is phosphorylated in response to IL-1 stimulation 
on three serine residues; 15, 78 and 82. Phosphorylation of HSP27 at serine 78 was detected at 
15 min and peaked at 30 min post-IL-1 (Fig. 3.4). However, residual Ser78 phosphorylation of 
HSP27 was still detectable at 90-120 min post-IL-1 stimulation. This would suggest that 
phosphorylation of HSP27 may mediate the regulation of IL-1-induced COX-2 mRNA 
stabilisation if only a small amount of HSP27 is required. The phosphorylation at serine 15 and 
serine 82 was not detected with the antibodies tried (data not shown). There are many reports in 
the literature that phosphorylation of small heat shock proteins such as HSP27 alters their 
oligomerisation state (Lelj-Garolla and Mauk, 2005; Rogalla et al., 1999). Therefore the 
oligomerisation state of HSP27 may be important for the regulation of IL-1-induced mRNA 
stabilisation. 
 
3.6 HSP27#5 siRNA inhibits IL-1-induced MK2 activity in HeLa cells 
 
 
Previous work in our laboratory using electrophoretic mobility shift assays (EMSAs) did not 
succeed in detecting HSP27 bound directly to RNA. However, it has been shown that p38 
MAPK stabilises ARE-containing mRNAs, such as COX-2, in response to inflammatory 
stimuli. Kotlyarov et al., observed that MK2 was important for the stabilisation of p38 MAPK 
and that p38 MAPK expression and activity was reduced in MK2-/- cells (Kotlyarov et al., 
2002). HSP27 is a substrate of MK2 and therefore may be involved in this feedback. It was 
decided to examine whether HSP27 depletion caused impairment of signalling by the p38 
MAPK pathway. It was not practical to perform all experiments using a large panel of siRNAs 
because of the need for detailed time courses, therefore a single siRNA was used. In previous 
work HSP27#5 was generally the most effective siRNA oligonucleotide for the depletion of 
HSP27 and therefore it was the principal HSP27 siRNA used in this study. Once the mechanism 
for HSP27 was elucidated the aim was to verify the results using rescue experiments or with 
alternative siRNAs.  
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Figure 3.4: Time course of IL-1-induced HSP27 phosphorylation at serine 78. Yamanouchi 
HeLa cells were stimulated with IL-1 for the times shown and lysed in whole cell lysis buffer, a 
Bradford assay was performed and the samples normalised. Proteins were separated by SDS-
PAGE on a 12 % polyacrylamide gel. Western blot analysis was performed to detect HSP27 
phosphorylated at serine 78 (P-HSP27) and total HSP27. This figure is representative of two 
experiments.  
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To investigate if HSP27 regulates MK2, the kinase downstream of p38 MAPK responsible for 
mRNA stabilisation, HeLa cells were transfected with either Scramble dsRNA or HSP27#5 
siRNA. 72 h later the cells were stimulated with IL-1 for different times and then lysed with 
kinase lysis buffer. MK2 was immunoprecipitated and its ability to phosphorylate recombinant 
HSP27 with [γ32P]ATP was measured. Western blots were also performed on the lysates to 
determine the level of HSP27 depletion achieved. IL-1 induced a 20-fold increase in MK2 
activity in Scramble-treated cells (Fig. 3.5). The peak IL-1-induced MK2 activity occurred 30 
min after IL-1 was added to the cells (Fig. 3.5). MK2 activity returned to basal levels after 2 h. 
In three experiments peak MK2 kinase activity was reduced by an average 57 % in cells treated 
with HSP27#5 (Fig. 3.5). At 1 h post-IL-1 there was an average 65 % inhibition of MK2 
activity (Fig. 3.5). The large error bar in Fig. 3.4 was due to different kinetics for peak IL-1-
induced MK2 activity. In two experiments the peak was 60 min post-IL-1 stimulation. These 
results suggest that the expression of HSP27 may be necessary for full activation of MK2 by IL-
1. Four hours post-IL-1 stimulation MK2 activity started to increase again in Scramble 
transfected cells and HSP27 depletion still inhibited the IL-1-induced activity at this time. This 
suggests that depletion of HSP27 with HSP27#5 inhibits both phases of MK2 activity and may 
link the regulation of IL-1 signalling to the inhibition of gene expression. It was not possible to 
examine MK2 expression because there is no suitable anti-MK2 antibody for western blotting 
human MK2 protein. 
 
3.7 HSP27#5 inhibits IL-1-induced p38 MAPK activation in HeLa cells 
 
HSP27 is required for full IL-1-induced MK2 activity therefore HSP27 may act on MK2 
directly or an upstream component of the IL-1 signalling pathway such as p38 MAPK. The 
effect of HSP27 depletion upon IL-1-induced p38 MAPK activation was investigated by 
immunoprecipitation of p38 MAPK and measurement of its ability to phosphorylate a 
recombinant MK2 substrate. The activation of MAPKs is triggered by phosphorylation and 
therefore phosphorylation can be used as a guide to the activation state of the MAPK. 
Activation of p38 MAPK was also analysed by western blot to detect phosphorylation of 
Thr180 and Tyr182, the phosphorylation sites essential for the activation on p38 MAPK. IL-1-
induced p38 MAPK activity peaked at 30 min post-IL-1 stimulation and returned to basal levels 
by 1 h (Fig. 3.6). In cells transfected with HSP27#5 siRNA, peak p38 MAPK kinase activity 
was reduced by 59 % (Fig. 3.6). A western blot showed that p38 MAPK phosphorylation was 
strongly inhibited in cells treated with HSP27#5 siRNA. p38 MAPK expression, as detected by 
western blot, was unchanged in HSP27#5-transfected compared with Scramble-transfected cells 
(Fig. 3.6). Therefore, the inhibition of detected p38 MAPK activity and activation was not  
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Figure 3.5: HSP27#5 siRNA inhibits IL-1-induced MK2 activity. Yamanouchi HeLa cells 
were transfected with either Scramble dsRNA or HSP27#5 siRNA. 72 h later the cells were 
stimulated with 20 ng ml-1 IL-1 and lysed with kinase lysis buffer at the times shown. MK2 was 
immunoprecipitated and a kinase assay was performed using recombinant HSP27 as the 
substrate. In the first two lanes of the phosphorimage a non-immune (anti-COX-2) antibody was 
used as a control. A. shows a phosphorimage of 32P-HSP27. Western blot analysis was carried 
out on the cell lysates, using 1/10th the amount as for the kinase assay, to detect HSP27 and α-
tubulin. B. Graph of mean MK2 activity induced by IL-1 in Scramble and HSP27#5-transfected 
cells from three separate experiments. Each experiment was normalised to the maximum MK2 
activity for that experiment. Error bars are standard error of the mean (S.E.M.).  
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Figure 3.6: HSP27#5 siRNA inhibits IL-1-induced p38 MAPK activation in HeLa cells. 
HeLa cells were transfected with either Scramble or HSP27#5 siRNA. Cells were incubated for 
72 h then stimulated with IL-1 for 30 min before lysis in kinase lysis buffer. p38 MAPK was 
immunoprecipitated and a kinase assay was performed on the immunoprecipitates by the 
measurement of recombinant MK2 phosphorylation. One tenth of the lysate used in the kinase 
assay was analysed by western blot. A. shows the phorphorimage of 32P-MK2 and western blots 
for HSP27, phosphorylated p38 MAPK and p38 MAPK. The western blots shown are 
representative of the three independent experiments. B. Graphical representation of 
phosphorimage results for Scramble and HSP27#5-transfected cells. Error bars are S.E.M. for 
three independent experiments. The data was normalised as for Fig. 3.5. 
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due to a decrease in p38 MAPK expression. The observed reduction in p38 MAPK activity and 
activation upon HSP27 depletion suggests that HSP27 targets p38 MAPK, or an upstream 
kinase and this causes the inhibition of IL-1-induced MK2 activity in HSP27-depleted cells.  
The extent of MK2 and p38 inhibition was similar therefore it appeared unlikely that HSP27 
exerts a direct / additional effect on MK2. 
 
3.8 In HeLa cells activation of JNK by IL-1 is inhibited by HSP27#5 siRNA 
 
The JNK and p38 MAPK pathways share some upstream components including the MKKK, 
TAK1. It was possible that HSP27 regulated IL-1-induced JNK as well as p38 MAPK activity. 
Cells were transfected with Scramble dsRNA or HSP27#5 siRNA. After 72 h incubation the 
cells were stimulated with IL-1 and lysed in kinase lysis buffer. Western blots were performed 
to identify JNK phosphorylated on its activatory residues, Thr183 and Tyr185 (Fig. 3.7). There 
were difficulties encountered in the detection of JNK phosphorylated at Thr183 and Tyr185 by 
western blot and the blot shown in Fig 3.7 is an overnight exposure. JNK activation was 
induced by IL-1 and peaked at 30 min post-IL-1 in Scramble-transfected cells. IL-1-induced 
JNK activation was strongly inhibited in HSP27-depleted cells (Fig. 3.7). There were no 
suitable anti-total JNK antibodies for western blot analysis therefore α-tubulin was used. The α-
tubulin blot confirmed that the inhibition of IL-1-induced JNK activity was not caused by a 
decrease in the total cellular protein or uneven loading of the gel.  
 
IL-1-induced JNK activity was assessed by kinase assay using recombinant ATF-2 as the 
substrate. The peak of JNK activity was at 30 min post-IL-1 stimulation and the activity had 
returned to basal levels by 1 h (Fig. 3.7). Peak kinase activity of JNK was inhibited by an 
average of 64 % in HSP27#5-transfected cells (Fig. 3.7). This result confirmed that the 
regulation of IL-1-induced JNK activation by HSP27 corresponded to a decrease in IL-1-
induced JNK activity. These results suggest that HSP27 may target a common upstream 
signalling pathway component or a phosphatase that can act on both JNK and p38 MAPK. 
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Figure 3.7: HSP27#5 siRNA inhibits IL-1-induced JNK activity in HeLa cells. HeLa cells 
were transfected with either Scramble dsRNA or HSP27#5 siRNA, as before. The cells were 
stimulated with IL-1 and lysed in kinase lysis buffer. JNK was immunoprecipitated and a kinase 
assay was performed on the immunoprecipitates by measurement of its ability to phosphorylate 
recombinant ATF-2. One tenth of the sample used for the kinase assay was analysed by western 
blot to detect phosphorylated JNK, HSP27 and α-tubulin (A). A shows the phosphorimage of 
ATF-2 phosphorylation and western blots representative of three separate experiments. B is a 
graph of phosphorimage data from three independent JNK kinase assays. Error bars show 
S.E.M. The data was normalised as for Fig. 3.5. 
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3.9 HSP27#5 siRNA does not inhibit IL-1-induced ERK activation  
 
IL-1 strongly activates p38 MAPK and JNK, however it can also activate the NF-κB pathway 
and to a lesser extent ERK. However, while the p38 MAPK, JNK and NF-κB pathways are 
activated by TAK1, ERK is activated by an alternative MKKK. ERK has been implicated in 
COX-2 expression, for example PMA has been shown to induce COX-2 expression through the 
activation of protein kinase C and subsequently ERK (Chang et al., 2005). However, PMA 
induced COX-2 expression was unaffected by HSP27 depletion (Alford, 2006). The effect of 
HSP27 depletion on IL-1-induced ERK activity was investigated to try and elucidate the HSP27 
signalling mechanism further.  
  
HSP27 was depleted in HeLa cells with HSP27#5 siRNA, as before, and activation of ERK by 
IL-1 was measured. Initially kinase assays were performed in an attempt to quantify ERK 
activity by following phosphorylation of recombinant myelin basic protein (MBP). However, 
these assays were unsuccessful due to non-specific phosphorylation of the substrate (data not 
shown) and therefore western blots to detect phosphorylated ERK were performed. ERK 
activation was assessed using an antibody that recognises ERK phosphorylated on its activatory 
residues Thr202 and Tyr204. As for p38 MAPK, IL-1 strongly induced phosphorylation of ERK 
at 30 min post stimulation. Transfection of cells with HSP27#5 siRNA had no effect on peak 
IL-1-induced ERK phosphorylation at these sites (Fig. 3.8). The expression of ERK was 
unaltered by transfection of the cells with HSP27#5 (Fig. 3.8). However, the ERK band 
underwent a small shift in mobility probably caused by phosphorylation at 30 min post-IL-1. 
The lack of HSP27-dependent regulation of ERK suggests that HSP27 may regulate a common 
upstream pathway component for JNK and p38 MAPK that is not shared with ERK, for 
example TAK1. 
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Figure 3.8: HSP27#5 siRNA does not inhibit peak IL-1-induced ERK phosphorylation. 
HeLa cells were depleted of HSP27 by RNAi with HSP27#5 siRNA as before. The cells were 
stimulated with IL-1 for the times shown. The cells were lysed in kinase lysis buffer and 
western blots were performed to detect phosphorylated ERK and HSP27. The blot was stripped 
and re-probed for total ERK as a loading control. Similar results were obtained in four separate 
experiments. 
 
Chapter 3                                                     Regulation of IL-1 signalling in HeLa cells by HSP27 
   
 96
3.10 HSP27 depletion inhibits IL-1-induced MKK3 / MKK4 / MKK6 / MKK7  
 
JNK and p38 MAPK are both activated by dual phosphorylation of Thr and Tyr of the 
phosphorylation motif Thr-Xaa-Tyr by MKKs. MKK3 and MKK6 are thought to be relatively 
specific activators of p38 MAPK whereas MKK4 and MKK7 phosphorylate JNK. However, 
MKK4 has been reported to be able to phosphorylate both p38 MAPK and JNK in vitro 
(Derijard et al., 1995). MKK3, 4 and 6 are highly homologous and therefore it would be 
possible for HSP27 to regulate both of them through the same mechanism. Regulation of the 
MKKs would directly affect the activation of p38 MAPK and JNK but not ERK. 
 
Other researchers in the laboratory used RNAi to determine if HSP27 regulates MKK3, MKK4, 
MKK6 and MKK7 activity and activation (Alford et al., 2007). Scramble and HSP27#5 
transfected cells were stimulated with IL-1, lysed and analysed by western blot to detect HSP27 
and MKK3 / MKK6 phosphorylated at their activation sites (Fig. 3.9A, Dr. J. Dean). Cell 
lysates were analysed by kinase assay to examine MKK4 (Fig. 3.9B, L. Rawlinson) and MKK7 
(Fig. 3.9C, L. Rawlinson) activity. Western blots were performed to detect HSP27 and α-
tubulin. The activities of all four MKKs were reduced in HSP27 depleted cells (Fig. 3.9). Peak 
MKK4 mean activity was reduced by 65 % and peak MKK7 mean activity by 60 % (Fig. 3.9B 
and 3.9C). The inhibition of the MKK activities is similar to that of p38 MAPK and JNK and 
therefore may account for the inhibition observed for these MAPKs. All four MKKs are thought 
to be activated by a common upstream activator, TAK1, in response to IL-1 signalling, whereas 
ERK is not activated by this MKKK. Therefore these results suggested that an upstream 
activator MKKK may be regulated by HSP27. 
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Figure 3.9: HSP27#5 siRNA inhibits IL-1-induced activation of the p38 MAPK (MKK3 
and MKK6) and JNK (MKK4 and MKK7) activators. A. Western blot analysis of MKK3 
and MKK6 activation using an antibody to detect MKK3 phosphorylated on Ser189 and Thr193 
and MKK6 phosphorylated on Ser207 and Thr211. The blot was stripped and re-probed for total 
MKK3 and MKK6. B. Kinase assay of MKK4 activity using a GST-JNK (K55R) mutant as the 
substrate. On the right is a graphical representation of the kinase assay phosphorimage data. 
Western blots were performed to detect HSP27 and α-tubulin. C. Kinase assay of MKK7 
activity and western blots of HSP27 and α-tubulin (as B). MKK3 / MKK6 experiments were 
performed by JL Dean and MKK4 / MKK7 experiments were performed by L. Rawlinson. 
Figure from taken from (Alford et al., 2007). 
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3.11 HSP27 depletion inhibits IL-1-induced TAK1 activity  
 
There are a number of MKKKs reported in the literature as important for the activation of 
MAPK signalling in response to pro-inflammatory stimuli. There has been some controversy 
over which MKKK is the most important. However, there is compelling evidence, particularly 
from work using TAK1 deficient mice, to suggest that TAK1 is physiologically important in 
MAPK signalling (Sato et al., 2005). If TAK1 was the MKKK responsible for the propagation 
of the IL-1 signal to p38 MAPK and JNK in HeLa cells it was possible that HSP27 may 
regulate IL-1 signalling through it. Work by other members of the laboratory added further 
credence to the possibility that TAK1 may be the target of HSP27 regulation when it was found 
that IL-1-induced IKKβ activity was inhibited in HSP27 depleted cells (Alford et al., 2007). To 
investigate this possibility an assay was used to measure TAK1 activity in lysates from HSP27 
depleted and Scramble-transfected cells. The kinase assay used was modified from Cheung et 
al., (Cheung et al., 2003).  
 
It is not possible to immunoprecipitate TAK1 directly in order to determine if there is any effect 
on TAK1 activity. However, TAK1 is found in a constitutive complex with TAB1 and TAB2 / 
TAB3. TAK1 was co-immunoprecipitated using an anti-TAB1 antibody. The 
immunoprecipitate was incubated with the recombinant substrate MBP-MKK6 and [32P]ATP 
for 30 min. The incorporation of 32P in MBP-MKK6 was then measured. Dr. S. Glennie found 
that total TAK1 protein was unaffected in HSP27 depleted cells (Fig 3.10A). TAK1 activity was 
only weakly inhibited (53 % at 5 min and 30 % at 10 min, the time post-stimulation with 
maximal TAK1 activity) in HSP27 depleted cells. The mean inhibition of IL-1-induced TAK1 
activity was lower than the 60-70 % inhibition of IL-1-induced MKK4, MKK7, p38 MAPK or 
JNK activity in HSP27-depleted cells. This would suggest that TAK1 may not be entirely 
responsible for the HSP27 regulation of p38 MAPK or JNK activity. It was possible that HSP27 
may regulate two points in the IL-1 signalling pathway, one at the level of TAK1 complex and 
another at the level of the MKKs. 
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Figure 3.10: HSP27 depletion partially inhibits IL-1-induced TAK1 activity in HeLa cells. 
Cells were transfected and stimulated with IL-1 as shown. An antibody raised against TAB1 
was used to immunoprecipitate TAK1 from Scramble (Scr)- or HSP27#5-transfected cells. 
TAK1 activity was measured through the incorporation of 32P in the recombinant substrate 
MBP-MKK6. A. A portion of the samples used for the kinase assay was analysed by western 
blot for HSP27, TAK1 and α-tubulin. B is a graphical illustration of mean TAK1 activity (± 
S.E.M.) for four independent experiments as a percentage of that in Scramble (Scr)- transfected 
cells at 10 min post-IL-1 stimulation. The experiments were carried out by S. Glennie and the 
figure was from Alford et al., (Alford et al., 2007). 
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3.12 Discussion 
 
Initial work was performed to investigate the expression of the murine orthologue of HSP27, 
HSP25, in different tissue types, with the aim to examine HSP25 function in inflammation in 
HSP25-/- mice. Constitutive expression of HSP25 was found to be highly variable. Strong 
expression of HSP25 was found in muscle. This variation could be partly due to technical 
difficulties in the dissection and homogenisation of tissues, including variations in extracellular 
matrix dissected with each tissue, with a potential to give misleading results. A recent paper 
replaced part of the hspb1 coding sequence with a lacZ reporter gene and 
immunohistochemistry was performed in order to determine the tissue-specific expression of 
HSP25 by immunohistochemistry (Huang et al., 2007). Huang et al., found that HSP25 was 
expressed in stratified squamous epithelium of the skin, oronasal cavity, tongue, esophagous, 
uterine cervix and most prominently in the musculature of adult mice (Huang et al., 2007). 
These observations correlate strongly with those found in this study (Fig. 3.1) where the same 
tissues were examined.     
 
HSP25 expression was highly variable under standard conditions in mice, however, it is 
believed that most signalling pathway molecules are similarly expressed between different 
tissues.  When it was clear that the arrival of HSP25-/- mice were delayed, it was decided to 
examine the importance of HSP25/27 in inflammation and IL-1 signalling in particular. 
Previous work in the laboratory had highlighted that HSP27 may have a role in regulating IL-1-
induced protein and mRNA expression of various inflammatory mediators and therefore it was 
thought that HSP27 may be involved in fine-tuning IL-1 / inflammatory signalling. This 
mechanism of regulation may be of different importance in various cell types, depending upon 
HSP25 constitutive expression and in certain cell types it may be delayed until HSP27 
expression is induced in response to cellular stress stimuli.  
 
RNAi was decided as the strategy to investigate the function of HSP25/27 in inflammatory gene 
expression and IL-1 signalling in vitro. The constitutive expression of HSP25/27 in cell types 
was therefore analysed to determine which cell type to use in these studies. HSP25 / 27 were 
expressed at high levels in all the immortalised cell lines tested except RAW cells. HSP27 was 
also expressed in human dermal fibroblasts (HDFs) and human M-CSF- and GM-CSF-
differentiated macrophages. Macrophages play a pivotal role in chronic and acute innate 
immune responses. Functions of macrophages include the phagocytosis of invading 
microorganisms, antigen presentation for T cells and the secretion of cytokines such as TNF, a 
potent cytokine largely responsible for rheumatoid arthritis. Therefore the expression of HSP27 
in these cells may be important because it suggests that HSP27 may play a role in these 
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processes in vivo. It was unexpected that human macrophages would express HSP27 because no 
HSP25 could be detected in murine bone-marrow-derived macrophages. However, it is possible 
that there are differences in expression between species. Alternatively, the difference in 
expression may be due to the extraction and differentiation methods used. In the absence of 
HSP25-/- mice RNAi was used as the method of choice to examine the function of the small heat 
shock protein. HeLa cells were used for this because of the ease of transfection in these cells 
and as this work was a continuation of a previous PhD student’s work in HeLa cells. An 
alternative approach to determine which cell type to use would have been to compare the tissue 
expression of HSP27 with that of the pro-inflammatory markers such as COX-2 and IL-6. 
 
Previous work in the laboratory had shown that IL-1-induced COX-2 and IL-6 protein and 
mRNA expression was inhibited in HSP27-depleted HeLa cells, but a direct interaction between 
HSP27 and these mRNAs could not be detected. An alternative hypothesis was that HSP27 
enhances IL-1-induced pro-inflammatory gene expression through positive regulation of the IL-
1 signalling pathway. HSP27 is itself phosphorylated by MK2 in response to IL-1 stimulation 
and therefore could be involved in a positive feedback mechanism. Low concentrations of 
siRNA were used to try and reduce potential off-target effects. Previous work in the laboratory 
had shown that several siRNAs targeted to HSP27 had inhibited the stabilisation of COX-2 and 
IL-6 mRNAs. It was decided to continue with the most potent siRNA, HSP27#5, for the 
remainder of the experiments in HeLa cells. 
 
Depletion of HSP27 from the cells caused a strong inhibition in the activity of many different 
kinases. This included MK2, p38 MAPK, JNK, the upstream kinases MKK3/4/6/7, IKKβ and 
TAK1 summarised in Fig. 3.11. However, HSP27 depletion did not inhibit IL-1-induced ERK 
activation. ERK is not directly activated by TAK1 and this could be the reason for the lack of 
regulation of ERK in this system. Raf1 is thought to be the principle activator of ERK in 
response to growth factors. However, recently Tpl2 has been suggested to be an alternate 
MKKK involved in the activation of ERK in response to pro-inflammatory stimuli (Dumitru et 
al., 2000). A recent report found that in IKK-deficient murine fibroblasts IKKβ was required for 
the activation of Tpl2 (Waterfield et al., 2004). If the IL-1-induced IKK complex activated ERK 
via Tpl2 in HeLa cells it would be expected that ERK activation would be inhibited in HSP27-
depleted cells similarly to IKKβ. However, this was not found, which may suggest that a 
different MKKK is important for the IL-1-induction of ERK in HeLa cells or that feedback of 
IKK on Tpl2 does not occur in these cells. 
 
The strong HSP27-dependent regulation of IL-1-induced MK2, p38 MAPK and JNK activities 
may account for the inhibition of IL-1-induced COX-2 and IL-6 protein and mRNA expression 
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Figure 3.11: Simplified schematic of IL-1- and TNF-induced signalling downstream of 
TAK1. IL-1 and TNF stimuli activate TAK1. Active TAK1 can lead to the activation of MKK3, 
MKK4, MKK6 and MKK7 and the IKK complex leading to JNK, p38 MAPK and NF-κB 
activation. The activation of p38 MAPK leads to the phosphorylation of HSP27 and also to the 
stabilisation of genes that encode pro-inflammatory mediators such as IL-6 and COX-2. 
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shown previously. MK2 and p38 MAPK activity has been reported to lead to the stabilisation of 
inflammatory mRNAs through the phosphorylation and subsequent inactivation of the 
destabilising AREBP, TTP, as discussed in the introduction. p38 MAPK also activates 
transcription via MSK-1 (Ananieva et al., 2008). JNK is known to be involved in the induction 
of transcription factors that are important in the inflammatory response, such as AP-1 (Manning 
and Davis, 2003). The experiments in this chapter do not rule out the possibility that other, 
additional pathways may contribute to the regulation of inflammatory gene expression by 
HSP27 in response to IL-1. Such mechanisms could include the direct enhancement of an 
AREBP involved in the stabilisation of pro-inflammatory mRNAs, or the sequestration of a 
destabilising AREBP. 
 
HSP27 is a member of the small heat shock protein family and has been reported to act as a 
chaperone like other family members for some proteins as discussed in the introduction (Lelj-
Garolla and Mauk, 2006; Rogalla et al., 1999). Chaperone activity is required for the correct 
folding of proteins after translation. If a protein is misfolded then it would usually be targeted to 
the proteasome for degradation. If HSP27 chaperone activity was required for the correct 
folding of a signalling component then in HSP27-depleted cells the total protein that is 
dependent upon this ability of HSP27 would be decreased compared to cells which express 
HSP27. HSP27 depletion from HeLa cells did not result in the decrease of any total protein 
expression tested, so therefore HSP27 is unlikely to act as a chaperone for these proteins. 
However, it is possible that HSP27 may act as a chaperone for a component of the IL-1 
signalling pathway between the IL-1R and TAK1, which had yet to be tested. 
 
The HSP27-dependent regulation of the IL-1-induced activity of downstream MKKs, p38 
MAPK and JNK was significantly greater than that of TAK1, found by Dr. Sarah Glennie. Data 
from longer exposures (not shown) revealed that the depletion of HSP27 I achieved was much 
greater than that by Dr. Sarah Glennie (data not shown) and this may account for the difference 
in the degree of regulation found. Alternatively, HSP27 may augment IL-1 signalling at more 
than one stage in the pathway for example at the level of the MKKs / IKKβ and also at the level 
of TAK1 or above. Or another MKKK expressed in HeLa cells may be more important for the 
propagation of the IL-1 signal to p38 MAPK and JNK in the HeLa cells and is more strongly 
regulated than TAK1 in cells depleted of HSP27. If the regulation was at the level of the 
activation of the MKKs / IKKβ this is could involve the ability of TAK1 to phosphorylate and 
activate its substrates either in vivo or in vitro, for example HSP27 may act as a scaffold protein 
to bring the substrates into close proximity to TAK1 and facilitate phosphorylation, or it could 
sequester or inhibit the expression of a phosphatase that acts upon TAK1.  
Chapter 4                                                  Regulation of IL-1 signalling to TAK1 in HeLa cells by HSP27 
     
 
 104
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
 
Regulation of signalling by HSP27 between the IL-1 receptor and 
TAK1 in HeLa cells 
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4.1 Introduction 
 
In the previous chapter it was shown that depletion of HSP27 in HeLa cells inhibited both IL-1 
signalling downstream of TAK1 as well as IL-1-induced gene expression. Various mechanisms 
were proposed which may explain how HSP27 might regulate different components of the 
signalling pathways activated by IL-1. In this chapter the aim was to find the mechanism 
whereby HSP27 regulates kinases activated by IL-1 through the examination of signalling in the 
pathway between the IL-1R and TAK1 in HSP27-depleted HeLa cells.  
 
4.2 HSP27 depletion inhibits IL-1-induced TAK1 activation 
 
HSP27 knockdown appeared to inhibit IL-1-induced TAK1 activity however the effect was 
weak and the mechanism whereby HSP27 regulates TAK1 was not examined (chapter 3). In 
response to IL-1 stimulation TAK1 is thought to oligomerise. The close proximity of TAK1 
subunits in the complex causes phosphorylation of Thr187 (Singhirunnusorn et al., 2005) and 
this may cause subsequent autoactivation of the kinase. A western blot to detect the levels of 
TAK1 phosphorylated at Thr187 revealed that TAK1 activation was inhibited following HSP27 
depletion (Fig. 4.1). The band corresponding to phosphorylated TAK1 ran at the same position 
as total TAK1 on the gel. Peak IL-1-induced TAK1 activation occurred at 30 min post-IL-1 
stimulation (Fig. 4.1) compared to 10 min post-IL-1 stimulation for TAK1 activity (Fig. 3.10). 
This was a surprise because both sets of experiments used the same preparation of IL-1 and the 
same source of HeLa cells (Yamanouchi). To address this disparity the same samples used to 
determine TAK1 phosphorylation (Fig. 4.1) were examined by immunocomplex kinase assay. 
The kinetics of TAK1 activity induced by IL-1 in three experiments correlated with those for 
TAK1 phosphorylation (Fig. 4.1) as would be expected if this phosphorylation was responsible 
for activation.  
 
In my hands, IL-1-induced TAK1 activity was inhibited by 53 % at 30 min post-IL-1 
stimulation in HSP27-depleted cells. However, significant TAK1 activity was detected in 
resting cells and IL-1 induced activity was actually inhibited by (60 %). In Fig. 4.1 at 30-60 min 
post-IL-1 the TAK1 total protein levels appear to be reduced in HSP27#5-transfected 
cells. However, this was not seen in an additional two independent experiments in which TAK1 
activity was inhibited following HSP27 depletion and therefore is unlikely to account for the 
reduced TAK1 activity. TAK1 activity appeared to be sustained at all time points tested 
including 60 min post-IL-1 and at all time points the activity was inhibited by HSP27 depletion. 
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Figure 4.1: HSP27#5 siRNA inhibits TAK1 activation and activity in HeLa cells. HeLa 
cells were transfected with Scramble dsRNA or HSP27#5 siRNA using Oligofectamine. 72 h 
post transfection the cells were stimulated with IL-1 for the times shown and lysed in TAK1 
lysis buffer. An antibody against TAB1 was used to immunoprecipitate TAK1 from Scramble- 
or HSP27#5-transfected HeLa cell lysates. A kinase assay was performed using MBP-MKK6 as 
a substrate. A proportion of the lysates were analysed by western blot to detect total TAK1, 
HSP27 and α-tubulin. A. The phosphorimage data is shown from a representative kinase assay 
together with the corresponding western blot analysis. B. The graph shows the mean TAK1 
activity for three independent experiments as a percentage of Scramble-transfected cell TAK1 
activity 30 min post-IL-1. Error bars show S. E. M. The data was normalised as for figure 3.5. 
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The strong inhibition of IL-1-induced TAK1 activity that I observed following HSP27 depletion 
is consistent with the blockade of downstream signalling and suggests that HSP27 may only act 
at the level of TAK1 or above.   
 
4.3 HSP27 enhances TNF-induced COX-2 protein expression, p38 MAPK and JNK 
activation 
 
It is thought that the major MKKK that activates the p38 MAPK and JNK pathways in response 
to TNF is also TAK1, therefore, from TAK1 downstream, the TNF and IL-1 signalling 
pathways are the same. However, TNF and IL-1 have different receptors and signal through 
different adaptor proteins and TRAF proteins to activate TAK1. Therefore it was decided to 
stimulate HSP27-depleted cells with TNF and determine if the same effects were seen on 
downstream pathway components as was the case for IL-1 signalling. This would provide an 
insight into whether the regulation of IL-1 signalling was likely to be at the level of TAK1 or 
common elements of the TNF or IL-1 signalling pathways, or alternatively if HSP27 
specifically regulates signalling in response to IL-1. 
 
HeLa cells were left untransfected, mock-transfected, transfected with Scramble dsRNA or 
HSP27#5 siRNA. Cells were stimulated with both and 20 ng ml-1 and 100 ng ml-1 TNF 
compared with 20 ng ml-1 IL-1. Cell lysates were analysed by western blot for COX-2 protein 
expression (Fig. 4.2). Depletion of HSP27 was found to inhibit both IL-1 and TNF-induced 
COX-2 protein expression (Fig. 4.2). As can be seen in Fig. 4.2 TNF was found to be a much 
weaker stimulus than IL-1 in Yamanouchi HeLa cells and this was why the dose of 100 ng ml-1 
was used. One possible explanation for this is that HeLa cells have fewer TNF receptors at the 
cell surface than IL-1 receptors. 
 
TNF-induced p38 MAPK and JNK activation was also examined. p38 MAPK activation was 
analysed using a western blot for p38 MAPK phosphorylated at the sites necessary for its 
activation. JNK activity was examined by performing kinase assays. The results are shown in 
Fig. 4.3 and are representative of two experiments with a direct comparison of 20 ng ml-1 IL-1, 
20 ng ml-1 TNF and 100 ng ml-1 and an additional experiment only comparing the two 
concentrations of TNF. TNF-induced p38 MAPK activation and JNK activity was inhibited in 
HSP27 depleted cells (Fig. 4.3). However, in these experiments the mean inhibition of TNF-
induced JNK activity using 20 ng ml-1 or 100 ng ml-1 was 58 and 50 % respectively in 
comparison to 80 % for IL-1-induced activity. Despite these discrepancies, these results suggest 
that there is a common mechanism whereby HSP27 regulates signalling triggered by IL-1 or 
TNF. HSP27 may play a more minor role in TNF signalling although the reason for this is  
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Figure 4.2: HSP27 depletion inhibits TNF-induced COX-2 protein expression. HeLa cells 
were depleted of HSP27 using HSP27#5 siRNA, transfected with control Scramble dsRNA, 
mock transfected or left untransfected. The cells were stimulated with either 20 ng ml-1 IL-1, 
TNF or 100 ng ml-1 TNF for 4 h. Cells were lysed in whole cell lysis buffer and equal amounts 
of protein were analysed by western blot for COX-2, HSP27 and the loading control, α-actin. 
This figure is representative of two experiments. 
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Figure 4.3: HSP27 depletion inhibited TNF-induced p38 MAPK activation and JNK 
activity. HeLa cells were left untransfected, mock transfected, transfected with the non-
targeting Scramble dsRNA control, or with HSP27#5 siRNA. Cells were stimulated with 20 ng 
ml-1 IL-1 or TNF or 100 ng ml-1 TNF for the times shown and lysed in kinase lysis buffer. JNK 
was immunoprecipitated from the lysate and a kinase assay performed using recombinant ATF-
2 as the substrate. A shows the phosphorimage from the kinase assay and western blot analysis 
of a portion of lysate for p38 MAPK phosphorylated at its activatory sites, HSP27 and total p38 
MAPK. B, C and D are graphical representations of mean JNK activity from at least two 
independent experiments for IL-1 and three for TNF (± S.E.M.) as a percentage of activity in 
Scramble-transfected cells 30 min post-IL-1 stimulation. 
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unclear. Both IL-1 and TNF pathways use upstream kinases to signal to TNF receptor 
associated proteins (TRAFs) that propagate the signal to TAK1 and the TAK1 binding proteins. 
Therefore it was possible that HSP27 may regulate one of these points in the two signalling 
pathways. 
 
4.4 HSP27 depletion may delay IL-1-induced TAB1 phosphorylation 
 
TAK1 is thought to oligomerise following the binding of its partner proteins, TAB2 / 3 to 
Lys63-linked polyubiquitin chains. It was possible that in HSP27-depleted cells TAK1 failed to 
oligomerise following IL-1 stimulation of the cells. This might occur as a result of reduced 
expression of either TAB2 or TAB3. The importance of TAB1 expression for TAK1 activity 
has been shown recently because neither IL-1 nor TNF was able to activate TAK1 in TAB1- / - 
MEFs (Mendoza et al., 2008). TAB1, TAB2 and TAB3 are phosphorylated in cells (Mendoza et 
al., 2008). Phosphorylation of these proteins causes distinct mobility shifts on SDS-PAGE. p38 
MAPK is known to form a complex with TAB1 (Ge et al., 2002) and phosphorylate it (Cheung 
et al., 2003). This phosphorylation causes inhibition of TAK1 activity (Cheung et al., 2003). 
p38 MAPK has also been suggested to form a complex containing MK2 and HSP27 (Zheng et 
al., 2006). In the absence of HSP27 p38 MAPK may be liberated and therefore the interaction 
with TAB1 might be promoted. Despite p38 MAPK activity being lower than normal in HSP27-
depleted cells increased interaction with TAB1 might actually result in an increase in the 
phosphorylation of TAB1 upon HSP27 depletion with subsequent inhibition of TAK1 activity. 
Therefore the expression and putative phosphorylation (mobility shifts) of TAB1, TAB2 and 
TAB3 in Scramble- and HSP27#5-transfected cells were examined by western blot. 
 
Proteins were separated on an 8 % polyacrylamide gel prior to western blotting to maximise 
resolution of unphosphorylated and phosphorylated forms of TAB1. TAB1 has a predicted 
relative molecular mass of 60 kDa. A non-specific band caused by a protein of slightly higher 
mobility runs above the TAB1 band, corresponding to a protein of relative molecular mass of 
about 70 kDa. There did not appear to be a difference in TAB1 protein expression between 
HSP27#5- and Scramble-transfected cells (Fig. 4.4A). TAB1 protein from Scramble-transfected 
cells underwent a shift in mobility on SDS-PAGE at 30 min and 60 min post-IL-1 stimulation. 
Interestingly, this putative phosphorylation was delayed in HSP27#5-transfected cells (Fig. 
4.4A). The data are consistent with reduced TAB1 phosphorylation due to the lower p38 MAPK 
activity in the HSP27-depleted cells.   
 
At the same time these experiments were performed a different approach was taken involving 
the use of p38 inhibitor, SB202190. The idea was to see if any increase in IL-1-induced 
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phosphorylation of TAB1 that may have been caused by HSP27 depletion was mediated by p38 
MAPK. HeLa cells were depleted of HSP27 using HSP27#5 siRNA with the control of 
Scramble dsRNA. Cells were then either treated with a low dose (1 µM) of SB202190 or the 
vehicle control, DMSO, or left untreated and 1 h later cells were stimulated with IL-1 for the 
appropriate times.    
 
In the presence of SB202190 a form of TAB1 with lower mobility than that seen in resting cells 
was detected with the anti-TAB1 antibody (Fig. 4.4B). This implies that TAB1 undergoes basal 
phosphorylation by p38 MAPK in resting cells, which is prevented in the presence of 
SB202190. Upon stimulation of cells with IL-1 TAB1 appeared to shift in mobility as observed 
previously (Fig. 4.4A) and most of the TAB1 had shifted up through three bands by 60 min 
post-IL-1 stimulation. In agreement with Fig. 4.4, depletion of HSP27 from the cells resulted in 
an apparent delay in the mobility shift of TAB1 and at 60 min post-IL-1 stimulation the TAB1 
was still more dispersed in these samples (Fig. 4.4B). In the presence of SB202190 the shift in 
mobility appeared to be slightly delayed. Since putative TAB1 phosphorylation was actually 
found to be delayed or inhibited in HSP27-depleted cells regulation of TAB1 by HSP27 is 
unlikely to be the mechanism responsible for the inhibition of IL-1-induced TAK1 activity. The 
effects of HSP27 depletion and SB202190 appeared to be additive, arguing that HSP27 
knockdown inhibits the phosphorylation of TAB1 via inhibition of p38 MAPK or another TAB1 
kinase. 
 
TAB2 protein was difficult to detect and on the 8 % polyacrylamide SDS-PAGE mini-gel used 
it appeared to resolve as two bands (Fig. 4.4A). In Scramble-transfected cells the upper band 
was fainter after 20-60 min IL-1 stimulation. Interestingly, the upper band did not disappear or 
become fainter in the HSP27#5-transfected cells. From these results it was unclear if HSP27 
regulates IL-1-induced TAK1 activity by acting on TAB2. The difficulty in the detection and 
determination of which band was TAB2 meant that the interpretation of TAB2 in this and future 
experiments was unclear and subsequent work on TAB2 has not been included in this thesis. 
Western blots to detect TAB3 protein expression were unsuccessful because of low antibody 
sensitivity. 
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Figure 4.4: The effect of HSP27 depletion upon TAB1 and TAB2. A. Proteins in Scramble- 
and HSP27#5-transfected HeLa cell lysates were separated by SDS-PAGE on an 8 % 
polyacrylamide mini-gel. The samples were then analysed by western blot for TAB2, HSP27 
and the loading control α-tubulin. The same samples were run on a separate gel and analysed by 
western blot for TAB1. The relative molecular mass markers shown are Abcam rainbow 
markers. A. is representative of four independent experiments. B. HeLa cells were depleted of 
HSP27 using HSP27#5 (#5) siRNA or transfected with the control, Scramble (S) dsRNA. Cells 
were pre-treated with 1 µM SB202190, a p38 MAPK inhibitor, or the vehicle control DMSO, 
stimulated with IL-1 and lysed in TAK1 lysis buffer. Samples were separated by SDS-PAGE 
and analysed by western blot for TAB1, HSP27 and α-tubulin. B. represents one experiment.
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4.5 HSP27 depletion does not disrupt the interaction between TAK1 and its binding 
partner TAB1 
 
In the experiments to analyse TAK1 activity an anti-TAB1 antibody was used to 
immunoprecipitate the TAK1 complex. In one experiment TAB1 was confirmed to co-
immunoprecipitate with its binding partners TAK1 and TAB2. This interaction was present in 
untreated cells and was not disrupted upon stimulation with IL-1 at 30 min post-IL-1 
stimulation (data not shown). If the TAK1 complex was disrupted in HSP27-depleted cells this 
would be expected to inhibit TAK1 and downstream signalling. 
 
To test if the TAK1 complex is disrupted in HSP27-depleted cells the same time course of IL-1 
treatment was used as for the TAK1 kinase assay and the cells were lysed as before. The TAK1 
complex was immunoprecipitated with anti-TAB1 antibody as previously and the 
immunoprecipitates were run on a SDS-polyacrylamide gel and analysed by western blot. 
Immunoprecipitation was either performed using 1μg anti-TAB1 antibody (raised in sheep) or 1 
μg of sheep IgG as a control. The anti-TAB1 antibody readily immunoprecipitated both TAB1 
and TAK1 (Fig. 4.5). The sheep IgG did not immunoprecipitate any detectable TAB1 or TAK1, 
which indicates that the interaction is likely to be specific (Fig. 4.5). TAB1 clearly interacted 
with TAK1 and this was not disrupted in HSP27#5- or Scramble-transfected cells at any of the 
times post-IL-1 stimulation tested (Fig. 4.5). There was little difference in the TAB1 band 
intensity in the supernatants that had been immunodepleted with anti-TAB1 antibody or sheep 
IgG, therefore only a small proportion of cellular TAB1 was successfully immunoprecipitated. 
It is therefore unsurprising that there was no difference in amount of TAK1 detected in the 
supernatants (Fig. 4.5). A faint smear was detected above the TAK1 protein band in Scramble-
treated cells stimulated with IL-1 for 30 min (Fig. 4.5) and there was a suggestion that this was 
inhibited in HSP27-depleted cells. There have been a few instances in the literature of TAK1 
polyubiquitination being reported (Thiefes et al., 2006) which may account for this smear.   
 
In the same experiment co-immunoprecipitation of p38 MAPK and HSP27 with TAB1 were 
also tested. The HSP27 western blot shows that the HSP27 depletion was effective in the 
HSP27#5 cells compared to Scramble-transfected cells (Fig. 4.5). However, it was not possible 
to detect any HSP27 that immunoprecipitated with either the TAB1 antibody or sheep IgG. 
Probing the membrane with anti-phosphorylated p38 MAPK, showed that the depletion of 
HSP27 inhibited p38 MAPK activation as detected in previous experiments. However, both the 
blots for phosphorylated and total p38 MAPK failed to detect any p38 MAPK that co-
immunoprecipitated with TAB1 in either resting cells or 30 min post-IL-1 stimulation. 
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Figure 4.5: HSP27 depletion does not disrupt the constitutive interaction between TAK1 
and its binding partner TAB1. HeLa cells were depleted of HSP27 with HSP27#5 (#5) siRNA 
or Scramble (Scr) dsRNA as used as a control. Cells were stimulated with IL-1 for the times 
shown and lysed in TAK1 lysis buffer. Equal amounts of total protein from cell lysates were 
immunoprecipitated with either 1 µg anti-TAB1 antibody or sheep IgG. The pellets were 
washed extensively and then separated by SDS-PAGE with wide range SigmaMarkersTM. 
Western blot analysis was performed for TAB1, TAK1, HSP27, phosphorylated p38 MAPK and 
total p38 MAPK. The antibody chains are marked as *Ab. This experiment was performed 
once. 
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In conclusion TAK1 forms a constitutive interaction with TAB1 in HeLa cells. This interaction 
is not disrupted in HSP27-depleted cells. There was no detectable interaction between TAB1 
and p38 MAPK or HSP27 in this experiment (Fig 4.5). These experiments suggest that HSP27 
does not enhance IL-1-induced TAK1 activation through the regulation of the TAK1 complex 
and therefore the function of HSP27 in upstream signalling was investigated. 
 
4.6 HSP27 does not regulate the expression of upstream signalling proteins TRAF6, 
IRAK1, IRAK4 and MyD88 
 
HSP27 is a member of the small heat shock protein family and like many other heat shock 
proteins there have been reports that it has chaperone properties (Jakob et al., 1993; Lelj-Garolla 
and Mauk, 2006; Rogalla et al., 1999). It is therefore possible that in the absence of HSP27 one 
or more components of the IL-1 signalling pathway could be misfolded. Most misfolded 
proteins are detected and targeted for degradation by the proteasome. If HSP27 had chaperone 
properties for an upstream component of the IL-1 pathway its expression would be expected to 
be diminished in HSP27-depleted cells. The protein expression of several key components in 
the IL-1 signalling pathway which propagate the signal from the receptor (IL-1R) to TAK1 was 
analysed.   
 
In response to IL-1 stimulation the adapter protein MyD88 is recruited to the IL-1R. To test 
whether HSP27 regulates MyD88 protein expression the cells were depleted of HSP27 using 
HSP27#5 siRNA. The anti-MyD88 antibody detected two bands of approximate relative 
molecular masses of 33 kDa and 28 kDa. MyD88 has a relative molecular mass of 33 kDa and 
therefore the upper band shown on Fig. 4.7A corresponds to a protein of the correct size. There 
was no difference in the MyD88 protein expression between HSP27#5- and Scramble-
transfected cells (Fig. 4.6A). In two experiments no band corresponding to the correct relative 
molecular mass for MyD88 was observed. However, Fig. 4.6A was representative of three 
independent experiments in which MyD88 was detected. 
 
MyD88 binds to and recruits the kinases IRAK4 and IRAK1 in response to IL-1 stimulation. 
Therefore it was important to test whether depletion of HSP27 affected IRAK1 or IRAK4 
protein expression. HSP27 was depleted from HeLa cells and IRAK1 and IRAK4 expression 
was examined by western blot. The IRAK1 antibody detected two bands of a relative molecular 
mass of about 80 kDa, the expected size of IRAK1, when compared to the SigmaMarker 
electrophoresed on the mini-gel. It was not clear which band was IRAK1 however neither of 
these bands were regulated in HSP27-depleted cells (Fig. 4.6B). The relative molecular mass of 
IRAK4 is 50 kDa. Although, two bands were detected by the anti-IRAK4 antibody used, it was 
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not clear which, if either corresponded to IRAK4. Neither of these bands were regulated (Fig. 
4.6B).  
 
The current dogma in the IL-1 signalling field is that TRAF6 becomes Lys63- polyubiquitinated 
in response to IL-1 signalling and this leads to the recruitment of multiple TAK1 complexes 
through the TAB2 / TAB3 subunits. TAK1 is then able to autophosphorylate other TAK1 
subunits and this leads to its activation and subsequent downstream signalling. To investigate if 
HSP27 knockdown resulted in reduced TRAF6 expression a western blot was performed for 
TRAF6. TRAF6 protein expression was unchanged after HSP27 depletion (Fig. 4.6C). In 
conclusion reduced expression of MyD88, TRAF6, IRAK1 and possibly IRAK4 did not appear 
to be responsible for the defect in IL-1 signalling in the absence of HSP27.  
 
4.7 Examination of Lys63-polyubiquitination of TRAF6 and IRAK1 
 
Polyubiquitination has recently been demonstrated to be critical in the signalling pathways from 
both the IL-1 and TNF receptors (Lamothe et al., 2007; Wang et al., 2001; Windheim et al., 
2008; Wu et al., 2006a). Initially for IL-1 signalling it was believed that TRAF6 possessed E3 
ubiquitin ligase activity and could autoubiquitinate in response to IL-1 stimulation of cells 
(Wang et al., 2001). If TRAF6 polyubiquitination is inhibited by the absence of HSP27 then the 
TAK1 complex, through TAB2, would be unable to bind to the polyubiquitin chains of TRAF6. 
In this situation the TAK1 complexes would be unable to come into close proximity, 
oligomerise, autophosphorylate and become activated. In order to examine this possibility it was 
first necessary to detect endogenous IL-1-induced TRAF6 polyubiquitination in HeLa cells. 
Polyubiquitination, in contrast to monoubiquitination, usually results in a laddering of proteins 
of higher relative molecular mass and lower mobility than the band of the unmodified protein on 
the SDS-PAGE gel. 
 
The method used to examine endogenous ubiquitinated proteins was adapted from Jaffray et al., 
(Jaffray and Hay, 2006). Samples were lysed in a highly denaturing buffer containing 2 % SDS. 
Ubiquitin ligases remove ubiquitin from proteins and are highly active even in sample 
preparations at low temperatures. Therefore the ubiquitin ligase inhibitors iodoacetamide and N-
ethylmaleimide were included in the buffers used. Alkylating agents such as iodoacetamide can 
achieve complete and irreversible inhibition of most deubiquitinating enzymes, which are 
cysteine proteases, in denaturing conditions. The viscosity of the sample was reduced by 
sonication and the SDS was diluted in a renaturation buffer. 
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Figure 4.6: HSP27 depletion had no effect on MyD88, IRAK1, IRAK4 or TRAF6 protein 
expression. HeLa cells were depleted of HSP27 with HSP27#5 siRNA or transfected with 
Scramble dsRNA. The cells were stimulated with IL-1 for the times shown and lysed in TAK1 
lysis buffer. The samples were separated by SDS-PAGE and analysed by western blot for A. 
MyD88, HSP27 and α-tubulin, B. IRAK1, IRAK4, HSP27 and α-tubulin and C. TRAF6, 
HSP27 and α-tubulin. A. was representative of three independent experiments. B. and C. were 
both representatives of two independent experiments.  
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 In order to determine if IL-1-induced ubiquitination of endogenous TRAF6 could be detected, 
TRAF6 was immunoprecipitated from the cell lysate and western blots were performed for 
ubiquitin. Under the conditions tried in eight experiments, endogenous TRAF6 ubiquitination 
could not be detected. Fig. 4.7 shows two representative experiments. A wide variety of time 
courses were used based on the times of TRAF6 ubiquitination reported in the literature. 
Additional time points were added in later experiments to take into account the delayed 
signalling found in the HeLa cells (Fig 4.7B). The analysis of lysate from one experiment 
showed the IL-1-induction of an extra band of higher relative molecular mass to the expected 
band for TRAF6 (data not shown). This band may have been due to ubiquitination of TRAF6 
however, it was never reproduced. It may be that upon ubiquitination of the endogenous protein 
the antibody used for immunoprecipitation is no longer able to recognise the epitope required to 
bind the protein of interest. Alternatively, ubiquitinated TRAF6 could be of extremely low 
abundance. 
 
The TAK1 binding proteins TAB2 and TAB3 are reported to mediate the binding of TAK1 to 
the polyubiquitin chains on TRAF6 after IL-1 stimulation. It was decided to determine if 
ubiquitination of a protein in the TAK1 complex could be detected. Therefore the membrane 
from Fig. 4.5 was re-probed with an anti-ubiquitin antibody. No ubiquitination could be 
detected (data not shown).  
 
In TNF signalling the equivalent protein in the pathway to IRAK1 is Rip1. IKKγ has been 
reported to interact with polyubiquitin chains on Rip1 after TNF stimulation (Wu et al., 2006a). 
Therefore it may be possible that IRAK1 in IL-1 signalling is able to act in a similar fashion to 
Rip1 in TNF signalling. HeLa cells were stimulated with IL-1 and lysed in a buffer containing 2 
% SDS, iodoacetamide and N-ethylmaleimide. In Fig. 4.8 protein from the lysate was 
immunoprecipitated with either 1 µg anti-IRAK1 antibody or rabbit IgG. A western blot was 
performed with anti-ubiquitin to analyse ubiquitination of immunoprecipitated material. A 
smear of a similar intensity was detected in all immunoprecipitated samples (Fig. 4.8). This 
would suggest that no significant, specific, IRAK1 ubiquitination occurred. However, there is 
the possibility that the ubiquitinated IRAK1 is hidden by the general smear with the anti-
ubiquitin antibody. A more intense smear was detected in the lysate and the supernatant. This 
was expected because more proteins would be in these samples and this experiment would also 
detect other ubiquitin linkages including Lys48-polyubiquitinated proteins that would be 
targeted to the proteasome. In the experiment shown in Fig 4.8 some cells were preincubated for 
1 h with the proteasome inhibitor MG132 (10 µM final concentration) as a positive control for 
ubiquitination. In the presence of the proteasome inhibitor intense laddering of bands was 
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Figure 4.7: Ubiquitination of endogenous TRAF6 could not be reproducibly detected. 
HeLa cells were grown in 10 cm dishes until confluent. HeLa cells were stimulated with IL-1 
for 10 min or left unstimulated. Cells were lysed with a highly denaturing buffer which 
contained 2 % SDS and renatured following the protocol in materials and methods. A. Equal 
protein amounts for the samples were separated by SDS-PAGE and western blot analysis was 
performed to detect TRAF6 and HSP27. B. Immunoprecipitation from equal amounts of total 
protein in cell lysates was performed with anti-TRAF6 or rabbit IgG. Samples were separated 
on SDS-PAGE and western blots performed for TRAF6 and ubiquitin. This figure is 
representative of seven independent experiments. 
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Figure 4.8: Ubiquitination of endogenous IRAK1 cannot be detected. HeLa cells were 
stimulated with IL-1 for the times shown. One point was pre-incubated with 10 µM MG-132 for 
1 h prior to lysis. The cells were lysed in a buffer that contained 2 % SDS and the samples were 
sonicated and renatured. Cell lysates with equivalent amounts of total protein were 
immunoprecipitated with either 1 µg anti-IRAK1 (IR) antibody or a rabbit IgG (Ig) control. 
Samples from the lysates (L), supernatant (S) and immunoprecipitate (IP) were analysed by 
SDS-PAGE and western blot was performed for ubiquitin and IRAK1. This experiment was 
performed once.   
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detected on the gel, presumably due to the accumulation of Lys48-polyubiquitinated proteins 
(Fig. 4.8).  
 
The ubiquitin blot was stripped and re-probed with anti-IRAK1 antibody to determine if the 
IRAK1 immunoprecipitation had occurred and was specific. IRAK1 was immunoprecipitated 
with anti-IRAK1 antibody but not rabbit IgG (Fig. 4.8). The band corresponding to IRAK1 was 
fainter at 15 min post-IL-1 stimulation potentially due to the degradation of IRAK1 reported to 
occur after IL-1 signalling. There was no noticeable smear indicative of polyubiquitinated 
IRAK1 in this blot.   
 
4.8 Examination of the interaction between IRAK1 and TRAF6. 
 
The interaction of IRAK1 with TRAF6 has long been reported as pivotal for the propagation of 
the IL-1 signal. In order to investigate the possibility that HSP27 may inhibit this interaction it 
was first necessary to try to co-immunoprecipitate the two proteins in untransfected cells. 
TRAF6 was successfully co-immunoprecipitated (Fig. 4.9) with the anti-IRAK1 antibody but 
not the rabbit IgG control. However, it was difficult to detect a clear band for TRAF6 because it 
resolved close to the antibody heavy chain. The antibodies that were used to immunoprecipitate 
IRAK1 and detect TRAF6 were both raised in rabbits and therefore the heavy chain showed as a 
strong band in the TRAF6 western blot due to cross-reactivity with the secondary antibodies. 
The TRAF6 blot was stripped and reprobed for IRAK1. IRAK1 was successfully 
immunoprecipitated by the anti-IRAK1 antibody and not the rabbit IgG (Fig. 4.9) in agreement 
with Fig 4.9. The IRAK1 band became fainter in both the lysate and the immunoprecipitate at 
20 and 30 min post-IL-1 stimulation, potentially due to degradation as discussed previously. 
The difficulty in the detection of a clear TRAF6 band in the immunoprecipitates prevented the 
pursuit of this strategy.   
 
4.9 IRAK1 is rapidly degraded in human dermal fibroblasts upon IL-1 signalling in 
contrast to HeLa cells 
 
IRAK1 is thought to degrade rapidly upon stimulation by IL-1 (Yamin and Miller, 1997). 
However, in experiments in HeLa cells it was found that IRAK1 did not degrade over the 20 
min IL-1 time course examined (Fig. 4.6B). In order to determine if this result in HeLa cells 
was an anomaly an IL-1 time course was performed in primary HDFs. It was found that upon 
stimulation IRAK1 was rapidly degraded in HDFs, in agreement with the literature and there 
was no detectable IRAK1 band at its unmodified molecular weight by 15 min post IL-1 
stimulation (Fig. 4.10). 
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Fig. 4.9: IRAK1 interacts with TRAF6. HeLa cells were stimulated with IL-1 for the times 
shown. Cells were lysed in TAK1 lysis buffer. Equal amounts of total protein per sample lysate 
were immunoprecipitated (IP) with either 1 μg rabbit IgG (Ig) or anti-IRAK1 antibody (IR). 
One tenth of the lysate used for immunoprecipitation and the immunoprecipitated samples were 
separated by SDS-PAGE and analysed by western blot for IRAK1 and TRAF6. The 60kDa 
band corresponding to TRAF6 is outlined by a box, in the upper panel. Antibody (Ab) heavy 
chains are marked. This figure was representative of three independent experiments.  
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Figure 4.10: IRAK1 protein rapidly degrades in human dermal fibroblasts following IL-1 
stimulation. HDFs were stimulated with IL-1 for the times shown and lysed in TAK1 lysis 
buffer. Samples were analysed by SDS-PAGE and analysed by western blot for IRAK1 and α-
tubulin. This experiment was performed once. 
Chapter 4                                                  Regulation of IL-1 signalling to TAK1 in HeLa cells by HSP27 
     
 
 124
4.10 Discussion. 
 
Both Dr. S. Glennie (Fig. 3.10) and I (Fig. 4.1) found an inhibition of IL-1-induced TAK1 
activity (and in Fig. 4.1 activation) in HSP27-depleted cells compared to Scramble-transfected 
cells. However, in the two sets of experiments there was a disparity between the kinetics of the 
activity. This may have been caused by the difference in stimulation method. In previous work 
cells were stimulated simultaneously and lysed at different times post-IL-1. However, I 
stimulated the cells at different times and lysed them together. The late, sustained activity seen 
in Fig. 4.1 was a surprise because downstream p38 MAPK and JNK activity peaked at 30 min 
post-IL-1 and returned to basal levels by 60 min (Figs. 3.6 and 3.7). However, sustained TAK1 
activity is consistent with the prolonged IL-1-induced activity of MKK7 (Fig. 3.9). This 
suggests that another form of regulation switches off signalling below the level TAK1, for 
example involving the MAPK phosphatase, MKP1, or another phosphatase. Dr. S. Glennie 
found a 30 % inhibition of IL-1-induced TAK1 activity in HSP27-depleted HeLa cells (Fig. 
3.10). This indicated that HSP27 regulated IL-1 signalling either at or (mainly given the weak 
inhibition) downstream of TAK1. However, my work to examine the IL-1-induced activation of 
TAK1 found a strong inhibition of TAK1 phosphorylation in HeLa cells depleted of HSP27 and 
a corresponding strong inhibition of IL-1-induced TAK1 activity. This may be because I 
achieved more efficient depletion of HSP27 in these cells than was obtained previously. This 
strong inhibition following HSP27 depletion is consistent with the blockade of downstream 
signalling and as a consequence suggests that HSP27 may only act at the level of TAK1 or 
above.  
 
In order to confirm that HSP27 augmented IL-1 signalling at the level of TAK1 a different 
approach was taken. IL-1 and TNF signal through different receptors however, their signalling 
pathways are thought to converge at the level of TAK1 (Fig. 1.1). TNF-induced COX-2 protein 
was inhibited by HSP27 depletion. It was also found that TNF-induced p38 MAPK activation 
and JNK activity was inhibited in the absence of HSP27. The regulation of IL-1-induced JNK 
activity in HSP27-depleted cells found in these experiments was higher than the 64 % in Fig. 
3.7. The results from Fig. 3.7 are more in line with the TNF results (Fig. 4.3). One reason may 
be a difference in the IL-1 preparation used between these two sets of experiments, or the 
HSP27 depletion may have been slightly greater in the set of experiments in section 4.3. Overall 
these results add further support to the conclusion that the effect of HSP27 depletion on the IL-1 
signalling pathway is at the level of TAK1 in HeLa cells. However, it was still possible that 
HSP27 regulates a common upstream element of the IL-1 and TNF pathways. 
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When total TAB1 levels were examined, HSP27 appeared to delay the putative phosphorylation 
of TAB1 that occurs upon IL-1 stimulation in HeLa cells. An alternative approach with the p38 
MAPK inhibitor, SB202190, was also used to determine if HSP27 delayed the phosphorylation 
of TAB1 through p38 MAPK (Cheung et al., 2003). SB202190 did not completely prevent the 
TAB1 putative phosphorylation mobility shifts. This suggests that either SB202190 was not 
completely suppressing p38 MAPK activity at the concentration used or an additional kinase 
could also phosphorylate TAB1. Other kinases reported to phosphorylate TAB1 include JNK1, 
JNK2 and ERK (Mendoza et al., 2008). HSP27 depletion had an additive effect with the 
SB202190 at 60 min post-IL-1. Potential explanations include that HSP27 depletion inhibits p38 
MAPK activity to a greater extent than SB202190 in this experiment or HSP27 depletion could 
inhibit another kinase(s) responsible for TAB1 phosphorylation. As IL-1-induced JNK activity 
was inhibited in HSP27-deleted HeLa cells this would be the most likely candidate. In 
conclusion these results suggest that HSP27 knockdown inhibits TAB1 phosphorylation, 
possibly via reduced p38 MAPK activity. However, this mechanism is unlikely to account for 
the regulation of IL-1-induced TAK1 phosphorylation or activity in HSP27-depleted HeLa 
cells. 
 
Two potential bands of about the correct relative molecular mass for TAB2 were observed in 
resting cells. It was unclear if either / both bands were TAB2. The upper band disappeared after 
20 min IL-1 in Scramble-transfected cells but was stabilised in HSP27-depleted cells. The upper 
band may be due to a post-translational modification of TAB2 such as phosphorylation. 
Alternatively, the upper band could be TAB2 and phosphorylation of TAB2 may shield the 
epitope with the result that the antibody can no longer detect it. However, TAB2 
phosphorylation has previously been shown to occur after IL-1 stimulation (Jiang et al., 2002) 
rather than be constitutive. Another possibility is that TAB2 is degraded after stimulation, 
although this has not been reported in the literature. The disappearance of the TAB2 protein 
corresponds with the time in which TAK1 is phosphorylated on its activation loop and becomes 
active. If the upper band is TAB2 this result may indicate a potential mechanism whereby 
HSP27 is involved in the degradation of a form of TAB2 that could regulate TAK1 activity 
correspondingly. However, the presence of TAB2 for a prolonged time period after stimulation 
would be expected to prolong the contact of the TAK1 complexes with polyubiquitinated 
TRAF6 and therefore this result would suggest that TAK1 activity would be prolonged in 
HSP27-depleted cells. Thus, this result does not explain the inhibition of IL-1-induced TAK1 
activation and activity in cells depleted of HSP27. 
 
The results pointed towards TAK1 as the point in the IL-1 pathway that was regulated by 
HSP27. It was therefore pertinent to investigate whether HSP27 was acting as a scaffold for the 
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formation and maintenance of the TAK1 complex. However, depletion of HSP27 from HeLa 
cells appeared to have no effect on the constitutive interaction of TAK1 with its binding 
partners, TAB1 and TAB2. With the commercial antibodies available TAB3 was unable to be 
detected and therefore it was not possible to test whether this recently discovered, alternative 
binding partner to TAB1 was affected. The ability of p38 MAPK to interact with TAB1 was 
tested because the reports in the literature (Cheung et al., 2003) and the experiment in Fig. 4.4B 
support the hypothesis that p38 MAPK binds to and phosphorylates TAB1. Surprisingly no 
interaction was found between p38 MAPK or HSP27 and TAB1. This may because the epitopes 
on the p38 MAPK and HSP27 recognised by their antibodies were shielded by the interaction 
with TAB1 or these interactions are transient. Further experiments would be required to 
examine this interaction. 
 
HSP27 has been reported to act as a chaperone (Jakob et al., 1993; Lelj-Garolla and Mauk, 
2006; Rogalla et al., 1999). If HSP27 was acting as a chaperone for a signalling pathway 
component it would be expected that in the absence of HSP27 they might be misfolded, and 
could then be targeted to the proteasome for degradation. In order to examine whether HSP27 
acts as a chaperone for the upstream signalling components, western blots were performed for 
TAK1 binding proteins (TAB1 and TAB2), TRAF6, IRAK1 and IRAK4 and MyD88. HSP27 
depletion had no effect on the expression on any of these proteins, therefore it was thought that 
HSP27 was not acting as a chaperone for these proteins. The effect of HSP27 depletion on the 
expression of the IL-1 receptor was not checked, and defective receptor expression cannot be 
completely ruled out as a possible explanation. At this point it was discovered that in HeLa cells 
IRAK1 was not degraded rapidly upon stimulation as reported in the literature, whereas later the 
expected degradation was shown in HDF cells. This raised the concern that there may be 
because of an anomaly in protein degradation or signalling in HeLa cells. 
 
The mechanism whereby the signal from the IL-1 receptor reaches TAK1 is still being 
elucidated, for a current model see Fig. 4.11. During the course of this work a large amount of 
evidence using overexpression has pointed towards Lys63-linked polyubiquitination of certain 
signalling pathway molecules as critical for the propagation of the signal. The strongest 
evidence suggested that polyubiquitination of TRAF6 led to the recruitment and activation of 
the TAK1 complex through the binding of TAB2 to the polyubiquitinated chains. Experiments 
to detect the polyubiquitination of endogenous TRAF6 were unsuccessful. Ubiquitinated 
proteins were only detected when the cells were pre-incubated for 1 hour in the presence of the 
proteasome inhibitor MG132. The proteasome inhibitor would lead to the accumulation of 
Lys48-polyubiquitinated proteins that would otherwise have been targeted to the proteasome for 
degradation. 
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Figure 4.11: Current proposal for signalling from the IL-1 receptor to the TAK1 and IKK 
complexes. IL-1 binds to the IL-1R and causes the dimerisation of the IL-1R to the IL-1RAcP. 
This causes the recruitment of accessory proteins including MyD88. The kinases IRAK1 and 
IRAK4 are recruited to the receptor complex. IRAK4 phosphorylates and activates IRAK1, 
which can then dissociate from the complex and recruit TRAF6. TRAF6 possesses E3 ubiquitin 
ligase activity and can attach Lys63-polyubiquitin chains to itself. IRAK1 and IRAK4 
phosphorylate Pellino and Pellino isoforms mediate the formation of Lys63-linked 
polyubiquitinated IRAK1. The TAK1 complex binds to Ly63-polyubiquitinated TAK1 and 
autoactivates. The IKK complex can bind to Lys63-polyubiquitinated IRAK1, which leads to 
the co-localisation of the TAK1 and IKK complexes and the resultant activation of IKKβ by 
TAK1. This figure is adapted from the website of Sir Philip Cohen’s laboratory. 
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TAK1 has also been reported to be ubiquitinated (Thiefes et al., 2006) and the membrane from 
Fig. 4.5 was re-probed for ubiquitin. No ubiquitination was observed. However, in this 
experiment TAK1 lysis buffer was used, which may not be optimal for the detection of 
ubiquitin. However, faint smears above the TAK1 band could be observed with long exposures 
of Fig. 4.5. These smears may be due to polyubiquitination. 
 
A later idea, postulated that polyubiquitination of IRAK1 should be investigated. Rip1 is the 
equivalent protein to the IRAK proteins in TNF signalling. Polyubiquitination of Rip1 has been 
reported as important in the recruitment of IKKγ to occupied cytokine receptors and the 
subsequent activation of the IKK complex (Ea et al., 2006; Wu et al., 2006b). Rip1 has also 
been reported to recruit the TAK1 complex through TAB2 (Kanayama et al., 2004) (Fig. 1.1), 
although this is still controversial. Experiments to detect endogenous polyubiqtuinated IRAK1 
were also unsuccessful. Recent work by Windheim et al., has shown that IRAK1 
polyubiquitination is important for the recruitment of the IKK complex (Windheim et al., 2008), 
which would suggest an equivalent role to Rip1, separate to the activation of TRAF6 and 
TAK1. No endogenous ubiquitination of IRAK1 in HeLa cells was detected. Only one 
experiment was tried because the same problems were likely occur in the detection of 
endogenous TRAF6 and IRAK1 ubiquitination in HeLa cells.  
 
The lack of ability to detect IRAK1 or TRAF6 ubiquitination may be a technical problem for 
example it could have been a result of the poor sensitivity of the anti-ubiquitin antibody, only a 
small proportion of the protein may need to be ubiquitinated and this could compound the low 
sensitivity of the antibody. It may be that the wrong population of complexes were 
immunoprecipitated by the antibodies, because it is necessary to immunoprecipitate IRAK1, 
TRAF6, TAK1 that has been bound to the receptor and activated in order to detect 
ubiquitination. Alternatively, the polyubiquitination may be transient and therefore it could have 
been missed with the time points of stimulation used. This would seem to be a common problem 
encountered when examining protein ubiquitination because most papers published in this field 
use overexpression of ubiquitin and sometimes the protein of interest as well to try to detect 
Lys63-polyubiquitinated proteins. Overexpression may indeed be necessary in order to study 
the Lys63-linked ubiquitination of these proteins. This strategy was not pursued because 
overexpression may generate artefacts and lead to incorrect conclusions. It is also difficult to co-
transfect siRNA and DNA together and yield high transfection efficiency to investigate the 
function of HSP27 depletion in polyubiquitination.  
 
In conclusion work from this chapter has shown that HSP27 enhances IL-1- and TNF-mediated 
cell signalling as well as gene regulation. HSP27 regulates pro-inflammatory signalling at the 
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level of TAK1 activation. It is possible that HSP27 regulates IL-1 signalling upstream of TAK1, 
however this proved difficult to analyse. The magnitude of the regulation of TAK1 by HSP27 is 
able to account for that of the downstream signalling and potentially the regulation of IL-1-
induced pro-inflammatory gene expression. The regulation of p38 MAPK downstream of TAK1 
may feedback onto TAB1 and maybe TAB2 and thus back onto TAK1 itself. Concerns over the 
validity in using HeLa cells to investigate IL-1 signalling arose because IRAK1 did not degrade 
as expected after IL-1 stimulation, whereas this did occur in the non-transformed HDF cells. 
Therefore work aimed at analysing upstream signalling was discontinued in HeLa cells. It was 
important to determine if HSP27 regulated IL-1-signalling in a more physiological cell type in 
future work. 
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Chapter 5 
 
Analysis of the function of HSP27 in human fibroblasts, A549 
and HeLa cells and with controls for off-target effects 
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5.1 Introduction 
 
The aim of the work in chapter 5 was to investigate whether HSP27 regulates inflammatory 
gene expression and signalling in two other cell types; HDFs and A549 cells. This should 
determine if the upregulation of the IL-1 signalling pathway by HSP27 is a general or HeLa 
cell-specific mechanism. The concerns raised in chapter 4 about the kinetics of IRAK1 
degradation and therefore IL-1 signalling in HeLa cells led to the desire to use a more 
physiological cell type and HDFs were chosen because they constitutively express large 
amounts of HSP27. A549 cells were used because these cells had previously been shown to be 
amenable to RNAi (Alford, 2006) and also constitutively express HSP27. During the course of 
this work it proved difficult to use HDF cells and therefore A549 cells were focussed on. Work 
in this chapter highlighted the importance of using thorough controls for RNAi experiments and 
different approaches were used address potential off-target effects. 
 
The most problematic sequence of siRNAs that cause off-target effects is thought to be the six 
nucleotide “seed region” at the 5´ end of the guide strand (Jackson et al., 2006b). It is thought 
that most off-target silencing due to complementarity of alternative mRNAs to the seed region 
cannot be distinguished from on-target effects by reducing the siRNA concentration. A variety 
of modifications to siRNA have been suggested to reduce the off-target effects. A new 
technology that is on offer by Applied Biosystems is termed locked nucleic acids (LNA). Other 
companies say that they have alternative products available, which reduce off-target effects; for 
example Dharmacon sell the product ON-TARGET plus. Dharmacon state that the sense strand 
has been modified to ensure that it is definitely not taken up by the RNA-induced silencing 
complex (RISC) and the anti-sense strand is also modified, but they do not reveal either 
modification. Another way to reduce most off-target effects is to perform a 2´-O-methyl ribosyl 
substitution at position 2 of the guide strand (Fedorov et al., 2006; Jackson et al., 2006a). The 
logic is that through the modification of the siRNA the RISC-mRNA interaction is weakened or 
disrupted in the seed region. This should eliminate off-target silencing of mRNA sequences 
with only partial complementarity to the siRNA guide strand.  
 
The ‘gold standard’ method to verify phenotypes observed in RNAi experiments is to perform a 
‘rescue’ experiment (2003). In a ‘rescue’ experiment the protein of interest is depleted and then 
the protein is reintroduced into the cell. The reintroduced protein may then ‘rescue’ the 
phenotype caused by the depleted protein. This may be achieved in a variety of ways. One 
classic experiment is to design the siRNA to target the 3´ untranslated region (UTR) of the 
mRNA and have an expression plasmid for the gene of interest that does not contain the 3´ UTR 
and can then be introduced into the cell.  
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5.2 Regulation of IL-1 signalling by HSP27 in HDFs  
 
HeLa cells are immortal and derived from a human cervical carcinoma and therefore it was 
preferable to use a more physiological non-transformed cell type, namely HDFs. If inhibition of 
IL-1 signalling and gene expression was also seen in HSP27-deficient HDFs this would suggest 
that the mechanism is neither HeLa cell-specific, nor was the regulation observed in chapters 3 
and 4 due to a HeLa cell-specific off-target effect. Cell type-specific off-target effects occur 
because cells have different gene expression patterns and therefore distinct mRNA profiles. The 
RISC complex may scan and find different mRNAs that have high complementarity to the 
siRNA sequence of interest and thus different mRNAs may be silenced dependent upon the cell 
type and condition used.  
 
5.2.1 IL-1-induced COX-2 protein expression is inhibited in HSP27#5-transfected HDFs 
 
It was decided to examine the function of HSP27 in the expression of IL-1-induced COX-2 
because it is an important pro-inflammatory mediator expressed in response to IL-1. Also, from 
previous work IL-1-induced COX-2 protein expression had been shown to be potentially more 
sensitive than IL-1-induced p38 MAPK activation to HSP27 knockdown in HeLa cells. A 
former PhD student in the laboratory had limited success with HSP27 siRNA in HDFs and work 
was stopped in these cells due to difficulties in achieving efficient depletion of HSP27. Since 
sequential transfection of siRNAs proved successful for the suppression of HSP27 in ATCC 
HeLa cells, I wanted to see if this improved the suppression of HSP27 expression in fibroblasts. 
Lipofectamine 2000 was the transfection reagent of choice because the Amaxa nucleofection 
system requires high concentrations of siRNA, for example, greater than 100 nM to yield strong 
depletion. High concentrations of siRNA have been shown to increase non-specific 
concentration dependent effects, including the interferon response (Moss and Taylor, 2003; 
Persengiev et al., 2004). 
 
Cells were seeded and 24 h later siRNA was transfected with Lipofectamine 2000. A mock 
transfection that omitted siRNA oligonucleotides was also performed. The siRNA transfection 
was repeated 24 h after the siRNA / lipid complexes were added to the cells. After a further 48 h 
the cells were stimulated with IL-1 for 4 h. A western blot was performed to detect COX-2 
protein (Fig. 5.1). A second siRNA, HSP27#2, was used to control for potential off-target 
effects with HSP27#5. HSP27#2 had been used in the initial experiments (Alford, 2006). Fig. 
5.1 shows that HSP27#2 and HSP27#5 efficiently depleted HSP27 from HDFs however 
HSP27#2, in agreement with previous work, was less effective and residual HSP27 was 
detected in HSP27#2-transfected cells. IL-1 treatment for 4 h induced COX-2 protein 
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expression in mock and Scramble-treated fibroblasts (Fig. 5.1). HSP27#5-treated fibroblasts 
displayed inhibition of COX-2 protein; however HSP27#2-treated fibroblasts did not (Fig. 5.1). 
In some experiments HSP27#2-transfected cells did show slight inhibition of IL-1-induced 
COX-2 protein expression. Residual HSP27 protein may be sufficient for the induction of COX-
2 protein by IL-1 in HSP27#2-transfected cells. The inhibition of IL-1-induced COX-2 protein 
in cells depleted of HSP27 with HSP27#5 agrees with the work in HeLa cells (Chapter 3). This 
gave some confidence that the function of HSP27 in IL-1-induced COX-2 protein expression 
may be relevant in a more physiological context. 
 
5.2.2 IL-1-induced p38 MAPK activity is inhibited in HSP27#5-transfected HDFs 
 
In order to investigate whether HSP27 depletion also inhibited IL-1 signalling in HDFs IL-1-
induced p38 MAPK activation in HDFs was examined. HSP27#2 siRNA was not used because 
sequential transfection with this siRNA was not sufficient for strong depletion of HSP27 and 
did not inhibit IL-1-induced COX-2 protein expression (Fig. 5.1). Cells were left untransfected, 
or were treated with transfection reagent alone (mock), or with Scramble dsRNA or HSP27#5 
siRNA with Lipofectamine 2000. 24 h later the transfection was repeated. After 48 h incubation 
the cells were either left untreated or treated with IL-1 for 30 min before lysis. Western blots 
were carried out to detect phosphorylated p38 MAPK, total p38 MAPK and HSP27. In two 
experiments  
 
HSP27 was strongly depleted (Fig. 5.2). Phosphorylation of p38 MAPK on Thr180 and Tyr182 
was decreased in HSP27#5-transfected cells compared to Scramble-transfected cells (Fig. 5.2). 
In one experiment p38 MAPK protein expression appeared to be lower in HSP27#5-transfected 
cells compared to Scramble-transfected cells (Fig. 5.2), although to a lesser extent than 
phosphorylation of p38 MAPK. In a third experiment inhibition of IL-1-induced p38 MAPK 
activation did not occur however, there was little depletion of HSP27. Therefore it was hard to 
determine if the effect on p38 MAPK phosphorylation detected was due to regulation of the 
activation or expression of p38 MAPK. There were also concerns as to how reproducible the 
depletion of HSP27 would be using this transfection technique. These difficulties led me to 
evaluate HSP27 function in a third cell type.    
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Figure 5.1: HSP27#5 siRNA inhibits IL-1-induced COX-2 protein expression in HDFs. 
HDFs were subjected to two rounds of siRNA transfection 24 h apart with Scramble dsRNA, 
HSP27#2 or HSP27#5 using Lipofectamine 2000. A mock transfection with transfection reagent 
only was also performed. 48 h after the second transfection, the cells were stimulated with 20 ng 
ml-1 IL-1 for 4 h and lysed in whole cell lysis buffer. SDS-PAGE and western blots were 
performed to detect COX-2, HSP27 and the loading control, α-actin. Fig. 5.1 is one of five 
experiments. 
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Figure 5.2: HSP27#5 siRNA inhibited IL-1-induced p38 MAPK activation in HDFs. HDFs 
were subjected to two rounds of transfection with Scramble (Scr) dsRNA or HSP27#5 siRNA. 
After 48 h incubation the cells were left unstimulated or stimulated with IL-1 for 30 min and 
then lysed with kinase lysis buffer. Samples were run on a 10 % SDS-polyacrylamide gel and 
analysed by western blots for phosphorylation of p38 MAPK, total p38 MAPK and α-actin. This 
figure was one of three experiments. 
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5.3 HSP27-dependent regulation of IL-1 signalling in A549 cells 
 
Human alveolar basal epithelial (A549) cells were chosen because these cells elicit strong IL-1 
responses and are relatively easy to transfect. It was thought that these cells may provide a 
system which would help elucidate whether the regulation of IL-1 signalling by HSP27 is a 
general mechanism. 
 
5.3.1 HSP27 depletion inhibits IL-1-induced COX-2 protein expression in A549 cells 
 
Lipofectamine 2000 is a stronger transfection reagent than Oligofectamine and therefore was 
chosen for the transfection of A549 cells because they were believed to be more difficult to 
transfect than HeLa cells. Previous work in the laboratory had also shown that strong 
suppression of HSP27 expression by HSP27#5 could be achieved with this transfection reagent 
in A549 cells (Alford, 2006). Lipofection of A549 cells was performed with either Scramble 
dsRNA or HSP27#5 siRNA to deplete HSP27. 72 hours after transfection the cells were 
stimulated using IL-1 and analysed by western blot for COX-2 protein expression. HSP27 
expression was very efficiently suppressed by a single transfection of HSP27#5 (Fig. 5.3). IL-1-
induced COX-2 protein was inhibited following HSP27 depletion in A549 cells (Fig. 5.3). This 
result would suggest that the augmentation of IL-1-induced COX-2 protein expression by 
HSP27 is a general phenomenon because it was observed in all the cell types tested. 
 
5.3.2 HSP27 depletion in A549 cells inhibits IL-1-induced p38 MAPK and MKK3 / 
MKK6 activation 
 
The aim was to use A549 cells to confirm that the general enhancement of IL-1-mediated events 
was not confined to COX-2 protein expression, especially because difficulties in the transfection 
of HDF cells made examination of IL-1 signalling difficult. p38 MAPK is known to be 
important in the stabilisation of pro-inflammatory mediator mRNAs. Fig. 5.4A shows that 
depletion of HSP27 with HSP27#5 siRNA in these cells inhibited IL-1-induced p38 MAPK 
activation compared to Scramble-transfected cells. p38 MAPK has slightly reduced expression 
in HSP27#5-transfected cells, however this was thought unlikely to completely account for the 
inhibition in the IL-1-induced phosphorylation of p38 MAPK observed in the three independent 
experiments.
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Figure 5.3: HSP27 depletion inhibits IL-1-induced COX-2 protein expression in A549 
cells. Lipofection of A549 cells was performed using Lipofectamine 2000 with Scramble (Scr) 
dsRNA or HSP27#5 siRNA. Cells were stimulated with IL-1 and lysed with whole cell lysis 
buffer. Proteins were separated by SDS-PAGE and analysed by western blot for COX-2, HSP27 
and α-tubulin. This figure is representative of one experiment performed at three different cell 
confluencies. 
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It was decided to examine the regulation of the p38 MAPK upstream activators MKK3 and 
MKK6 in the same samples. Fig. 5.4A shows that in A549 cells HSP27 depletion was found to 
inhibit IL-1-induced MKK3 and MKK6 phosphorylation at their activatory phosphorylation 
sites; Ser189 on MKK3 and Ser207 on MKK6. MKK3 (40 kDa) and MKK6 (41 kDa) are highly 
homologous and only one band was seen on the phospho-western blot. However, when the blot 
was stripped and reprobed with another antibody which should recognise a shared epitope on 
both MKK3 and MKK6 two bands were detected of about the correct relative molecular mass. It 
is possible that these two bands are MKK3 and MKK6 respectively, however it may be that the 
proteins have not resolved sufficiently and one band is a non-specific band. Alternatively one of 
the two proteins could be predominantly phosphorylated in the presence of IL-1 and account for 
the fact that only one band was detected with the anti-phospho MKK3 / MKK6 antibody. The 
conclusion from these experiments was that the enhancement of signalling by the p38 MAPK 
pathway via HSP27 was a general phenomenon. 
 
5.3.3 The investigation into the effect of HSP27#5 siRNA on IL-1-induced TAK1 
activation 
 
The pivotal point in HeLa cells for regulation by HSP27 of IL-1 signalling appeared to be 
TAK1 and therefore the regulation of TAK1 in A549 cells was examined. A549 cells were 
transfected with 10 nM Scramble dsRNA and HSP27#5 siRNA with Lipofectamine 2000. Cells 
were stimulated with IL-1 and lysed in TAK1 lysis buffer. Surprisingly, upon analysis, 
phosphorylation of TAK1 at its activation site (Thr187) was found to be prolonged in the A549 
cells (Fig. 5.5) compared to Scramble-transfected cells. Peak TAK1 activation also appeared to 
be slightly increased in HSP27-depleted cells. This is in marked contrast to the inhibition seen 
with this siRNA in HeLa cells (Fig. 4.1). The same result was seen in three independent 
experiments. The inhibition of IL-1-induced MKK3 and MKK6 activation made this result even 
more unexpected. This result may put into doubt whether TAK1 is the MKKK responsible for 
the activation of MKK3 and MKK6 in A549 cells. Alternatively, this result could suggest that 
HSP27 is able to regulate several points in the IL-1 signalling pathways. 
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Figure 5.4: HSP27 depletion inhibits IL-1-induced p38 MAPK, MKK3 and MKK6 
activation in A549 cells. Lipofection of A549 cells was performed using Lipofectamine 2000 
with Scramble (Scr) dsRNA or HSP27#5 siRNA. Cells were stimulated with IL-1 and lysed 
with TAK1 lysis buffer. A. A western blot was performed to analyse the phosphorylation of p38 
MAPK, and total protein levels of HSP27 and p38 MAPK. B. A western blot was performed to 
detect MKK3 / MKK6 phosphorylated at the activation sites, HSP27, total MKK3 / MKK6 and 
α-tubulin. A and B are representative of three independent experiments each.  
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Figure 5.5: HSP27#5 depletion prolongs IL-1-induced TAK1 activation in A549 cells. A549 
cells were transfected with Scramble dsRNA or HSP27#5 siRNA. 72 h after transfection the 
cells were stimulated with IL-1 for the times shown and lysed in TAK1 lysis buffer. Equal 
amounts of total protein were separated by SDS-PAGE and analysed by western blot for 
phosphorylated TAK1 (Thr187), total TAK1, HSP27 and α-tubulin. This figure was 
representative of three independent experiments.   
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5.3.4 HSP27 depletion using HSP27#5 siRNA augments IL-1-induced JNK and ATF-2 
phosphorylation in A549 cells 
 
TAK1 is thought to activate both the JNK and p38 MAPK pathways. The effects of HSP27 
depletion on IL-1-induced TAK1, MKK3, MKK6 and p38 MAPK in A549 cells were 
confusing. Since MKK3 / MKK6 was inhibited by HSP27 depletion but TAK was not, it was 
unclear what the effect of HSP27 depletion on IL-1-induced JNK activation might be. To find 
out whether HSP27 enhanced activation of both p38 MAPK and JNK pathways by TAK1, or 
p38 MAPK only the IL-1-induced activation of JNK, and its substrate ATF-2 were examined. 
Fig. 5.6A shows that HSP27#5 enhances the IL-1-induced phosphorylation of JNK. This 
experiment was repeated twice. In one experiment HSP27#5 appeared to prolong rather than 
enhance JNK activation. IL-1-induced ATF-2 phosphorylation was both enhanced and 
prolonged in A549 cells transfected with HSP27 siRNA compared to Scramble-transfected cells 
(Fig. 5.6B). These results indicate that TAK1 is responsible for the phosphorylation of JNK in 
A549 cells and is therefore likely to also activate MKK3 / MKK6. Therefore these results do not 
explain the disparity between the regulation of TAK1 and p38 MAPK in HSP27-depleted A549 
or HeLa cells. 
 
5.4 Use of different siRNAs to examine the regulation of IL-1 signalling by HSP27 in 
A549 cells  
 
HSP27 depletion using HSP27#5 showed different effects on the regulation of TAK1 activation 
in HeLa cells and A549 cells and a disparity between the affect of HSP27 depletion upon TAK1 
and MKK3 / MKK6 activation. One aforementioned possibility was that HSP27#5 siRNA 
causes cell type-specific off-target effects in one or both of the two cells types tested. The 
prevalence of off-target effects means that all RNAi experiments need to be interpreted with 
caution. The most common problem reported is off-target mRNA degradation (Baek et al., 
2008). siRNA oligonucleotides are small 21-23 nucleotide sequences that bind to 
complementary mRNA sequences and target these for degradation by argonaute, a subunit of 
the RISC complex. However, it is possible that the gene of interest is not the only sequence in 
the genome with exact or near complementarity to the siRNA sequence. RNAi makes use of a 
natural pathway of gene regulation and protection from RNA viruses, used by microRNAs 
(miRNA). miRNAs do not require perfect complementarity with the sequence of interest to 
silence the target, the most important region is the ‘seed region’ residues 2-7 on the 5´ end 
(Lewis et al., 2005; Lewis et al., 2003). Therein lies the problem, if perfect complementarity is 
not required, many more sequences could be silenced and this leads to off-target sequence 
degradation. 
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Figure 5.6: Depletion of HSP27 with HSP27#5 caused a slight increase in IL-1-induced 
JNK activation and ATF-2 phosphorylation in A549 cells. Scramble dsRNA or HSP27#5 
siRNA were transfected into cells using Lipofectamine 2000. Cells were stimulated with IL-1 
for the times shown and lysed in TAK1 lysis buffer. Equal amounts of total protein were 
separated by SDS-PAGE and western blot analysis performed for phosphorylated JNK, 
phosphorylated ATF-2, HSP27 and α-tubulin. Fig. 5.6A was representative of two independent 
experiments and B of one experiment.  
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Some of the off-target effects may be concentration dependent (Semizarov et al., 2003). In order 
to address this problem a relatively low concentration of siRNA, 10 nM, was used in chapters 3, 
4 and 5. Strategies that may be employed to validate RNAi results include the confirmation of 
results in other cell lines or types, use of multiple siRNA sequences, overexpression of the 
protein of interest and phenotype rescue by the re-introduction of the protein of interest. 
 
Each siRNA sequence may lead to the generation of unique patterns of off-target effects. 
Therefore the use of multiple siRNAs decreases the chance that a mutual effect observed after 
transfection would be an off-target effect. The aim of this experiment was to determine if the 
effects of HSP27 depletion upon IL-1-induced TAK1 and signalling downstream of MKK3 / 
MKK6 were reproducible with other siRNA sequences. A search through the literature 
suggested that another siRNA, described by Rocchi et al., named in this work as HSP27#7, was 
also very efficient at depleting HSP27 (Rocchi et al., 2006). Therefore HSP27#7 was used to 
deplete cells of HSP27 and examine the effect upon IL-1-induced TAK1 and p38 MAPK 
activation. Fig. 5.7 shows that both HSP27#5 and HSP27#7 deplete HSP27 very efficiently in 
A549 cells. Both HSP27#5 and #7 inhibited IL-1-induced p38 MAPK phosphorylation. As 
observed previously HSP27#5 also appeared to slightly reduce p38 MAPK total protein. 
HSP27#5 siRNA prolonged TAK1 activation as seen previously however, HSP27#7 siRNA 
inhibited IL-1-induced TAK1 activation. In Fig. 5.7 TAK1 expression appears to be slightly 
uneven and there is an edge effect in the untransfected samples. However, this cannot account 
for the variations in TAK1 phosphorylation observed under the different conditions. The 
inhibition of IL-1-induced TAK1 phosphorylation in HSP27#7-transfected conditions agrees 
with the TAK1 data in HeLa cells using HSP27#5 siRNA and suggested that HSP27#5 may 
exert off-target effects on TAK1 activation in A549 cells. To test this possibility two additional 
previously reported siRNAs, HSP27#8 (Rocchi et al., 2006) and HSP27#9 (Park et al., 2003) 
were used. A549 cells were transfected with HSP27#8 and #9 as before. HSP27 depletion by 
these two siRNAs was suboptimal, especially for HSP27#8 (Fig. 5.8). In agreement with my 
previous work in HeLa cells (Fig. 3.6) it appeared that only a small amount of HSP27 protein is 
needed in cells for normal IL-1-induced p38 MAPK activation (Fig. 5.8). The phospho-p38 
MAPK membrane was stripped and re-probed for total p38 MAPK. Fig. 5.8 shows a time-
dependent reduction in p38 MAPK expression at 10 and 20 min post-IL-1, however this is 
likely to be a re-probe effect because phosphorylated p38 MAPK runs at the same position as 
the total protein and would have been removed from the membrane during the stripping 
procedure. In conclusion despite having different effects on TAK1 both HSP27#5 and HSP27#7 
siRNAs inhibited IL-1-induced p38 MAPK activation compared to Scramble-, mock-  
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Figure 5.7: HSP27#5 and #7 inhibit p38 MAPK activation; however HSP27#7 inhibits 
rather than prolongs the activation of IL-1-induced TAK1 in A549 cells. A549 cells were 
transfected with Scramble dsRNA and HSP27#5 and HSP27#7, siRNAs to deplete HSP27, 
using Lipofectamine 2000. 72 h post transfection the cells were stimulated with IL-1 and lysed 
with TAK1 lysis buffer. Equal amounts of total protein per sample were separated by SDS-
PAGE and western blots were performed to detect phosphorylated p38 MAPK, p38 MAPK, 
phosphorylated TAK1, TAK1, HSP27 and α-tubulin. This experiment was performed once.  
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Figure 5.8: Analysis of IL-1 signalling in HSP27-depleted A549 cells using multiple siRNA 
oligonucleotides. A549 cells were left untransfected (Un), mock-transfected using 
Lipofectamine 2000 or transfected with Scramble (Scr) dsRNA, 10 nM siRNAs targeting 
different parts of the HSP27 sequence. HSP27#5 was used along with three siRNAs that had 
been used in the literature; HSP27#7, #8 and #9. Equal amounts of protein were separated by 
SDS-PAGE and western blot analysis was performed for phosphorylated p38 MAPK, p38 
MAPK, HSP27 and α-tubulin. Fig. 5.8 was representative of two experiments.  
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transfected or untransfected cells. This is consistent with the results in HeLa cells and still 
points to a general mechanism of IL-1 signalling upregulation by HSP27. 
 
5.4.2 The employment of modified siRNAs to try to resolve off-target effects in A549 
cells 
 
HSP27#5 and HSP27#7 siRNAs with the 2′-O-Me modification were synthesised by MWG 
Eurofin. The RNAi experiment was performed with one round of 10 nM siRNA using 
Lipofectamine 2000. 72 h post transfection the cells were stimulated with IL-1 and lysed in 
TAK1 lysis buffer. Western blot analysis was performed to examine the degree of HSP27 
depletion by the modified siRNAs and p38 MAPK protein was analysed as a loading control. 
Modified HSP27#5 efficiently depleted HSP27 in contrast to modified HSP27#7 which did not 
(Fig. 5.9). The modified HSP27#7 siRNA did not affect the expression levels of HSP27. 
Therefore, unfortunately, it was not possible to use this modification of the siRNAs to clarify 
whether both / one siRNA caused an off-target effect on IL-1-induced TAK1 phosphorylation in 
A549 cells. 
 
5.5 Attempts to rescue the HSP27 RNAi phenotype  
 
5.5.1 Transient transfections of HSP27 expression plasmids in HDFs 
 
Only one siRNA had been used for most of the work in HeLa cells and HDFs. Therefore it was 
decided to try to rescue the HSP27 RNAi phenotype to find out if these results were caused by 
RNAi off-target effects. Unfortunately, no appropriate siRNA sequences could be found for the 
3´ UTR of HSP27. Therefore an expression plasmid containing the DNA sequence of HSP27 
with a silent mutation in the siRNA target region that rendered the mRNA resistant to HSP27#5 
whilst the amino acid sequence of the protein was unchanged (siRNA resistant, sRR) was used. 
If the ‘rescue’ experiments worked it was intended to use this technique to investigate the 
function of HSP27 phosphorylation in IL-1 signalling through the transfection of plasmids that 
encode the non-phosphorylatable and phospho-mimetic versions of the protein. 
 
Previous work in the laboratory with SuperFect suggested that a 40 % transfection efficiency of 
HeLa cells with DNA could be achieved. It was believed that this would be sufficient to observe 
a partial restoration of IL-1-induced COX-2 protein expression after HSP27 depletion. 
Therefore initial work was performed using transient transfections. Rescue experiments were 
initially attempted in HDFs because these cells were thought to be more physiological model 
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Figure 5.9: HSP27 depletion with 2′ O-Methyl-modified siRNAs. A549 cells were 
transfected by Lipofectamine 2000 with either Scramble (S) dsRNA, HSP27#5 (#5), HSP27#7 
(#7) or the latter two siRNAs modified by a 2´ O-Me group at position 2 on the antisense strand 
(#50 or #70). 72 h after transfection the cells were stimulated with IL-1 for the times shown and 
lysed in TAK1 lysis buffer. Samples were separated by SDS-PAGE and western blot analysis 
performed for HSP27 and p38 MAPK. This experiment was performed once. 
 
  
 
Chapter 5           HSP27 function in multiple cell types with controls for off-target effects 
   
 
 148
than HeLa cells. IL-1-induced COX-2 protein expression was examined because the HSP27-
dependent inhibition of IL-1-induced COX-2 had been more reproducible than p38 MAPK 
between experiments with HSP27#5 siRNA. Lipofectamine 2000 can be used for the co-
transfection of both 10 nM siRNA and 1 μg DNA plasmid simultaneously, therefore this was 
the transfection reagent of choice. Cells were simultaneously co-transfected with siRNA and 
DNA using Lipofectamine 2000. 24 h later a second transfection of siRNA was performed. The 
cells were stimulated with IL-1 42 h after the second transfection. The lysates were analysed by 
western blot to detect COX-2, HSP27 and α-actin (Fig. 5.10). Transfection with HSP27#5 
caused strong depletion of HSP27 protein (Fig. 5.10), however it was weaker than had been 
observed in previous experiments using HSP27#5 (Fig. 5.1). sRR HSP27 DNA resulted in 
strong expression of FLAG-HSP27 protein (Fig. 5.10) and the intensity of untagged HSP27 was 
also immersed. Surprisingly, transfection of cells with wild-type HSP27 DNA (WT) resulted in 
a similarly strong induction of both tagged and untagged HSP27 expression despite the fact that 
this plasmid does not confer siRNA resistance (Fig. 5.10). This may be because too much 
mRNA was produced for all the mRNA to be degraded. A plasmid expressing a FLAG-tagged 
form of HSP27 was used to try and distinguish between endogenous and exogenous HSP27. 
The FLAG-tag is an octapeptide that increases the relative molecular mass of HSP27 by about 1 
kDa. However, FLAG-HSP27 resolved at a position on the gel corresponds to a protein of 32 
kDa, for reasons that are unclear. The WT and sRR DNA also caused the expression of HSP27 
that appeared to lack the FLAG tag (Fig. 5.10). This is probably because the expression 
plasmids contain an internal methionine start codon after the FLAG tag and hence express a 
mixture of FLAG-tagged and untagged HSP27.  
 
HSP27#5 siRNA did not inhibit IL-1-induced COX-2 protein expression in these experiments 
(Fig. 5.10). This may be the result of the weaker depletion of HSP27 in this experiment. The 
difficulties in balancing transfection efficiencies for both siRNA and DNA suggested that 
rescue experiments would be difficult to perform in HDFs and may be more easily performed in 
fibroblasts from a HSP25-/- mouse, where it is necessary only to transfect the DNA. 
 
5.5.2 Transient transfection of HSP27 DNA with calcium phosphate in HeLa cells 
 
Since HDFs were found to be unsuitable for ‘rescue’ experiments a similar approach was taken 
using HeLa cells. To investigate whether the phenotype observed in HSP27-depleted HeLa cells 
could be rescued initially a calcium phosphate kit was used to transiently transfect the DNA. 
Previous attempts to co-transfect siRNA and DNA with Lipofectamine 2000 failed in HeLa 
cells due to toxicity. Therefore the calcium phosphate kit, believed to be a less toxic method of  
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Figure 5.10: Attempt to rescue inhibition of IL-1-induced COX-2 expression in HSP27#5-
transfected HDFs by expression of exogenous HSP27 protein. 150 000 HDFs were seeded 
into each well 6 well plates, before transfection, 24 h later with either cells were left 
untransfected, mock-transfected or transfected with 10 nM Scramble dsRNA or HSP27#5 
siRNA using Lipofectamine 2000. 24 h afterwards the cells were simultaneously co-transfected 
with siRNA and DNA. DNA expression plasmids that encode HSP27 (WT) or siRNA resistant 
HSP27 (sRR) were made up to 1 µg DNA using pCMV FLAG 2 empty vector (EV). 24 h later 
the cells were stimulated with IL-1 and lysed. Lysates were analysed by western blot to detect 
COX-2, HSP27 and α-actin. This figure is representative of three experiments.  
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DNA transfection, was tried. In this transfection procedure a precipitate forms that consists of 
calcium phosphate and DNA. The precipitate adheres to the cell surface (Graham and van der 
Eb, 1973) and is believed to be taken up by endocytosis (Loyter et al., 1982).  
 
Cells were transfected with Scramble dsRNA and HSP27#5 siRNA and after 4 h of incubation 
the medium was replaced. 2 h later the cells were transfected with DNA using a calcium 
phosphate transfection kit (Sigma Aldrich) with wild-type HSP27 DNA (WT), siRNA-resistant 
(sRR) HSP27 and pCMV FLAG2 empty vector (EV). Two different amounts of HSP27 DNA 
were tried: 0.5 µg and 5 µg, to determine the amount of DNA that was needed to rescue HSP27 
expression in siRNA-transfected cells to a similar level to the endogenous protein. WT and sRR 
plasmids expressed similar amounts of HSP27 (Fig. 5.11), as observed in Fig. 5.10. The total 
DNA transfected was made up to 5 µg per point with empty vector. COX-2 protein was detected 
in Scramble-transfected cells (Fig. 5.11). In the absence of the expression plasmid HSP27#5-
transfected cells were strongly depleted of HSP27 protein (Fig. 5.11). HSP27#5 siRNA 
inhibited IL-1-induced COX-2 protein expression however this was not rescued by exogenous 
HSP27 expression (Fig. 5.11). This was surprising because it appeared as if rescue of HSP27 
expression had been achieved and it was thought that this would be sufficient to observe a small 
rescue in COX-2 protein expression. One explanation may be that the transfection efficiency 
was worse than the predicted 40 % with the calcium phosphate kit and the HSP27 seen on the 
blot is due to extremely high expression in relatively few cells.   
 
5.5.3 Flow cytometry analysis to determine transient transfection efficiencies 
 
To determine whether the failure to rescue IL-1-induced COX-2 protein expression in HeLa 
cells was due to poor transfection efficiency, flow cytometry was performed. In these 
experiments cells were transfected with the pmaxGFP plasmid, which encodes green fluorescent 
protein (GFP), instead of a plasmid that contains DNA to encode HSP27. GFP fluoresces at 509 
nm when excited at 488 nm and thus the number of cells that express GFP may be detected by 
flow cytometry analysis. This method was used to examine the transfection efficiency with the 
calcium phosphate kit, compared to the commonly used transfection reagent, SuperFect, which 
others in the laboratory have shown gives a transfection efficiency of approximately 40%. As 
mentioned above it was thought that 40 % transfection efficiency would be sufficient to observe 
a rescue effect however, it was not known if the calcium phosphate kit transfection efficiency 
was comparable to that of SuperFect.   
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Figure 5.11: Attempt to rescue inhibition of IL-1-induced COX-2 expression by re-
introduction of exogenous HSP27 protein in HSP27#5 -transfected HeLa cells. HeLa cells 
were transfected with Scramble dsRNA or HSP27#5 siRNA using Oligofectamine. After 4 h 
incubation the medium was replaced. 2 h later HeLa cells were transiently transfected with 
either 0.5 µg or 5 µg of a plasmid expressing wild-type HSP27 (WT), siRNA resistant HSP27 
(sRR) or empty vector using a calcium phosphate kit or were left untransfected. The DNA was 
made up to 5 µg per point with empty vector. 72 h after DNA was added the cells were 
stimulated with IL-1 for 4 h and lysed in whole cell lysis buffer. Lysates were analysed by 
western blots to detect COX-2, FLAG, HSP27 and α-actin. The FLAG-tag causes a shift in 
mobility of HSP27. This figure was representative of two experiments. 
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HeLa cells were left untransfected or transfected with Scramble dsRNA. Cells were transiently 
transfected with 50 ng of a plasmid expressing GFP (pmaxGFP) made up to 5 µg or 1 µg of 
DNA using pCMV FLAG 2 empty vector for transfections using calcium phosphate or 
SuperFect respectively. Forward scatter and side scatter measurements gave information on the 
cell size and granularity. This allowed live cells only to be ‘gated’ and used for the analysis of 
GFP expression. A threshold of GFP expression was defined, 10 fluorescence intensity (relative 
units), and a gate (M1 on Fig 5.12) was used to count the proportion of ‘events’ (cells) that had 
a higher level of GFP fluorescence than the control untransfected cells in a set number of total 
cells counted. With this method calcium phosphate transfection was found to result in a greater 
number of cells with GFP expression (42 %) above the threshold compared to SuperFect (26 %) 
(Fig. 5.12). The transfection efficiency was not altered by the presence of Scramble dsRNA 
(data not shown). The histograms show that the calcium phosphate mediated transfection 
produced a broader spread of expression of GFP compared to SuperFect-transfected cells (Fig. 
5.12). With the transfection levels achieved it would be expected that some rescue of IL-1-
induced COX-2 protein expression would be observed. 
 
The results from the flow cytometry analysis suggested that transfection efficiency may not 
account for the lack of rescue observed and therefore alternative rescue techniques may not 
overcome the difficulties encountered. At this point it was believed that the use of mouse 
embryonic fibroblasts (MEFs) from the HSP25-/- mouse would provide a more definitive 
strategy to confirm the results of HSP25/27 on IL-1 signalling.  
 
5.6 Confirmation of the function of HSP27 in IL-1 signalling in HeLa cells through the 
use of multiple siRNAs 
 
One reason that could account for the failure of the rescue experiments in HeLa cells was if the 
HSP27-depleted phenotype was an off-target effect. This was thought to be unlikely because 
initial work by others in the laboratory used six oligonucleotides against different regions of the 
HSP27 sequence to examine the effects of HSP27 depletion upon IL-1-induced gene regulation 
in HeLa cells. The three siRNAs (HSP27#1, HSP27#2 and HSP27#5) that efficiently depleted 
HSP27 all inhibited IL-1-induced COX-2, IL-6 and IL-8 expression (Alford, 2006). The results 
in the A549 cells confirmed that it is not sufficient to use one siRNA when using RNAi to 
examine a phenotype. This highlighted the need to confirm data on the enhancement of IL-1 
signalling in HeLa cells by HSP27. Whilst waiting for the generation of HSP25-/- mice it was 
decided to use multiple siRNAs in HeLa cells. HSP27#7 siRNA was used because although it 
produced contrasting results to HSP27#5 in A549 cells it was the most efficient siRNA of those 
tried for HSP27 depletion. It was also found that HSP27#2 siRNA was more efficient at 
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Sample siRNA DNA DNA transfection 
reagent 
Transfection 
efficiency (%) 
1 No No None 1 
2 No Yes Calcium Phosphate 42 
3 No Yes SuperFect 26 
Figure 5.12: Comparison of the DNA transfection efficiency of HeLa cells using calcium 
phosphate or SuperFect. HeLa cells were transfected with Scramble dsRNA or left 
untransfected. 24 h later HeLa cells were transfected with 50 ng pmaxGFP expression plasmid 
using calcium phosphate or SuperFect. Cells were trypsinised 72 h after the DNA transfection 
and analysed by flow cytometry. In the histograms (right panel) the Y-axis (counts) represents 
the number of cells and the X-axis represents the fluorescent intensity detected. A. Scatter plot 
(left) to show cell population and histogram (right) to show light emission by GFP detected in 
FL1 by the untransfected cell population. B. Scatter plot and histogram to show GFP 
transfection efficiency in cells transfected with DNA using calcium phosphate. C. Scatter plot 
and histogram to show transfection efficiency in cells transfected with DNA using SuperFect. 
D. Table to compare the transfection efficiency of cells that were untransfected with siRNA and 
transiently transfected with DNA using the calcium phosphate kit or SuperFect. This figure was 
representative of two experiments. 
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depleting HSP27 from cells when two sequential transfections were performed 24 h apart using 
10 nM siRNA. Therefore HSP27#2 and HSP27#7 siRNA oligonucleotides were used to confirm 
the HeLa cell results previously obtained using HSP27#5. 
 
HeLa cells were transfected with 10 nM HSP27#7 siRNA using Oligofectamine once. 72 h later 
the cells were stimulated with IL-1 and lysed in whole cell lysis buffer. Fig. 5.13 shows that 
HSP27 is strongly depleted in HeLa cells using HSP27#7 siRNA. The peak IL-1-induced 
phosphorylation of p38 MAPK on Thr180 and Tyr182 was inhibited in HSP27#7 compared to 
Scramble-transfected or untransfected cells (Fig. 5.13). 
 
IL-1-induced JNK phosphorylation was focussed on because there had been a disparity in its 
regulation in HSP27#5-transfected HeLa and A549 cells. HeLa cells were transfected using 
Oligofectamine once with HSP27#7 and twice sequentially 24 h apart with HSP27#2 siRNA. 
With these conditions both HSP27#7 and HSP27#2 siRNAs efficiently depleted HSP27 from 
HeLa cells (Fig. 5.14). Cells were stimulated with IL-1 and lysed in TAK1 lysis buffer. IL-1-
induced JNK phosphorylation was reduced in both HSP27#2 (Fig. 5.14A) and HSP27#7 (Fig. 
5.14B) compared to Scramble-transfected cells. 
 
TAK1 was the key point in the IL-1 signalling pathway regulated by HSP27 in HSP27#5 
transfected cells. TAK1 kinase assays were performed on HeLa cell lysates from cells 
transfected with HSP27#2 and HSP27#7. Both siRNA oligonucleotides efficiently depleted 
HSP27 from the cells and inhibited TAK1 by 50 % or greater (Fig. 5.15, HSP27#7 data not 
shown). These results are in agreement with those where HSP27 was depleted with HSP27#5 
siRNA (Fig. 4.1) and thus give confidence that the results in HeLa cells in chapter 3 / 4 are 
unlikely to be caused by off-target effects. 
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Figure 5.13: Depletion of HSP27 with HSP27#7 siRNA confirms the inhibition of IL-1-
induced p38 MAPK in HSP27-depleted HeLa cells. HeLa cells were left untransfected (Un) 
or transfected with Scramble dsRNA or HSP27#7 siRNA using Oligofectamine. 72 h post 
transfection the cells were stimulated with IL-1 for the times shown and lysed in whole cell 
lysis buffer. Equal amounts of protein were separated by SDS-PAGE and analysed by western 
blot for phosphorylated p38 MAPK, p38 MAPK, HSP27 and α-tubulin. This experiment was 
performed once.   
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Figure 5.14: HSP27#2 and HSP27#7 inhibit IL-1-induced JNK activation in HeLa cells. 
HeLa cells were left untransfected (Un) or transfected with Scramble dsRNA, HSP27#2 (A) and 
HSP27#7 (B) using Oligofectamine. In B the cells are sequentially transfected 24 h apart with 
HSP27#2. The cells were stimulated with IL-1 and lysed in TAK1 lysis buffer 96 h after the 
cells were seeded. Equal amounts of total cellular protein were separated by SDS-PAGE and 
western blot analysis was performed for phosphorylated JNK, HSP27 and α-tubulin. This figure 
was representative of two experiments with HSP27#2 and three experiments with HSP27#7. 
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Figure 5.15: Transfection of HSP27#2 inhibits IL-1 induced TAK1 activity in HeLa cells. 
Lipofection was performed on HeLa cells with Oligofectamine using Scramble dsRNA or 
HSP27#2 and repeated 24 h later. 96 h after seeding the cells were stimulated with IL-1 for the 
times shown and lysed in TAK1 lysis buffer. TAK1 kinase assays were performed. The upper 
panel shows the phosphorimage data of phosphorylated recombinant MKK6. The lower two 
panels consists of western blots to detect HSP27 and α-tubulin after one tenth of the material 
used for the kinase assay separated by SDS-PAGE. This figure is representative of two 
experiments. 
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5.7 Discussion 
 
Initial work to examine the function of HSP27 signalling was performed in HDF cells because 
these are a more physiological cell type. This showed that HSP27-depletion inhibited IL-1-
induced COX-2 expression in agreement with data obtained using HeLa cells, indicating that 
this regulation was not HeLa cell specific. Unfortunately, the examination of the function of 
HSP27 in IL-1-induced p38 MAPK phosphorylation in HDFs was unclear due to inconsistent 
data on p38 MAPK expression. Therefore the focus of work turned to a third cell type, A549 
cells. The kinetics of the IL-1 signalling appeared to be faster in A549 cells rather than HeLa 
cells. In HeLa cells the peak of TAK1 activity appeared to be at 30 min post-IL-1 stimulation 
(Fig. 4.1), whereas in A549 cells the peak was at 10 min IL-1, in closer agreement with the 
reports in the literature (Cheung et al., 2003). This adds confidence that A549 cells may be a 
more representative cell type than HeLa cells. 
 
The results in A549 cells proved not to be simple because IL-1-induced MKK3 / MKK6 and 
p38 MAPK phosphorylation was inhibited in HSP27#5-transfected cells, whereas IL-1-induced 
TAK1 and JNK phosphorylation was enhanced / prolonged. The phosphorylation of ATF-2 was 
also enhanced by HSP27 depletion, which was unsurprising as it is reported to be a good 
substrate of JNK (Botteron and Dobbelaere, 1998). This disparity in the regulation of MKK3 / 
MKK6 downstream signalling compared to TAK1 and JNK was surprising because TAK1 is 
thought to phosphorylate and activate both MKK3 / MKK6 and MKK4/7. Therefore the effect 
of HSP27 depletion on the downstream kinases would be expected to be the same as for TAK1. 
These results may suggest that TAK1 may not be the most important upstream regulator of 
MKK3 / MKK6 in A549 cells and HSP27 may regulate a different MKKK. Alternatively, 
HSP27 may act at multiple points in the IL-1 signalling pathway and one (or more) of the 
regulatory points is different in HeLa cells and A549 cells. For example a regulated protein may 
be present in only one cell type and not the other. An alternative possibility is that HSP27#5 
may cause cell type-specific off-target effects in either HeLa cells or A549 cells at the level of 
TAK1 and that the specific regulation is directly on MKK3 / MKK6. MKK3 / MKK6 could 
activate p38 MAPK leading to phosphorylation of the TAK1 binding protein TAB1 and cause 
negative feedback onto TAK1 (Cheung et al., 2003). If the feedback mechanism is only present 
in A549 cells but not HeLa cells it is possible that any regulation at the level of TAK1 would be 
masked in A549 cells but not HeLa cells. 
 
An alternative siRNA was used to deplete HSP27 in an attempt to determine if the results with 
HSP27#5 were repeatable and not an off-target effect. However, it was found that HSP27 
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depletion using HSP27#7 resulted in the inhibition of both IL-1-induced p38 MAPK and TAK1 
phosphorylations. This result was in agreement with the HeLa cell results (chapters 3 and 4) and 
therefore one is inclined to think that HSP27#5 causes a cell-type specific off-target effect in 
A549 cells. However, the possibility that HSP27#7 was instead exerting an off-target effect 
could not be ruled out. Unfortunately, other siRNAs that target HSP27 did not efficiently 
deplete HSP27 and therefore the analysis of HSP27 depletion upon IL-1-induced TAK1 
phosphorylation could not be conducted with these conditions.  
 
One conclusion that can be drawn from the work in the A549 cells is that it is likely that HSP27 
regulates more than one point in the IL-1 signalling pathways. Regardless of which siRNA gave 
off-target effects, IL-1-induced TAK1 phosphorylation was regulated independently of the 
regulation of IL-1-induced MKK3 / MKK6 and downstream signalling by HSP27 in these cells. 
It could be that HSP27 acts as a scaffold protein to bring MKK3 / MKK6 into close proximity 
to TAK1 and facilitate the activation of MKK3 / MKK6 in this way. HSP27 has previously been 
reported to interact with MK2 and p38 MAPK (Zheng et al., 2006), therefore it is possible that 
HSP27 acts as a scaffold protein for MK2, p38 MAPK, MKK3 / MKK6 and TAK1.  
 
The work in A549 cells highlighted the importance of correct controls in RNAi experiments and 
at this point it was decided to consolidate the work previously performed in HDF cells and 
HeLa cells. The ‘gold standard’ technique to confirm RNAi results is thought to be ‘rescue’ 
experiments. These can be performed in a variety of ways. Our approach was to perform RNAi 
and co-transfect an expression plasmid for the gene of interest with a silent mutation rendering 
it resistant to the siRNA. Initial work in HDF cells with Lipofectamine 2000 showed a lack of 
inhibition of IL-1-induced COX-2 in HSP27-depleted cells. In previous experiments where 
HSP27 knockdown had caused an inhibition in IL-1-induced COX-2 protein expression the 
depletion of HSP27 had been more complete. The transfections of siRNA alone were performed 
using 30-50 % confluent cells however the co-transfections of DNA and siRNA were performed 
using 90 % confluent cells. Co-transfection of siRNA and DNA into 40 % confluent cells 
caused a large number of cells to detach from the monolayer, which strongly suggests that these 
conditions were toxic to the cells. This suggested that Lipofectamine 2000 was not suitable for 
the purpose of siRNA and DNA co-transfection in HDFs. An additional difference that may 
account for the poor knockdown of HSP27 was that in the rescue experiments, unlike all 
previous RNAi experiments, the cells were lysed 72 h after the initial transfection compared to 
96 h. Protein synthesis is naturally in balance with protein degradation, a process termed protein 
turnover. HSP27 may have a slow turnover rate and therefore at 72 h post-transfection sufficient 
HSP27 may still be present in the cell to upregulate IL-1 signalling.  
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Attempts to rescue the inhibition of IL-1-induced COX-2 protein expression in HeLa cells 
failed. There are many potential reasons that might account for this problem. The first is that 
insufficient cells were successfully transfected and could express FLAG-HSP27. However, 
analysis by flow cytometry suggested that 42 % of cells were successfully transfected with the 
calcium phosphate kit. With this transfection efficiency it would still be expected to observe a 
partial rescue of the COX-2 expression. As this was not observed it suggests that an alternative 
problem is involved. One possibility is that the FLAG-tag on the HSP27 may interfere with the 
natural properties of HSP27. The FLAG–tag contains five aspartic acid residues and would 
therefore be negatively charged. This may prevent the HSP27 proteins from either forming the 
homooligomers that have previously been reported to be important for various functions 
(Rogalla et al.,) or the FLAG-tag may prevent an important interaction with a client protein. The 
expression of untagged HSP27 would be expected to rescue COX-2 expression. However, even 
if some untagged HSP27 was expressed it was possible that the FLAG-tagged form or highly 
elevated expression of untagged HSP27 might have had a dominant negative effect. There is 
often a delicate stoichiometry between a scaffold protein and its interaction partners. The 
disruption of this stoichiometry through overexpression of a protein may cause a dominant-
negative effect (Kracht, personal communication).  
 
Alternative strategies for rescue experiments include the use of the Penetratin-1 peptide to 
directly transfect protein into the HSP27-depleted cells. Alternatively an shRNA could be used 
to generate a stable depleted cell line, into which the protein or expression plasmid could be 
transfected. A further strategy would be to generate a stable cell line expressing the protein of 
interest (lacking the 3´ UTR) and use a siRNA against the 3´UTR of the mRNA to deplete 
endogenous protein. The most efficient way would be to use a cell type that does not express 
HSP27 and stably overexpress HSP27 in this line. For example work in the Arrigo laboratory 
successfully generated stable cell lines that express wild type and mutant HSP25 in the murine 
fibroblast cell line, L929 (Mehlen et al., 1995). However, before this could be performed it 
would be necessary to check that the role of HSP25 in inflammation is the same in murine and 
human cells. It was possible that cells that do not constitutively express HSP27 lack the 
appropriate cellular components for the regulation of IL-1 signalling to take place. There have 
been comparatively few successful rescue experiments reported in the literature for reasons that 
are unclear. At this point it was still thought that MEFs from the HSP25-/- mice would be 
available by the end of the project and would be a better system to confirm the results.  
 
The focus of work was returned to the verification of the HeLa cell results. Two additional 
HSP27 siRNAs; HSP27#2 and HSP27#7 were employed to examine HSP27 depletion in HeLa 
cells. Two sequential transfections of HSP27#2 siRNA 24 h apart improved the depletion of 
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HSP27 with HSP27#2 siRNA and facilitated the examination of IL-1 signalling regulation. In 
HeLa cells all three siRNAs used, HSP27#2, #5 and #7, inhibit IL-1 signalling including TAK1 
activity, p38 MAPK and JNK activation. An individual siRNA sequence may result in a 1.5-4 
fold change in the expression of dozens to hundreds of genes (Birmingham et al., 2006). A 
large-scale siRNA screen of the human signalling proteome found 5 % of siRNAs caused a 
change in either direction in transferin uptake and therefore in a worse case scenario 10 % of 
siRNAs would cause an off-target change on this readout (Galvez et al., 2007). Taken together 
and assuming that there is a 5 % chance of an siRNA having an off-target effect on any given 
gene, the probability of three siRNA sequences that are non-overlapping and target a different 
part of the HSP27 mRNA causing the same off-target effect is 0.053 (P = 0.000125). These 
results indicate that it is extremely unlikely that the regulation of the signalling in HeLa cells by 
siRNAs targeting HSP27 (Chapter 3 and Fig. 4.1) is caused by off-target effects. 
 
In conclusion the results in this chapter emphasise the importance of including controls in RNAi 
experiments. Although it is difficult to perform rescue experiments, multiple siRNAs that target 
different parts of the target protein sequence should be used to increase the confidence in the 
RNAi results. The employment of multiple siRNAs was therefore a future strategy for the rest 
of the work in this thesis. The use of multiple siRNAs complemented the HSP27#5 siRNA 
results in HeLa cells and it is highly likely that HSP27 depletion inhibits IL-1-induced TAK1 
activation and activity in these cells.  
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6.1 Introduction 
 
The work in chapter 5 highlighted the importance of using controls for RNAi experiments. The 
lack of clarity in the function of HSP27 in A549 cells made it more important to find a way of 
reducing the toxicity of the transfection and improving the depletion of HSP27 in HDF cells, to 
try to confirm if the regulation of IL-1-induced TAK1 and downstream signalling was a general 
mechanism. Sequential transfection of siRNAs to deplete HSP27 with Lipofectamine 2000 
proved successful but toxic in HDF cells (chapter 5), therefore Oligofectamine was tested as an 
alternative transfection reagent to see if the toxicity of transfection could be reduced.  
 
6.2 Optimisation of HSP27 depletion in HDFs 
 
The initial work in HDFs described in chapter 5 was performed using Lipofectamine 2000, a 
transfection reagent that is toxic to HeLa cells, because it had been used with some success in 
the laboratory previously. However, using the sequential method of transfection with 
Lipofectamine 2000 there was a variable response and some evidence of toxicity to the cells 
(chapter 5). HDF cells were left untransfected, treated with transfection reagent alone (mock) or 
transfected with 10 nM Scramble dsRNA or HSP27#5 twice 24 h apart using either 
Lipofectamine 2000 or Oligofectamine. The cell viability was determined by performing an 
MTT assay. Mock-transfection caused a decrease in viability of 25 % with Oligofectamine and 
37 % with Lipofectamine 2000. However, the difference between the cell viability of mock-
transfected cells compared to Scramble-transfected cells was not great with both transfection 
reagents. This suggests that it is the transfection reagent rather than the addition of dsRNA, 
which leads to the loss of cell viability. In the Oligofectamine-transfected cells there was little 
difference between the mock-, Scramble- and HSP27#5-transfected cells (Fig. 6.1), which 
suggests that the depletion of HSP27 in these cells does not affect cell viability. However, in the 
Lipofectamine 2000 transfected samples the transfection of HSP27#5 decreased the cell 
viability to less than 50 % (Fig. 6.1), which indicates that the combination of HSP27 depletion 
together with the stress of transfection with Lipofectamine 2000 leads to a decrease in cell 
viability. These results suggest that transfection with Oligofectamine improves cell viability, in 
particular when using HSP27#5 siRNA (Fig. 6.1), and therefore two sequential 10 nM siRNA 
transfections 24 h apart using Oligofectamine were used for work in this chapter.   
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Figure 6.1: Sequential siRNA transfection of HDF with Lipofectamine 2000 is more toxic 
than Oligofectamine. HDFs were left untransfected, mock-transfected, or transfected with 10 
nM Scramble dsRNA or HSP27#5 siRNAs using either Lipofectamine 2000 or Oligofectamine 
as the transfection reagent. 24 h later the transfection was repeated. 48 h after the second 
transfection an MTT assay was performed on the unstimulated cells. This figure is 
representative of two experiments. 
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 6.3 HSP27 depletion inhibits IL-1-induced COX-2 and IL-6 protein expression in 
HDFs 
 
It was necessary to confirm that the change of transfection reagent from Lipofectamine 2000 to 
Oligofectamine did not affect the regulation of IL-1-induced COX-2 protein expression by 
HSP27 in HDFs. As mentioned previously, two different siRNAs were now used to control for 
off-target effects. Cells were stimulated with IL-1 for 4 h to allow time for the induction of the 
inflammatory mediators. A western blot was performed to detect COX-2 protein (Fig. 6.2A). 
IL-1 induced COX-2 protein expression in mock and Scramble-transfected fibroblasts (Fig. 
6.2A). The expression of IL-1-induced COX-2 protein was strikingly reduced in HSP27#5- and 
HSP27#7-transfected fibroblasts (Fig. 6.2). Overall the results with Oligofectamine showed a 
greater depletion of HSP27 expression and a stronger inhibition of IL-1-induced COX-2 
expression compared to the experiments with Lipofectamine 2000 (Fig. 5.1). 
 
IL-6 and IL-8 are two other pro-inflammatory mediators which had been shown by a previous 
student in the laboratory to be regulated by HSP27 in HeLa cells (Alford, 2006). IL-6 and IL-8 
protein in culture medium was measured by ELISA. From two experiments of untransfected or 
Scramble-transfected cells IL-1 induced an average of 6.2 ng ml-1 IL-6 and 10.6 ng ml-1 IL-8. 
IL-1-induced IL-6 and IL-8 protein expression was inhibited by 50 % in cells depleted of 
HSP27 with HSP27#7 (Fig. 6.2B/C). IL-1-induced IL-6 protein expression was also inhibited 
by 50 % in HSP27#5-transfected compared to Scramble-transfected or untransfected HDFs 
(Fig. 6.2B). However, IL-8 expression was not inhibited in HSP27#5-transfected cells (Fig. 
6.2C). HSP27 depletion was greater in HSP27#7- rather than HSP27#5-transfected cells (Fig. 
6.2A) and this result could imply that a greater depletion of HSP27 is required to inhibit IL-1-
induced IL-8 protein expression.   
 
6.4 HSP27 depletion inhibits IL-1-induced p38 MAPK activation in HDFs. 
 
Previous experiments using Lipofectamine 2000 in HDFs showed an inhibition of IL-1-induced 
p38 MAPK phosphorylation in HSP27-depleted cells (Fig. 5.2). However, it was unclear if this 
was due to an effect on p38 MAPK protein expression. These experiments were repeated with 
the transfection reagent Oligofectamine. HSP27#2 was used as well as HSP27#5 and HSP27#7 
because it was thought preferable to use three siRNAs to control for possible off-target effects. 
These conditions had improved the transfection efficiencies observed for the other siRNAs and 
it was thought this may lead to a good depletion of HSP27 with HSP27#2 siRNA. Sequential 
transfections of either HSP27#5 or HSP27#7 siRNA inhibited IL-1-induced p38 MAPK 
Chapter 6                                       The function of HSP27 in IL-1 signalling in human dermal fibroblasts 
   
 
 166
 
Figure 6.2: The effect of HSP27#5- or HSP27#7-transfection upon IL-1-induced COX-2, 
IL-6 and IL-8 protein expression in HDFs. HDFs were left untransfected or subjected to two 
rounds of siRNA transfection 24 h apart with Scramble dsRNA (Scr), HSP27#5 (#5) or 
HSP27#7 (#7) using Oligofectamine. A mock transfection containing transfection reagent only 
was also performed. 48 h after the last transfection, the cells were stimulated with IL-1 for 4 h 
and lysed in whole cell lysis buffer. A. SDS-PAGE and western blots were performed to detect 
COX-2, HSP27 and the loading control α-tubulin. Fig. 6.3A is representative of two duplicate 
experiments and a further repeat experiment. B/C. Culture medium was removed from the cells 
before lysis and used for analysis by ELISA to determine the amount of IL-6 and IL-8 
expressed in culture medium from HSP27-depleted, Scramble-transfected or untransfected cells. 
Fig. 6.3B/C were each representative of two experiments. 
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phosphorylation compared to Scramble-transfected, mock or untransfected cells in three 
experiments (two experiments are shown in Fig. 6.3) at both 15 and 30 min post-IL-1. There 
was no effect of the HSP27 siRNAs on p38 MAPK protein expression (Fig. 6.3A). This 
suggests that HSP27 regulates IL-1-induced activation of p38 MAPK, rather than its expression. 
In the second experiment shown the inhibition of IL-1-induced p38 MAPK phosphorylation 
(Fig 6.3B) was greater than that of the first experiment (Fig. 6.3A) at 15 min post-IL-1. The 
inhibition of IL-1-induced p38 MAPK phosphorylation in HSP27-depleted HDFs also appeared 
to be greater at 30 min post-IL-1 in Fig. 6.3A compared with Fig. 6.3B, however because the 
signals were weak at this time point it was not possible to determine this with accuracy. 
HSP27#2 depleted HSP27 from the cells to a lesser extent than HSP27#5 or HSP27#7 as seen 
previously, and IL-1-induced p38 MAPK activation was not inhibited by this siRNA (Fig. 6.3). 
 
6.5 The effect of HSP27 depletion on IL-1-induced JNK activation in HDFs 
 
In HeLa cells depletion of HSP27 resulted in inhibition of IL-1-induced JNK phosphorylation 
and activity (Fig. 3.7). However, in A549 cells HSP27 depletion with HSP27#5 siRNA 
enhanced IL-1-induced JNK activation. It was therefore pertinent to examine the role of HSP27 
in IL-1-induced JNK activation in HDF cells. Therefore the same samples used to analyse p38 
activation (Fig. 6.3A) were used to assess JNK activation.  IL-1-induced phosphorylation of 
JNK was detected by western blot. Depletion of HSP27 with HSP27#2 at both 15 and 30 min 
post-IL-1 and HSP27#7 at 30 min post-IL-1 had no effect on the IL-1-induced JNK activation 
(Fig. 6.4). In the case of HSP27#2 this was not unexpected because there had been no detectable 
effect of HSP27#2 on IL-1-induced p38 MAPK activation in these cells. At 15 min post-IL-1 
stimulation HSP27#5 and particularly HSP27#7 appeared to increase p54 (and for HSP27#7 
p46) JNK phosphorylation compared to the control conditions (Fig. 6.4). At 30 min post-IL-1 
stimulation there was a weak inhibition of JNK phosphorylation in HSP27#5-transfected cells 
however the signal at the time point was weak in all conditions. Depletion of HSP27 with either 
HSP27#5 or HSP27#7 inhibited IL-1-induced p38 MAPK phosphorylation in the same samples 
(Fig. 6.3). In a second experiment HSP27#2 and HSP27#7 siRNAs had no effect on JNK 
phosphorylation (data not shown). However, depletion of HSP27 with HSP27#5 inhibited p46 
JNK phosphorylation at both 15 and 30 min post-IL-1 stimulation. Therefore there was no 
strong and consistent effect (between siRNAs and experiments) on the IL-1-induced 
phosphorylation of JNK in HSP27-depleted HDFs. The lack of inhibition of IL-1-induced JNK 
phosphorylation in HSP27-depleted HDFs was unexpected because TAK1 is believed to be the 
MKKK responsible for the activation of both p38 MAPK and JNK and it was regulated in HeLa 
cells. 
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Figure 6.3: HSP27#5 and HSP27#7 siRNAs inhibited IL-1-induced p38 MAPK activation 
in HDFs. HDFs were subjected to two rounds of transfection. After 48 h incubation the cells 
were left unstimulated or stimulated with IL-1α for 30 min. The cells were lysed with kinase 
lysis buffer. Samples were run on a 10 % SDS-polyacrylamide gel and analysed by western blot 
for phosphorylation of p38 MAPK and HSP27. The membrane was re-probed for total p38 
MAPK and α-tubulin. Short and long exposures of HSP27 are shown in A to highlight the 
difference in knockdown achieved with the three siRNAs in HDFs. A and B are two 
independent experiments. This experiment was performed three times and A was the most 
representative experiment. 
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Figure 6.4: HSP27 depletion has little effect on IL-1-induced JNK phosphorylation in 
HDFs. HDFs were left untransfected (Un), subjected to two rounds of mock-transfection or 
transfection of either 10 nM Scramble dsRNA, HSP27#2, HSP27#5 or HSP27#7 siRNAs. Cells 
were stimulated with IL-1 for the times shown. The cells were then lysed in TAK1 lysis buffer 
and lysates were separated on a 10 % polyacrylamide SDS-PAGE gel and analysed by western 
blot for phosphorylation of JNK, total p38 MAPK and HSP27. 
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6.6 HSP27 depletion does not affect IL-1-induced TAK1 activity in HDFs 
 
In HDFs the regulation of IL-1-induced JNK by HSP27 did not appear to be strongly regulated 
by HSP27, whereas in the same samples HSP27 depletion inhibited IL-1-induced p38 MAPK. 
Since TAK1 is thought to be the upstream activator of p38 MAPK and JNK in IL-1 signalling it 
was possible that TAK1 is not regulated by HSP27 in HDFs. Therefore it was important to 
determine if IL-1-induced TAK1 activity was affected by HSP27 knockdown in HDFs. The 
same samples used to analyse p38 MAPK activation (Fig. 6.3B and data not shown) were used 
to investigate the effect of HSP27 depletion on IL-1-induced TAK1 activity. An additional 
experiment was also carried out. In the three experiments performed IL-1-induced TAK1 
activity was unaffected by HSP27 depletion (Fig. 6.5A and B). In two experiments the same 
samples showed inhibited IL-1-induced p38 MAPK activation upon HSP27 depletion (Fig. 6.3). 
In the third experiment examination of p38 MAPK phosphorylation was unsuccessful. These 
results suggest that either HSP27 specifically regulates p38 MAPK, but not JNK or TAK1, or 
that TAK1 may not be the MKKK responsible for both p38 MAPK and JNK activation in 
HDFs. 
 
 6.7 The effect of TAK1 depletion upon IL-1-induced p38 MAPK and JNK activation 
 
It is not known if TAK1 activates p38 MAPK and JNK in human fibroblasts and studies in 
MEFs are controversial (Mendoza et al., 2008). It was decided to deplete TAK1 in HDFs to 
determine if TAK1 was the MKKK responsible for the activation of either / both p38 MAPK 
and JNK in these cells. TAK1 was depleted in HDFs using a siRNA described previously 
(Singhirunnusorn et al., 2005). TAK1 siRNA depleted TAK1 protein quite strongly however, 
the knockdown was not complete (Fig. 6.6). It should be noted that TAK1 protein from IL-1 
stimulated cells shifts in mobility on SDS-PAGE relative to that from resting cells. TAK1 
protein probably shifts in mobility as a result of an IL-1-inducible phosphorylation.  
 
In TAK1-depleted cells the IL-1-induced phosphorylation of p38 MAPK was inhibited at 30 
min post-IL-1, with little effect at the peak time of phosphorylation, 15 min (Fig. 6.6). In the 
case of JNK, the upper band corresponding to phosphorylated 54 kDa JNK was inhibited in 
TAK1-depleted cells at both 15 and 30 min post-IL-1. This suggests that certain JNK isoforms 
in the cell are activated downstream of TAK1 in response to IL-1 stimulation. However, the 
stronger bands for phosphorylated JNK appeared to be barely affected by TAK1-depletion (Fig. 
6.6). 
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Figure 6.5: HSP27 depletion does not inhibit IL-1-induced TAK1 activity in HDFs. HDF 
cells were left untransfected, mock transfected (transfection reagent alone), transfected with 
either Scramble dsRNA, HSP27#2, HSP27#5 or HSP27#7 siRNAs twice 24 h apart, stimulated 
with IL-1 and lysed with TAK1 lysis buffer. TAB1 was immunoprecipitated from the lysates 
and a TAK1 kinase assay performed. A. shows two of the phosphorimages from the TAK1 
kinase assays performed. Western blots were performed to detect phosphorylated p38 MAPK, 
p38 MAPK, HSP27 and α-tubulin (Fig. 6.3) with 1/10th material used for the material for the 
kinase assays. These were the same samples used in Fig. 6.3 and the western blots are shown in 
that figure. B. The radioactive signal for the band that corresponds to MKK3 was measured 
from the phosphorimage with the AIDA software. The background was measured in the same 
size area directly above the MKK3 band. The background signal was removed from the signal 
for each P-MKK3 band. A graph of the results from three experiments is shown. Error bars are 
standard error of the mean for three experiments. One experiment extended the IL-1 time course 
to 240 min and because this was only one experiment no error bars are shown for those time 
points. 
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This result was confirmed in one experiment with an alternative TAK1 siRNA (data not shown). 
It is possible that a greater inhibition of JNK and p38 MAPK phosphorylation was not found in 
TAK1-depleted cells because the knockdown was not complete and the remaining TAK1 
present could be sufficient for the activation of the downstream kinases. Alternatively, it may be 
that there is redundancy with one of the other candidate MKKKs such as ASK1 or the MEKKs. 
Overall, it appeared that the effects of TAK1 and HSP27 siRNAs on the phosphorylation of p38 
MAPK were similar. The effects on phosphorylation of JNK did not correlate as closely but 
overall phosphorylated JNK was only weakly inhibited by either TAK1 or HSP27 siRNAs. 
 
6.8 Identification of suitable antibodies for MKK3 and MKK6 kinase assays 
 
IL-1-induced TAK1 activity was not inhibited in HSP27-depleted cells and was unlikely to 
contribute directly to the regulation by HSP27 of IL-1-induced p38 MAPK activation in HDFs. 
It was possible that the activation of MKK3 or MKK6 by TAK1 or another MKKK was 
enhanced by HSP27. Therefore it was important to determine if IL-1-induced MKK3 and 
MKK6 activity was inhibited in HDFs depleted of HSP27. Previous work to investigate MKK3 
and MKK6 activation had used an antibody that detects the phosphorylation of the kinases at 
their active sites. This antibody did not consistently detect two bands corresponding to MKK3 
and MKK6 respectively, which may suggest that they are either not expressed to equal amounts 
in the cell types used or not activated to the same extent. In some experiments it was difficult to 
detect a band at all. Failure in the use of this antibody led to the desire to design an assay to 
measure the kinase activity of the two upstream activators as an alternative.  
 
The first difficulty encountered when finding a suitable antibody for this purpose was that 
MKK3 and MKK6 are highly homologous. There is little amino acid sequence that is specific to 
either kinase and therefore most antibodies that are commercially available detect both kinases. 
Previously our laboratory had raised antisera against five different peptide sequences, some of 
which were specific for MKK3 or MKK6 or were present in both kinases, however they had not 
been characterised. First the ability of the antisera to immunoprecipitate MKK3 or MKK6 was 
tested, using the same antiserum to try and detect the kinase from the immunoprecipitate or 
lysate by western blot. Only one antiserum appeared to successfully immunoprecipitate the 
kinase and also detect the immunoprecipitate in the lysate (Fig. 6.7A). This antiserum, 
designated RAW1, was raised against a sequence that is not present in MKK6 and therefore was 
thought to be specific for MKK3.  
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Figure 6.6: The effect of TAK1 depletion by RNAi on IL-1-induced p38 MAPK and JNK 
phosphorylation in HDFs. HDFs were subjected to two rounds of 10 nM siRNA transfection 
with either Scramble dsRNA or TAK1 siRNA #1 (and in some experiments also #2) or left 
untransfected. Cells were stimulated with IL-1 for the times shown or left untreated. Cells were 
lysed in TAK1 lysis buffer (see Materials and Methods). The samples were separated on a 10 % 
polyacrylamide SDS-PAGE gel and western blots were performed to detect total TAK1, 
phosphorylated p38 MAPK, phosphorylated JNK and α-tubulin. This figure was representative 
of three independent experiments. A second siRNA against TAK1 showed the same effect (data 
not shown). 
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Millipore sells an antibody which is suggested to be specific for MKK6. Cells were transfected 
with a DNA construct for MKK6 and the ability of each antibody to immunoprecipitate MKK6 
or detect the MKK6 by western blot was analysed. The MKK6 antibody from Millipore 
successfully immunoprecipitated the exogenous MKK6 and detected this in the lysate (Fig. 
6.7B). It was also possible to detect a very faint band that corresponds to endogenous MKK6 
immunoprecipitated with the anti-MKK6 antibody (Fig. 6.7B). From this analysis it was also 
clear that the RAW1 (anti-MKK3) antiserum did not immunoprecipitate recombinant MKK6 or 
detect it by western blot and therefore was likely to be specific for MKK3 (Fig. 6.7C). The blots 
were stripped and re-probed with RAW1 to detect MKK3. From these data (not shown) it was 
clear that no immunoprecipitated MKK3 could be detected in western blot with the anti-MKK6 
antibody; also no MKK6 could be detected in the lysate after stripping. This suggested that the 
antiserum against MKK3 and the anti-MKK6 antibody were specific for their respective kinases 
and could be used to specifically immunoprecipitate the respective target proteins in kinase 
assays. When the supernatants were removed from the immunoprecipitate and analysed by 
western blot it was also apparent that both anti-MKK6 antibody and anti-MKK3 antiserum 
completely removed all of the respective kinase from the lysate with the conditions used. 
Therefore these conditions were used as the basis for the MKK3 and MKK6 kinase assays (see 
Materials and Methods).     
 
6.9 Depletion of HSP27 has no effect on IL-1-induced MKK3 activity 
 
Antibodies/antisera had been characterised that could specifically immunoprecipitate either 
MKK3 or MKK6, therefore it was possible to examine the effect of HSP27 on their activities 
(Fig. 6.7). A kinase assay was performed to examine MKK3 activity with GST-p38 MAPK as 
the substrate. Two bands were observed on the gel corresponding to the addition of a [32P]-
labelled phosphate group on the GST-p38 MAPK substrate and p38 MAPK which had lost the 
GST-tag, when compared to the relative molecular mass markers run along side on the gel. 
However, both substrates showed the same pattern of phosphorylation in the kinase assay, 
therefore only the band corresponding to the GST-p38 MAPK has been displayed in Fig. 6.8. In 
three independent experiments it was observed that successful depletion of HSP27 had no effect 
on IL-1-induced MKK3 activity (Fig. 6.8). 
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Figure 6.7: Immunodepletion experiments for MKK3 and MKK6. Antibodies were tested 
for the ability to immunoprecipitate MKK3 (3) or MKK6 (6). A. Five antibodies were tested 
with the appropriate pre-immune (PI) control for the ability to immunoprecipitate MKK3 / 
MKK6 from HDF lysate. Lysate, supernatant and immunoprecipitate were separated by SDS-
PAGE and western blots were performed for MKK3 / MKK6. B/C. HDF cells were transfected 
either with empty vector or MKK6 expression plasmid. MKK3 was immunoprecipitated with 
RAW1 or MKK6 was immunoprecipitated with anti-MKK6 antibody (Millipore). Western blot 
analysis was performed to detect MKK6 using the same anti-MKK6 antibody used for 
immunoprecipitation. 
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Figure 6.8: Depletion of HSP27 has no effect on IL-1-induced MKK3 activity in HDFs. 
HSP27 was depleted from HDFs using two sequential Oligofectamine-mediated siRNA 
transfections 24 h apart. The dsRNA, Scramble, was used as a control or the cells were left 
untransfected. Cells were stimulated with IL-1 for the times shown. MKK3 was 
immunoprecipitated using RAW1 antiserum overnight and a kinase assay was performed with 
recombinant GST-p38 MAPK as the substrate. The results were visualised and quantified by 
phosphorimage (A). 1/10th material used for the kinase assay was separated by SDS-PAGE. 
Western blots were performed for HSP27 and the loading control, α-tubulin.  
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6.10 Difficulties encountered with HSP27 depletion in HDFs 
 
At this point the efficiency of HSP27 depletion significantly reduced (Fig. 6.9A). It was unclear 
why this had occurred because there was no obvious difference between the series of 
experiments that worked and the one that did not. Initially, the experiment was repeated in case 
a mistake had been made in the siRNA transfections, however the HSP27 depletion was still 
poor (Fig. 6.9B) COX-2 protein expression was analysed to determine if HSP27 depletion was 
able to regulate IL-1 signalling and gene expression because it was thought to be potentially 
more sensitive to HSP27 depletion than p38 MAPK phosphorylation. There was no regulation 
of IL-1-induced COX-2 protein expression in the experiment with poor HSP27 depletion (Fig. 
6.9B). RNAs, including siRNAs in deprotected form, can degrade over time and the siRNA 
oligonucleotides in use had been deprotected and stored at -20°C for 6 months. Therefore new 
siRNAs oligonucleotides were bought from MWG and tested on HDFs. This did not improve 
the HSP27 depletion in HDFs (Fig. 6.9C) thus siRNA oligonucleotide degradation was not the 
cause of the loss of transfection efficiency. New batches of HDFs and Oligofectamine were 
purchased from Lonza and Invitrogen respectively. HSP27 depletion improved (Fig. 6.9D) and 
the problem of transfection efficiency in HDFs appeared to be solved. The improvement in 
transfection efficiency appeared sufficient to reproduce the inhibition of IL-1-induced COX-2 
protein expression by HSP27 depletion in these cells (Fig. 6.9D). 
 
6.11 Depletion of HSP27 has no effect on IL-1-induced MKK6 activity 
 
It was possible that MKK6, rather than MKK3, is the dominant regulator of p38 MAPK activity 
in HDF cells therefore a MKK6 kinase assay was performed. In this experiment the HSP27 was 
strongly depleted by HSP27#5 and HSP27#7 siRNAs (Fig. 6.10). IL-1-induced MKK6 activity 
was not inhibited in HSP27-depleted cells under conditions where IL-1-induced p38 MAPK 
activation was weakly inhibited at 30 min post-IL-1 (Fig. 6.10). Although, the HSP27 depletion 
was better than Fig. 6.9A-C it was not as good as the initial experiments Fig. 6.3. This might 
account for the weaker inhibition of IL-1-induced p38 MAPK phosphorylation observed 
compared to Fig. 6.3. These results suggest that HSP27 does not regulate IL-1-induced 
signalling at the level of MKK3 and MKK6 in HDFs. Therefore it is likely that HSP27 
augments IL-1 signalling to COX-2 protein expression in HDF cells through the direct 
regulation of p38 MAPK activation. The phosphorimage was much weaker for MKK6 than 
MKK3, suggesting that MKK3 may be the more important activator of p38 MAPK in HDFs. 
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Figure 6.9:  Difficulties in HSP27 depletion in HDFs. HSP27 was depleted from HDFs using 
two sequential siRNA transfections 24 h apart. The controls were leaving the cells 
untransfected, mock-transfection or transfection of Scramble dsRNA. In C new, recently 
deprotected, siRNA and Scramble dsRNA was used. In D new cells from Lonza and a new 
batch of Oligofectamine was used. In four experiments (A-D) cells were lysed in whole cell 
lysis buffer, separated by SDS-PAGE and analysed by western blot for HSP27 and COX-2. All 
HSP27 blots shown were 5 min exposures. 
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Figure 6.10: HSP27 depletion has no effect on IL-1-induced MKK6 activity in HDFs. 
HSP27 was depleted from HDFs using two sequential Oligofectamine transfections of the 
siRNAs, HSP27#5 and HSP27#7, 24 h apart. The dsRNA, Scramble, was used as a control or 
the cells were left untransfected. The cells were stimulated with IL-1 for the times shown. 
MKK6 from the samples was immunoprecipitated overnight and a kinase assay was performed 
using recombinant GST-p38 MAPK as the substrate. A. The results were analysed by 
phosphorimage. 1/10th of the material used for the immunoprecipitation was separated by SDS-
PAGE and analysed by western blot to detect phosphorylated p38 MAPK and HSP27. B. 
Graphical representation of MKK6 activity. This experiment was performed once.  
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One potential concern with both the MKK3 and MKK6 assays was auto-phosphorylation of the 
GST-p38 MAPK substrate. Auto-phosphorylation has been reported in the literature (Ge et al., 
2002), however it is thought to be a TAB1-dependent process, competitive with the ability of 
p38 MAPK to bind to MKK3 (Lu et al., 2006). In one experiment the reaction mixture including 
GST-p38 MAPK was incubated on protein G beads that had never been in contact with lysate. 
There was no phosphorylation of the substrate observed with unstimulated samples (data not 
shown). The phosphorylation of the substrate was reduced in immunoprecipitates that had been 
stimulated with IL-1 for 60 min, which makes it unlikely that autophosphorylation of the 
substrate was induced following MKK3-mediated phosphorylation. It is unlikely that 
autophosphorylation of the GST-p38 MAPK substrate is responsible for the lack of regulation 
by HSP27 observed, although it could possibly mask a weak effect of HSP27 depletion on 
MKK3 / MKK6 activity.  
 
6.12 MKK3 is a more important activator of p38 MAPK than MKK6 in IL-1 signalling 
in HDF cells 
 
Two experiments were performed to try to determine if MKK3 or MKK6 is the major activator 
of p38 MAPK in response to IL-1 in HDFs. This was investigated by performing a kinase assay 
under conditions where the two antibodies completely immunodeplete their respective kinase 
from the lysate, thereby ensuring that the total pool of each kinase in the cell was directly 
compared (Fig. 6.11A). IL-1 stimulation resulted in a much greater induction of MKK3 
compared to MKK6 (Fig. 6.11). This result would suggest that MKK3 is likely to be the more 
important of the two kinases in the activation of p38 MAPK by IL-1 in HDFs. 
 
6.13 p38 MAPK is a negative regulator of TAK1 activity in both HeLa cells and HDFs 
 
The role of p38 MAPK in the negative regulation of TAK1 activity through the phosphorylation 
of TAB1 has been previously mentioned as a mechanism whereby pro-inflammatory signalling 
may be switched off (Cheung et al., 2003). It was possible that HSP27 is able to augment IL-1 
signalling by activating both p38 MAPK and TAK1 directly. It was hypothesised that the 
regulation of TAK1 by HSP27 could be disguised in HDF cells by reduced negative feedback 
on TAK1 by p38 MAPK in HSP27-depleted HDFs. Therefore the apparent difference in TAK1 
activity in HDF and HeLa cells following HSP27 depletion may be due to the respective 
presence or absence of the feedback mechanism respectively. The existence of this feedback 
mechanism in the two cell types was tested by pre-incubation of HDF or HeLa cells with the 
p38 MAPK inhibitor, SB202190, before stimulation with IL-1 and analysing signalling 
downstream of TAK1 (Fig. 6.12). At the low dose used, 1 µM, this inhibitor is thought to be  
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Figure 6.11: MKK3 rather than MKK6 is the major activator of p38 MAPK in HDFs. 
HDFs were stimulated with IL-1 for the times shown. Cells were lysed in whole cell lysis 
buffer. 80 µg total cellular protein was immunoprecipitated with antibodies against either 
MKK3 or MKK6 overnight. A kinase assay was performed for MKK3 and MKK6 using 
recombinant GST-p38 MAPK as the substrate. A. 8 µg total protein was analysed by western 
blot for either total MKK3 and MKK6 in both the lysate and the supernatant removed after the 
immunoprecipitation, in order to check the immunodepletion of the antigen during the 
immunoprecipitation. B. Graphical representation of MKK3 and MKK6 activity. Data shown 
above are representative of two experiments. 
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 relatively specific for p38 MAPK (Davies et al., 2000). DMSO was used as a vehicle control. 
In both cell types the pre-incubation with SB202190 caused an increase in the phosphorylation 
of both p38 MAPK and JNK at 60 min post-IL-1 stimulation (Fig. 6.12). In HDF cells 
phosphorylation of JNK at 30 min post-IL-1 was also increased (Fig. 6.12). These data are 
consistent with negative feedback by p38 MAPK on TAK1 occurring in both cell types. These 
results suggest that the feedback mechanism may be present in both the cell types tested and 
therefore the presence or absence of the feedback loop cannot account for the differences in 
signalling in the absence of HSP27 in these cells. 
 
6.14 Examination of the subcellular localisation of p38 MAPK in HDFs 
 
An alternative mechanism whereby HSP27 may enhance the activation of p38 MAPK is 
through the regulation of p38 MAPK localisation in the cell. The p38 MAPK activators, MKK3 
and MKK6 are reported to be present in both the cytoplasm and the nucleus. p38 MAPK is 
thought to be activated in the nucleus and then transported to the cytoplasm by its substrate 
MK2 (Ben-Levy et al., 1998). There have been reports that HSP27 can retain p38 MAPK in the 
cytoplasm (Gorska et al., 2007). If this was the case then in HSP27-depleted cells more p38 
MAPK would be expected to be found in the nucleus than in untransfected or scramble-
transfected cells. To investigate the hypothesis subcellular fractionation studies were performed. 
 
It was first decided to analyse the nuclear-cytoplasmic distribution of p38 MAPK using a 
detergent lysis method. In this method a buffer containing 0.5 % IGEPAL CA-350 was used to 
rupture the cytoplasmic membrane. Once the cytoplasmic fraction was removed, the nuclear 
pellets were washed and nuclear protein was extracted with a buffer containing a high 
concentration of salt (0.42 M sodium chloride). The samples were then analysed by western blot 
for p38 MAPK, MKK3 and MKK6. HSP27 is thought to be predominantly cytoplasmic, except 
under conditions of heat stress, and therefore could be used as a cytoplasmic marker (McClaren 
and Isseroff, 1994). Histone H1 was used as a nuclear marker because this is a DNA-binding 
protein, localised only in the nucleus. From the localisation of the nuclear and cytoplasmic 
markers the cell fractionation appeared to be effective (Fig. 6.13). MKK3, MKK6 and p38 
MAPK (both phosphorylated and total protein) were localised in the cytoplasmic fraction (Fig. 
6.13). In another experiment the wash step was omitted in case any material was lost in this 
step, however this made no difference (data not shown). In further experiments the nuclei were 
sonicated in either nuclear extraction buffer, as used above, or in whole cell lysis buffer for 10 
min to try and shear the DNA and release more proteins in this fraction for analysis however, 
this made no difference to the localisation of p38 MAPK observed (data not shown).
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Figure 6.12: p38 MAPK blockade increases phosphorylation of p38 MAPK and JNK in 
IL-1-treated HDF and HeLa cells. HeLa cells (A) or HDFs (B) were pre-treated with either 
0.01% DMSO, 0.1 % DMSO, 1 µM (in 0.01 % DMSO) or 10 µM (in 0.1 % DMSO) of the p38 
MAPK inhibitor, SB202190, for 1 h, or left untreated and then stimulated with IL-1 for the 
times indicated. Western blots for phosphorylated p38 MAPK, phosphorylated JNK and total 
p38α MAPK (as a loading control) are shown. 
 
 
Chapter 6                                       The function of HSP27 in IL-1 signalling in human dermal fibroblasts 
   
 
 184
 
 
 
 
 
 
 
Figure 6.13: Cell fractionation by detergent lysis to determine the localisation of p38 
MAPK in HDF cells. HDF cells were cultured on 10 cm dishes until confluent. The cells were 
stimulated with IL-1 for the times indicated. The cells were initially scraped gently into a 
cytoplasmic lysis buffer that contains 0.5 % IGEPAL CA-360 to penetrate the cytoplasmic 
membrane. The cell lysate was centrifuged at 400 × g and the cytoplasmic fraction was 
removed. The nuclear pellet was washed twice to remove cytoplasmic proteins before being 
burst in a nuclear lysis buffer that contains a high concentration of sodium chloride (0.42 M). 
For cytoplasmic fractions equal amounts of total protein were loaded onto a 10 % 
polyacrylamide SDS-PAGE gel. Cell equivalents of nuclear fractions were also loaded. The 
samples were separated by SDS-PAGE and analysed by western blot for phosphorylated p38 
MAPK, total p38 MAPK, MKK3, MKK6, HSP27 and the nuclear marker, Histone H1. 
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This result was unexpected because p38 MAPK is reported to be nuclear in unstimulated cells 
and is believed to shuttle between the cytoplasm and the nucleus upon stimulation with arsenite 
or anisomycin (Ben-Levy et al., 1998). MKK3 and MKK6 have also been reported to be present 
in both the nucleus and the cytoplasm. It was possible that the detergent caused the kinases to 
“leak” out from the nuclei. Therefore an alternative fractionation method was used. The same 
distribution of p38 MAPK and HSP27 was found between the nuclear and cytoplasmic fractions 
when cells were lysed by Dounce homogenisation (data not shown). These results could 
indicate that there are differences in the localisation of these proteins between cell types. 
Alternatively, it is possible that p38 MAPK leaks from the nucleus into the cytoplasm in both of 
these cell fractionation techniques because for Dounce homogenisation the cells were not pre-
swollen in an isotonic buffer and this may also have caused proteins to leak out from the nuclei. 
It would be expected, if this was the case, that there would at least be some residual, detectable 
p38 MAPK left in the nucleus.   
 
A lot of the information reported on p38 MAPK localisation was obtained by 
immunofluorescence (Ben-Levy et al., 1998; Gorska et al., 2007). Therefore it was decided to 
use this technique to determine if the cellular localisation of p38 MAPK in HDFs was the same 
as that observed using detergent lysis or Dounce homogenisation. This technique should also 
overcome the difficulties encountered in the examination of HSP27-depleted cells because 
individual cells can be visualised by confocal microscopy. The aim was to judge the knockdown 
of HSP27 on a cell-by-cell basis and analyse the results accordingly. The cells were cultured on 
microscope slides, stimulated with IL-1 and fixed. The same antibodies that were used to detect 
total p38 MAPK or HSP27 by western blot were used to immunostain the respective proteins 
because both antibodies only detected one band of the correct relative molecular mass as their 
target protein by western blot analysis. Propidium iodide was used to stain nuclei. Alexa-fluor-
conjugated secondary antibodies raised against the appropriate species were used. In 
experiments where the detection of multiple proteins within the same cell was required then 
secondary antibodies conjugated to fluorophores with different excitation and emission 
wavelengths were used.  
 
Fig. 6.14 shows cells stained with the above-mentioned antibodies. In each strip a greyscale 
image is shown of a section of cells stained with either anti-p38 MAPK or anti-HSP27 
antibodies or propidium iodide. The overlay shows the propidium iodide stain coloured red and 
the antibody stain in green and where the two stains co-localise the overlayed colour should 
appear as yellow. HSP27 was found to localise entirely with the cytoplasm (Fig. 6.14) in 
agreement with the other fractionation techniques (Fig. 6.13). In contrast the anti-p38 MAPK 
antibody stained both the nucleus and the cytoplasm (Fig. 6.14) and the staining appeared to be 
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more intense in the nucleus for all cells observed. This was seen in all three confocal 
experiments performed. In another experiment the secondary antibody alone was incubated on 
the fixed cells under the same conditions used and very little background staining was observed. 
The microscope settings were fixed between each condition examined with the same stain to 
enable the slides to be directly compared. However, it was difficult to eliminate slide-to-slide 
variation in the efficiency of staining. The nuclear to cytoplasmic localisation of p38 MAPK 
observed in Fig. 6.14 did not change considerably following IL-1 stimulation. Western blot 
analysis of lysates obtained from the same experiment confirmed that IL-1 did induce p38 
MAPK phosphorylation in this experiment (data not shown). In Fig. 6.14B after IL-1 
stimulation it appeared, by visual observation, that there was a slight shift of p38 MAPK from 
the cytoplasm to the nucleus. In another experiment images were taken of multiple cell sections 
from each slide and the ImageJ software used to determine the number of pixels of fluorescence 
in the cytoplasm and nuclei. There was no statistically significant difference found in the 
nuclear: cytoplasmic ratios of p38 MAPK under any of the conditions examined (data not 
shown). Staining with the anti-phospho-p38 MAPK antibody did not show any induction of 
phosphorylation in response to IL-1 stimulation, which indicates that this antibody is not 
suitable for confocal microscopy under the conditions used (data not shown). An attempt was 
made to examine HSP27-depleted HDFs (data not shown). However, it was not possible to draw 
conclusions from this experiment due to problems with the phospho-p38 MAPK staining of the 
cells, as mentioned above.  
 
6.15 HSP27 depletion enhances MKP1 expression in HDF cells 
 
The previous results indicate that HSP27 enhances IL-1-induced p38 MAPK phosphorylation. 
One way that this may occur is through the inhibition by HSP27 of a phosphatase that targets 
p38 MAPK. A candidate phosphatase is MKP1 for which p38 MAPK is a substrate (Franklin 
and Kraft, 1997). HSP27 was depleted from cells and the lysates were analysed by western blot 
for MKP1 expression. HSP27 was strongly depleted from the cells transfected with either 
HSP27#5 or HSP27#7 siRNAs (Fig. 6.15). In Fig. 6.15 peak MKP1 expression occurred at 60 
min post-IL-1 and at this time it did not appear to be regulated by the presence or absence of 
HSP27. In contrast in resting cells and the other times of stimulation examined, except 30 min 
post-IL-1, depletion of HSP27 appeared to result in a small increase in MKP1 expression. A 
kinase assay was performed to check IL-1-induced p38 MAPK activity in the same samples that 
were analysed for MKP1 expression (Fig. 6.15A and B). In this experiment IL-1-induced p38 
MAPK activity was inhibited by about 50 % in cells transfected with either HSP27#5 or 
HSP27#7 siRNAs at both 15 min and 30 min  
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Figure 6.14: Confocal microscopy analysis of p38 MAPK and HSP27 subcellular 
localisation in HDFs. HDF cells were grown on microscope slides. The cells were stimulated 
with IL-1 for the times shown before fixation onto the microscope slide. The cells were 
permeabilised and incubated in primary antibody against HSP27 or total p38 MAPK. Excess 
antibody was washed off and the cells were incubated with the appropriate Alexa-Fluor 
conjugated secondary antibody and the nuclear stain propidium iodide. The alexa-fluor 
conjugate was excited by a laser at the appropriate wavelength and a camera was used to record 
the fluorescence emission from the cells. The panels above show the imunofluorescent staining 
of p38 MAPK and HSP27 from different cell sections at A. 0 min IL-1, B. 15 min IL-1 and C. 
30 min IL-1. The right-hand panel shows the overlay of each protein stain with propidium 
iodide. 
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post-IL-1 (Fig. 6.15B). p38 MAPK activity returned to basal levels at 60 min, which correlates 
with the time of peak IL-1-induced MKP1 expression.  
 
This experiment was repeated an additional three times (data not shown). In the second 
experiment HSP27 depletion was less efficient (residual protein appearing on a 2 min rather 
than 30 min exposure). In this experiment HSP27 depletion only correlated with a marginal 
enhancement of MKP1 expression 120 min post-IL-1 with HSP27#5 and 30 min post-IL-1 with 
HSP27#7. In this experiment HSP27#5 slightly inhibited IL-1-induced p38 MAPK 
phosphorylation at 30 min post-IL-1 and HSP27#7 had no effect. In a third experiment residual 
HSP27 was apparent on a 5 min exposure, HSP27#5 had no effect on MKP1 expression, 
HSP27#7-transfected samples exhibited a marginal increase in MKP1 at 30 and 60 min post-IL-
1 and no effect on p38 MAPK phosphorylation. In a fourth experiment neither IL-1-induced 
MKP1 expression was increased nor was IL-1-induced p38 MAPK activity inhibited when 
HSP27 was depleted. In experiment four the HSP27 depletion was poor. The reduction in 
HSP27 depletion in the last three experiments may have affected the regulation of p38 MAPK 
phosphorylation and possibly MKP1 expression. The reason the variability in HSP27 
knockdown was unclear. Possibly it was due to the passage number of the fibroblasts which 
may cause the depletion of HSP27 to be weaker than observed in early experiments. However, 
the effect of HSP27 depletion on MKP1 expression and p38 MAPK phosphorylation did, in 
general, seem to inversely correlate. There also appeared to be a correlation in the strength of 
effects on p38 MAPK activation and MKP1 expression. Therefore it was possible that HSP27 
may be able to regulate MKP1 expression. 
 
6.16 Analysis of the regulation of MKP1 mRNA expression by HSP27 
 
The presence of HSP27 in HDFs appeared to inhibit the expression of MKP1 protein. Therefore 
it was possible that HSP27 exerted its effects through the regulation of MKP1 transcription; 
mRNA stability; translation or protein turnover. HSP27 was depleted with sequential 
transfection of HSP27#7 siRNA. HSP27#7 was used because this was the most effective siRNA 
for HSP27 depletion. The intention was to confirm any interesting results with HSP27#5 siRNA 
in the future. Cells were stimulated with IL-1, or left untreated and RNA extracted. Real-time 
polymerase chain reaction was used to quantify the MKP1 mRNA expression (Fig. 6.16). 
GAPDH mRNA was measured as a control. Fig. 6.16A is representative of two experiments and 
shows that MKP1 mRNA expression was not affected by the depletion of HSP27. In order to 
determine if HSP27 had been successfully depleted in these cells one well of Scramble- and 
HSP27#7-transfected cells each was stimulated with IL-1 for 30 min, lysed and analysed by 
western blot. HSP27 was depleted very strongly by HSP27#7 siRNA however, when the 
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Figure 6.15: Effect of HSP27 depletion upon MKP-1 protein expression in HDFs. HSP27 
was depleted from HDFs using two sequential Oligofectamine transfections 24 h apart with 
either HSP27#5 (5) or HSP27#7 (7), or the control dsRNA, Scramble (S). After 72 h the cells 
were stimulated with IL-1 for the times shown. A. A p38 MAPK kinase assay was performed as 
outlined in materials and methods and the phosphorimage shown. The samples were analysed 
by western blot for MKP1, p38 MAPK and HSP27. B. Graphical representation of the p38 
MAPK kinase activity. Weak upregulation of MKP1 was observed in HSP27-depleted cells in 
three experiments, albeit at different time points. 
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membrane was analysed for the phosphorylation of p38 MAPK, this was found not to be 
inhibited in HSP27-depleted cells. Therefore it was impossible to ascertain from this experiment 
whether HSP27 regulates MKP1 mRNA expression, or if the regulation lies at the level of 
translation or protein turnover. 
 
At this point it was a concern that the inhibition of IL-1-induced p38 MAPK activation upon 
HSP27 depletion with either HSP27#5 or HSP27#7 was no longer reproducible. One reason 
may be that the depletion achieved by the siRNAs was reduced however this was difficult to 
measure quantitatively because the analysis had been performed by western blot and enhanced 
chemiluminescence. Alternatively, new HDFs were raised every 10-12 passages and it may be 
that certain batches of HDFs were less responsive to HSP27 depletion.    
 
6.17 Investigation of the interaction between p38 MAPK and MKK3 
 
An alternative mechanism whereby HSP27 could regulate p38 MAPK was also examined at the 
same time. The indication that HSP27 regulates p38 MAPK activation but not MKK3 activity 
suggested that in the absence of HSP27, MKK3 may not be able to bind and phosphorylate p38 
MAPK: HSP27 may act as a scaffold protein as suggested by Zheng et al., who described a 
complex containing p38 MAPK, MK2 and HSP27 (Zheng et al., 2006). It was decided to try 
and co-immunoprecipitate MKK3 and p38 MAPK and investigate whether HSP27 promoted the 
interaction between the two proteins. SAK7b, the antibody from p38 MAPK kinase assays, was 
used to immunoprecipitate p38 MAPK from whole cell lysates and RAW1 (anti-MKK3) 
antiserum was employed to detect co-immunoprecipitated MKK3 by western blot. From two 
experiments it was determined that p38 MAPK and MKK3 form a constitutive interaction 
which is not disrupted by stimulation with IL-1 for 30 min (Fig. 6.17). An experiment was then 
performed in order to determine if this complex was disrupted in the absence of HSP27. 
Analysis of the supernatants after the immunoprecipitation of p38 MAPK revealed that HSP27 
was strongly depleted in HSP27#5 or HSP27#7-transfected cells. The membrane was probed 
with an antibody against phosphorylated p38 MAPK and there was reduced phosphorylated p38 
MAPK detected in the supernatant from samples immunoprecipitated with the MKK3 antiserum 
compared to the pre-immune anti-serum. This agrees with the data from the immunoprecipitates 
that suggest that p38 MAPK specifically forms a complex with MKK3 (Fig. 6.17). However, no 
inhibition of IL-1-induced p38 MAPK activation was observed in HSP27-depleted cells (Fig. 
6.17). 
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Figure 6.16: HSP27 depletion does not significantly effect MKP1 mRNA expression in 
HDFs. Cells were depleted of HSP27 using two sequential Oligofectamine transfections of the 
siRNA oligonucleotide HSP27#7 or transfected with the dsRNA control, Scramble. Cells were 
stimulated with IL-1 for the times shown. A. RNA was isolated and analysed by qRT-PCR for 
MKP1 and GAPDH. This graph is shows the mean of two experiments. B. Scramble- and 
HSP27#7-transfected cells that had been cultured at the same time as those for analysis by qRT-
PCR were lysed in kinase lysis buffer. Samples were separated by SDS-PAGE and analysed by 
western blot to detect phosphorylated p38 MAPK, HSP27 and α-tubulin.  
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Figure 6.17: MKK3 and p38 MAPK form a constitutive interaction in HDF cells.  HDFs 
cells were sequentially transfected with Scramble (S) dsRNA, HSP27#5 (#5) or HSP27#7 (#7) 
siRNAs with Oligofectamine. Cells were stimulated with IL-1 for the times shown and lysed in 
whole cell lysis buffer. The lysates were incubated with SAK7b antiserum for 2 h to 
immunoprecipitate p38 MAPK. The supernatant was removed, separated by SDS-PAGE and 
analysed by western blot for phosphorylated p38 MAPK and HSP27. The immunoprecipitate 
was washed five times with a high salt concentration lysis buffer to remove non-specific 
interactions, before separation by SDS-PAGE. Analysis by western blot was performed to 
detect MKK3 (RAW1 antiserum) and total p38 MAPK (Cell Signalling Technology). This 
experiment was performed once. 
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6.18 Phosphorylation of p38 MAPK was not inhibited by HSP27 in the MKK3 kinase 
assay experiments 
 
The concerns about the lack of reproducibility of the inhibition of IL-1-induced p38 MAPK 
phosphorylation in HSP27-depleted HDFs in the later work prompted the re-examination of 
experiments that had been used to determine the effect of HSP27 on MKK3 activity (Fig. 6.8). 
This is a pivotal result because it was used to underline the importance of p38 MAPK as the 
potential point in IL-1 signalling regulated by HSP27. The membranes that had been used to 
check HSP27 depletion and loading were stripped and re-probed for phosphorylated p38 
MAPK. From this analysis it appeared that the IL-1-induced phosphorylation of p38 MAPK 
detected on the re-probed membranes was not inhibited upon HSP27 depletion (Fig. 6.18). In 
the two experiments successfully re-probed IL-1-induced MKK3 activity was also unaffected.  
 
6.19 Analysis of the role of HSP25 phosphorylation in IL-1 signalling through the use of 
MK2-/- MEFs 
 
The irreproducibility of p38 MAPK regulation by HSP27 in late experiments led to the use of 
an alternative strategy to examine the function of HSP27 in IL-1 signalling. Initially, it was 
thought that the role of HSP27 phosphorylation in IL-1 signalling could be examined through 
the use of rescue experiments or the reintroduction of mutant proteins into HSP25-/- MEFs. 
Unfortunately these techniques had either not been successful or were unavailable during the 
time of my PhD. It was thought that the phosphorylation of HSP27 could be involved in a 
positive feedback onto the pathway. Therefore it was decided to try a different approach using 
MK2-/- MEFs. MK2 is thought to be the principal kinase that phosphorylates HSP25 / HSP27 in 
response to IL-1 stimulation. It was therefore thought that the MK2-/- MEFs would facilitate the 
examination of the function of HSP25 phosphorylation in fibroblasts.  
 
Immortalised MK2-/- MEFs that had been stably transfected with wild-type and mutant forms of 
MK2 were used for these experiments. Three cell lines were analysed; mock-infected with the 
retro-virus; infected with kinase-dead MK2 or wild-type MK2. These lines were derived from 
the same parent line of MEFs and allowed for the controlled comparison of phenotypes between 
cells that either possess or lack the ability to phosphorylate HSP25. MK2-/- MEFs displayed 
reduced p38 MAPK protein expression (Fig. 6.19), in agreement with a previous report 
suggesting that MK2 stabilises p38 MAPK protein (Kotlyarov et al., 2002). This difference is 
independent of MK2 kinase activity because total p38 MAPK expression levels in cells that 
express a kinase-dead or wild-type construct of MK2 were similar (Fig. 6.19), again this is in 
agreement with Kotlyarov et al (Kotlyarov et al., 2002). Phosphorylation of p38 MAPK and 
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Figure 6.18: HSP27 depletion has no effect on IL-1-induced p38 MAPK phosphorylation 
in the MKK3 kinase assay experiments. 1/10th of material used in for the MKK3 kinase 
assays graphically illustrated in Fig. 6.8B was separated by SDS-PAGE and analysed by 
western blot for HSP27 and α-tubulin. One of these experiments is shown above. The 
membrane was stripped and re-probed for phospho-p38 MAPK. The phosphorimage from the 
MKK3 kinase assay which corresponds to the western blot samples is shown in the upper panel. 
This figure is representative of two experiments.  
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JNK peaked at 15 min post-IL-1 stimulation and at this time point was almost unaffected by the 
expression of MK2, with only slightly elevated p38 MAPK phosphorylation in cells that express 
the kinase-dead construct (Fig. 6.19). As the total expression of p38 MAPK was reduced in cells 
lacking MK2 this indicates that p38 MAPK is phosphorylated to a greater extent in the absence 
of MK2 than in its presence. The total levels of JNK were not measured by western blot and 
therefore it is not clear if MK2 has a role in the stabilisation of JNK as well. MKP1 was 
expression was greater in MK2-/- MEFs at all time points of IL-1 stimulation examined, in 
particular 30 min and 60 min post-IL-1 stimulation. 
 
Analysis of HSP25 phosphorylation in the MEF lines showed that the peak phosphorylation of 
HSP25 occurred at 15 min post-IL-1 (Fig. 6.19). A non-specific band was observed of relative 
molecular mass 30 kDa instead of 25 kDa. However, although this phosphorylation was 
inhibited in MK2-/- cells it was not absent, suggesting that MK2 may be partially redundant in 
the MEFs. One possible kinase that could account for the residual phosphorylation in the MK2-/- 
cells is the homologue of MK2, MK3, which has been demonstrated to have similar substrate 
specificity (Ronkina et al., 2008). Surprisingly, when the membrane was stripped and  re-probed 
for total HSP25 protein it was discovered that the small heat shock protein was expressed at 
high levels in MK2-/- cells, slightly reduced levels in kinase-dead MK2-mutant expressing cells 
and at much reduced levels in cells that express wild-type MK2 (Fig. 6.19). The differences in 
HSP25 expression in the different conditions observed make it more difficult to determine if 
HSP25 phosphorylation has a role in IL-1-induced signalling in these cells. It also indicates that 
a much greater proportion of HSP25 is phosphorylated in cells expressing wild-type MK2 than 
suggested by the phospho-HSP25 blot. In MK2-deficient MEFs there is a high proportion of 
phosphorylated p38 MAPK at 15 min post-IL-1 relative to total protein levels. These are cells 
that express the lowest level of phosphorylated HSP25 tested. In the cells that express the wild-
type MK2 there is the greatest proportion of phosphorylated HSP25 and proportionately less 
phosphorylation of p38 MAPK. These results suggest a possible role for phosphorylation of 
HSP25 in switching off regulation of the pathway by HSP27 / 25.  
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Figure 6.19: Investigation of the role of HSP25 phosphorylation in IL-1 signalling in MK2-
/- MEFs. MK2-/- MEFs were supplied by Dr. Alexy Kotlyarov. The MEFs provided had been 
produced following infection of MK2-/- MEFs with retroviruses expressing empty vector (mock 
/ M), a kinase-dead mutant of MK2 (KD) or wild-type MK2 (W). Cells were grown until 
confluent and stimulated with IL-1 for the times shown. Cells were lysed in whole cell lysis 
buffer. Equal amounts of each lysate were analysed by western blot for phosphorylated HSP25, 
JNK and p38 MAPK. The blots were also probed for total p38 MAPK, HSP25, MKP1 and α-
tubulin. This figure is representative of three experiments however HSP25 expression was only 
examined once.  
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 6.20 Discussion    
 
The use of sequential transfection 24 h apart with Oligofectamine partially overcame toxicity 
problems associated with Lipofectamine 2000 and allowed the function of HSP27 in IL-1 
signalling to be studied in HDFs. In initial work strong depletion of HSP27 by two siRNAs 
inhibited IL-1-induced COX-2 protein expression and p38 MAPK activation in HDFs, in 
agreement with the data from HeLa and A549 cells (chapters 3 and 5). This was confirmed 
when Oligofectamine was used as the transfection reagent in this chapter. These results suggest 
that augmentation of IL-1-induced COX-2 expression and p38 MAPK activation is a general 
mechanism of IL-1 signalling regulation shared in human epithelial cells and fibroblasts.  
 
HSP27 depletion in HDF cells was shown to inhibit IL-6 and IL-8 protein expression in HDF 
cells, as had been previously observed in HeLa cells (Alford, 2006). However, HSP27#5-
transfection, in contrast to HSP27#7-transfection, did not inhibit IL-1-induced IL-8 expression. 
One possible explanation for the effect of HSP27-depletion on IL-6 and IL-8 protein expression 
may lie with the p38 MAPK-dependence of the expression of the particular pro-inflammatory 
protein. Previous work from this laboratory using the p38 MAPK inhibitor SB203580 had found 
that of the three proteins examined, expression of COX-2 was the most and that for IL-8 the 
least dependent upon p38 MAPK activity (Ridley et al., 1997).     
 
IL-1-induced TAK1 activity in HDF cells was not inhibited by two different siRNAs that target 
HSP27, which indicates that the regulation of IL-1 signalling by HSP27 in HDF cells is 
different to that in HeLa cells. The possibility that TAK1 was not the MKKK responsible for the 
activation of p38 MAPK in these cells was investigated. p38 MAPK phosphorylation at 30 min 
post-IL-1 was inhibited by TAK1 depletion, however at 15 min post-IL-1 there was no apparent 
difference, reminiscent of the results in HSP27-depleted HDFs. One explanation for the 
incomplete dependence of p38 MAPK phosphorylation on TAK1 may be the presence of 
residual TAK1 protein. Or alternatively, there is some redundancy between TAK1 and another 
MKKK. There was only a weak depletion of the p54 JNK isoform by TAK1-depletion in HDFs 
and JNK phosphorylation was again only weakly inhibited by HSP27 depletion in HDFs. In 
contrast, work by other members of the laboratory in HeLa cells showed a strong dependence of 
p38 MAPK and JNK phosphorylation on the presence of TAK1 (S. Glennie, unpublished). 
Therefore it may be that in HDF cells there is a preferential activation of p38 MAPK over JNK, 
whereas in HeLa cells both pathways appear to be strongly activated by TAK1. 
 
In the experiment in which IL-1-induced MKK6 activity was examined phosphorylation of p38 
MAPK was weakly inhibited in HSP27-depleted cells. In two experiments that examined 
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MKK3 activity IL-1-induced p38 MAPK phosphorylation was unaffected by HSP27-depletion 
however, the HSP27 depletion was weaker than the first MKK3 kinase assay for which the anti-
phospho-p38 MAPK re-probing of the membrane was unsuccessful. The first experiment 
analysed for MKK3 kinase assay activity had an equivalent depletion of HSP27 to the MKK6 
kinase assay experiment. Therefore, it is likely that IL-1-induced MKK3 and MKK6 activity is 
unaffected in HSP27-depleted cells. These results suggest that in HDF cells, in contrast to HeLa 
cells, IL-1-signalling upstream of p38 MAPK may not be inhibited in the absence of the small 
heat shock protein. This further suggests that the mechanism of regulation of IL-1-induced p38 
MAPK activation in HDF cells might be at the level of p38 MAPK itself, or lie between the 
MKK3 / MKK6 and p38 MAPK. An interaction was found between MKK3 and p38 MAPK in 
HDFs and HSP27 may be required for the formation or maintenance of this complex. However, 
the possibility that IL-1-induced MKK3 activity is actually inhibited under certain conditions in 
HSP27-depleted HDFs cannot be ruled out from my results. If MKK3 activation is regulated by 
HSP27 in HDFs this could argue for a mechanism in which HSP27 regulates the TAK1 
complex in both HeLa cells and HDF cells. For example in HeLa cells this regulation could 
directly affect TAK1 activation, whereas in HDF cells the activation of MKK3 and MKK6 
could be regulated by HSP27.  
 
p38 MAPK activity was inhibited with SB202190 and prolonged IL-1-induced p38 MAPK and 
JNK activity was observed in both cell types. This was indicative that the mechanism whereby 
p38 MAPK phosphorylates TAB1 leading to the inactivation of TAK1 is present in both cell 
types. An alternative explanation is that the expression of a phosphatase, MKP1, which targets 
both p38 MAPK and JNK is reduced following p38 MAPK blockade. This has been previously 
reported to occur (Hu et al., 2007). Another possibility for the difference in regulation of IL-1 
signalling in the two cell types is the presence of a protein in HeLa cells that mediates the 
effects of HSP27 onto TAK1, which is not expressed in the protein complement of HDF cells. 
However, the regulation of p38 MAPK phosphorylation in all three cell types examined 
suggested that this is likely to be a site of important regulation, potentially linked to the 
regulation of inflammatory mediator expression including COX-2. Therefore possible 
mechanisms for the regulation of p38 MAPK by HSP27 were examined. 
 
HSP27 has been previously reported to regulate the localisation of p38 MAPK (Gorska et al., 
2007). It was reported that HSP27 retained p38 MAPK in the cytoplasm after IL-1 stimulation 
(Gorska et al., 2007). This presented as a possible mechanism for HSP27 action in IL-1 
signalling because it would be expected that retention of p38 MAPK in the cytoplasm may 
cause it to co-localise with upstream activators. When p38 MAPK localisation was examined 
with subcellular fractionation by either detergent lysis or Dounce homogenisation all of the p38 
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MAPK was localised to the cytoplasm and this did not alter upon IL-1 stimulation. This was 
surprising given the reports in the literature. Therefore it was decided to analyse the nuclear-
cytoplasmic localisation of p38 MAPK by confocal microscopy, a method of choice to examine 
subcellular localisation. The results from confocal microscopy were in closer agreement with 
the reports in the literature (Ben-Levy et al., 1998; Gorska et al., 2007) because in these 
experiments the stain for p38 MAPK was present in both the cytoplasm and the nucleus. The 
nuclear staining appeared more intense, however HDFs have a large surface area and the 
volume of cytoplasm was much larger than the nucleus and therefore the staining between the 
two compartments was similar. However, the concentration of p38 MAPK may more important 
than the overall amount present within each compartment. Once again the reported shift in p38 
MAPK localisation upon stimulation was not observed. HSP27 appeared to be localised to the 
cytoplasm using confocal microscopy, dounce homogenisation or detergent lysis. There have 
been some reports that phosphorylated HSP27 can be recruited to nuclear speckles (Bryantsev et 
al., 2007). Although some weak nuclear staining can be seen with the anti-HSP27 antibody this 
staining is not punctuate and is likely to be caused by bleed through.  
 
It was not clear why the cell fractionation techniques yielded different results, however each has 
potential flaws. In the detergent lysis and Dounce homogenisation it is possible that proteins, 
which are not tightly associated with DNA, leak into the cytoplasm. The potential difficulty, 
which may account for the observed localisation of p38 MAPK in confocal microscopy, is the 
presence of non-specific staining. An anti-phospho-p38 MAPK antibody showed a similar 
pattern of staining to the total p38 MAPK antibody raised in different species, which may add 
confidence to the confocal microscopy results. However, this phospho-specific antibody did not 
show induction of p38 MAPK phosphorylation upon IL-1 stimulation, although the western blot 
from the same experiment did. The lack of clarity in p38 MAPK localisation led to the 
abandonment of this approach. Unfortunately, it could not be concluded whether HSP27 was 
able to regulate the subcellular localisation of p38 MAPK in this system. Nethertheless, my 
results do not concur with and may raise doubts about the validity of observations made by 
others (Gorska et al., 2007) on the regulation of p38 MAPK localisation by HSP27. 
 
Another potential mechanism is the inhibition of a phosphatase to dephosphorylate p38 MAPK 
in the presence of HSP27. MKP1 was chosen as the candidate because it is widely reported to 
dephosphorylate p38 MAPK. MKP1 protein levels were slightly increased in HSP27-depleted 
cells even in the absence of stimulation in an experiment where IL-1-induced p38 MAPK 
activity was strongly inhibited. The increase in MKP1 expression appeared to correlate with the 
degree of inhibition of IL-1-induced p38 MAPK phosphorylation observed. This was slightly 
surprising because there is strong evidence that MKP1 dephosphorylates JNK as well as p38 
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MAPK and IL-1-induced JNK activation did not appear to be inhibited to a significant extent 
following HSP27 depletion. The increase in MKP1 expression levels was small however, 
MKP1 is a potent phosphatase and this small increase may be sufficient to reduce p38 MAPK 
phosphorylation. Unfortunately, the regulation of IL-1-induced p38 MAPK by HSP27 became 
less reproducible and it was therefore not possible to get convincing repeats of the MKP1 
protein expression or examine the regulation of MKP1 at the mRNA level. 
 
The regulation of MKP1 or p38 MAPK itself may not be sufficient to explain the regulation of 
IL-1-induced COX-2 protein expression at 4 h post-IL-1 stimulation because at 60-240 min 
post-IL-1 stimulation p38 MAPK activity is so low it is difficult to detect in HDFs. Therefore it 
may be that the early IL-1-induced p38 MAPK activity, augmented by HSP27, activates MK2 
and this activity persists in HDFs and is responsible for the stabilisation of COX-2 expression in 
these cells. However, IL-1-induced COX-2 protein expression may be more sensitive to HSP27 
and the regulation of an alternative protein downstream of the peak of p38 MAPK activity may 
be more important for gene regulation. The regulation of early p38 MAPK activity by HSP27 
may actually be the most important point for the enhancement of COX-2 protein expression. 
The problem of loss of p38 MAPK regulation also hindered the ability to examine if HSP27 
depletion disrupted the complex between MKK3 and p38 MAPK, another potential mechanism.  
 
MK2-/- cells were used to examine the function of HSP25 phosphorylation in IL-1 signalling. 
The interpretation of these results was hindered by the variation in the total protein expression 
of p38 MAPK and HSP25 itself. The reduction in HSP25 expression in wild type MEF 
compared to MK2-/- or kinase-dead MK2 mutant MEFs may be predicted to inhibit IL-1-induced 
p38 MAPK phosphorylation based on earlier work in this thesis. However, this was no 
observed. It is possible that, as seen for previous experiments on HSP27, the expression level of 
HSP25 in cells that express wild-type MK2 is not low enough to inhibit IL-1-induced p38 
MAPK signalling. MK2 had been previously reported to have a role in stabilising of p38 MAPK 
(Kotlyarov et al., 2002). The higher levels of expression of HSP25 in cells that lack MK2 or 
MK2 kinase activity (kinase-dead mutant) may be a stress response, although there was no 
indication of a change in cell viability between the cell types. Upon enquiry with the laboratory 
that donated the cells it was discovered that HSP25 expression varies considerably between 
different MEF lines. When the differences in total protein expression were taken into account 
the results indicate that an increase in HSP25 phosphorylation correlates with a decrease in p38 
MAPK phosphorylation. Therefore the phosphorylation of HSP27 may prevent further 
augmentation of the signalling pathway, acting as a potential switch. However, this role of 
phosphorylation does not fit with the early work in HeLa cells that suggests that late signalling 
(MK2) when HSP25 phosphorylation is very low is also regulated by the small heat shock 
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protein. Although it was not possible to determine if phosphorylation of HSP25 is required for 
full activation of p38 MAPK the enhanced MKP1 expression in cells lacking MK2 suggests that 
there may be a connection between MK2 activity and MKP1 protein expression. 
 
An additional conclusion from work in this chapter was that MKK3 is a more important 
activator of p38 MAPK in HDF cells stimulated with IL-1. There has been a lot of controversy 
over which MKK is primarily responsible for the activation of p38 MAPK and there does 
appear to be cell type and stimuli-specific differences. It has been reported that in fibroblast-like 
synoviocytes dominant-negative mutants of both MKK3 and MKK6 have equivalent and non-
redundant roles in p38 MAPK activation in response to IL-1 (Inoue et al., 2005). Targeted gene 
disruption studies in mice have shown that activation of p38 MAPK by TNF in MEFs requires 
both MKK3 and MKK6 (Brancho et al., 2003). MKK3-/- fibroblast-like synoviocytes 
demonstrated a dependence of TNF-induced p38 MAPK on MKK3 however in these cells IL-
1β-induced p38 MAPK was MKK3-independent (Inoue et al., 2006). Therefore the relative 
importance of MKK3, MKK6 and possibly MKK4 (not examined in this study) appears to differ 
between conditions and cell type. If HSP27 regulation of IL-1 signalling is able to act at this 
level it is important to have confidence in the dependency of p38 MAPK on the MKKs in the 
appropriate cell type before further clarification of the mechanism. 
     
The major problem encountered when working on HDFs was the variability in HSP27 
depletion. A change to a new batch of Oligofectamine and low passage cells from Lonza 
appeared to restore the good HSP27 knockdown efficiencies. However, most of the HSP27 
knockdowns after this time were not as efficient as the initial Oligofectamine experiments and 
this may account for the loss and variable strength of the regulation of IL-1-induced p38 MAPK 
by HSP27. It may be that only a small threshold of HSP27 is required for the regulation of IL-1-
induced signalling and gene expression. Unfortunately it is not easy to determine the exact 
efficiency of the knockdown achieved. Some people use real time PCR to examine the mRNA 
levels however, this is not necessarily the same as protein expression because of residual protein 
left that had been translated before the siRNA was transfected into the cells. 
 
One possibility for the reduction in HSP27 depletion efficiency that was not investigated was 
the change in batch of Biosera foetal calf serum. This could have altered the growth rate of the 
cells and directly affected the depletion efficiency of the RNAi experiments. Alternatively, this 
could have altered the signalling in response to IL-1. Another member of the laboratory has 
recently found that reducing the cell confluency causes a dramatic decrease in the IL-1-induced 
expression of MKP-1 in HDFs (R. Perelli, unpublished). Thus if the regulation of p38 MAPK 
by HSP27 was dependent upon MKP-1, this may depend upon the confluency of the cells.  
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Ways to improve the depletion of HSP27 in HDFs may include the use of three sequential 
transfections, increasing the dose of siRNA used, or using Amaxa technology. None of these 
techniques are ideal. It may not be practical to do three sequential depletions of HSP27 24 h 
apart in HDFs. This could also increase the toxicity of transfection because the MTT assay 
showed that exposure to the transfection reagent was the main factor in the loss of cell viability. 
Increasing the amount of siRNA used both with Oligofectamine or the Amaxa kit would 
increase the risk of off-target effects and the interferon response (Moss and Taylor, 2003; 
Persengiev et al., 2004). However, this work suggests that lipofection may not be the best 
approach for RNAi in HDFs. 
 
Alternative depletion strategies include the use of short hairpin (shRNAs) to produce a stably 
depleted cell line or pool (Amarzguioui et al., 2005). The advantage with using shRNA to 
generate either a stable pool or a stable cell line expressing little or no HSP27 over the use of 
transient siRNA transfection would be that the degree of depletion achieved would be consistent 
for each experiment with the particular pool or cell line. shRNA RNAi uses RNA polymerase 
III promoters. The use of a tetracycline-inducible H1 promoter has facilitated the inducible 
knockdown of a protein from cells with shRNA (Amarzguioui et al., 2005) and allows for a 
control in the level of depletion achieved. Thus it would be possible to examine the threshold of 
HSP27 required to regulate IL-1 signalling. Although a shRNA approach would eliminate the 
difficulty of variable transfection efficiency between experiments, shRNAs are just as 
susceptible to causing sequence-specific off-target effects as siRNAs and therefore this strategy 
does not eliminate this significant problem. Multiple depleted cell lines would need to be used 
in order to ensure that an off-target effect was not the cause of the phenotype being examined.    
 
The loss of regulation of IL-1-induced signalling may be a result of difficulties in achieving a 
sufficient depletion of HSP27 in HDF, as seems likely from Fig. 6.9.  This indicates that HSP27 
does regulate IL-1-induced p38 MAPK and COX-2 expression and only a small amount of 
HSP27 is required. However, if the loss of regulation was related to confluency then it is 
unclear if the regulation would be present and relevant in vivo. It is difficult to determine what 
the confluency of dermal fibroblasts is in vivo and whether the contact with other cell types or 
the extracellular matrix would affect any regulation by HSP27. Therefore it would be of greater 
relevance and interest to pursue the investigation into the function of HSP27 / 25 in 
inflammation in HSP25-/- mice, currently being bred by our laboratory. 
 
In conclusion work from this chapter confirmed that TAK1 has a role in the propagation of the 
IL-1 signal to p38 MAPK but not the major JNK isoforms in HDF cells. MKK3 was found to be 
a more important activator of p38 MAPK than MKK6 in HDF cells in response to IL-1. p38 
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MAPK activation and activity and COX-2 protein expression are inhibited in the absence of 
HSP27 in all three cell lines examined. The augmentation of p38 MAPK activation by HSP27 is 
likely to be an important general fine-tuning mechanism in IL-1-mediated signalling. The 
investigation into a possible mechanism of action of HSP27 suggested that HSP27 may regulate 
the expression of the phosphatase MKP1, however difficulties in achieving consistently strong 
depletion of HSP27 made this unclear. Further work is required to dissect this mechanism.     
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HSP27 has been shown to have many functions in the cell, for example cytoprotection, 
chaperone function and regulation of cell migration. For almost two decades pro-inflammatory 
stimuli, such as IL-1, have been known to cause the phosphorylation of HSP27. Changes in 
HSP27 expression and function have been reported for a large number of diseases, as discussed 
in the introduction. Many of these diseases involve an inflammatory process. However, whether 
and in what way HSP27 contributes to inflammation was unclear. Previous work in the 
laboratory using RNAi found that HSP27 was involved in IL-1-induced COX-2 and IL-6 
mRNA stabilisation in HeLa cells (Alford, 2006). I have investigated how HSP27 regulates 
signalling pathways that are activated by IL-1, which may contribute to the expression of pro-
inflammatory mediators such as COX-2.  
 
Work in this thesis has shown a novel role of HSP27 in IL-1 signalling downstream of TAK1 in 
HeLa cells. The depletion of HSP27 by RNAi inhibited the IL-1-induced activation of TAK1, 
MKK4/7 (L. Rawlinson), MKK3 / MKK6 (J. Dean), p38 MAPK, JNK and MK2 but not ERK in 
HeLa cells. Three different siRNAs that target HSP27 were found to inhibit IL-1-induced TAK1 
activity and JNK phosphorylation and two HSP27 siRNAs inhibited IL-1-induced p38 MAPK 
phosphorylation. The agreement of multiple siRNAs increases confidence that the results were 
not caused by off-target effects. Examination of HSP27 function in IL-1 signalling in HDF cells 
with two different siRNAs showed that HSP27 is not required for IL-1-induced TAK1 
activation but is required for IL-1-induced p38 MAPK activation and COX-2 protein 
expression. The latter observation is important because HDFs are a more physiological system 
than HeLa cells. IL-1-induced p38 MAPK phosphorylation and COX-2 expression were also 
regulated by two HSP27-targeting siRNAs in a third cell type, A549 cells, suggesting that this 
regulation by HSP27 is a general mechanism. 
 
Work to determine if IL-1-induced TAK1 activation was regulated in A549 cells, proved 
inconclusive. In HSP27#7-transfected A549 cells both IL-1-induced p38 MAPK and TAK1 
phosphorylation were inhibited compared to control cells, in agreement with the HeLa cell data. 
This would suggest that in both epithelial cell types the regulation of IL-1 signalling was at 
TAK1 activation or above. However, in HSP27#5-transfected A549 cells IL-1-induced TAK1 
phosphorylation was increased whilst MKK3 / MKK6 and p38 MAPK phosphorylation was 
inhibited. This suggests that HSP27 may target the event whereby TAK1 activates MKK3 / 
MKK6. The agreement of data obtained in A549 cells with HSP27#7 siRNA and HeLa cell data 
suggest that HSP27#5 rather than HSP27#7 siRNA causes an off-target effect in A549 cells. 
Unfortunately, a lack of other efficient siRNAs that target HSP27 prevented any verification of 
this hypothesis.  
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Further work would be required to elucidate the mechanism of HSP27 regulation of TAK1 and 
signalling upstream in epithelial cells. Recent work by Shi et al., suggests that HSP90 may also 
regulate IL-1 signalling through TAK1 (Shi et al., 2008). In this paper HSP90 inhibition is 
found to inhibit IL-1-induced MAPK activation, NF-κB activation and COX-2 protein 
expression through the destabilisation of TAK1. HSP90 has well-characterised chaperone 
functions and it is proposed that this chaperone activity is required for the stability of TAK1. 
HSP27 has also been proposed to have chaperone activity (Rogalla et al., 1999) however, there 
have been far fewer substrates identified for HSP27. Work in this thesis suggests that the 
chaperone function of HSP27 is not required for the regulation of IL-1-induced TAK1 
activation because no effect was found on the protein expression of TAK1 upon HSP27 
depletion in HeLa cells. HSP27 depletion also has no effect on the expression levels of TRAF6, 
IRAK1, IRAK4 or MyD88. This is not an exhaustive list of the upstream IL-1 signalling 
pathway components and thus further work would be required to determine if HSP27 can act as 
a chaperone for the IL-1R, TOLLIP, Ubc13-Uev1A. 
 
Work in this thesis was unable to detect endogenous ubiquitination of either TRAF6 or IRAK1 
and therefore it was not possible to determine if HSP27 was able to regulate these important 
points in signal transduction. Most reports in the literature use overexpression of ubiquitin or to 
a lesser extent the protein of interest. This approach was not used in this work because 
overexpression can generate artefacts and future work to examine the function of HSP27 in the 
process would require co-transfection of DNA and siRNA. It is difficult to optimise the co-
transfection of DNA and siRNA as demonstrated by the attempts to rescue the COX-2 
phenotype in HDF cells (chapter 5).  
 
It is possible that the difficulty in the detection of endogenous ubiquitination was a result of 
technical difficulties, for example the immunoprecipitation of the wrong complex. It is 
important to immunoprecipitate proteins that had been bound to the receptor. If, in the 
experiments in this study, the immunoprecipitated proteins had not been involved in the initial 
signalling event from the receptor it is possible that endogenous ubiquitination may not have 
been observed. HSP27 is reported to interact with polyubiquitin chains and the 26S proteasome 
and degrade IκBα (Parcellier et al., 2003). The interaction between ubiquitin and HSP27 was 
shown in this report with lysates of U937 cells that overexpress HSP27 incubated with 
recombinant GST-ubiquitin. The same group also showed that HSP27 favours the ubiquitination 
and degradation of the cyclin-dependent kinase inhibitor, p27Kip1 (Parcellier et al., 2006). 
Gln31 and Gln190 of HSP27 have been shown to cross-link to Lys29 and Lys48 of ubiquitin in 
Alzheimer’s patients (Nemes et al., 2004) and therefore it was proposed that HSP27 could link 
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two polyubiquitin chains. If HSP27 could cross-link the polyubiquitin chains of TRAF6 and 
IRAK1 (or possibly TAK1 itself) this could be a potential way in which HSP27 could regulate 
IL-1 signalling, at least in terms of NF-κB activation. It would be interesting to determine if 
HSP27 could act in this way. The structure of the lysine 48 and lysine 63-linked polyubiquitin 
chains are thought to be very different (D. Komander, personal communication) and therefore it 
is unlikely that HSP27 would be able to recognise both linkages. In a recent report, 
overexpression of HSP27, TRAF6 and ubiquitin uncovered an interaction between HSP27 and 
TRAF6 (Wu et al., 2008). This interaction enhanced the ubiquitination of TRAF6 and is 
disrupted by the phosphorylation of HSP27 at Ser78 and Ser82. Although, I did not see an 
interaction between TRAF6 and HSP27, this would be a plausible mechanism to explain my 
results in epithelial cells. Further work is required to examine the possibility that HSP27 is 
acting as a scaffold in this way. 
 
The data in this thesis may all suggest that HSP27 impinges on a signalling complex, involving 
MKK3 / MKK6, p38 MAPK, TAK1 and possibly TRAF6. For reasons outlined in chapter 6 it 
was not possible to be certain as to whether MKK3 was regulated by HSP27 in HDFs. 
However, MKK6, which was shown to be the minor activator of p38 MAPK in HDFs, was 
unaffected by HSP27 depletion. MKK3 was found to be in a complex with p38 MAPK in 
HDFs. It would be of interest to determine if TAK1 was also in this complex and if the complex 
was disrupted in HSP27-depleted HDFs. If such a complex also contained TAK1 the presence 
of HSP27 in HeLa cells may facilitate the binding of TAK1 from this complex to TRAF6 
polyubiquitinated chains and thus lead to the activation of TAK1. In HDFs and A549 cells, 
HSP27 may be required for the interaction of MKK3 with either p38 MAPK or TAK1, leading 
to a loss of signalling in its absence.  
 
The loss of regulation of IL-1 signalling and gene expression in HDFs prevented the thorough 
investigation of the regulation of IL-1-induced MKK3 activity by HSP27. This was likely to be 
a result of reduced efficiency of HSP27 deletion by RNAi, as discussed in chapter 6. My results 
suggest that there is a small threshold of HSP27 required for the enhancement of IL-1 signalling 
and therefore a near complete knockdown of HSP27 protein expression is required to observe 
the phenotype. HDFs are more difficult to transfect than either HeLa or A549 cells and therefore 
it was more difficult to achieve the required transfection efficiencies. Future work should either 
use three sequential transfections or an alternative technique such as Amaxa technology to 
overcome this difficulty. The regulation of MKK3 / MKK6 by HSP27 is a critical point and 
therefore it would be important, once the conditions of p38 MAPK regulation by HSP27 
depletion have been re-established, to verify whether this occurs in HDF cells. Further work 
would need to be done to determine if the general mechanism of enhancement of IL-1 signalling 
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by HSP27 occurs at the activation of p38 MAPK or at the level of MKK3 / MKK6 / TAK1 
activation.  
 
The potential disparity between the regulation of IL-1 signalling in HeLa and HDF cells could 
indicate that HSP27 regulates multiple points in the signalling pathways activated by IL-1 in 
HeLa cells. HSP27 may enhance signalling at the level of TAK1 or above in HeLa cells and 
regulate p38 MAPK activation (or MKK3 activity / activation) in both cell types. This situation 
could arise due to the variation in the expression of proteins found in different cell types. For 
example a protein that interacts with HSP27 to regulate signalling at or above the level of TAK1 
may only be expressed in HeLa / epithelial cells and not HDF cells, leading to the apparent 
difference in the point of regulation by HSP27. IL-1-induced p38 MAPK was inhibited by 
multiple siRNAs in A549 cells suggesting that the enhancement of p38 MAPK activation is a 
general mechanism, because it was observed in three cell types.  
 
The potential mechanisms of regulation of IL-1-induced MKK3/MKK6 or p38 MAPK by 
HSP27 could be similar. As mentioned before, HSP27 may act as a scaffold protein. HSP27 has 
been reported to act as a scaffold protein for p38 MAPK, MK2 and Akt (Zheng et al., 2006). 
Work in our laboratory was unable to find any inhibition of Akt following HSP27 depletion (S. 
Glennie, unpublished). This complex would be unlikely to explain an effect on either p38 
MAPK or MKK3 / MKK6 activation. However, in HDFs I was able to detect a constitutive 
interaction between p38 MAPK and MKK3. In order to be sure that this was a bone fide 
interaction it would be important to check that using the complementary antibodies for 
immunoprecipitation and western blots could also result in a detectable interaction. One 
possible mechanism is that HSP27 promotes an interaction and facilitates the phosphorylation 
of p38 MAPK by MKK3.  
 
If HSP27 sequesters a phosphatase, this could give rise to increased phosphorylation of either 
p38 MAPK or MKK3 / MKK6. Work in HDFs indicated that HSP27 depletion may cause a 
small increase in the expression of the dual specificity phosphatase, MKP1. The expression of 
MKP1 was strongly induced 30-60 min post IL-1 stimulation. However, a small amount of 
MKP1 was detected in resting cells and the basal expression appeared to be increased upon 
HSP27 depletion. One way that HSP27 could regulate MKP1 expression is through stabilisation 
of MKP1 mRNA. The MKP1 3'UTR contains an AU-rich element and is highly unstable. A 
recent report provides evidence that HSP27 can regulate and bind directly to the TNF ARE 
(Sinsimer et al., 2008). It is possible that MKP1 mRNA could be regulated in a similar manner. 
Further work is required to determine if the increase in MKP1 expression in HSP27-depleted 
cells is sufficient to account for the inhibition of p38 MAPK activity observed following HSP27 
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depletion. Regulation of MKP1 by HSP27 would provide a link between HSP27 and 
glucocorticoid action. MKP1 is also thought to dephosphorylate JNK. It is therefore surprising 
that IL-1-induced JNK phosphorylation was not inhibited by HSP27 depletion. The lack of 
regulation of TAK1 in HDFs argues that in these cells there must be a p38 MAPK pathway-
specific mechanism instead. Alternatively, in HDFs, HSP27 could regulate another phosphatase 
that targets p38 MAPK / MKK3/ MKK6, but not JNK. 
 
The importance of the phosphorylation of HSP27 in the enhancement of IL-1 signalling is 
unclear. Lasa et al., found that phosphomimetic mutants of HSP27, in which the serine 
phosphorylation sites are mutated to glutamate, cause stabilisation of COX-2 ARE reporter 
mRNA (Lasa et al., 2000). This stabilisation was weak when compared with overexpressed 
MKK6 or MK2. In this thesis MK2-/- MEFs were used to address this question because MK2 is 
believed to be the principal kinase responsible for HSP25 / 27 phosphorylation. However, one 
difficulty which complicated the interpretation of the role of phosphorylation was the much 
increased expression of HSP25 in MK2-/- MEFs compared to kinase-dead mutant MK2-
expressing cells or wild-type MEFs. Further complicating the interpretation of the results was 
the requirement of MK2 for p38 MAPK protein stability, as previously reported (Kotlyarov et 
al., 2002). Taking into consideration the differences in total protein expression there is the 
greatest proportion of phosphorylated HSP25 and proportionally less p38 MAPK 
phosphorylation in the wild type MEFs. These results would suggest, in contrast to Lasa et al., 
that the phosphorylation of HSP25 / 27 may inhibit IL-1 signalling. Therefore one could 
postulate that unphosphorylated HSP27 (large oligomers) can enhance IL-1 signalling. 
However, the subsequent phosphorylation of HSP27 (dimers) by MK2 in response to the 
activation of the pathway, can act to switch off the regulation. Further work would be required 
to evaluate this hypothesis.   
 
The findings of this thesis, summarised in Fig. 7.1, strongly indicate that HSP27 has a role in 
pro-inflammatory IL-1 signalling. Therefore HSP27 could be involved in inflammatory disease 
phenotypes and be a potential drug target for chronic and destructive inflammatory conditions. 
However, there have been several recent papers that claim HSP27 is an anti-inflammatory agent 
rather than a pro-inflammatory agent.  
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Fig. 7.1: Regulation of IL-1 signalling by HSP27. HSP27 enhances IL-1-induced p38 MAPK 
phosphorylation and activation in all cell types tested. HSP27 also enhances IL-1-induced 
TAK1 phosphorylation and activity in HeLa cells and possibly A549 cells. This positive 
regulation leads to the regulation of the gene expression and mRNA stability of a variety of IL-
1-induced inflammatory mediators including COX-2 and IL-6.   
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Park et al., found that HSP27 associated with the IKKα and IKKβ complex in HeLa cells (Park 
et al., 2003). The high abundance of HSP27 can cause difficulties in the detection of specific 
interactions due to non-specific protein binding however, the association between HSP27 and 
IKKβ was increased by TNF-induced phosphorylation of HSP27, suggesting that this 
interaction is specific and induced by TNF. In this study depletion of HSP27 using HSP27#9 (in 
this thesis) increased TNF-induced IKK activity. The opposite result was found in our 
laboratory for IL-1 induced IKK activity in HSP27#5-transfected HeLa cells (Alford et al., 
2007). In my experience HSP27#9 siRNA is very poor at depleting HSP27 from cells and had 
no effect on IL-1-induced p38 MAPK phosphorylation. Therefore these results do not fit with 
the pattern expected from work performed using HSP27#5 and HSP27#7 siRNAs in this thesis. 
However, the result was supported by an experiment overexpressing HSP27 and an NF-κB 
reporter construct. Overexpression of FLAG-tagged constructs of HSP27 which were mutated 
to prevent phosphorylation of HSP27 indicated that phosphorylation of HSP27 downregulated 
TNF-induced NF-κB and its association with IKKβ.  
 
Sur et al. examine the role of HSP27 in the regulation of TNF signalling in keratinocytes (Sur et 
al., 2007). When HSP27 is depleted they find increased prostaglandin E2 in both resting and 
TNF-stimulated cells. Downregulation of HSP27 expression with the same siRNA used by Park 
et al. (Park et al., 2003) caused an increase in TNF-induced IL-8 protein expression that was 
mediated by an increase in NF-κB activity. They found an association between HSP27 and the 
IKK complex and postulated that this may be the mechanism for regulation. Sur et al. use 100 
nM siRNA against HSP27, which is quite a high concentration and may cause off-target effects. 
This may have been necessary due to the weak depletion caused by the siRNA they used 
(HSP27#9), as seen in this thesis. Only one siRNA has been used and no attempt made to rule 
out off-target effects. Another potential reason for the difference in HSP27 function in 
inflammatory signalling compared to the work in this thesis may be the use of different cell 
types. As has been seen from this thesis, HSP27 appears to have a different function in the 
regulation of signalling upstream of p38 MAPK in HeLa cells and HDFs.  
 
Su et al., reported that depletion of HSP27 from human lung microvascular endothelial cells did 
not have any effect on TNF-induced ICAM-1 or IL-8 expression (Su et al., 2008). In this study 
cells were transfected with a 60 nM pool of three siRNAs targeting different parts of the HSP27 
sequence. This is not ideal because in the pool there are three sets of sequences which can cause 
off-target silencing. It is very difficult to directly compare knockdown efficiencies by western 
blot analysis, however the knockdown they find is not complete and from the experience of the 
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work in this thesis a residual level of HSP27 is often sufficient for the regulation of signalling. 
This has directly been shown in this thesis for IL-8 expression in HDFs. 
 
Wu et al., overexpressed HSP27 in HeLa cells and found that it enhanced IL-1 stimulated 
phosphorylation of IKKα / IKKβ but not IL-1- or TNF-induced p38 MAPK or JNK 
phosphorylation (Wu et al., 2008). HSP27 is very abundant in HeLa cells and work in this thesis 
shows that only a small amount of the small heat shock protein is required to enhance IL-1-
induced p38 MAPK signalling. Therefore swamping the system with yet more HSP27 would 
not be expected to have any effect on the MAPK signalling.  
 
High levels (2μg ml-1) of exogenous HSP27 have been reported to stimulate the p38 MAPK-
mediated production of IL-10 and to a lesser extent TNF (De et al., 2000). However, it is not 
clear that HSP27 would ever reach these extracellular levels in a physiological context. 
Exogenous HSP27 has also recently been reported to bind to the Scavenger Receptor-A and 
prevent acLDL uptake (Rayner et al., 2008). However, no one particular receptor has been 
proposed to act as a HSP27 receptor and it is possible that exogenous HSP27 is taken into the 
cell by pinocytosis and thereby acts in the same way as endogenous HSP27 in the enhancement 
of p38 MAPK signalling. Alternatively, it is possible that endogenous HSP27 is able to be 
secreted from the cell in response to IL-1 stimulation and act as an autocrine stimulus to 
increase p38 MAPK signalling, through an unknown receptor. However, it is unlikely that this 
mechanism would be sufficiently fast to account for the regulation of peak IL-1-induced 
signalling in my experiments. HSP27 secretion was detected in the medium of macrophages 1 h 
after the addition of 17β-estradiol but peaked after 24 h (Rayner et al., 2008). Further work 
would be required to elucidate exogenous and endogenous HSP27 act in the same way. 
 
Epithelial cells are the first line of defence against invading microorganisms and these cells 
together with endothelial cells and fibroblasts have important roles in the repair response to 
injury and the defence against infection. HSP27 is expressed at high levels in all of these cells. 
Work in this thesis has highlighted an important role of HSP27 in enhancing the production of 
pro-inflammatory mediators in response to IL-1 and TNF. Previous work in the laboratory 
(Alford, 2006) and the experiments in this thesis demonstrate the importance of HSP27 in the 
expression of COX-2, IL-6 and IL-8. COX-2 is important in chronic inflammation (Mitchell et 
al., 1995) and rat adjuvant arthritis (Anderson et al., 1996). COX-2 catalyses the conversion of 
arachidonic acid into prostaglandin H2, the precursor of prostaglandins and thromboxane. 
Prostaglandins in turn mediate vasodilation. IL-6 is particularly important in the acute phase 
response and the T cell-dependent antibody response against certain viruses including vesicular 
stomatitis (Kopf et al., 1994). IL-8 is an important chemokine for neutrophils and therefore has 
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an important role in acute inflammation. The regulation of p38 MAPK (and JNK in HeLa cells) 
by HSP27 suggests an involvement of HSP27 in the expression of all the inflammatory 
mediators downstream of these MAPKs. This includes the regulation of adhesion molecules on 
the vascular endothelium, important in selecting leucocytes to migrate to the site of infection, 
through binding to leucocytes and initiating leucocyte rolling before extravasation. Another 
laboratory found a decrease in the expression of vascular cell adhesion molecule (VCAM)-1 in 
HUVECs depleted of HSP27 with RNAi (Gorska et al., 2007). VCAM-1 selectively recruits T 
cells and eosinophils and thus adds further evidence for a role of HSP27 in chronic 
inflammation. HSP27 may also have a role in the expression of matrix metalloproteinases, the 
expression of several of which has been shown to be p38 MAPK-dependent (Ridley et al., 1997; 
Underwood et al., 2000). One report of suggests that HSP27 overexpression up-regulates the 
expression and activity of MMP-9 (Hansen et al., 2001). MMPs have been reported to have 
many functions in inflammation (Parks et al., 2004). MMPs can degrade the extracellular 
matrix, however recently MMPs have also been implicated in the modulation of cytokine and 
chemokine activity and establishing chemokine gradients (Parks et al., 2004). Therefore the 
function of HSP27 in the regulation of IL-1-induced signalling and gene expression may be 
important in both acute and chronic inflammation. An involvement in chronic inflammation 
would suggest a potential role of HSP27 in diseases such as RA and Crohn’s disease, although 
further work is needed to determine if this hypothesis is correct.  
 
Important work to resolve whether HSP27 is important in inflammation in vivo is the generation 
of HSP25-/- mice. Unfortunately, although these mice were in the process of being made during 
the course of this work, they were not generated in time to be used. Recently a group produced 
HSP25-/- mice, which were viable, fertile and without any morphological abnormalities (Huang 
et al., 2007). In this study ~0.6 kb of genomic sequence downstream of the start codon, 
including the first exon and 0.3 kb of the first intron were replaced with the lacZ reporter gene. 
This disruption allowed the examination of tissue distribution of HSP25 expression during 
mouse development, whilst eliminating HSP25 protein. Under heat challenge HSP25 was found 
to act synergistically with HSP70 in the development of thermotolerance and protected cells 
from apoptosis (Huang et al., 2007). Surprisingly, no significant changes were found in HSP25-/- 
MEFs compared to wild type when challenged with the apoptosis-inducing ionising radiation, 
etoposide, serum starvation or menadione (Huang et al., 2007). HSP27 had previously been 
reported to protect against apoptosis induced by these agents (Huot et al., 1996; Paul et al., 
2002). However, this group have yet to report whether inflammation is dysregulated in the 
HSP25-/- mice. It would be exciting to investigate the function of HSP25 in inflammation in vivo 
in the future. 
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HSP25-/- mice in which all three exons have been removed are in the final stages of 
development in our laboratory. Specific cell types could be removed from the mice and 
challenged with IL-1, TNF and LPS. The use of cells from the HSP25-/- mice will be 
instrumental for future studies through providing a more definitive analysis of which genes are 
actually regulated by HSP25 / HSP27 and the elucidation of the signalling mechanism. In 
particular, use of HSP25-/- cells will overcome the hurdles imposed when RNAi was attempted 
in human dermal fibroblasts. Future work could include the use of inflammatory models to 
determine if the absence of HSP25 ameliorates inflammation. Infiltration of cells into inflamed 
tissue could be examined with the air-pouch model using IL-1 as a stimulus. The ability of the 
knockout mice to clear infections owing to defects in the innate immune response could be 
studied after the introduction of bacteria such as Listeria Monocytogenes. It would also be of 
great interest to examine the role of HSP25 in collagen-induced arthritis. 
 
Future work in vitro to further elucidate the mechanism of HSP27 action in IL-1 signalling 
could include expanding the confocal microscopy studies. Different stimuli could be used 
activate p38 MAPK, such as anisomycin or heat shock to determine if the nuclear / cytoplasmic 
ratio of p38 MAPK is altered. The use of additional stimuli may help reveal the mechanism of 
action. HSP27 has been shown to form a complex with p38 MAPK, MK2 and Akt (Rane et al., 
2001; Zheng et al., 2006) and potentially with upstream activators such as TRAF6 (Wu et al., 
2008). Therefore it would also be interesting to use confocal microscopy to determine if HSP27 
depletion alters the nuclear-cytoplasmic ratio or localisation of any upstream activators. An 
alternative strategy to investigate this could include gel filtration of nuclear and cytoplasmic 
fractions to examine potential complexes. Immunophilin FKBP12 could be fused to HSP27 and 
used to investigate protein-protein interactions and the effect of oligomerisation of HSP27 on 
IL-1 signalling, in a similar way to previous studies of TRAF2 and TRAF6 (Baud et al., 1999). 
It would also be of interest to determine if HSP27 regulates IL-1 signalling in cell types 
particularly relevant for chronic inflammatory conditions, such as RA. These could include 
synovial fibroblasts or capillary endothelial cells. 
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Heat shock protein (HSP) 27 has long been known to be a
component of the p38 mitogen-activated protein kinase
(MAPK) signaling pathway. p38MAPKhas important functions
in the inflammatory response, but the role of HSP27 in inflam-
mation has remained unknown.We have used small interfering
RNAs to suppress HSP27 expression in HeLa cells and fibro-
blasts and found that it is required for pro-inflammatory cell
signaling and the expression of pro-inflammatory genes. HSP27
is needed for the activation by interleukin (IL)-1 of TAK1 and
downstream signaling by p38 MAPK, JNK, and their activators
(MKK-3, -4, -6, -7) and IKK!. IL-1-induced ERK activation
appears to be independent ofHSP27.HSP27 is required for both
IL-1 and TNF-induced signaling pathways for which the most
upstream common signaling protein is TAK1. HSP27 is also
required for IL-1-induced expression of the pro-inflammatory
mediators, cyclooxygenase-2, IL-6, and IL-8. HSP27 functions
to drive cyclooxygenase-2 and IL-6 expression by augmenting
the activation of the kinase downstream of p38 MAPK, MK2,
resulting in stabilization of cyclooxygenase-2 and IL-6 mRNAs.
The mechanism may not occur in cells of myeloid lineage
because HSP27 protein was undetectable in human monocytes
and murine macrophages.
Heat shock proteins (HSP)4 are constitutively expressed in
certain cell types and are also induced upon exposure of cells to
elevated temperatures and other cell stresses (1). HSP27 (or
HSPB1) is a widely expressed 27-kDa protein and one of ten
members of the small HSP family. These proteins include the
lens proteins !A- and !B crystallin, and they all share a con-
served C-terminal motif, the !-crystallin domain (2). The func-
tion of HSP27 is poorly understood, but recently missense
mutations in the gene encoding it have been associatedwith the
human neurodegenerative disorders, Charcot-Marie-Tooth
disease, and distal hereditary motor neuropathy (3). However,
the role of the HSP27 in these diseases is unclear.
HSP27 is phosphorylated in response to heat shock, cell
stresses, pro-inflammatory stimuli, and various agonists
including phorbol 12-myristoyl 13-acetate (PMA) (4–6). In
fact HSP27 was found to be a major protein phosphorylated
upon interleukin (IL)-1 treatment of fibroblasts (7). Phospho-
rylation of the human protein occurs at three serine residues
Ser-15, Ser-78, and Ser-82 (6) and is performed by mitogen-
activated protein kinase (MAPK)-activated protein kinase-2
(MK2) (8). In vitro phosphorylation of HSP27 by a kinase in cell
lysates allowed the purification of an IL-1-activated protein
kinase cascade now known as the p38 MAPK pathway (9). It
consists of upstream activators (later identified as MAPK
kinase (MKK)3 andMKK6 andRefs. 10 and 11), p38MAPK, the
downstream kinase, MK2, and HSP27 (9, 12). Phosphorylation
of the protein by MK2 has been suggested to modulate dif-
ferent functional properties of HSP27, including oligomer-
ization; the unphosphorylated protein exists as large !700-
kDa oligomers (e.g. 24-mers), which dissociate to form
dimers upon phosphorylation (13–15).
Various cellular functions have been proposed for HSP27. It
is cytoprotective against heat shock (16) and apoptotic agents
including tumor necrosis factor (TNF) (17), Fas/APO-1, stau-
rosporine (18), H2O2 (19), and anticancer drugs (20). HSP27
possesses chaperone-like activity and refolds denatured pro-
teins, preventing their aggregation (21). Reduced glutathione-
dependent chaperone activity against misfolded or oxidized
proteins has been suggested to be responsible for the HSP27
protective role (22). Several other anti-apoptotic functions have
also been proposed (23); however, at present, there is no com-
mon mechanism that explains the cytoprotective function of
HSP27. HSP27 may also regulate cytoskeletal dynamics. Over-
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expression of HSP27 stabilizes actin filaments, and this process
appears to require phosphorylation (24, 25).
The p38 MAPK pathway, in addition to phosphorylating
HSP27, plays a key role in the induction of many genes of the
inflammatory response. An important function is to stabilize
otherwise unstable mRNAs, thereby increasing their expres-
sion (26). The mechanism involves AU-rich elements (ARE)
present in the 3"-untranslated regions (UTR) of mRNAs that
direct instability but also allow for stabilization by p38 MAPK
(27, 28). The process requires the downstream kinase, MK2
(27–29) and is thought to involve proteins that interact with the
ARE and thereby regulate the decay of mRNA (26).
The fact that HSP27 is a substrate of MK2 makes it a candi-
date for involvement in the inflammatory response. Although
its phosphorylation following IL-1 treatment of cells was first
described some 20 years ago (30), its function in inflammation
remains unknown. To examine the role of HSP27 in the inflam-
matory response we suppressed the expression of the protein in
HeLa cells and human fibroblasts by RNA interference (RNAi).
We found that HSP27 is needed for the induction by IL-1 of
COX-2 and IL-6 protein and mRNA. In HSP27-depleted cells,
the inhibition of COX-2 and IL-6 mRNA was a result of insta-
bility of these mRNAs, which was caused by reducedMK2 acti-
vation. These findings led us to uncover an unexpected func-
tion for the small heat shock protein in pro-inflammatory cell
signaling.
EXPERIMENTAL PROCEDURES
Cell Culture—HeLa cells and human dermal fibroblasts were
cultured inDulbecco’smodified Eagle’smedium supplemented
with 10% fetal calf serum and 100 units ml#1 penicillin and 100
$g ml#1 streptomycin. Cells were maintained at 37 °C in a
humidified atmosphere containing 5% CO2.
Oligonucleotides—21-nucleotide double-stranded siRNA
oligonucleotides with 3"-dTdT overhangs were designed
according to Tuschl and co-workers (31). They were synthe-
sized in 2"-ACE protected form (Dharmacon) and were depro-
tected according to the manufacturer’s instructions. dsRNAs
used were as follows: Scramble 2 (Scr): 5"-CAGUCGCGUUU-
GCGACTGGdTdT-3" HSP27#1: 5"-GGAUGGCGUGGUGG-
AGAUCdTdT-3"; HSP27#2: 5"-CGAGAUCACCAUCCCAG-
UCdTdT-3"; HSP27#3: 5"-GUGGUUAGGCGGCAGCA-
GCdTdT-3"; HSP27#4: 5"-GAUCCGGCACACUGCGGACd-
TdT-3"; HSP27#5: 5"-UGCCCAAGCUAGCCACGCAdTdT-
3"; HSP27#6: 5"-UCCGAUGAGACUGCCGCCAdTdT-3";
TAK1 siRNA: 5"-UGGCUUAUCUUACACUGGAdTdT-3".
siRNA Transfection—HeLa cells were seeded in 6-well plates
(105 cells per well) and cultured for 24 h. Cells were transfected
with siRNAs at a final concentration of 10 nM using oligo-
fectamine (Invitrogen) according to the manufacturer’s
instructions. After addition of liposome-siRNA complexes,
cells were incubated in a final volume of 1 ml of serum-free
OptiMEM I (Invitrogen) for 4 h. Cells were then washed with
phosphate-buffered saline and then incubated in 1.5 ml of 5%
fetal calf serum/OptiMEM I including 100 unitsml#1 penicillin
and 100 $g ml#1 streptomycin. Cells described as untrans-
fected were subjected to identical changes of the culture
medium but were not treated with lipid or siRNA.
Human fibroblasts were seeded in 6-well plates (5$ 104 cells
per well) and cultured for 24 h. The cells were transfected with
dsRNA (10 nM final concentration) using Lipofectamine 2000
(Invitrogen) according to the instructions supplied. Cells were
re-transfected 24-h later in the sameway. Cells were stimulated
and harvested for the times indicated at 72 h after the initial
transfection.
Western Blotting—Cells were lysed in lysis buffer (20 mM
Tris-HCl, pH 7.5, 150mMNaCl, 1% Igepal CA-630, 1mMphen-
ylmethylsulfonyl fluoride, 3$gml#1 aprotinin, 10$ME64, 2$g
ml#1 pepstatin, 10mMNaF, 5mM sodium orthovanadate, 1$M
microcystin, 2mMdithiothreitol), and protein was separated by
10% SDS-polyacrylamide gel electrophoresis and transferred
onto polyvinylidene difluoride membranes. The membranes
were stained with rabbit anti-COX-2 antibody (Alexis), a
mouse anti-!-tubulin antibody DM-1A (Sigma-Aldrich), a
mouse monoclonal antibody against actin (Sigma), a rabbit
antiserum raised against MKK3/6 (32), a rabbit antiserum to
human HSP27 (7), a rabbit antiserum that recognizes both
human HSP27 and murine HSP25 (Stressgen), a rabbit anti-
serum to the C-terminal peptide of p38!MAPK (33), a rabbit
antiserum against TAK1 (sc-7162; Santa Cruz Biotechnology),
and a rabbit antiserum against I#B! (sc-203; Santa Cruz Bio-
technology). Rabbit anti-phospho-ERK1/2, rabbit anti-phos-
pho-p38MAPK, rabbit anti-phospho-MKK3/6 antibodies, and
mouse anti-phospho-JNK1/2 monoclonal antibody were from
Cell Signaling, and secondary antibodies coupled to horserad-
ish peroxidase were from Dako. Protein detection was carried
out by enhanced chemiluminescence (GE Healthcare).
Enzyme-linked Immunosorbent Assay (ELISA)—IL-6 and
IL-8 concentrations in medium were determined by ELISA
using a kit (BD Biosciences) according to the manufacturer’s
instructions. A prostaglandin E2 (PGE2) ELISA kit was from
R&D Systems and was used according to the instructions sup-
plied. All samples were developed using the TMB peroxidase
substrate system (Kirkegaard & Perry Laboratories), and the
reactions were stopped using 1 M H2SO4. Absorbance was read
on an ELISAMultiskan Biochromic plate reader (Labsystems).
Data were analyzed using Ascent software (Labsystems).
RNA Isolation and Northern Blotting—RNA was isolated
from cells using an RNA Blood Mini kit (Qiagen) according to
the manufacturer’s instructions. 8 $g of HeLa cell RNA was
electrophoresed on denaturing formaldehyde/1% agarose gels
with 0.41 M formaldehyde. RNA was capillary-transferred onto
Hybond XL membranes (GE Healthcare) and fixed by UV
cross-linking. For cDNA probes, membranes were prehybrid-
ized for 3 h and then hybridized overnight with [!-32P]dCTP-
labeled cDNA probe at 42 °C in Ultrahyb (Ambion). Blots were
thenwashed three times for 1 h at 52 °Cwith 2$ SSC/0.1% SDS,
1$ SSC/0.1% SDS, and 0.1$ SSC/0.1% SDS. For GAPDH ribo-
probe pre-hybridization, hybridization, and washes were car-
ried out at 65 °C. RNA was visualized and quantified using an
FLA-2000 phosphorimager (Fuji, Tokyo, Japan). The GAPDH
riboprobe template was from BD Biosciences and prepared
according to Ref. 34. The HSP27 probe was prepared using a
fragment of pCMVFLAGHSP27 plasmid (28) obtained by
BamHI digestion. IL-6 and COX-2 probes have been described
previously (35, 36).
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Cell Viability Assay—3-(4,5-Dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide (MTT) (0.5 mg ml#1 final concen-
tration) was added to 1.5 ml of cell culture medium, and cells
were incubated for 4 h. 1.5 ml of 10% SDS in 10 mM HCl was
then added, and cells were incubated at 37 °C overnight. Ali-
quots were transferred to a 96-well plate, and absorbance at 620
nm was measured using an ELISAMultiskan Biochromic plate
reader (Labsystems).
Kinase Assays—For MK2 and p38 MAPK, these were per-
formed as described previously (36). JNK was immunoprecipi-
tated in an identical fashion but
using an antiserum against long
JNK2 (37). p38 MAPK and JNK
assays were performed using either
recombinant His-tagged MK2 or
GST-ATF-2 substrates, respectively.
MKK4 was immunoprecipitated
using a rabbit antiserum (sc-964;
Santa Cruz Biotechnology). MKK7
was immunoprecipitated with a
previously described antiserum
(37).MKK4 andMKK7were immu-
noprecipitated with a buffer lacking
deoxycholate but using protein G
beads, and they were assayed using
GST-JNK2 (K55R) as previously
described (37). IKK" was assayed
for after immunoprecipitation with
an anti-IKK% (764) antibody (BD
Pharmingen) in lysis buffer contain-
ing 400 mM NaCl. Immunoprecipi-
tates were washed in the same
buffer and assayed using GST-I#B!
as substrate (gift from Michael
Karin, University of California San
Diego, La Jolla, CA). TAK1 was
immunoprecipitated with a sheep
antibody against TAB1 and assayed
using recombinant MBP-MKK6
(both gifts from Mark Windheim,
MRC Protein Phosphorylation
Unit, University of Dundee) as a
substrate as described previously
(38).
RESULTS
HSP27 Is Required for the Induc-
tion of COX-2, IL-6, and IL-8 Pro-
teins by IL-1—To investigate
whether HSP27 is required for the
regulation of inflammatory response
genes, its expression was suppressed
in HeLa cells by RNAi, and the
induction by IL-1 of COX-2, IL-6,
and IL-8 was measured. Cells were
transiently transfected separately
with six different siRNA targeted
against HSP27 (HSP27#1–6) or
with a scrambled double-stranded oligonucleotide (Scr) as a
control orwere left untransfected. Cells were incubated for 72 h
to allow for suppression of HSP27 protein. They were then
incubated for a further 4 h with or without IL-1. Culture
mediumwas then removed, and cells were harvested, lysed, and
HSP27, COX-2, and !-tubulin (as a loading control) were
detected by Western blotting (Fig. 1A).
All siRNAs, except for HSP27#4, suppressed HSP27 protein
expression, with HSP27#2 and HSP27#5 as the most effective
(Fig. 1A). IL-1 induced COX-2 protein to a similar extent in
FIGURE 1. HSP27 is needed for induction by IL-1 of COX-2, IL-6, and IL-8 protein in HeLa cells. HeLa cells
were transiently transfected separately with six different siRNAs targeted to HSP27 (HSP27#1–6; 10 nM final
concentration), a control scrambled dsRNA (Scr; 10 nM final concentration), or left untransfected (Untr) and
incubated for 72 h. Cells were then treated with IL-1 (20 ngml#1) for 4 h. A, Western blot of COX-2, HSP27, and
!-tubulin (as a loading control). Theblot shown is representativeof six different experiments.B, HeLa cellswere
transfectedwithScr,HSP27#2, orHSP27#5, or left untransfectedand treatedwith IL-1 as above.Bar chart shows
IL-6 ELISA (mean and S.E. of four experiments) data plotted as a percentage of IL-6 protein secretedby untrans-
fected cells treated with IL-1 (20 % 8 ng ml#1). C, IL-8 ELISA as in B. IL-1-treated untransfected cells secreted
46 % 19 ng ml#1 IL-8 protein. D, expression of HSP27 in different cell types. Lysates were prepared from
different cell types (indicated), and 15 $g of total protein were electrophoresed on SDS-PAGE and Western-
blotted for HSP27 with an antibody that recognizes both human HSP27 and its murine orthologue, HSP25.
E, requirement of HSP27 for IL-1-induced COX-2 expression in human fibroblasts. Human fibroblasts were
transfected with Scr or HSP27 siRNAs (10 nM final concentration) as indicated or treated with Lipofectamine
2000 (Mock), and incubated for 24 h. Cells were then transfected again with the same amount of each dsRNA,
or treated with Lipofectamine 2000 only, and incubated for a further 48 h. Cells were treated with IL-1 for 4 h,
harvested, and lysed. Lysateswereblotted for COX-2, HSP27, andactin as a loading control. Similar resultswere
obtained in two or more separate experiments for each panel (A–E).
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untransfected cells and in cells transfected with the scrambled
oligonucleotide (Fig. 1A). The induction of COX-2 protein by
IL-1was inhibited by four different siRNAs but not byHSP27#3
or HSP27#4 (Fig. 1A). It is possible that HSP27#3 exerts off-
target effects that block the inhibition of COX-2 upon HSP27
depletion. Because HSP27#2 and HSP27#5 siRNAs were the
most effective at depleting HSP27 protein, they were selected
for subsequent experiments. The effect of depleting HSP27 on
IL-1-induced PGE2 secretion was also examined. The amount
of PGE2 secreted following a 4-h IL-1 treatment was inhibited
by 47 and 60% by HSP27#2 and HSP27#5 siRNAs compared
with untransfected cells (data not shown).
The amounts of IL-6 and IL-8 secreted into the culture
medium in response to IL-1 were also measured (Fig. 1, B and
C). These were reduced in cells in which HSP27 expression was
suppressed: siRNAs HSP27#2 and #5 inhibited IL-6 secretion
by 72% 8% and 81% 7%, respectively (Fig. 1B) and reduced IL-8
secretion by 65% 4% and 68% 9%, respectively (Fig. 1C).
HSP27 Is Required for Induction by IL-1 of COX-2 Protein in
Human Fibroblasts—To investigate whether HSP27 functions
in inflammatory gene expression in cells other than HeLa cells,
HSP27 expression was examined in different cell types. HSP27
was undetectable in human monocytes, human T cells, murine
bone marrow-derived macrophages, and the RAW 264.7
murinemacrophage-like cell line (Fig. 1D). HSP27 could not be
detected in lipopolysaccharide-treated monocytes or macro-
phages (data not shown). It was expressed to a similar degree in
HeLa cells and human fibroblasts and was also expressed in the
293 cell line (Fig. 1D). HSP27was also detected in human endo-
thelial cells and human chondrocytes (data not shown).
FIGURE 2.HSP27 regulates IL-1-induced COX-2 and IL-6mRNA levels and
stabilization. A, HeLa cells were transfected with HSP27 siRNAs, Scr, or left
untransfected (as in Fig. 1) andeither left untreatedor treatedwith IL-1 for 2h.
Cells were then harvested, lysed, and RNA was isolated. Northern blots for
COX-2, IL-6, HSP27, and GAPDHmRNA (as a loading control) are shown. Data
are representative of two independent experiments. B, cells were transfected
(as above), treated with IL-1, and incubated for 1.5 h before addition of acti-
nomycin D (final concentration 5 $g ml#1) to block transcription. Cells were
harvested at the times shown, and RNAwas isolated andNorthern-blotted as
above. Graphs show COX-2 or IL-6 mRNA levels normalized to GAPDHmRNA
levels for representative actinomycin D chase experiments. Data shown in
each panel are representative of at least two independent experiments.
FIGURE 3.HSP27 is needed for IL-1-induced activation of MK2. Cells were
transfectedasbefore and treatedwith IL-1 for the times shown. The cellswere
harvested and lysed. Lysates were immunoprecipitated with an antiserum
against MK2 and assayed for MK2 activity using recombinant HSP27 protein.
A portion of the lysates was Western-blotted for HSP27 and !-tubulin. The
plot showsMK2activity in Scr- andHSP27#5-transfected cells as a percentage
of peak activity in Scr-transfected cells. MK2 activity was inhibited to a similar
extent in another three comparable independent experiments.
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RNAi was used to test whether HSP27 functions in inflam-
matory gene expression in human fibroblasts. A single round of
transfection by lipofection was found to be insufficient for
strong depletion of HSP27 protein (data not shown). The cells
were therefore transfected twice by lipofection, with an interval
of 24 h between transfections, to improve depletion of HSP27.
The suppression achieved by HSP27#2 after sequential trans-
fection of the fibroblasts was still not as complete as in HeLa
cells (compare Fig. 1, A and E) and was not sufficient to inhibit
COX-2 expression (Fig. 1E). However in fibroblasts, HSP27#5
strongly suppressed HSP27 expres-
sion and, also inhibited the induc-
tion of COX-2 protein by IL-1 (Fig.
1E). Thus the pro-inflammatory
function of HSP27 is not limited to
HeLa cells but also occurs in human
fibroblasts.
HSP27 Is Required for the Induc-
tion of COX-2 and IL-6 mRNA by
IL-1—Suppression of HSP27 expres-
sion might inhibit the translation of
COX-2 and IL-6 or reduce their
mRNA levels. To test this, cells were
treated with the siRNAs as before
and were left unstimulated or stim-
ulated with IL-1. The cells were har-
vested after 2 h, and RNA was iso-
lated and examined by Northern
blotting. IL-1 treatment induced
COX-2mRNA in untransfected and
Scr-transfected cells to a similar
extent (Fig. 2A). HSP27#2 and
HSP27#5 inhibited COX-2 mRNA
by 50 and 56%, respectively, com-
pared with untransfected cells (Fig.
2A). Stronger inhibition was seen
for IL-6 mRNA (68% inhibition for
both siRNAs) (Fig. 2A). The inhibi-
tion of IL-1-induced IL-6 mRNA
(Fig. 2A) reflected the reduction in
IL-6 protein (Fig. 1B). Therefore,
HSP27 does not appear to regulate
IL-6 translation. These results indi-
cate that HSP27 regulates either the
transcription or the stability of these
inflammatory transcripts. Northern
blots were also performed to meas-
ure the degree of suppression of
HSP27 mRNA (Fig. 2A). Both
siRNAs suppressed HSP27 mRNA
(HSP27#2: 65 % 8%; HSP27#5:
71 % 7%).
HSP27 has previously been
reported to have a cytoprotective
role. It was possible that the inhibi-
tion of expression of inflammatory
proteins in response to IL-1 was
caused by the death of cells in which
HSP27 expression was suppressed. To check this, the viability
of oligonucleotide-treated cells was measured by the MTT
assay. In three experiments, Scr and HSP27#2 had no effect on
cell viability, and only a small reductionwas seenwithHSP27#5
(14 % 3%). Decrease in viability did not account for the differ-
ences in COX-2, IL-6, and IL-8 expression.
HSP27 Is Needed for Stabilization of IL-1-induced COX-2
and IL-6 mRNAs—Because HSP27 is a component of the p38
MAPK signaling cascade and this pathway has an important
post-transcriptional role in inflammatory gene expression, we
FIGURE 4. HSP27 regulates IL-1-induced p38 MAPK and JNK activity but not ERK activation. Cells were
transfected as indicated and treated with IL-1 for different times. Cells were harvested and lysed. A, p38MAPK
was immunoprecipitated from lysates and assayed for its ability to phosphorylate His-tagged MK2. Graph
showsmeanp38MAPKactivity from three independent experiments (%S.E.) as a percentageof peak activity in
Scr-transfected cells. A portion of the lysates wasWestern-blotted for HSP27 and p38MAPK. B, JNKwas immu-
noprecipitated from lysates, and JNK activity was assayed with GST-ATF-2 as a substrate. Graph shows JNK
activity (as for A). An aliquot of lysate was analyzed by Western blotting for HSP27 and !-tubulin.
C, activation of ERK in lysates was detected by Western blotting with an antibody that recognizes ERK phos-
phorylated on Thr-185 and Tyr-187. Theblotwas stripped and re-probed for total ERK.D, cellswere transfected
with Scr, HSP27#2, or HSP27#5 twice (with a 24-h interval between transfections) and harvested and lysed 24 h
after the second transfection. Phosphorylation of p38 MAPK on Thr-180 and Tyr-182, JNK1 on Thr-183 and
Tyr-185, JNK2 on Thr-221 and Tyr-223, and ERK (as in C) in lysates was examined by Western blotting with
phosphospecific antibodies. p38 MAPK was blotted as a loading control. Data in each panel (A–D) are repre-
sentative of at least two independent experiments.
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examined the stability of COX-2 and IL-6 mRNAs in HSP27-
depleted cells. Cells were transfected with dsRNA as before,
then stimulated with IL-1 for 1.5 h. Actinomycin D was added
to block transcription, and cells were then incubated further
and harvested at different times. RNA was isolated and exam-
ined by Northern blotting tomeasuremRNA decay rates. After
1.5 h of IL-1 treatment, COX-2 mRNA in Scr-transfected cells
was stable; however, in HSP27#2-suppressed cells, it was
reduced in amount and decayed rapidly (Fig. 2B). IL-6 mRNA
behaved similarly (Fig. 2B). The stability of various other
mRNAs (Bcl-x, GADD45, c-Fos, p21, Bax, Mcl-1, and L32) was
unaffected by HSP27 depletion (supplemental Fig. S1) showing
that of the mRNAs tested, the effect is not general and may be
specific to COX-2 and IL-6 mRNAs.
Overexpression of HSP27 has previously been shown to pro-
tect against the cytotoxic effects of actinomycin D (39). To
check whether actinomycin D affected the viability of cells in
which HSP27 protein was suppressed, MTT assays were per-
formed. Scr- and HSP27#2-transfected cells were left un-
treated, treatedwith IL-1 for 2 h, treatedwith actinomycinD for
1.5 h, or treated with IL-1 for 2 h followed by actinomycin D for
1.5 h. In two separate experiments, cell viability was unaffected
by any of these treatments (data not
shown). Thus the instability of
COX-2 and IL-6 mRNAs in
HSP27-suppressed cells was not
caused by death of the cells, which
might have been caused by
actinomycin D.
HSP27 Is Required for Activation
of MK2 by IL-1—It is possible that
suppression of HSP27 protein
(which is phosphorylated by MK2)
was affecting upstream signaling by
the p38 MAPK pathway. To exam-
ine this possibility, Scr or HSP27#5-
transfected cells were stimulated
with IL-1 for different times. Activa-
tion ofMK2wasmeasured in lysates
by immunoprecipitating it and
assaying for its ability to phospho-
rylate recombinant HSP27 in vitro
(Fig. 3). MK2 activity peaked at 30
min after IL-1 treatment and was
inhibited by 56% by HSP27#5
siRNA (Fig. 3). Because MK2 activ-
ity is required for stabilization of
COX-2 and IL-6 mRNAs, the
reduced stability of these transcripts
in HSP27-depleted cells is entirely
consistent with inhibition of MK2
following HSP27 depletion.
HSP27 Is Needed for Full Activa-
tion by IL-1 of p38 MAPK and JNK,
but Not ERK—Because HSP27 reg-
ulatesMK2, the activation by IL-1 of
its upstream activator, p38 MAPK,
was measured in Scr and HSP27#5-
transfected cells. p38 MAPK activity was measured by immu-
nocomplex kinase assay using recombinant MK2 as substrate
(Fig. 4A). p38 MAPK activity was maximal at 30 min after IL-1
stimulation and was inhibited by 59 % 14% following HSP27
depletion (Fig. 4A). The reduction in p38 MAPK activity in
HSP27 knockdown cells was not a result of reduced p38MAPK
expression as this was the same in Scr- and HSP27#5-trans-
fected cells.
JNK is a MAPK, which, like p38 MAPK, is strongly activated
by inflammatory stimuli including IL-1. ERK, the first discov-
ered MAPK, is typically activated by mitogens, but is also acti-
vated by IL-1 in many cells. To find out whether the effect of
HSP27 depletion on signaling is limited to the p38MAPKpath-
way or affects the otherMAPK pathways, the activation of JNK
and ERK was examined. JNK was immunoprecipitated from
dsRNA-transfected cell lysates and assayed using recombinant
ATF-2 protein as a substrate (Fig. 4B). As for p38 MAPK, JNK
was strongly activated by IL-1 in Scr-transfected cells, peaking
at 30 min IL-1 (Fig. 4B). Peak JNK activity was reduced by 64%
2% in HSP27-depleted cells compared with Scr-transfected
cells (Fig. 4B). Thus the role of HSP27 in regulating signaling is
not restricted to the p38 MAPK pathway.
FIGURE 5.HSP27 is needed for activation by IL-1 of the p38MAPK activators (MKK3 andMKK6) and the
JNK activators (MKK4 and MKK7). Cells were transfected and treated as before. A, activation of MKK3 and
MKK6 was detected with an antibody that recognizes phosphorylation of Ser-189 and Thr-193 of MKK3 and
Ser-207 and Thr-211 of MKK6. The blot was stripped and re-probed with an antibody that recognizes total
MKK3 and MKK6. B, kinase assay for MKK4 using a GST-JNK2 (K55R) (a mutant form that is incapable of auto-
phosphorylation) andWestern blots for HSP27 and!-tubulin. C, kinase assay forMKK7 (as for B). Similar results
were obtained in two separate experiments for each panel.
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ERK activationwas assessed byWestern blotting lysates with
an antiserum that detects phosphorylated and activated ERK.
Phosphorylation of ERK in Scr-transfected cells peaked at 0.5 h
IL-1 as seen for the two other MAPKs (Fig. 4C). In HSP27-
depleted cells, phosphorylation of ERK also peaked at 0.5 h and
was induced by IL-1 to a similar degree compared with Scr-
transfected cells (Fig. 4C). Phosphorylation of ERK (at 0.5 h
post-IL-1) caused some of the ERK protein to shift in mobility
on the gel (Fig. 4C, bottom panel). HSP27 has been previously
suggested to form a complex with protein kinase-B (PKB) and
to be required for its activation (40). PKBwas phosphorylated in
resting cells, and IL-1 treatment for 30 min resulted in only a
small increase in its activation (data not shown). Activation of
PKBwas not affected by suppression ofHSP27 expression (data
not shown). Therefore, of the kinases tested thus far, HSP27
specifically regulates MK2, p38MAPK, and JNK. To verify that
the effects of HSP27#5 on MAPK activity were caused by
HSP27 depletion, an additional siRNA was employed. Activa-
tion of p38 MAPK, JNK, and ERK was analyzed by Western
blotting with phosphospecific antibodies. For p38 MAPK and
JNK, but not ERK, this was inhibited in cells transfected with
both HSP27#2 and HSP27#5 (Fig. 4D). The inhibition of p38
MAPK and JNK is not an off-target effect associated with a
single siRNA.
HSP27 Is Required for Activation of MKK3/MKK6 and
MKK4/MKK7—It was possible that HSP27 directly targets p38
MAPK and JNK or, alternatively, it could regulate upstream
signaling. To test the latter possibility, the activation of the
upstream activators of p38MAPK and JNKwas analyzed. Acti-
vation of MKK3 and MKK6, the kinases directly upstream of
p38 MAPK, was detected by Western blotting with a phos-
phospecific antibody that recognizes activated forms of both
kinases (Fig. 5A). As for MK2 and p38 MAPK, activation of
MKK3 and MKK6 peaked at 30 min IL-1 and was inhibited
upon suppression of HSP27 expression (Fig. 5A). The reduced
signal for phospho-MKK3 and -MKK6 in HSP27 knockdown
cellswas not caused by a decrease in expression of these kinases,
as this was normal in the HSP27-depleted cells (Fig. 5A). These
results prompted us to examine the activation of the kinases
responsible for JNK activation, MKK4 and MKK7.
These two kinases were immunoprecipitated and assayed
for their ability to phosphorylate a kinase-dead mutant form
of recombinant JNK protein. This mutant kinase (JNK K55R)
does not undergo autophosphorylation during the assay,
allowing MKK activity to be measured. IL-1 induced MKK4
activity, which peaked at 30-min post-IL-1 (Fig. 5B). Unlike
the activation of the other IL-1-regulated kinases examined,
which declined rapidly after their peak at 30 min, MKK7
activity was more sustained, with similar activity detected at
30 min and 1 h IL-1 (Fig. 5C). PeakMKK4 andMKK7 activity
was lower in HSP27 knockdown cells by 65 and 60%, respec-
tively (Fig. 5, B and C). The inhibition of MKK4 and MKK7
upon depleting HSP27 fully accounts for the inhibition of
JNK. The amount of MKK4 and MKK7 protein in cells was
found to be unchanged following HSP27 depletion (data not
shown).
HSP27 Regulates IKK"Activation but Not I#B!Degradation—
The p38 MAPK and JNK pathways are both strongly activated
by pro-inflammatory stimuli, and the degree of activation
depended upon HSP27. Another pathway that plays a pivotal
role in the expression of inflammatorymediator genes is that of
activating the nuclear factor (NF)-#B. It is possible that this is
also regulated byHSP27.The transcription factorNF-#B is held
in the cytoplasm of resting cells by an interactionwith an inhib-
itor of NF-#B-!, the major form of which is I#B!. Upon cell
activation, IKK" phosphorylates I#B!, triggering its degrada-
tion and releasing NF-#B, which translocates to the nucleus to
activate transcription. IKK" activity and I#B! degradation
were analyzed in HSP27-depleted cells.
IKK" exists in a complex with IKK! and IKK% (41). Activa-
tion of IKK" was measured by immunoprecipitating IKK% and
assaying phosphorylation of recombinant I#B! (Fig. 6A). IKK"
was activated by IL-1, with activity peaking at 15-min post-IL-1
(Fig. 6A). HSP27 depletion inhibited IKK" activity by 51% at 15
min IL-1 (Fig. 6A). Thus HSP27 regulates the activity of three
IL-1-activated protein kinase cascades, namely the p38MAPK,
JNK, and IKK" pathways, to similar extents. Despite inhibition
FIGURE 6. HSP27 depletion inhibits IKK! activation but not I"B# degrada-
tion. A, IKK" was immunoprecipitated from lysates of Scr- or HSP27#5-trans-
fected cells using an antibody against IKK%. IKK" activity was measured using
GST-I#B! as substrate, and a portion of the lysates was Western-blotted for
HSP27 and!-tubulin.Graph showsmean IKK" activity (%S.E.) for four independ-
ent experiments as a percentage of that in Scr-transfected cells treatedwith IL-1
for 15 min. B, Western blot for I#B!, HSP27, and !-tubulin in lysates from cells
treated as indicated. Data in A and B are representative of two separate
experiments.
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of IKK" upon HSP27 knockdown, IL-1 induced normal degra-
dation of I#B! in HSP27 siRNA-transfected cells (Fig. 6B).
HSP27 Regulates TAK1 Function—IL-1 activates the p38
MAPK, JNK, and NF-#B pathways via a common activator,
transforming growth factor-"-activated kinase-1 (TAK1) (42).
In cells, TAK1 exists in a complex with its binding partners
TAK1-binding protein (TAB)1, TAB2, andTAB3.The complex
was immunoprecipitated from lysates with an antibody against
TAB1 and assayed for its ability to phosphorylate recombinant
MKK6 (Fig. 7). In resting cells, significant TAK1 activity could
be detected, and this was not regulated byHSP27 (Fig. 7). TAK1
activity peaked at 10 min post-IL-1 in Scr- and HSP27 siRNA-
transfected cells (Fig. 7). IL-1-inducedTAK1 activity was inhib-
ited by 53% 4% and 30% 7% at 5 and 10 min IL-1, respectively
(Fig. 7). HSP27 depletion did not affect the amount of TAK1
protein in the cells (Fig. 7). Thus HSP27 activates pro-inflam-
matory signaling pathways by augmenting the function of
TAK1.
It is generally accepted that TAK1 regulates the JNK, p38
MAPK, and NF-#B pathways. It was therefore surprising that
I#B! degradation was unaffected by HSP27 depletion (Fig. 6B).
To investigate whether TAK1 regulates I#B! degradation in
HeLa cells, TAK1 expression was suppressed by RNAi (supple-
mental Fig. S2). TAK1 siRNA suppressed TAK1 protein levels
and strongly inhibited IL-1-induced IKK" activity, but had little
effect on I#B! degradation (supplemental Fig. S2).
HSP27 regulates a signaling event common to TNF and IL-1—
TNF and IL-1 both activate theMAPK andNF-#B pathways via
activation of TAK1 (42). However, these two cytokines activate
TAK1 by different upstream mechanisms. IL-1 signaling
involves MyD88, IRAK1, IRAK4, and TRAF6 (41), whereas
TNF signaling requires TRADD,
TRAF2, and TRAF5 (41). To inves-
tigate whether HSP27 regulates sig-
naling that is restricted to IL-1, or is
common to both IL-1 and TNF, the
effect of HSP27 depletion on TNF-
induced JNK activation was exam-
ined (Fig. 7B). As seen for IL-1,
TNF-induced JNK activity was also
inhibited following HSP27 deple-
tion (Fig. 7B). Thus TAK1 is the
most upstream component com-
mon to both pathways that is tar-
geted by HSP27.
DISCUSSION
We found that HSP27 functions
in IL-1-induced cell signaling and
pro-inflammatory gene expression.
HSP27 is needed for full activation
by IL-1 of TAK1 and signaling by
the p38 MAPK, JNK, and IKK"
pathways. It is also required for the
induction by IL-1 of three inflam-
matorymediators whose expression
is known to be dependent on these
pathways, namely COX-2, IL-6, and
IL-8. In the case of COX-2 and IL-6, we found that HSP27
regulated expression of the mRNAs. This was, at least in part,
because of regulation of the stability of these mRNAs in IL-1-
treated cells. HSP27 depletion had no effect on cell viability. Its
effect onmRNA stability was not general andmay be specific to
mRNAs of inflammatory mediators such as COX-2 and IL-6. It
is possible that IL-8 transcripts are regulated in a similar way.
COX-2 and IL-6mRNAs are known to be stabilized uponp38
MAPK activation (36, 43). Reporter mRNAs bearing either the
COX-2 (28), IL-6, or IL-8 (27) AREs are stabilized by co-expres-
sion of an activemutant ofMK2 in a HeLa cell line. IL-6mRNA
is also unstable in lipopolysaccharide-treated macrophages
fromMK-2-null mice (29). We found that HSP27 is needed for
activation of both p38MAPK andMK2. Thus the regulation of
p38 MAPK/MK2-mediated mRNA stabilization represents a
mechanism whereby HSP27 contributes to the expression of
pro-inflammatory mediators.
Regulation of pro-inflammatory cell signaling by HSP27 is
not limited to the p38MAPK pathway. HSP27 also functions in
the activation by IL-1 of the JNK andNF-#Bpathways. Reduced
activity in these pathways inHSP27 knockdown cells was due to
a defect in the function of the upstream activator, TAK1. TAK1
was originally thought to be involved in transforming growth
factor-" signaling. It is now known to play an important role in
signaling induced by a range of pro-inflammatory stimuli in
fibroblasts (42), B cells (42), and T cells (44–46). TAK1 knock-
out is lethal (42). Embryonic fibroblasts fromTAK1-null mice
display impaired activation by IL-1 and TNF of the p38
MAPK, JNK, and NF-#B pathways (42). Depletion of TAK1
by RNAi in HeLa cells also inhibits IL-1- and TNF-induced
FIGURE 7. HSP27 is needed for full activation of TAK1 by IL-1 and activation of JNK by TNF. A, cells were
transfected and treated with IL-1 for the times shown. TAK1 was immunoprecipitated from lysates of Scr- or
HSP27#5-transfected cells using an antibody against TAB1. TAK1 activity was detected using MBP-MKK6 as sub-
strate.Aportionof the lysatesused in thekinaseassaywasWestern-blotted for theproteins indicated.Graphshows
meanTAK1activity (%S.E.) for four independentexperiments as apercentageof that inScr-transfectedcells treated
with IL-1 for 10min.B, cellswere transfectedasbefore and treatedwithTNF (20ngml#1) or IL-1 (20ngml#1) for the
times shown. JNK was immunoprecipitated from lysates and assayed using GST-ATF-2 as substrate.Graph shows
JNKactivityasapercentageof that inScr-transfectedcells treatedwithTNF for30min. Similar resultswereobtained
in two separate experiments.
HSP27 Regulates Pro-inflammatory Cell Signaling
MARCH 2, 2007•VOLUME 282•NUMBER 9 JOURNAL OF BIOLOGICAL CHEMISTRY 6239
 at Institute of Cancer Research on M
ay 23, 2009 
www.jbc.org
Downloaded from
 
NF-#B activation (47) and TNF-induced p38MAPK and JNK
activation (48).
HSP27may act directly on TAK1, or could be required for its
activation by upstreammechanisms.Our data suggest the latter
because TAK1 activity was not regulated in unstimulated cells
and was only regulated at early times following IL-1 treatment.
MyD88, IRAK-1, and IRAK-4 are involved in signaling proxi-
mal to the IL-1 receptor. It is unlikely that HSP27 regulates
these proteins, because they do not participate in signaling in
response to TNF, which is also regulated by HSP27. Another
difference between IL-1 and TNF signaling is that the IL-1
receptor interacts with TRAF6, whereas that for TNF binds
TRAF2 and TRAF5. TRAF6 is a ubiquitin ligase, and TRAF2
has been shown to have ubiquitin ligase activity in vitro (49).
They may both catalyze their autopolyubiquitination by Lys-
63-linked ubiquitin chains (49). TAB2 and TAB3 then bind to
these chains, initiating formation and activation of the TAK1
complex (50). HSP27 might play a role in ubiquitination medi-
ated by TRAF6 and TRAF2. It will be interesting to test this in
the future.
HSP27 regulates p38 MAPK, JNK, and IKK". It is thus pos-
sible that in addition to regulating mRNA stability, the small
heat shock protein also activates transcription. In cells, JNK
phosphorylates and activates the AP-1 transcription factors
c-Jun andATF-2 (51, 52). It is possible that transcription driven
by AP-1 binding is regulated by HSP27. Despite regulation of
IKK" activity upon HSP27 depletion, the degradation of I#B!
induced by IL-1 was not regulated. TAK1 depletion also inhib-
ited IKK" activity with almost no effect on I#B! degradation.
Cells from TAK1#/# mice do show an impairment in NF-#B-
driven transcription (42). The lack of an effect of either HSP27
or TAK1 siRNA on I#B! degradation is likely to be a result of
residual IKK" activity. Thus it is possible that HSP27-null cells
would also show a defect in NF-#B-regulated transcription.
Phosphorylation causes dissociation of HSP27 multimers
and may regulate the proposed function of HSP27 as a chaper-
one. It is unclearwhether phosphorylation ofHSP27 is required
for it to promote signaling. The kinetics of HSP27 phosphoryl-
ation following IL-1 stimulation are similar to those for the
activation of MK2 and p38 MAPK. TAK1 activity is regulated
by HSP27 at 5 min following treatment of cells with IL-1. It is
unclear to what extent HSP27 is phosphorylated at this time,
because MK2 and p38 MAPK activity peak later (at 30-min
post-IL-1).
HSP27 is known to have a cytoprotective role, and may also
be involved inmodeling of the actin cytoskeleton. Both of these
processes could be regulated by HSP27 as a consequence of its
function in cell signaling and gene expression. Cellular stresses,
including heat shock, activate the p38 MAPK pathway, and
HSP27 could contribute to signaling induced by these stimuli.
Modeling of the actin cytoskeleton necessary for cell migration
is regulated by LIM kinase, a kinase activated by MK2 (53).
Thus the function of HSP27 may not be limited to pro-inflam-
matory signaling and the expression of only pro-inflammatory
genes.
Wehave shown thatHSP27 is required for pro-inflammatory
gene expression inHeLa cells and human fibroblasts. The func-
tion of HSP27 may be to sensitize these cells to pro-inflamma-
tory stimuli by augmenting pro-inflammatory signaling. It is
likely that HSP27 plays a similar role in other cell types. It does
not appear to be constitutively expressed in leukocytes, nor is it
induced by lipopolysaccharide treatment of human monocytes
or macrophages. It is perhaps rather surprising that these cells
do not require HSP27 for pro-inflammatory signaling. The
absence of HSP27 in hemopoietic cells suggests that it may
function in innate, but not adaptive immunity.
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